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This longitudinal study of children with type 1 diabetes (T1 D) and contemporary 
controls through puberty attempts to elucidate differences in their growth, pubertal 
development and the relationship with pubertal hormones. 
Fifty two T1 D prepubertal children aged 7.7- 14.4y and 125 control children aged 8.3 -
11.96y were recruited. Auxology and puberty were assessed and blood samples were 
obtained 6 monthly until the age of 16 years. Annual bone age was assessed in T1 D 
subjects. 
Puberty onset and PHV was later in T1 D boys compared to controls, while T1 D girls 
were younger at puberty onset with an advanced bone age and their peak height 
velocity was earlier compared with controls. Overall compared to the UK references, 
T1 D girls had a reduced peak height velocity whereas the boys had normal pubertal 
growth. 
T1 D children had greater increases in BMI during puberty but whereas in the girls this 
was due to greater acquisition of fat mass, in the boys it related to gains in fat free 
mass. 
Levels of DHEAS, IGF-I, A4, testosterone and oestradiol were lower in T1 D boys and 
girls whereas leptin and SHBG were higher. 
The pubertal delay in T1 D boys was partially explained by bone age but diabetes 
presence was also contributory. The earlier puberty, advanced pubertal bone age and 
reduced height gain in T1 D girls were associated with complex hormonal changes. 
The advanced bone age at pubertal onset was not influenced by adrenal hormones but 
by BMI. Loss in height gain in these girls was related to E2 levels and glycaemic 
control at the start of puberty. 
This study helps clarify some of the relationships between hormonal changes and 
variation in auxological factors during normal puberty. Differences in these parameters 
between T1 D and control children are only partially explained by endocrine 
relationships; other factors, relating to T1 D including glycaemic control and insulin 
dose, are important. 
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But also to the memory of Clara whose optimism and dreams she passed on to 
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"Who was your mother?" 
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"Never had any mother? What do you mean? 
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Chapter 1. Introduction 
1.1 Normal Human Growth 
1.1.1 The Human Growth Curve: Growth in terms of Karlberg's 
ICP model 
The curve of human physical growth results from a complex interaction of cells 
responding to messages from the brain via neurotransmitters, from endocrine 
glands via hormones, from adipocytes via leptin and other adipocytokines, from 
the environment via nutritional intake as well as social/emotional circumstances 
and from the genetic endowment bestowed on the individual. 
The characterisation of the shape of the human growth curve has varied with 
time and differing analysis. It was undoubtedly the work of Frank Shuttleworth 
(1899-1958) who elegantly defined the shape of the curve based on his 
analysis of a large number of children aged 5 to 17 years from the Harvard 
School of Education Study. His work was based on that of Boas (1858-1942) 
who earlier had discovered that individuals' curves had a different shape to 
those of averaged curves. It was Shuttleworth who clearly showed the 
difference between longitudinal studies and cross-sectional ones with his 
diagram of height velocity showing individual curves centred around the age of 
maximum velocity and the mean curve based on average velocities of a 
number of different children (Tanner 1999). The latter presents a curve that is 
flattened and spread out along the age axis losing entirely the concept of 
individuality. 
Postnatal growth is characterised by a period of rapid but decelerating growth 
during the first three years of life. This is followed by a relatively quiescent 
period of slow deceleration through childhood reaching a nadir before the 
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tumult of the pubertal growth spurt. This is superbly demonstrated in the first 
known recorded longitudinal study of growth (1759-1777) on an individual, that 
of Count de Montbeillard's son (Tanner 1962). Measurements were taken 
every 6 months from birth to 18 years of age and in addition to the three phases 
of growth just mentioned also demonstrates the often smoothed over mid-
childhood spurt that occurs between 6 and 8 years of age in many children 
(Butler et al. 1990). 
The mathematical analysis of these phases of growth by Karlberg (Karlberg et 
al. 1987a; Karlberg et al. 1987b) into three distinct functions corresponds to the 
accepted understanding of the endocrinology of the growth process (Hindmarsh 
and Brook 1995). According to Karlberg, the first component of the model is 
that of 'infancy' and is described by an exponential function that is largely 
nutrition dependent. The second phase of 'childhood' begins from an average 
age of 9 months and is depicted by a second-degree polynomial regression that 
is felt to be growth hormone dependent. The third phase of 'puberty' described 
by a logistic function is hormonally dependent on both growth hormone and the 
sex steroids (either directly or through their effect on growth hormone). 
Karlberg did not include the mid-childhood growth spurt (claimed by Molinari et 
al (Molinari et al. 1980) to occur in 2/3rds of children) in his model since he 
claimed it couldn't be used to predict puberty. Although disputed, some 
investigators (Hindmarsh 2002) claim that this can be explained by an increase 
in adrenal androgens at this time prior to a true pubertal initiation. 
1.1.2 The midchildhood growth spurt 
The existence of a midchildhood growth spurt, occurring between the ages of 6-
8 years, has often occasioned controversy. In a detailed analysis, Butler, 
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McKie and Ratcliffe (Butler et al. 1990) reviewing the literature found that 
although a spurt between 6 and 8 years of age was often demonstrated in width 
and circumference measurements (Molinari et al. 1980; Tanner and Cameron 
1980) its recurrent presence for height was disputed (Tanner and Cameron 
1980; Meredith et al. 1981; Berkey et al. 1983). The work of Bock and 
Thiessen in 1980 (cited by Butler et al 1990) on the Berkeley California data 
and the mathematical analyses of Molinari et al and Gasser et al on the Zurich 
Longitudinal Growth Study (Stuetzle et al. 1980; Gasser et al. 1985) has, 
however, indisputably demonstrated its presence. Studying 80 boys and 55 
girls from the Edinburgh Longitudinal Growth Study, Butler et al (Butler et al. 
1990) observed a midchildhood spurt in all the children except one girl. They 
also found evidence for two further spurts; one they called the pre-school spurt 
which occurred in 92.50/0 of boys and 81.8% of girls at mean ages of 4.8 and 
4.6 years respectively, the other they labelled the late-childhood spurt which 
was observed in 96% of boys and 80% of girls at 9.2 and 8.6 years 
respectively. Bock (Bock 2004) analysing data on 167 boys and 152 girls from 
the Fels Longitudinal Study found similar results of multiple prepubertal growth 
spurts using different analytical methods compared to Butler et al. He 
commented that the generality of this phenomenon occurring at random times, 
though more frequent in some children than others, points to the view that they 
are unrelated to any physiological developmental stage i.e. adrenarche. This 
agrees with Remer and Manz (Remer and Manz 2001) who claimed that no 
previous longitudinal study had ever been performed looking at both the 
hormonal and auxological parameters of the mid-childhood growth spurt. They 
studied 19 children seen annually with auxology and urine samples (although 
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the final analysis for this purpose was only done on 8 children) and observed a 
significant overall increase of adrenal androgen secretion from 2 years before 
the spurt to 2 years after. However, 'after multiple testing' they concluded that 
significant increments were only seen 1 year after the spurt (for DHEAS) or 2 
years after (for 17 ketosteroids) and therefore could not be the primary cause of 
the accelerated growth. They did, however, comment that higher androgen 
levels such as those seen in premature adrenarche could have a growth 
accelerating effect. 
1.1.3 Pubertal Growth and Peak Height Velocity 
Pubertal growth, the third phase of Karlberg's model, encompasses the 
pubertal growth spurt, which will be the main focus of this thesis. This spurt, 
also termed 'peak height velocity' (PHV) is the fastest annual velocity during 
puberty calculated over a twelve-month period and centered over the year of 
occurrence. When the calculation is done on data that has been graphically or 
mathematically smoothed to reduce measuring error, seasonal variation and 
overcome the problem of missing data, it is referred to as 'instantaneous peak 
height velocity'. Measurements taken every 3-4 months during this period will 
maximise the accuracy of the assessment but due to practical considerations, 
those taken six monthly are often used. There are a number of widely 
accepted facts concerning PHV observed by Tanner et al (Tanner et al. 1966a; 
Tanner et al. 1966b) in British children but also by others in different 
populations, these include: PHV invariably occurs approximately 2 years earlier 
in girls than boys and at different stages of puberty between the sexes (early in 
girls and late in boys); there is a marked sex difference in the magnitude of the 
spurt (boys greater than girls) and those children who have an earlier spurt 
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have a more vigorous spurt than those who have a later spurt. Growth velocity 
reaches its nadir in the year before the spurt and this is usually more evident in 
boys than girls (Tanner et al. 1966a). Although most boys will grow 5cm/yr in 
the year preceding their spurt, some may decelerate sharply and grow more 
slowly at 3.5cm/yr. It is widely held that children who begin puberty early (i.e., 
age 7yrs in girls and 9yrs in boys), are taller before puberty, shorter at the onset 
of puberty but have a final height similar to later maturing children (Karlberg et 
al. 1987b; Vizmanos et al. 2001). 
1.1.3.1 Timing 
The age at which peak height velocity occurs is a definite landmark in the 
growth process of each individual but can only be ascertained retrospectively. 
This age varies from country to country (and from region to region within a 
country) and depends on the circumstances of the individual. In boys in the 
south of England this occurs at a mean (sd) age of 13.9 (0.9) years and is 
relatively late in the pubertal process. In girls, PHV occurs at the beginning of 
puberty with the mean age of occurrence in England at 11.9 (0.9) years 
(Tanner et al. 1966b). Although the timing of the onset of puberty (first 
appearance of 82/G2) is not very different between the sexes (11.15 y in the 
girls and 11.64y in the boys (Marshall and Tanner 1969; Marshall and Tanner 
1970), the two-year difference in the timing of PHV means that there are often 
several years when many girls will be taller than their age matched male 
contemporaries. This is a short-lived phenomenon but for many youngsters a 
difficult rite of passage to endure. Most of the final height difference between 
the sexes is attributed to this two-year difference (Tanner et al. 1976). 
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1.1.3.2 Magnitude 
There are different ways that PHV is calculated that yields different values. The 
mean (sd) whole year peak height velocity-centred peak velocity is 9.5 (1.1) 
cm/yr in boys and 8.4 (0.9) cm/yr in girls (Tanner et al. 1966b). This is velocity 
calculated over a whole year (and is less than the instantaneous peak height 
velocity), centred on the peak that includes 6 months before and 6 months after 
it. Using an automated algorithm, Coste et al (Coste et al. 2002) found not only 
similar ages for PHV in both boys and girls; 13.9 (0.9)y and 12.2 (0.9) Y 
respectively but also PHV magnitudes very similar; 9.6 (1.3) cm/y and 8.4 (1.3) 
cm/y respectively. When an attempt at ascertaining the exact moment of 
instantaneous peak height velocity is made, measurements every 3 or 6 
months in themselves are not adequate and a smoothed curve must be fitted 
either graphically or mathematically. The instantaneous PHV on the 
Harpenden data was 10.3 (1.5) cm/yr in boys and 9 (1.0) cm/yr in girls (Tanner 
etaI.1966b). 
The magnitude of peak height velocity is greater the earlier it occurs and there 
is a negative relationship between the magnitude and its age of occurrence in 
both sexes. Tanner et al (Tanner et al. 1966a) found the regression of PHV on 
the age it occurs to be -0.77 in boys and -0.47 in girls. This means that for 
every year of age of later occurrence of PHV, there is a decrease in magnitude 
(b ± se) of 0.77± 0.21 cm/yr in boys and 0.47± 0.17 cm/yr in girls. There is 
therefore less difference in the peaks of early and late spurting girls than there 
is for boys. This negative relationship of magnitude of PHV to its age of 
occurrence is a universal finding although the exact regression varies. 
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1.2 Normal Puberty 
'Puberty' defined as 'that period of time in which adolescents reach sexual 
maturity and become capable of reproduction'. The origin of the word is from 
the late Middle English, from the Latin, pubertas related to pubes or pubic hair 
(The New Oxford Dictionary of English 1998). 
In their seminal papers on patterns of puberty in girls and boys, Marshall and 
Tanner (Marshall and Tanner 1969; Marshall and Tanner 1970) meticulously 
described the normal variation of pubertal events in each sex. These 
observations were based on longitudinal data on 192 girls and 228 boys in a 
children's home seen every three months during puberty in their Harpenden 
Growth Study that ran from 1948-1972. The genitalia (G), breasts (8) and 
pubic hair (PH) were rated according to 'Tanner' stages (Tanner 1962) with 
stage 1 being pre-pubertal and stage 5 being adult. These were adapted and 
simplified from the work of Reynolds and Wines (Reynolds and Wines 1948; 
Reynolds and Wines 1951) in their study of growth and development from the 
Fels Longitudinal Study (Yellow Springs, Ohio, 1929 - current). Pubic hair and 
genitalia / breast were each given a separate rating in recognition that they 
were under different hormonal control. Marshall and Tanner (Marshall and 
Tanner 1969; Marshall and Tanner 1970) demonstrated that although there 
was great variation in individuals in the timing of the onset of puberty and great 
overlap among the different events, there remained an overall synchrony. 
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1.2.1 Stages of Puberty 
1.2.1.1 Girls 
Ages on reaching the different stages of puberty 
The ages from Marshall and Tanner (Marshall and Tanner 1969) at first 
appearance of each pubertal stage is shown in the following table: 
82 PH2 PHV 83 PH3 PH4 84 M PH5 85 
mean 11.15 11.69 12.14 12.15 12.36 12.95 13.11 13.47 14.41 15.33 
sd 1.10 1.21 0.88 1.09 1.1 1.06 1.15 1.02 1.12 1.74 
Table 1.2a, Girls: Age at first appearance of each pubertal stage, Marshall and Tanner 
These puberty ratings were done from the standardised photographs taken of 
each child at each visit, the authors commented that the age of PH2 was 
probably later than in real life due to the difficulty in assessing the first 
appearance of this stage on a photograph. There was also a comment that 
although the mean age of menarche in this group was observed to be 13.47 
years, it is generally 4 months (O.3y) earlier in girls raised in normal 
conventional home environments in the south of England. In fact in the earlier 
1966 British Standards paper, Tanner et al reported the mean age of menarche 
as 13.2y but felt a more appropriate age was 13 (quoting data from the London 
County Council) and so used this as the age of menarche that best represented 
urban British girls. 
Time to go through puberty 
The longitudinal nature of the Harpenden study and the frequency of visits 
allowed the possibility of examining the length of time it took for each girl to 
pass through the various stages of puberty. Looking at the interval from B2 to 
85 it was observed that some girls might take 1.5 years to traverse this and 
others could take more than 6 years although the average tended to be about 4 
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years. A girl could begin breast development slowly and continue until stage 4 
but the time spent in stage 4 was not related to the length of time spent in the 
earlier stages. Tanner and Marshall (Marshall and Tanner 1969) made the 
interesting speculation that the breast might be under different hormonal 
controls in early puberty compared to later puberty. The average interval 
between 82 and menarche is approximately 2.5 years but this can range from 
less than a year to up to nearly 6 years. There appears to be no clear 
relationship between the age a girl begins to develop and the time she takes to 
get to full maturity. 
Age and the length of time to go through puberty 
This question of whether children who mature early move through puberty 
faster was addressed by Marshall and Tanner by looking at the interval from 
the beginning of breast development (82) and age of menarche. One is early 
in puberty and the other relatively late and so can be used as an indicator of 
time in puberty. The correlation coefficient between the age midway between 
the two [(82 age+Menarcheal age)/2] and the time interval between them 
(Menarcheal age-82 age) was 0.17, not significantly different from zero. ''Thus 
the interval between the two events does not appear to be related to the age at 
which they take place." 
In conclusion, it is the sequence of events, although not exactly the same for 
each individual, that is less variable than the age at which the events occur. It 
appears that the relationship between the different pubertal events is a more 
important indicator of normality than the actual age at which they occur. 
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1.2.1.2 Boys 
Ages on reaching the different stages of puberty 
Similarly to the girls, puberty in the boys develops sequentially from one stage 
to the other with no stages being omitted. 
G2 G3 PH2 G4 PH3 PHV PH4 G5 PHS 
mean 11.64 12.85 13.44 13.77 13.9 14.06 14.36 14.92 15.18 
sd 1.07 1.04 1.09 1.02 1.04 0.92 1.08 1.10 1.07 
Table 1.2b, Boys: Age at first appearance of each pubertal stage, Marshall and Tanner 
Again Marshall and Tanner (Marshall and Tanner 1970) commented that the 
age for the appearance of pubic hair (PH2) was unlikely to be accurate due to 
the difficulty of noticing this stage on photographs. Of interest to point out is 
that between the ages of 13 and 14 they noted that normal boys could be found 
in any stage of sexual development. 
Time to go through puberty 
There is great variation in the time taken to pass through puberty. The average 
for passing from G2 to GS was 3.0S years with a range from 1.86 to 4.72 years. 
There is also great variation in the time spent in anyone stage of puberty, for 
example G2 in some boys will last 0.4 years and in others 2.2 years. 
The extent of the variability with which individual boys pass through puberty is 
such that one may go from G2 to GS in less time than another may take to go 
from G2 to G3. The use of photographs to assess the beginning of pubic hair 
development inevitably gives rise to errors and data from the Dutch study of 
Van Wieringen et al (van Wieringen et al. 1968) was used with a mean age of 
11.7S years (instead of the 13.44y from the photos) for the appearance of PH2 
(using the Harpenden study sd of 1.1y). 
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Age and the length of time to go through puberty 
To examine if the time taken to pass through puberty was related to the age at 
which puberty occurs the regression of the interval G2-G5 on the age at the 
midpoint of this interval was calculated and was not significantly different from 
zero. Therefore, as in the girls there is no relation to the speed with which a 
boy progresses through puberty and the age at which it occurs. 
1.2.2 Growth during puberty 
1.2.2.1 Introduction 
Rapid changes in size, shape and body composition characterise the pubertal 
years in both sexes. Increased linear growth rate and sexual differentiation are 
the hallmarks of this period. Girls reach each stage of puberty before boys 
although there is a great deal of individual variation. From the preadolescent 
dip or nadir in the growth velocity (approximately 1 year before PHV) to final 
height there is a gain (mean, sd) in height of 28 (3.5) cm in boys and 25 (4.1) 
cm in girls (Marshall and Tanner 1969; Marshall and Tanner 1970). 
Approximately 160/0 (11-21%) of adult final height can be attributed to height 
attained during the growth spurt (Tanner et al. 1976). 
1.2.2.2 Sexual dimorphism 
The sexual dimorphism in adult height in England is approximately 13cm and it 
is claimed that most of this (2/3 rdS) is due to the two-year later onset of the male 
pubertal growth spurt (Tanner et al. 1976). Hauspie et al (Hauspie 2002) 
analysed the dynamics of sex differences on various measurements in British 
children. They found a 12 cm difference in adult height of which 7.9 cm was 
due to the later onset of the spurt in the boys, with 2.1 cm attributable to sex 
differences in prepubertal growth and 2cm to differences in the adolescent gain. 
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A mathematical analysis using smoothed spline functions by Largo et al (Largo 
et al. 1978) on 222 children (112 boys) from the Zurich Longitudinal Study 
(1955-1976) observed that the adult sex difference in height of 12.6 cm in the 
Swiss population could be attributed to: +1.6cm by more prepubertal growth in 
boys, +6.4 cm by the boys' delayed spurt, +6.0 cm by the more vigorous spurt 
in boys and -1.4 cm by more post-spurt growth in girls. An analysis by Gasser 
et al (Gasser et al. 2000) found that 48% of the adult sex difference in height 
could be due to the later onset of the pubertal growth spurt in the boys. There 
appears to be a consensus that it is the later spurt of the boys that is the most 
significant factor in their greater final height although the exact proportion varies 
not only between populations but with differing analyses within a population. 
1.2.2.3 Final Height 
There is some controversy as to how the age of pubertal onset affects final 
height. Several investigators have reported that the timing of puberty does not 
affect final height (Largo et al. 1978; Zacharias and Rand 1983; Tanner and 
Davies 1985; Stanhope et al. 1988; Vizmanos et al. 2001), although Hagg and 
Taranger (Hagg and Taranger 1991) observed that delayed puberty resulted in 
taller young men (although no difference in final height in their girls). A large 
American study of girls by Biro et al (Biro et al. 2001) using menarche as a 
marker for early, average and late maturers found that those Caucasian girls 
who had an early menarche «11.7 years) were shorter as adults than those 
who had an average (11.7-13.5 years) or late menarche (>13.5 years) by 1.2 
and 2.6 cm respectively. They also found that the early maturers gained more 
height after menarche than later maturers but that this was balanced by the 
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shorter prepubertal growth period. Consistent with most published research 
they also observed that early maturers had greater peak height velocities. 
1.2.3 Tempo I Relationship with growth 
1.2.3.1 "Tempo" 
Franz Boas (1892) was the first to introduce the concept of 'tempo of growth' as 
well as that of 'physiological age' (Tanner 1999). This is the now well known 
observation that children do not all develop at the same rate; that some are 
early developers while others are late developers who will for the most part 
catch up their earlier developing peers. In his 1989 book 'Foetus into Man' 
(Tanner 1989), JM Tanner said that this analogy came from classical music 
where some children grow andante (moderate tempo), others allegro (quick 
tempo) and still others lentissimo (slow tempo). As previously mentioned, the 
velocity curves of Frank Shuttleworth (Tanner 1962) markedly illustrated the 
different conclusions that could be drawn when pubertal growth was assessed 
without allowing for the individuality of each child's growth curve. 
1.2.3.2 Girls 
Marshall and Tanner's data (Marshall and Tanner 1969) showed that there was 
considerable variation in the stages of breast development that the girls were in 
for any given stage of pubic hair and vice versa. Peak height velocity 
(instantaneous) and menarche were also each reached at different breast and 
pubic hair stages. The French study of Coste et al (Coste et al. 2002) included 
a longitudinal study of 50 normal children (25 boys) in whom they evaluated the 
relationships between growth and pubertal stages. 
The following table has been adapted to summarise the findings of both sets of 
investigators and presents the percentage of girls in each stage of breast 
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development on reaching each stage of pubic hair, peak height velocity and 
menarche: 
Breast Stages 
Marshall et al: 1 2 3 4 5 
PH2 16 49 27 8 0 
PH3 3 23 50 24 1 
PH4 2 4 43 45 6 
PHS 0 1 11 49 39 
PHV 0 26 51 23 0 
Menarche 0 1 26 62 11 
Coste et al: 
PHV 10 40 30 20 0 
Table 1.2c, Girls: Percentage m each breast stage on reachmg each PH stage, PHV and menarche, 
Marshall/Tanner and Coste 
It is of interest to note that the automated method of identifying a peak of Coste 
et al (Coste et al. 2002) identified a spurt in only 80% of girls. They also 
observed that 10% had a spurt when there was no detectable breast 
development. This is in contrast to Marshall and Tanner and one has to 
conjecture whether this may be due to the subjectivity in pubertal assessments 
since it would be difficult to explain physiologically. The distribution of breast 
stages between the two studies differs and again this may be due to the 
unreliability of pubertal assessments or population differences or perhaps a 
secular trend that affects the timing of the beginning of puberty but not 
menarcheal age. However, in both studies, 700/0 or more are in stages 2 and 3 
when PHV occurs and none were in stage 5. Just over 10% were in stage 5 
when menarche happened and in those girls where data on both menarche and 
PHV existed, menarche always occurred after PHV. 
Marshall and Tanner reported correlations for the interrelationship of pubertal 
events as: age at menarche and age at PHV = 0.91, age at B2 and age at PHV 
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= 0.82, and age at 82 and age at menarche = 0.64 (Marshall and Tanner 
1969). 
1.2.3.3 Boys 
As in the girls, there was great variation in the stage of genital development for 
any pubic hair stage and vice versa. From the data of both Marshall and 
Tanner (Marshall and Tanner 1970) and Coste et al (Coste et al. 2002), the 
following table summarises the percentage of boys in each stage of genital 
development for each pubic hair stage and peak height velocity: 
Genital Stages 
Marshall et al: 1 2 3 4 5 
PH2 1 13 45 41 0 
PH3 0 4 17 75 4 
PH4 0 0 6 65 29 
PH5 0 0 0 10 90 
PHV 0 0 2 76 22 
Coste et al: 
PHV 0 8 60 28 4 
Table 1.2d, Boys: Percentage m each genital stage on reachmg each PH stage and PHV, Marshall/Tanner and 
Coste 
Yet again, as in the girls, it is interesting to note that the distribution of stages in 
which PHV occurs is different. In the data of Marshall and Tanner (Marshall 
and Tanner 1970), 760/0 of boys were G4 and 22% G5, in the data of Coste et 
al (Coste et al. 2002), 60% were G3 and 28% G4. It is not possible to know if 
this is a population difference, a secular trend effect or whether it represents 
variability in pubertal assessments. 
1.2.3.4 Sexual Dimorphism in the interrelationships between puberty 
stages and growth 
Although there is only about 6 months difference between the start of breast 
development in the girls and the first signs of genital enlargement in the boys 
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(Marshall and Tanner 1969; Marshall and Tanner 1970), there appears to be a 
universal two year difference in the timing of the peak height velocity between 
the sexes. There is also a marked difference in the timing of the growth spurt in 
relation to pubertal events. In the girls PHV occurs early in the sequence of 
pubertal changes, with approximately 70-76% at 82/3 while in the boys PHV 
occurs late in their physical development with 60-750/0 of them at G3/4. 
Although the details of the events of puberty are extremely variable in both 
sexes the general sequence remains exceedingly constant. 
1.2.4 Body Composition during Puberty 
1.2.4.1 Methods of assessment 
Body mass index (BMI), defined as weightlheight2 (kg/m2), has long been 
regarded as a reasonable surrogate of body fat. In 1985, Garrow and Webster 
(Garrow and Webster 1985) showed that BMI was not a measure of percent 
body fat but an estimate of fat mass (kg). Other investigators have confirmed a 
closer relationship of total body fat and BMI than that of percent body fat and 
BMI (Pietrobelli et al. 1998). Since the confidence limits of both percent body 
fat and total body fat (the latter to a lesser extent) were found to be wide, the 
suggestion from these researchers was that BMI is a useful indicator of 
adiposity on a group level but cannot predict an individual's fatness. BMI has 
been shown to have a high correlation with body fat and, as is statistically 
required, a minimal correlation with height (Fung et al. 1990; Deurenberg et al. 
1991). More recent work, however, from the Fels Longitudinal Study group has 
shown that this does not universally hold for children at all ages. Maynard et al 
(2001) reported that BMI and stature are related in early adolescence in boys 
although the relationship in girls was less clear (Maynard et al. 2001). Although 
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8MI does not distinguish between fat mass (FM) and fat free mass (FFM) it is 
widely accepted as a "reasonable index of adiposity ...... and is the preferred 
measure of adiposity for routine clinical and public health purposes" (Dietz and 
Robinson 1998). The advantages of using this index are apparent; weight and 
height are relatively easy, inexpensive and accurate to obtain using simple 
equipment. In addition, although 8MI has high positive correlations with 
measures of adiposity, it also has positive correlations to fat free mass. Again, 
using the data from the Fels Study group, Maynard et al observed that annual 
increases in 8MI were primarily due to increases in fat free mass/ht 2 until late 
adolescence and as expected, total body fat/he was a larger proportion of the 
8MI increases in girls than boys. Thus, a larger 8MI does not necessarily 
mean greater body fatness. Wells (Wells 2000) emphasized this very clearly 
with his use of a Hattori chart in infants and children and Prentice and Jebb 
(Prentice and Jebb 2001) reviewing the literature demonstrated that individuals 
with the same 8MI could have widely differing body fat. Since 8MI varies with 
age and sex across age in children, data are often expressed as 8MI standard 
deviation scores (8MI SDS) for a given age and sex (Cole et al. 1995). 
The human body consists of more than 30 different components at the atomic, 
molecular, cellular, tissue, and whole body levels (Houtkooper 1996). Since the 
direct measurement by chemical analysis of body composition in human beings 
is not possible, indirect methods are used. Various methods available for the 
assessment of body composition include: densitometry, isotope dilution, total 
body potassium, dual-energy X-ray absorptiometry (DXA), anthropometry and 
bioelectrical impedance analysis (8IA). The first four are often regarded as 
'reference' or 'criterion' methods and the latter two as bedside or field 
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techniques. They vary in accuracy, complexity, cost and availability; some are 
impractical, unwieldy or too expensive for field situations and may require 
equipment and procedures not suitable for use in children. At present there is 
not a true 'gold standard' for the measurement of body composition in children 
(Treuth et al. 2001; Mast et al. 2002). All current methods use method and 
algorithm specific estimates of fat and lean tissues that are based on a number 
of assumptions. Densitometry and DXA have been used in adults but not 
extensively in children where in general standard techniques and published 
algorithms have been employed. 
Skinfold measurements and bioelectrical impedance are indirect methods that 
are easily used in a paediatric population and both have %body fat estimates 
that are within 3-4% of criterion values (Houtkooper 1996). The results of the 
measurements are placed in prediction equations that have been validated 
against direct methods (Chumlea and Guo 2002). These equations are 
population specific and assume that body density does not change with age or 
sex. In spite of these assumptions, the FM and FFM estimates obtained 
correlate well to criterion estimates (Zemel 2002). Two terms are often used in 
relation to the fat free tissues; one, 'lean body mass' refers to the fat free mass 
plus 'essential lipids' and the other is 'fat free mass' (FFM) which is the weight 
of all tissues minus the ether extractable fat and is the term that will be used 
here. 
The simplest estimation of body composition is that based on a two-
compartment model and most studies to date have used this (Rolland-Cachera 
1993). In this model the body is divided into fat mass (weight of all extractable 
lipid with ether as the solvent) and the rest are grouped together as the fat free 
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mass. The assumptions involved are that fat mass is anhydrous and has a 
density of 0.9g/cm3 while fat free mass is assumed to have a constant chemical 
composition and have a density of 1.1g/cm3 and water content of 72-74% and 
there is no change with age (Siri 1956). Although there is evidence that this 
assumption holds for fat mass (Guo et al. 1989) which changes little with age, it 
is not valid for fat free mass. Lohman (Lohman 1986) has shown fat free mass 
increases with age since it is dependent on the relative proportion of bone and 
muscle and therefore varies with age, sex, and maturation as well as state of 
hydration (young children have greater body water and therefore a lower body 
density). Density of FFM cannot be measured accurately and is determined 
only by cadaver analysis; it is a function of the relative amounts of water, 
protein and minerals (Weststrate and Deurenberg 1989). Whole body cadaver 
analyses during childhood have not been done (Ellis 2000). 
1.2.4.2 Girls and Boys 
Although total body weight increases from childhood through puberty to 
adulthood (the UK reference (Freeman et al. 1995) shows an average increase 
of 60% from 11 to 18 years in girls and 78% in boys from 12 to 19 years) the 
different components of body composition vary during this time. There is the 
well known decrease in 8MI during childhood until its nadir around the age of 5 
- 6 years before it starts to increase. Fat free mass and fat mass increase 
steadily in girls whereas percent body fat increases overall but may display a 
mid-pubertal dip, overall some observers have stated that percent body fat is 
relatively constant in girls. In the boys, fat free mass increases, fat mass 
increases then appears to decrease during mid puberty before increasing again 
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and percent body fat increases, decreases and then increases again. Boys 
appear to lose fat temporarily and percent body fat progressively decreases. 
The various methods of assessment of body composition and different study 
designs give rise to a variety of results which are often reported in different 
ways. The following tables attempt to summarise some of the literature from 
the past two decades in both sexes but is by no way exhaustive. 
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GIRLS Author Study Method Results 
FFM Buckler 1990 Leeds long, N=102 skinfolds An increase from 24kg at 1 Oy to 39kg at 17y or an increase of 2.3kg/y from 10-17y 
Cameron,Demerath 2002 Citing Forbes 1987 An increase of 16kg from 10 to 20 y Review data 
Guo 1997 Fels long, N=114, 8- hydrodensitometry Mean increase from 24g at 9y to 44kg at 19y 23y 
Ellis 2000 Cross sec, TBW (D20), TBK Increases from 21.3kg at 8y to 45.1 kg at 17y Caucasian N=292 
Lloyd 1998 Penn State DXA Increases steadily from 11 to 18y LonQitudinal N=82 
FM Cameron, Demerath 2002 Citing Roche 95 and Increases at an annual rate of 1.1 kg/yr Review Chumlea 83 
Buckler 1990 Leeds long, N=102 skinfolds Skinfold values increased by 50% 
Guo 1997 Fels, N=114 hyd rodensitometry Mean increases from 6.4kg at 9y to 16.32kg at 19y 
Ellis 2000 Cross sec, TBW (D20), TBK and Increases from 9kg at 8y to 23.5kg at 16y Caucasian N=292 Wt-FFM 
Lloyd 1998 Penn State, 11-18y, DXA Average increase of 6kg from 12-18y fastest velocities before 12y Longitudinal N=82 and after 16v 
PCBF Cameron, Demerath 2002 Citing Roche 95 and Claim there is a general agreement of little or no change in pcbf Review Chumlea 83 
Schaefer 1998 German cross sec, skinfolds Steady increase with age. By puberty, observed 'dip' at stage 3-4 N=2554 6-19y 
Gasser 93,94 Zurich Long skinfolds Quoted by Schaefer as also observing this mid-pubertal 'dip' 
Guo 1997 Fels Long hydrodensitometry Overall mean increase from 20 to 26% from 9 to 19y 
Lloyd 1998 Penn State DXA Decreases between 13.5 and 16y, greatest increases before 12y LonQitudinal N=82 and after 16y 
McCarthy 2006 English cross bioimpedance 50th c increases from 21.2% at 8y to 24.6% at 18y 
sec N=869 5-18.5J1 
Buckler 1990 Leeds long, N=102 skinfolds An increase from 19.6% at 10y to 25% at 17y 
- --
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BOYS Author Study Method Results 
FFM Buckler 1990 Leeds long, N=96 skinfolds An increase from 25kg at 10y to 53kg at 18y or an increase of 3.8kg/y from 10 to 17y 
Cameron,Demerath 2002 Citing Forbes 1987 Increases by 33kg from 10 to 20y, more rapid between 12-15y Review data 
Citing Roche 95 and Chum lea 83 An annual increase of 4.38kg/y 
Guo 1997 Fels long, N=130, 8- hydrodensitometry Mean increase from 24.5kg at 9y to 60.2kg at 19y 23y 
Ellis 2000 Cross sectional, TBW (D20), TBK Increases from 22.7kg at 8y to 61.9kg at 18y total Caucasian N=292 
FM Cameron, Demerath 2002 Citing Roche 96 and An almost unchanging fat mass Chumlea 83 
Buckler 1990 Leeds long, N=96 skinfolds Relative constancy throughout pubertal age range 
Guo 1997 Fels long, N=130, 8- hydrodensitometry An increase from 4.7kg at 9 y to 9.7kg at 19y 23y 
Ellis 2000 Cross sectional, TBW (D20), TBK and Increases from 5.5kg at 8y to 20.2 kg at 13Y,then decreases total Caucasian N=292 Wt-FFM t010.7kg at 16y and plateaus 
PCBF Buckler 1990 Leeds long, N=96 skinfolds Not much change, 17% at 10y, then decreases slightly until16y and then increases to 18.9% at 18y 
Cameron, Demerath 2002 Citing Roche 95 and A decrease of 1.15%/y due to increase in FFM and almost Chumlea 83 unchanging FM 
Schaefer 1998 German cross sec, skinfolds Increases up to 13y, then decreases followed by a small increase N=2554, 6-19y after 16y. Decreases late prepub to G4 and then a slow increase. 
Gasser 93,94 Zurich Long skinfolds Schaefer quotes long Zurich study also reports this mid-pubertal dip 
Guo 1997 Fels long, N=130, 8- hyd rodensitometry Increases from 14.9-17.6% from 8-14y, decreases from 17.6-11.4% 23y from 14-18y and then 11.4-13% from18-20y 
McCarthy 2006 English cross sec, bioimpedance 50
th C relatively flat from 15.6% at 5y to 15.4% at 18y rising to 17.8 
N=869, 5-18.5y % at 10-11 years 
- ---
Table 1.2f, Boys: Summary of selected body composition studies 
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1.2.4.3 Effect of timing of puberty 
Whether the age at onset of puberty affects body composition or conversely 
whether body composition affects the age of pubertal onset has long been an 
area of research. More than 40 years ago Tanner cited a number of 
investigators who observed an association between higher weight for height and 
early maturation (Tanner 1962). The critical weight hypothesis of Frisch and 
Revelle in the 1970's (Frisch and Revelle 1970) suggested that there was a 
direct relation between a 'critical weight' (said to be about 48kg) and menarche. 
They claimed that both early and late maturers would have menarche at the 
same weight. Johnston et al (Johnston et al. 1971) claimed that using mean 
weights for menarcheal age groups led to erroneous conclusions and using a 
multiple regression analysis involving age at menarche, height and weight they 
refuted Frisch and Revelle's hypothesis. Their findings were based on the fact 
that height, weight and age at menarche are interrelated and at a constant 
height, weight and age at menarche are significantly negatively related. 
Forbes (Forbes 1992) pointed out that Frisch et al did not perform any body 
composition analyses but used height and weight to estimate body fat. It is 
clear from the studies on body composition (see previous tables) that there is a 
greater increase in lean tissue than fat tissue in both sexes and thus body fat 
cannot be singled out as the main trigger for the onset of menarche. 
It is well recognised that there is a negative relation between BMI and/or body 
fat and age at menarche (Tanner 1962; Buckler 1990; van Lenthe et al. 1996b) 
but it remains unclear if early adiposity causes an earlier puberty or if an early 
puberty leads to an increase in body fat. Although it has been observed that 
early maturers tend to be heavier than average or late maturers not all 
overweight girls are early maturers. In fact, de Ridder et al (de Ridder et al. 
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1992) found that the age of pubertal onset in a group of 68 girls followed for 3 
years was not related to fat mass. An Australian study using peak height 
velocity as the 'pubertal' marker found no relation to the age of PHV and weight 
or fat mass in either 60 boys or 53 girls studied (Iuliano-Burns et al. 2001) 
Interestingly, the longitudinal study of Biro et al found that 443 girls out of 859 
(51.6%) had an 'asynchronous' pubertal maturation (Biro et al. 2003). They 
used this term to differentiate between those girls who presented with pubic hair 
as their first pubertal sign (adrenarche pathway) or those with breast 
development (thelarche pathway). Their main conclusion was that those girls 
who entered puberty through the thelarche path had greater percent body fat 1 
year before and throughout puberty compared to those who entered through the 
adrenarche path. 
Siervogel et al (Siervogel et al. 2003) analysed menarcheal data from two 
cohorts in the Fels Longitudinal Study; the first was composed of girls born from 
1929 to 1954 and the second group was born between 1955 and 1982. There 
was no difference in the mean stature or the mean age of menarche between 
the two cohorts analysed longitudinally by years from menarche. There was, 
however, a significant difference in BMI from 4 years before menarche to 6 
years after. Their conclusions were that in spite of a significantly greater BMI 
(an indicator of adiposity, albeit imperfect) between the two cohorts, there was 
no change in the rate of growth or sexual maturation (including age at 
menarche). They also found that those children who were more pubertally 
advanced tended to be taller and have a greater percentage of body fat. This 
confirms our clinical impression stated above that adiposity does affect pubertal 
development or rate of growth to the extent that puberty affects growth and body 
composition. 
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1.2.4.4 Sexual dimorphism 
Regardless of the study, the general pattern of body composition change during 
puberty shows that girls have both greater total body fat and percent body fat 
than boys and that this difference increases with age between 10 and 18 years. 
Mean values for height, weight and fat free mass are often not too dissimilar in 
early puberty but from the age of 14 onwards a growing dichotomy occurs as 
the boys overtake the girls. In a recent elegant review Wells discusses the 
sexual dimorphism and says that although it is evident from fetal life it becomes 
apparent during puberty (Wells 2007). 
The weight gain in boys during puberty is primarily due to the great increase in 
the acquisition of fat free mass and a concomitant decrease of percent body fat. 
Girls, on the other hand, have a greater increase of fat mass relative to fat free 
mass. The resulting sexual dimorphism is that young females have 22-24% 
body fat compared to 16-18% in young males. (Cameron and Demerath 2002). 
McCarthy et al (McCarthy et al. 2006) state that at 18 years of age girls have 
proportionately 600/0 more body fat than boys (24.6% vs 15.4%). 
Most of the studies looking at an association of sexual maturity and adiposity 
have been done in girls as detailed above. Wang (Wang 2002), however, 
observed that early maturing boys were less likely to be obese (OR=O.4 (0.2-
0.8)) than their counterparts whereas early maturing girls were twice as likely 
(OR=1.96 (1.11-3.47)) to be obese. 
1.3 Endocrinology of Growth, Puberty and Body Composition 
1.3.1 Adrenarche and the adrenal androgens 
Adrenarche has been defined as the "puberty" of the adrenal gland and is 
characterized by increases in DHEA and DHEAS production from the zona 
reticularis of the adrenal cortex (Ibanez et al. 2000). These hormones are 
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generally referred to as the adrenal androgens because they can be converted 
peripherally to testosterone. They are, however, regarded as androgen 
precursors since they have negligible binding or activating roles with respect to 
the androgen receptors. 
In the 1940's Albright et al coined the term 'adrenarche' to refer to increased 
adrenal androgens and the descriptive clinical term 'pubarche', the appearance 
of pubic hair (Ibanez et al. 2000). Adrenarche occurs between the ages of 6 
and 8 years, approximately two years before gonadal maturation. Grumbach 
and Styne (Grumbach and Styne 2003) have postulated that there may be an 
unknown pituitary hormone that triggers adrenarche or perhaps some internal 
adrenal sensing mechanism that initiates it. 
A number of studies show that adrenal androgens appear to partially control 
skeletal maturation. Jaaskelainen and Voutilainen observed accelerated growth 
in infants and young children with CAH before the initiation of glucocorticoid 
therapy (Jaaskelainen and Voutilainen 1997). Tall stature and advanced bone 
age was observed by Ibanez et al (Ibanez et al. 1992) in 127 girls with isolated 
premature pubarche that was felt to be secondary to increased adrenal 
androgen secretion and a progressive increase in DHEA and DHEAS paralleled 
an increase in skeletal age in normal children in several studies (Reiter et al. 
1977; Sizonenko and Paunier 1986). Androstenedione (A4) , however, does not 
reflect levels of adrenal production since it can be formed peripherally from 
DHEAS as well as from the gonads. Although it has been tempting to try and 
link elevated adrenal hormones at adrenarche to the midchildhood growth spurt 
and to an initiation of pubertal growth there is no definitive data to support either 
of these suggestions. 
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Insulin and leptin have been proposed as triggers for the onset of adrenarche 
(Biason-Lauber et al. 2000) and Tanner (Tanner 1989) suggested that there 
might be some relation to the increase in subcutaneous fat at the age of 
adrenarche. Remer (Remer and Manz 1999) observed that adrenal androgen 
production was related to increases in BMI regardless of age or sex and in 
obese women, DePergola et al (De Pergola et al. 1993) found an association 
between IGF-I and DHEAS. It has since been reported in case control studies 
that IGF-I and insulin are higher in girls (Ibanez et al. 1997; Silfen et al. 2002) 
and boys (Denburg et al. 2002) with premature adrenarche than in controls. 
However, Guercio et al (Guercio et al. 2002; Guercio et al. 2003) observed a 
sexual dimorphism in a study of 61 normal Argentinean girls and 56 boys from 
infancy to post puberty in their observational studies of the relationships 
between BMI, IGF-I, insulin and DHEAS from prepuberty through puberty. A 
positive correlation between IGF-I and DHEAS in the prepubertal but not the 
pubertal girls was seen that was not evident in the boys at any stage. Another 
suggestion has been that insulin or IGF-I increases 17,20 lyase activity and thus 
promotes adrenal androgen production (Zhang et al. 1995). 
Although there have been numerous studies exploring adrenal steroid 
production in children looking for the trigger for adrenarche, many have been 
confounded by cross sectional study and often coincident gonadarche with the 
exception of the studies of Kelnar, Sizoneko and Remer (Sizonenko et al. 1976; 
Kelnar and Brook 1983; Remer and Manz 1999). Palmert et al studied a group 
of girls longitudinally who were being treated for central precocious puberty 
thereby removing possible confounding effects of puberty. They concluded that 
adrenarche may be the result of a 'progressive maturational event not 
characterised by abrupt increases in adrenal production'. 
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1.3.2 Puberty and the Adrenal Androgens 
There is not a great deal of evidence that adrenal androgens play much of a role 
in the onset of puberty or the maturation of the hypothalamic-pituitary-gonadal 
axis in normal children (Grumbach and Styne 2003). It is of interest to note that 
although pubic and axillary hair in girls is thought to be under adrenal androgen 
influence (Sklar et al. 1980), studies using an LHRH analogue have shown that 
some girls with precocious puberty have a regression of their breast 
development as well as that of their pubic hair (Neely et al. 1992). 
Ibanez et al observed that most children with premature adrenarche enter 
puberty at a normal age and have menarche within the normal range (Ibanez et 
al. 1992). Equally children with adrenal insufficiency have been reported to 
have puberty at a normal age and to have a normal pubertal growth spurt 
(Grumbach and Styne 2003). On the other hand, Parker (Parker 1991) 
observed that children with poorly controlled or untreated CAH, had high levels 
of androgens and entered puberty early. From these results it was postulated 
that the adrenal androgens might initiate activation of the hypothalamic-pituitary-
gonadal axis. 
Their role in humans is unclear; however, and although it is not known what 
triggers the adrenarche process (since there is no change in ACTH or cortisol 
secretion at this time), it is felt to be independent of gonadarche (increased 
production of the gonadal sex steroids) (Sklar et al. 1980). 
The presence or absence of adrenarche and its affect on the onset of puberty 
remains controversial. 
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1.3.3 GnRH Pulse Generator 
The medial basal hypothalamus (MBH) contains the LHRH neurosecretory 
neurons that translate neural signals into an oscillating chemical signal (LHRH). 
This MBH complex is referred to as the 'LHRH pulse generator' and releases 
LHRH into the hypothalamic pituitary portal circulation. Thus control of the 
onset of puberty lies in the central nervous system. Studies of Knobil et al 
(Wildt et al. 1980) on immature female rhesus monkeys established that 
pulsatile injections of GnRH was sufficient to initiate ovulatory menstrual cycles 
despite the immature gonad and pituitary and on cessation of the infusion the 
animals reverted to their prepubertal status. 
After the heightened activity of the hypothalamo-pituitary-gonadal axis during 
the first six months of life, there is then a period of relative calm before the 
pubertal avalanche (Conte et al. 1980). In a commentary by Palmert and 
Boepple (Palmert et al. 2001), they pointed out that the change from a quiescent 
state of GnRH production in childhood to the adolescent pattern is not an abrupt 
one but occurs gradually. Citing animal models and human studies they 
suggest that the hypothalamic neurons are synthesising and secreting GnRH 
throughout childhood. Pulses of LH and/or FSH have been seen in children as 
young as 4 years old with the use of highly sensitive immunoassays. The 
predominant night-time secretion changes to daytime as well and the increased 
levels are due to an increase in the amplitude and possibly pulse frequency. 
This latter observation seems to be under debate and may depend on the 
method used. 
Bridges et al (Bridges et al. 1994) studied the pulsatile changes in 24-hour 
profiles of LH and FSH in children aged 4.2-15.6 years. They observed that 
children aged 4.2 to 6.9 years of age had higher baseline levels of LH than 
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those aged 7.1-9.8 years and in both groups pulse frequency was slow. In the 
older pre-pubertal children, they saw an increase in the mean 24-hour 
concentrations of both LH and FSH with changes in LH of increasing amplitude 
(with no baseline change) and increase in LH pulse frequency. They speculated 
that this increase was similar to that seen in the isolated rat hypothalamus 
before puberty (Bourguignon and Franchimont 1984) and might trigger the onset 
of puberty. They did comment, however, that this might also be a response of 
the hypothalamus to changing concentrations of adrenal androgens at this time. 
The answer to what initiates the onset of puberty lies in finding the cause of the 
pubertal increase in the pulsatile secretion of LHRH (which stimulates the 
pituitary to increase its release of LH and FSH). The mechanism for this is still 
elusive although in an extensive review, Terasawa and Fernandez (Terasawa 
and Fernandez 2001) discuss various theories. They reviewed the original 
'gonadostat' or 'differential sensitivity to ovarian steroids' hypothesis that was 
originally proposed more than 50 years ago. This stated that puberty occurred 
when the regulating system for gonadotrophin secretion became desensitised to 
steroid feedback as maturation proceeded and this then permitted 
gonadotrophin secretion. Their suggestion is that the term of 'gonadal steroid 
dependent LHRH increase' coined by Reiter and Grumbach (Reiter and 
Grumbach 1982) most accurately describes the gonadostat theory. This 
suggested that since a smaller amount of gonadal steroids were needed to 
suppress FSH and LH in prepubertal children compared to adults that a gonadal 
steroid dependent increase in LHRH occurs at puberty. It would seem that a 
low level of LHRH maintains a minimum amount of gonadotrophin secretion that 
is subject to the negative feedback of oestrogen and testosterone. The onset of 
puberty then is the result of decreasing sensitivity. In a recent review, Veldhuis 
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et al (Veldhuis et al. 2006) claim that while this theory may be valid in the 
rodent, it does not hold for the monkey or human and to support this statement 
cited studies where a pathological lack of sex steroids did not lead to 'castrata-
like' high levels of gonadotrophins. 
The second hypothesis of 'central inhibition' of GnRH or the 'intrinsic restraint 
concept' refers to the quiescence of the system before puberty independent of 
any negative feedback of gonadal steroids, i.e. a central inhibitory restraint on 
GnRH release. As puberty approaches, this central inhibition is removed or 
decreased allowing an increase in the amplitude and frequency of GnRH. 
1.3.4 Growth Hormone 
1.3.4.1 Growth and Puberty 
Finkelstein and colleagues did one of the earliest studies on the dynamic 
secretion of GH in 1972 (Finkelstein et al. 1972). They performed 24-hour 
overnight studies with 20 minute sampling and demonstrated the episodic 
release as well as the pubertal increase in the pattern of GH secretion. This 
pubertal increase has since been substantiated by numerous authors (Miller et 
al. 1982; Mauras et al. 1987; Blizzard et al. 1989; Martha et al. 1989; Edge et al. 
1990). The increase in the secretion of growth hormone happens as a result of 
a change in the amplitude of the GH pulse whereas its periodicity of 180-220 
minutes remains unchanged (Mauras et al. 1987; Hindmarsh et al. 1988b; 
Blizzard et al. 1989; Edge et al. 1990). Rose et al (Rose et al. 1991) 
corroborated these findings by performing 24-hour GH profiles, bone ages and 
pubertal assessments on 132 normal children and adolescents. They found that 
GH levels increased in girls earlier than boys and that this was most evident at 
night and that this increase was as a result of an increase in pulse amplitude 
and not pulse frequency. They divided their prepubertal girls into two groups, 
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those less than 8 years and those 8-10 years, it is of interest to note that they 
saw an increase in GH in the latter group before there was any clinical signs of 
puberty. The earlier pubertal rise in GH in girls compared to boys reflects the 
close temporal relationship to the adolescent growth spurt. 
Numerous studies have shown that the 2-3-fold increase in GH secretion during 
puberty is paralleled by an acceleration of growth (Hindmarsh et al. 1988b; 
Stanhope et al. 1988; Edge et al. 1990; Delemarre-van de Waal et al. 2001). In 
the study of Edge et al (Edge et al. 1990) all measures of pulse height of GH 
were at their maximum at breast stages 2-3 in the girls and genital stages 4--5 
in the boys corresponding to the adolescent growth spurts in each sex. 
Veldhuis et al (Veldhuis et al. 2000) addressed the question of sex differences 
using overnight 12-hour profiles sampling at 10-minute intervals in prepubertal 
and late adolescent (stage 4 and 5) youngsters. GH pulsatility was observed in 
both prepubertal and pubertal subjects of both sexes. There was a greatly 
heightened increase in the secretory burst mass of GH in the adolescents, 
which the authors were able to break down as due to an increase in both 
amplitude and duration. The main sex difference was the disorderliness of the 
GH patterns in the late adolescent girls. 
1.3.4.2 Body Composition 
An inverse relationship of weight or obesity to GH secretion during puberty has 
been observed by some researchers (Loche et al. 1987; Martha et al. 1993; 
Albertsson-Wikland et al. 1994). A more recent report by Roemmich et al 
explored GH secretory dynamics with 12 hour overnight profiles in lean and 
overweight subjects both prepubertal and pubertal (Roemmich et al. 2005). 
Using deconvolution analyses to quantify GH secretory events, they concluded 
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that there was a lower mean GH concentration in overweight subjects due to a 
decrease in amplitude with no effect on frequency. 
A sex difference in this relationship in normal children was seen by Rose et al 
(Rose et al. 1991) who observed it in girls but not boys. They used body mass 
index (BMI) expressed as an SO score and found a significant negative 
correlation in the girls that was most marked from stages 3 to 5. The greater fat 
mass that the girls accrue during puberty was felt to be responsible for this sex 
difference. 
The relationship between body fat and GH is seen in growth hormone deficient 
children and adolescents who often have increased body weight with central 
adiposity in relation to their height. Treatment with GH has been shown to result 
in a decrease in fat mass and increased lean mass (Carroll et al. 2004; Gleeson 
et al. 2007). 
1.3.5 Insulin-like Growth Factor I (IGF-I) 
1.3.5.1 Growth and Puberty 
It has long been accepted that most of the postnatal growth promoting effects of 
growth hormone are mediated by insulin like growth factor-I (IGF-I) (Salmon and 
Oaughaday 1957; Oaughaday 1997; Salmon and Burkhalter 1997). IGF-I, a 
peptide of 70 amino acids, is produced predominantly by the liver but also by a 
variety of other tissues where it can act in an autocrine, paracrine or endocrine 
manner. It has a high degree of structural homology to both proinsulin and 
insulin and has short-term metabolic effects and long-term growth effects. 
There are no identifiable tissue stores of IGF-I and although it is produced by a 
number of different tissues, the liver is the main source. It circulates largely 
bound to one of the six binding proteins that modulate its activity and this 
binding protein (IGFBP- 3) binds more than 95% of IGF-I. This dimer forms a 
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ternary complex with the acid labile subunit (ALS) and acts as a circulating 
reservoir of IGF-I with a half-life of several hours (Le Roith 1997). IGF-I acts on 
almost every organ in the body and plays a prominent role in postnatal growth. 
The actions of IGF-I are mediated through the IGF-I receptor which is 
structurally similar to the insulin receptor and although IGF-I can bind to the 
insulin receptor it does so with a lower affinity than insulin (Neely et al. 1991; 
LeRoith et al. 1994). 
In the 1980's, studies by Luna et ai, Pescovitz et ai, Rubin et al and Cara et al 
(Luna et al. 1983; Pescovitz et al. 1985; Rubin et al. 1986; Cara et al. 1987) 
demonstrated that serum levels of IGF-I were low in childhood and rose 
gradually with a steep increase during puberty. The obvious question was 
whether this pubertal increase in IGF-I played a role in the pubertal growth 
spurt. The data, however, is difficult to untangle, Pescovitz et al studying 
children with central precocious puberty observed that growth velocity levels 
returned to normal prepubertal growth rates after treatment with a GnRH 
analogue but that levels of IGF-I were only marginally decreased (Pescovitz et 
al. 1985). Cara et ai, in a small longitudinal study, observed that the peak in 
IGF-I levels occurred approximately 1 year after peak height velocity (Cara et al. 
1987). Juul (Juul et al. 1994) in a large cross sectional study reported that the 
peak occurred at about 14.5 years in girls and 15.5 years in boys and then 
slowly returned to prepubertal levels. 
Both Juul et al and Lofqvist et al were able to observe an age dependency 
within pubertal stages and saw a positive relationship between age and IGF-I 
levels in early puberty although a negative one in late puberty (Juul et al. 1994; 
Lofqvist et al. 2001). Lofqvist observed a sex difference in midpuberty with the 
girls showing no age effect while the boys still demonstrated a positive age-IGF-
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I relationship. It would appear that the change from a positive relationship to a 
negative one between IGF-I and age or height velocity occurs since height 
velocity decreases in mid to late puberty while IGF-I levels are still increasing. 
Since levels of IGF-I remain high while the growth velocity is decreasing this 
would appear to support the suggestion for a further role for IGF-I in the 
continuing post pubertal growth that occurs in cortical bone, muscle and adipose 
tissue (Cara et al. 1987). 
IGF-Ilevels displayed a significant sex difference (girls >boys) in pubertal 
children but not prepubertal ones in the data of Juul (Juul et al. 1994). Lofqvist 
et al examined this more closely by looking at older (>8y) prepubertal children 
(Lofqvist et al. 2001) where they did observe a sex difference as well as one in 
those in puberty. The small study (12 boys and 8 girls) by Cara et al (Cara et al. 
1987), however, reported no difference in the peak IGF-I values between the 
sexes. 
Studies on pubertal children of both sexes have demonstrated a correlation 
between IGF-I levels and sex steroids (Juul et al. 1995; Lofqvist et al. 2001; 
Clayton and Hall 2004). It is known that gonadal steroids increase the pulsatile 
secretion of GH (Ho et al. 1987) and that GH is correlated to IGF-I. The 
stimulation of IGF-I by gonadal steroids is thought to be indirect, primarily 
through increased GH secretion (Harris et al. 1985; Juul et al. 1995). In a study 
of 10 boys with hypopituitarism, Mauras et al reported an increase in IGF-I 
levels with testosterone treatment that was increased 3 times with the addition 
of GH (Mauras et al. 2003). The study of the interaction of sex steroids and the 
IGF-I/GH axis has been complicated by the fact that sex steroids can act directly 
on the growth plate. This has been demonstrated in the study of Attie et al on 
children with central precocious puberty (CPP) and GHD; the results after 
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treatment with a GnRH analogue showed that although growth velocity 
decreased, IGF-Ilevels were not much altered (Attie et al. 1990). However, Juul 
et al studying children with CPP compared the use of a GnRH analogue and a 
combination of a GnRH analogue with an anti androgen (cyproterone acetate, 
CP) (Juul et al. 1995). Although the progress of puberty was halted with the 
suppression of the gonadotrophins as well as a decrease in growth velocity, 
they showed no effect on IGF-Ilevels (in agreement with Attie et al) with the 
analogue alone although there was an increase in IGFBP-3. This led to the 
speculation that the decrease in velocity might be due to a decrease in the 
biologically 'free' IGF-I. Treatment with both the analogue and CP resulted in a 
decrease of both IGF-I and IGFBP-3. Height velocity was correlated to IGF-I 
and IGFBP-3 and not E2 in these children with precocious puberty. 
High doses of E2 have been shown to decrease IGF-Ilevels in tall girls by 
speeding up epiphyseal closure leading to a reduction in final height (Rooman et 
al. 2005). The results of a study by Coutant et al in children 8-16y exploring the 
effects of high doses of oestradiol on IGF-I concentrations in 14 girls with 
delayed puberty observed an inhibition in the responsiveness to GH although 
they observed the usual increase in IGF-I from pre- to mid-puberty. Thus they 
reinforced the concept that low doses of oestrogen, as seen in the early stages 
of puberty, stimulate responsiveness of IGF-I to GH whereas high 
concentrations could inhibit responsiveness (Coutant et al. 2004). Testosterone 
priming in 14 delayed boys in this study was seen to not change the 
responsiveness of IGF-I to GH stimulation. 
In elderly adults, Veldhuis et al reported that testosterone increased levels of 
IGF-I compared to a placebo in men and oestradiol lowered IGF-I levels in 
postmenopausal women (Veldhuis et al. 2005). 
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There are obviously factors involved in the modulation of IGF-I other than the 
sex steroids. In a review by Clayton and Hall (Clayton and Hall 2004) a number 
of regulators of IGF-I (both general and hormonal) are cited; they include: age, 
gender, puberty, nutritional status, body composition, IGF binding proteins, GH, 
testosterone, oestradiol, thyroxine, cortisol and insulin. 
1.3.5.2 Body Composition 
Nutritional status is an important regulator of IGF-I; subjects with anorexia 
nervosa and girls, whose intensive training as gymnasts or ballerinas might put 
them in negative energy balance, have low IGF-I levels. Argente et al found low 
levels of IGF-I and IGFBP-3 in a group of girls with anorexia and with either high 
or low levels of GH suggesting that the low IGF-I was due to nutrition and not 
GH levels (Argente et al. 1997). Both Juul et al and Wilson et al looked at the 
relationship between body composition and IGF-I levels in healthy normal 
prepubertal children (Wilson et al. 1991; Juul et al. 1994). Using body mass 
index (BMI) as a surrogate for body composition, neither found a significant 
relationship between IGF-I and BMI. Ong et al (Ong et al. 2002), however, 
employing more sensitive indicators of body composition in a large longitudinal 
cohort of 497 five year olds observed a significant correlation between IGF-I 
levels and both fat mass (p<0.05) and fat free mass (p<0.0005). They also saw 
an association between IGF-Ilevels at five years of age and weight gain 
between 0 and 2 years of age and speculated whether the effects of early 
nutrition were mediated through IGF-I to affect later growth and maturation. 
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1.3.6 Insulin 
1.3.6.1 Growth and Puberty 
Insulin is synthesised in the pancreatic beta cells as proinsulin and then cleaved 
to form insulin and C peptide (Steiner et al. 1967). It circulates in picomolar 
concentrations and has a half-life of minutes. Insulin acts on the liver, muscle 
and adipose tissue. 
It has long been known that plasma concentrations of insulin increase with age 
(Grant 1967) however, it is puberty rather than age that is the key factor in this 
increase (Lautala et al. 1985; Smith et al. 1988). Fasting insulin levels were 
seen to be highest in puberty stages 4-5 in the study of Smith et al with no 
difference between boys and girls (Smith et al. 1988). Insulin is known to have 
growth promoting effects, Hindmarsh et al observed a linear relationship 
between height velocity and fasting insulin levels in normal children and noted 
that the doubling of growth velocity at puberty is accompanied by a 2 to 3 fold 
increase in insulin (Hindmarsh et al. 1988c). 
Amiel et al (Amiel et al. 1986) and Bloch et al (Bloch et al. 1987) independently 
were the first to demonstrate that it was the hormonal and physical changes of 
puberty itself that played a role in the insulin resistance seen in adolescents. 
Using the euglycaemic hyperinsulinaemic clamp technique they showed a 
reduction in insulin mediated glucose metabolism during normal puberty 
compared to prepubertal children and adults. Bloch had also observed an 
increased insulin response to an oral glucose tolerance test in pubertal children 
compared to prepubertal ones. 
To assess the effects of insulin on protein metabolism, Amiel and Caprio et al 
(Amiel et al. 1991) used the euglycaemic hyperinsulinaemic clamp technique 
and observed that the insulin resistance selectively affected peripheral glucose 
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metabolism, there was no resistance to the anabolic effects of insulin. 
Confirming this a few years later, Caprio et al using an infusion of labelled 
leucine also found a reduction in insulin stimulated glucose uptake in pubertal 
compared to pre pubertal children and adults but observed no effect of this 
normal pubertal insulin resistance on insulin stimulated protein metabolism 
(Caprio et al. 1994). 
The compensatory increase in insulin secretion, that maintains glucose 
homeostasis during puberty, in the face of the insulin resistance, was 
demonstrated by the hyperglycaemic clamp technique (Caprio et al. 1989). 
Caprio et al showed that there was a 2-3 times increase in the insulin responses 
in pubertal subjects compared to adults (Caprio 1999). They corroborated the 
earlier conclusions of Holly (Holly et al. 1989) that the insulin resistance of 
puberty results in a compensatory hyperinsulinaemia and thus a decrease in 
IGFBP-1 levels that in turn increases the bioavailability of free IGF-I and thus 
insulin modulates pubertal growth. 
1.3.6.2 GH and Insulin sensitivity 
These pubertal changes occur at the same time as the pubertal increase in 
growth hormone and the antagonistic effects of growth hormone on insulin are 
well known (Rizza et al. 1982). A number of studies have suggested a causal 
relation of the rise of growth hormone and the insulin resistance and 
hyperinsulinaemia of puberty (Amiel et al. 1986; Smith et al. 1988; Edge et al. 
1990; Savage et al. 1992). Amiel et al observed that the response to insulin 
during a euglycaemic insulin clamp was inversely related to the 24 hour GH 
level but not with the level of IGF-I in all the children (Amiel et al. 1986; Amiel et 
al. 1991). Changes in insulin concentrations during puberty and their 
relationship to growth hormone were studied by Hindmarsh et al who saw the 
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highest levels of insulin in those children who had the highest growth hormone 
levels on 24 hour testing (Hindmarsh et al. 1988a). Although it seems 
contradictory that at a time of rapid growth there should be an antagonistic 
conflict between these two anabolic hormones, it has been suggested that the 
compensatory hyperinsulinaemia may enhance the anabolic effects of GH, IGF-I 
and sex steroids on protein metabolism during pubertal growth (Mauras et al. 
1996). 
1.3.6.3 Insulin Resistance of Puberty 
In a large cross sectional study on 357 normal children aged 10-14 years of 
age, (encompassing all five puberty stages), Moran et al (Moran et al. 1999), 
using the euglycaemic clamp technique, reiterated that insulin resistance was a 
transient event of normal puberty. They observed an increase in resistance at 
the beginning of puberty that peaked at stage 3 in both sexes and returned to 
near prepubertal levels by stage 5. Girls were more insulin resistant at all 
stages than boys and insulin resistance was strongly associated with 8MI, 
triceps skinfold measurement and waist circumference. This relationship was 
independent of sex or pubertal stage; however, the sex difference was only 
partially explained by differences in adiposity. Insulin resistance was related to 
both 8MI and adiposity in each of the pubertal stages but factors other than 
body composition were felt also to be part of the explanation of the insulin 
resistance of puberty. 
Other hormonal influences (in addition to the previously mentioned GH) on 
insulin and insulin resistance during puberty have been addressed by a number 
of investigators. Smith et al found a positive correlation between IGF-I and 
insulin throughout childhood and puberty in normal subjects (Smith et al. 1989). 
They conjectured whether this relationship was related to changes in the 
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pulsatile release of growth hormone. Independently of growth hormone, 
however, IGF-I and insulin and their receptors have a high degree of sequence 
homology (Neely et al. 1991; LeRoith et al. 1994). 
1.3.6.4 Insulin resistance and IGF-I 
Caprio et al were the first to suggest that there might be a relation between the 
insulin resistance of puberty and IGF-I levels (Caprio et al. 1989). Moran et al 
on their large number of children who had euglycaemic clamps were able to 
investigate this across the whole pubertal range on 342 subjects (Moran et al. 
2002). They found that the pattern of change of IGF-I was similar to that of 
insulin resistance during puberty. They found an association of IGF-I with 
fasting insulin that was different between the sexes; was related to adiposity in 
the girls but not the boys, and was stronger in the thinnest girls. When the 
relation between insulin and insulin resistance (as assessed by the clamp 
method) was examined it was observed that a significant relation existed 
between the two in both sexes and it was independent of adiposity (although 
hyperinsulinaemia was dependent on body fat). 
The longitudinal study of Hoffman showed insulin sensitivity greater in pre and 
early pubertal boys compared to girls and the girls compensated with higher 
insulin responses (Hoffman et al. 2000). 
1.3.6.5 Body Composition 
8MI and body fat increase during puberty and there are numerous studies to 
show that body fat is associated with insulin resistance during puberty (Bloch et 
al. 1987; Cook et al. 1993; Travers et al. 1995; Arslanian and Suprasongsin 
1996; Caprio et al. 1996; Gower et al. 1999; Travers et al. 2002). This may only 
be part of the picture, however, since Cook et al observed that insulin resistance 
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could occur in puberty without an increase in BMI and it has been observed that 
young adult women, who may have more body fat than pubertal girls, are more 
insulin sensitive (Amiel et al. 1986; Caprio et al. 1989). It appears, however, 
that there may be a different relationship of body composition to insulin 
operating in children compared to adults. This relates to the question of 
whether insulin resistance plays a causal role or is a consequence of fat gain. 
Studies on 2 groups of children favoured the theory that hyperinsulinaemia and 
insulin resistance favoured fat gain in childhood and puberty but opposed it in 
adults (Maffeis et al. 2002). In one longitudinal study of 137 children (mean 
baseline age of 8.1 years) followed for 3-6 years and seen annually by Johnson 
et al (Johnson et al. 2001), changes in body fat mass were associated with 
changes in insulin parameters over time. An increase in total fat mass of 15.6% 
I year that was not influenced by sex or puberty stage was observed and both 
initial fasting insulin and the acute insulin response to an IVGTT had a positive 
effect and insulin sensitivity (assessed by Bergman's 'minimal model') a 
negative effect on the increase in fat mass. Thus, high fasting levels of insulin 
and a high acute insulin response plus low insulin sensitivity were associated 
with increased rates of fat gain during early puberty. This study was in some 
contradiction to the generally regarded view (Rico et al. 1993; Travers et al. 
1995; Moran et al. 1999) that girls gain more fat mass during puberty than boys, 
have a higher fat to lean ratio and generally a higher insulin resistance (partially 
explained by the adiposity difference). 
1.3.6.6 Androgensl Sex Steroids 
Bloch observed a negative relation between insulin sensitivity and DHEAS and 
thought that adrenarche might be an early predictor of insulin sensitivity (Bloch 
et al. 1987). Smith et al found a positive relationship between DHEAS and 
42 
fasting and stimulated insulin levels in the combined pre and pubertal groups; 
however, in the prepubertal group assessed alone they found no relationship 
and concluded that adrenarche is not associated with increased insulin levels 
before puberty (Smith et al. 1989). Caprio et al did not find any relation between 
DHEAS and insulin response to the hyperglycaemic clamp causing them to 
conclude that a direct effect of sex steroids was unlikely (Caprio et al. 1989). 
Wickman et al when treating a group of boys with constitutional delay of puberty 
with testosterone and an aromatase inhibitor (which prevents the conversion of 
androgens to oestrogens) observed a decrease in insulin, a five-fold increase in 
testosterone (over placebo group), and no change in 17-Q, oestradiol or IGF-I. 
This contrasted with the results in a second group who were treated only with 
testosterone and had no change in insulin levels but an increase in the 
concentrations of 17 -Q, oestradiol and IGF-I. They found that the changes over 
12 and 18 months in insulin and IGF-I were correlated. They concluded that this 
demonstrated that androgens had no direct effect on insulin sensitivity in early-
mid puberty (Wickman et al. 2002). In an earlier study of delayed boys, 
Arslanian et al had also seen no deterioration of insulin action with testosterone 
treatment (Arslanian and Suprasongsin 1997). To try and tease out the effect of 
sex steroids on insulin sensitivity without the influence of growth hormone, Saad 
et al used dihydrotestosterone (DHT) in boys with delayed puberty (Saad et al. 
2001). DHT is a nonaromatizable androgen that has been shown to increase 
height velocity without an increase in growth hormone (Keenan et al. 1993; 
Eakman et al. 1996). Ten boys were studied for 4 months before and after 
treatment with DHT: height, weight and fat free mass increased while 
percentage body fat decreased but there was no change in insulin stimulated 
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glucose metabolism. Again the conclusion here is that insulin resistance during 
puberty is not attributed to gonadal sex steroids in boys. 
1.3.7 Sex Hormone Binding Globulin (SHBG) 
1.3.7.1 Description 
SHBG is a circulating glycoprotein synthesized in the liver, with a high binding 
affinity to both 17-[1 oestradiol and testosterone, whose biological function is the 
transport of these two sex steroids in the circulation. Less than 2% of sex 
steroids are 'free' in the circulation, the rest are bound to carrier proteins the 
most abundant of which are albumin and SHBG. About 44% of testosterone in 
adult males and 66% in women is bound to SHBG, whereas 20% of oestradiol 
in men and 37% in women is bound to SHBG (Bolton 1984). 
1.3.7.2 Puberty and Sex Steroids 
During puberty a decrease in the levels of SHBG has been observed in both 
sexes (Bartsch et al. 1980; Apter et al. 1984; Maruyama et al. 1987; Holly et al. 
1989; Blogowska et al. 2003) at a time when there is a concomitant rise in 
oestrogen and testosterone. Although it has generally been shown that a 
degree of regulation of SHBG appears to be by sex steroids, with oestrogens 
having a stimulating effect (Kalme et al. 1999) and androgens an inhibiting one 
(Anderson 1974) this is not universally observed and there are differences 
reported between in vivo and in vitro studies. 
In a cross sectional study of 69 adolescents, Holly et al observed a reduction in 
SHBG that was inversely correlated to the increase in testosterone, DHEAS and 
androstenedione in the boys although only to DHEAS levels in the girls while no 
relationship between SHBG and oestrogen was found in either sex (Holly et al. 
1989). In a more recent and larger study (903 subjects) Sorensen et al 
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confirmed the negative association of SHBG with testosterone and DHEAS but 
also with oestradiol as well in boys and only with DHEAS in girls (Sorensen et 
al. 2007). Kim et ai, in a study of 77 boys 1 0-18years old, saw a decrease in 
SHBG from puberty stage 1 to 2 then a slight increase which plateaued through 
to stage 5 (Kim et al. 1999). 
Although sex steroids are involved in the regulation of SHBG, it can be seen 
from the above studies that although there were increasing levels of sex 
steroids they did not in themselves determine SHBG levels. Of the other factors 
involved, it has been shown that thyroid hormone (Yosha et al. 1984); insulin 
and IGF-I play vital roles as well. 
1.3.7.3 Relation to Insulin and IGF-I 
Strong negative correlations have been found to exist between the falling SHBG 
levels and rising insulin concentrations in both sexes during puberty as well as a 
negative relationship between SHBG and IGF-I in boys (Holly et al. 1989). 
Singh et al 1990 using cultured human hepatoma cells confirmed the inhibitory 
effect of both insulin and IGF-I on SHBG (Singh et al. 1990). This was thought 
to show the effect of dietary factors as mediated through IGF-I on SHBG. This 
may tie in with the observations by Kim et al on the interrelationships of BMI, 
insulin and SHBG during puberty. They suggested that the inverse association 
of SHBG and BMI from puberty stage 1 to 3 might play an important role in the 
regulation of SHBG during early puberty via body fatness and thus insulin 
sensitivity (Kim et al. 1999). 
Kalme et al (Kalme et al. 2003) using human hepatoma cells (which secrete 
SHBG) demonstrated that insulin inhibited production of SHBG at 48 hours by 
about 35% whereas IGF-I reduced the levels of SHBG levels after only 6 hours 
incubation by 24%. An earlier study in 1995 by Loukovaara et al also produced 
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a reduction by insulin after 48 hours incubation that resulted in a greater effect 
than IGF-I in lowering the levels of SHBG (Loukovaara et al. 1995). An in vivo 
study by Strain et al during weight loss in men found that the relationship 
between insulin and SHBG was remarkably constant despite the changes in the 
individual relationships of insulin and BMI to SHBG. They concluded that the 
inverse association points to the fact that insulin controls SHBG in man (Strain 
etaI.1994). 
Several researchers have investigated the suggestion that SHBG could be a 
marker for hyperinsulinaemia. Most relevant to us is the work of Galloway et al 
(Galloway et al. 2001) looking at prepubertal children to see if SHBG could be a 
predictor of hyperinsulinaemia and thus target vulnerable children who may be 
at risk for premature onset of the metabolic syndrome and consequent 
cardiovascular problems. 
1.3.7.4 Body Composition 
Sorensen et al (Sorensen et al. 2007) in a large cross sectional study of 903 
children confirmed many previous reports of a negative correlation of SHBG and 
measures of body composition. This negative relationship remained even after 
adjusting for testosterone, oestradiol and DHEAS. 
Kim et al found an inverse relationship of BMI and SHBG in boys in early -mid 
puberty (stages 1 to 3) (Kim et al. 1999). This is at a time when the insulin 
resistance of puberty is high and lends support to the theory that body fat, 





Zhang et al working with the ob/ob mouse discovered the gene encoding for the 
16-kda peptide, leptin, secreted by adipocytes and thought to act primarily 
through specific receptors at the level of the hypothalamus (Zhang et al. 1994). 
In the mouse, leptin has effects on appetite, energy expenditure and the neuro-
endocrine axis (Maffei et al. 1995; Stephens et al. 1995; Vaisse et al. 1996). In 
humans, congenitalleptin deficiency and mutations in the human leptin receptor 
gene result in severe obesity (Montague et al. 1997; Clement et al. 1998; Strobel 
et al. 1998). It is unknown if the normalleptin level variation merely reflects fat 
mass or determines future fat mass accumulation (Qureshi and Kopelman 
1997). Longitudinal study of Japanese Americans indicated that higher baseline 
plasma leptin levels in a study of Japanese Americans were associated with fat 
accumulation (Chessler et al. 1998) whereas studies in the Pima Indians 
observed that low leptin levels predicted subsequent weight gain (Ravussin et al. 
1997). 
1.3.8.2 Puberty 
Work in mice and rats led to the hypothesis that leptin could have a role in 
pubertal development (Ahima et al. 1997; Chehab et al. 1997; Cheung et al. 
1997). Other animal studies also indicate that leptin signalling results in 
interaction with hypothalamic neurotransmitters, principally neuropeptide Y 
(Stephens et al. 1995; Rohner-Jeanrenaud et al. 1996), and this may influence 
gonadotrophin secretion. In the human subjects with leptin deficiency or 
receptor mutations, there was no initiation of puberty or establishment of 
secondary sexual characteristics (Clement et al. 1998; Strobel et al. 1998). It is 
not clear whether the accumulation of fat mass, leading to a permissive leptin 
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signal, is required for the initiation of puberty or whether dynamic short term 
changes in leptin levels result in pubertal development (Apter 1997). 
Leptin levels in pre-pubertal children were no different in boys and girls (Blum et 
al. 1997; Carlsson et al. 1997; Clayton et al. 1997; Garcia-Mayor et al. 1997). 
Clayton et al. reported a gradual increase in leptin concentrations in pre-
pubertal children aged 5-9 years. A longitudinal study in 8 boys by Mantzoros et 
al suggested that there might be a brief pulse of leptin preceding the onset of 
puberty this however, has not been observed in other studies (Mantzoros et al. 
1997). A sexual dimorphism in leptin levels occurring during puberty with an 
increase in girls and a decrease in boys has been observed in a number of 
cross sectional studies (Blum et al. 1997; Carlsson et al. 1997; Clayton et al. 
1997; Garcia-Mayor et al. 1997). These differences may be partly explained by 
differences in body mass index or hormone levels (Blum et al. 1997; Wabitsch 
et al. 1997). Unfortunately better estimates of fat mass were only available in a 
minority of the subjects studied and the cross-sectional design of most of the 
studies would not allow a true picture of associations with puberty stage and 
pubertal hormone levels. 
An early puberty or menarcheal age has long been associated with greater 
gains in weight during childhood (Stark et al. 1989; Beunen et al. 1994; van 
Lenthe et al. 1996a; Wattigney et al. 1999; Adair 2001; Cameron and Demerath 
2002; Tam et al. 2006). The original proposal of Frisch and Revelle (Frisch and 
Revelle 1971) that a 'critical weight' (48kg) is needed for the initiation of puberty 
provoked much controversy. Delemarre-van de Waal (2002) quoting Ruf from 
1973: "how can the brain be informed of the nutritional state of the organism and 
how can it 'know' when to initiate puberty" (Delemarre-van de Waal 2002). 
Twenty years later the discovery of leptin gave credence to the idea of a 
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'sensor' of body fat levels that feeds back to the hypothalamus to activate 
central gonadotrophin secretion. Studies of leptin replacement for congenital 
leptin deficiency (Strobel et al. 1998) and in several animal models, Cheung et 
al (Cheung et al. 1997) suggest that leptin is the permissive signal. However, 
although overweight children tend to have an earlier puberty, they do not 
invariably have precocious puberty and so the permissive effect of leptin must 
also be linked to other maturational events in the hypothalamus. 
1.3.8.3 Body Composition 
The characteristic sex-specific changes in body composition where gains in fat 
mass are greater in girls and gains in fat free mass greater in boys that 
becomes obvious at puberty has been long known (Forbes 1978). In the 
longitudinal study of Ahmed et ai, these differences in body composition during 
puberty were also observed (Ahmed et al. 1999). The pubertal divergence in 
leptin levels between the sexes may be attributed to the differences in this 
acquisition of adult body composition (Blum et al. 1997; Carlsson et al. 1997; 
Clayton et al. 1997; Garcia-Mayor et al. 1997). Ahmed et al (Ahmed et al. 1999) 
observed similar relations between leptin and body composition in each sex; 
allowing for fat free mass, fat mass was positively related to leptin and allowing 
for fat mass, fat free mass negatively related to leptin levels. Together, fat mass 
and fat free mass accounted for 54% of the variance in leptin levels in boys, and 
31 % in girls. Fat mass is a major source of circulating leptin (Zhang et al. 1994) 
and thus a close relationship with leptin levels is expected, however the 
negative relationship with fat free mass is unexplained and may relate to parallel 
effects of other hormones on both leptin production and the acquisition of fat 
free mass. 
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1.3.9 Sex Steroids 
1.3.9.1 Testosterone 
1.3.9.1.1 Description 
Testosterone is produced by the Leydig cells of the testes and is the main sex 
steroid of male sexual development. A small amount is also derived from 
conversion of androstenedione secreted by the testes and adrenals. In girls, 
almost all the circulating testosterone is from the conversion of ovarian and 
adrenal androstenedione. Prepubertal children of both sexes have undetectable 
levels of plasma testosterone although a diurnal rhythm has been shown to exist 
in boys as young as 4-5 years old (Mitamura et al. 1999), well before any 
pubertal signs. Detectable increases in daytime testosterone levels in boys 
usually begin about the age of 11 years corresponding to a testis volume of 4 
mls and then continue to increase throughout puberty. In girls, \londo et al 
(\londo et al. 1982) observed a peak and plateau of testosterone in girls at stage 
3 (pubic hair). 
1.3.9.1.2 Growth and Puberty 
It has long been thought that testosterone was the main hormone in boys 
responsible for acting in concert with GH during the pubertal growth spurt and 
for fusion of the epiphyses. Testosterone administration to prepubertal subjects 
has been shown to increase GH secretion (Illig and Prader 1970; Martin et al. 
1979). Preece and colleagues (Preece et al. 1984) in a longitudinal study of 
male puberty found a significant relationship of height velocity and levels of 
testosterone in puberty stages 1-3 and a negative one in stages 4 and 5. The 
most dramatic increase in testosterone was observed to be around the year of 
the pubertal growth spurt suggesting the importance of testosterone in this 
event. Zemel and Katz (Zemel and Katz 1986) in a three year mixed 
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longitudinal study of 181 boys observed similar relationships. Delemarre-Van 
de Waal et al in two short longitudinal study over one year observed an increase 
in testosterone levels in boys from stage 2 and then an even greater increase 
from stage 3 to 4 corresponding to the timing of the growth spurt (Delemarre-
van de Waal et al. 2001). 
Testosterone increases growth hormone secretion by an increase in pulse 
amplitude (or area under the curve) (Link et al. 1986; Martha et al. 1989) and 
also acts directly on the growth plate (Corvol et al. 1987). Keenan et al showed 
that whereas testosterone increased growth hormone (by its aromatization to 
E2) and growth velocity in short boys with constitutional delay; DHT, a 
metabolite of testosterone and a non-aromatizable androgen, also accelerated 
growth velocity in the face of a 500/0 decrease of GH and it was felt that this 
effect was directly on the epiphyseal chondrocyte (Keenan et al. 1993). 
In order to achieve an optimal pubertal growth spurt, it is necessary to have 
normal levels of testosterone. Untreated hypogonadal subjects (Uriarte et al. 
1992), extremely late maturing boys (Hagg and Taranger 1991) and boys with 
Klinefelters syndrome (Smals et al. 1974) have only a small growth spurt 
although they eventually attain a normal or even tall stature. In the absence of 
gonadal steroids, a taller stature may be achieved since epiphyseal closure will 
be delayed. In studies where growth was compared in children with both GH 
and gonadotrophin deficiency compared to those with just GH deficiency, it was 
observed that in the first group the double deficiency gave better growth results 
(Burns et al. 1981; Hibi et al. 1989). Current research and clinical practise has 
included treatment of children with a GnRH analogue to try and reverse puberty 
to increase growth and in some instances combining this with GH although 
controversy exists about the efficacy of this treatment (Carel et al. 2004). 
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1.3.9.1.3 Body Composition 
The increase in lean body mass that occurs in boys during puberty is a direct 
consequence of increasing levels of testosterone. Direct evidence comes from 
clinical work with delayed puberty; Arslanian and Suprasongsin gave low dose 
testosterone for four months to boys with delayed puberty that led to an 
increase in fat free mass and a decrease in fat mass (Arslanian and 
Suprasongsin 1997). Other clinical examples to support this include (1) studies 
on replacement doses of testosterone given to hypogonadal men result in an 
increase in fat free mass as well as muscle size and strength (Bhasin et al. 
1997), (2) studies in women with CAH or those given exogenous androgens 
develop a more male - like fat pattern with greater central fat distribution, and 
(3) women with androgen producing tumours develop a virilised body 
composition with an increase in lean mass (Rosenbaum and Leibel 1999). 
1.3.9.2 Oestrogen 
1.3.9.2.1 Description 
Oestradiol is the principal oestrogen produced by ovarian granulosa cells in 
females and circulates bound to SHBG. Estrone is the next most abundant and 
results from conversion from androstenedione. In males, the testes secrete a 
small amount of oestradiol but most of the oestrogen in males comes from 
peripheral conversion (mainly in adipose tissue) of testosterone to oestradiol 
and androstenedione to estrone. 
Oestrogen has long been known to be the main sex steroid in the female 
responsible for pubertal growth, sexual maturation, skeletal maturation and 
acquisition of peak bone mass. It had always been thought that testosterone 
fulfilled these roles in males. 
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1.3.9.2.2 Growth and Puberty 
Oestrogen promotes linear growth in children and in vitro, Corvol (Corvol et al. 
1987) demonstrated that both sex steroids exerted growth-promoting effects 
directly at the growth plate. It has more recently been realised that oestrogen is 
the most important hormone for determining final height by its role on 
epiphyseal closure. 
Evidence of oestrogen's role in growth came with the identification in 1994 of a 
man with an oestrogen receptor mutation causing oestrogen resistance that 
meant he was unable to respond to circulating levels of oestrogen. He was 
204cm tall, had open epiphyses, a bone age of 15 years, was still growing and 
could not remember having had a pubertal growth spurt (Smith et al. 1994). A 
year later a case of aromatase deficiency was described with a similar 
phenotype (Morishima et al. 1995). In this case, a mutation in the P 450 
aromatase enzyme that converts androgens to oestrogens was discovered. 
Treatment with oestrogens closed his epiphyses and stopped growth (Bilezikian 
et al. 1998). 
Several authors have shown that it is the aromatisation of testosterone to 
oestrogen in boys and oestrogen itself in girls that is the sex hormone stimulus 
for the increasing secretion of GH at puberty as evidenced by an increase in GH 
pulse amplitude (Keenan et al. 1993; Eakman et al. 1996; Veldhuis et al. 1997). 
Early evidence for the role of oestrogen in the pubertal growth spurt and on 
epiphyseal fusion came from the study by Zachmann et al (Zachmann et al. 
1986). In this study of 8 phenotypic females with complete androgen 
insensitivity (AIS: XY genotype and normal female external genitalia as a result 
of aromatisation of androgens to oestrogens) the girls were observed to have 
peak height velocities with magnitudes and timings similar to normal girls. Their 
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bone ages corresponded better to the male standards and their final heights 
were closer to the mean final height of normal men not women. In one patient 
who underwent a gonadectomy and oestrogen replacement, a higher than 
normal growth spurt was observed but a lower final height than those who did 
not have their gonads removed. 
Delemarre van de Waal et al observed a significant association of oestradiol 
levels to height velocity in girls in puberty stages 1-3 however, in stages 4 and 
5, when velocity was decreasing, oestradiol levels continued to increase. In 
boys they observed an increase of oestradiol during the later stages of puberty 
consistent with the timing of the pubertal growth spurt (Delemarre-van de Waal 
et al. 2001). 
1.3.9.2.3 Body Composition 
Pubertal increases in oestrogen production results in the greater accumulation 
of fat in girls compared to boys. Although a difference in body composition has 
been reported in prepubertal children (Taylor et al. 1997; Mast et al. 1998), this 
sexual dimorphism in body composition is seen particularly after menarche. In 
the study by Legro et al percent body fat (by both DXA and skinfolds) showed 
no appreciable increase from 2 years before menarche until at least 1 year after 
at which time an increase as assessed by DXA became apparent. This was in 
spite of exponential increases in urinary estradiol from two years before 
menarche (Legro et al. 2000). An interesting study by deRidder et al observed 
that there was no evidence that body fat mass triggers the onset of puberty but 
rather that body fat was negatively associated with the rate of pubertal 
development from the onset to menarche. They found that the girls with the 
later onset of puberty had higher levels of oestrogen and moved faster from 82 
to menarche, i.e. that the levels of hormones at the onset of puberty were 
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predictive of the rate of development. No hormonal differences were observed 
between the girls in the lowest or highest quartile of skinfold distribution. (de 
Ridder et al. 1992). Clinical support for the fat promoting effects of oestrogen 
come from the observation that genetic males with AIS have a female fat 
distribution whereas postmenopausal women develop a more male like habitus 
with an increase in the visceral adipose site and subsequent increase in the 
waist-hip ratio (Rosenbaum and Leibel 1999). 
1.3.9.3 Sex differences 
In 1988, Stanhope and Brook (Stanhope and Brook 1988) conjectured that girls 
are more sensitive to changes in GnRH concentrations than boys and hence 
their slightly earlier entrance into puberty. They attributed the difference in the 
timing of the growth spurt to the fact that only low concentrations of oestradiol 
are needed to affect GH levels compared to higher levels of testosterone for the 
same effect. 
Although data had suggested that the prepubertal ovary secreted oestrogen, it 
wasn't until the ultra sensitive assay of Klein et al (Klein et al. 1994) that this has 
been possible to observe. A greater bioactivity in prepubertal girls compared to 
boys may explain the earlier pubertal timing in girls. 
1.3.10 Thyroxine 
Thyroxine is a 'permissive' hormone, essential for normal pubertal growth and 
development. In cases of deficiency, whether congenital or acquired, a child's 
growth slows, skeletal and dental maturation is delayed and weight gain 
increases (Hernandez-Cassis et al. 1995). The longitudinal study of thyroid 
hormones during puberty by Dunger et al in children 9.5-15.5 years showed that 
levels of free T 4 fell by 16% from 10 years to a nadir at 12.5 years in girls 
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(puberty stage 3-4) then increased to a maximum by 15 years, in the boys a 
similar pattern, although a less marked fall (a decrease of 12%) was observed 
with the nadir again at puberty stages 3-4 (at age 13.5 years) and rose by 15 
years but did not return to baseline levels (Dunger et al. 1990). Total T4 levels 
followed a similar pattern in the girls although the nadir was slightly later at 
stage 4 before it rose again. In the boys, however, the prepubertal levels were 
lower and the fall was again less marked and the nadir occurred at age 4-5 
again slightly later than the free T 4 and did not return to the early puberty levels. 
Since IGF-I and IGFBP-3 levels are dependent on adequate thyroid hormone 
levels (Miell et al. 1993) either directly or indirectly through effects on GH 
secretion (Nanto-Salonen et al. 1993) it can be seen that adequate levels need 
to be maintained for normal growth and development. 
1.4 Growth and Pubertal Development in Type I Diabetes 
Mellitus (T1D) 
1.4.1 Introduction 
Glycaemic control in children with T1 D often deteriorates during puberty and 
poor growth could be one manifestation of this (Ahmed et al. 1998). The 
teenagers in the Diabetes Control and Complications Trial (DCCT) had higher 
HbA1c levels than the adults (Drash 1993). Yet it has proved to be difficult to 
identify a clear relationship between glycaemic control, as judged by HbA 1 c, 
and growth in children and adolescents with T1 D. Two studies have reported a 
relationship (Wise et al. 1992; Pitukcheewanont et al. 1995) although there have 
been other studies where no association could be observed (Jivani and Rayner 
1973; Salardi et al. 1987; Thon et al. 1992). It is unclear why some children with 
'good' control grow poorly and others with poor control seem to grow normally. 
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It is well known that abnormalities of the GH/lGF-1 axis exist, particularly during 
puberty in T1 D, and could account for some of the poor growth observed. 
However, levels of IGF-I are low in both boys and girls (Ahmed et al. 1998) yet it 
is only in the girls that a marked blunting of the pubertal growth spurt is 
observed (Brown et al. 1994). Despite high levels of GH (Edge et al. 1990; 
Miller et al. 1992; Pal et al. 1992) levels of IGF-I and IGFBP-3 tend to be low 
(Batch et al. 1991; Clayton et al. 1994; Strasser-Vogel et al. 1995). Portal insulin 
insufficiency, growth hormone receptor resistance (as measured by levels of 
GHBP which is identical to the extra cellular domain of the GH receptor) and 
therefore low levels of IGF-I may be the cause of this dysregulation. These 
abnormalities may exist since insulin is a significant factor in the regulation of 
the GH/IGF-I axis; insulin increases hepatic IGF-I production either by regulation 
of the GH receptor or by effects on post receptor events (Baxter et al. 1980; 
Maes et al. 1986). Insulin and IGFBP-1 vary inversely with each other with 
insulin having an inhibitory effect on IGFBP-1 (Holly et al. 1988) and it has been 
reported that IGFBP-1 is an inhibitor of IGF-I bioactivity (Taylor et al. 1990; 
Bereket et al. 1996). The reduced circulating IGF-I levels and reduced IGF 
bioactivity observed (Taylor et al. 1988) may be a product of the high levels of 
IGFBP-1 in pubertal children with T1 D. One large cross-sectional study failed to 
observe any direct correlations between IGF-I levels and growth velocity 
(Strasser-Vogel et al. 1995), however since growth velocity needs a longitudinal 
study, this result may be misleading. 
It would seem that by intensifying insulin therapy, the abnormalities should be 
corrected but this does not appear to be the case. Although intensive insulin 
therapy increases IGF-I levels (Dunger and Cheetham 1996), it is not perfect 
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and it appears to be the levels in the portal vein not the peripheral circulation 
that determine IGF-I, IGFBP-1 and bio availability in T10 (Brismar et al. 1994). 
1.4.2 Growth 
1.4.2.1 Height at diagnosis 
A number of studies spanning twenty years have presented data demonstrating 
that children with T1 0 are taller at diagnosis than control children (Jivani and 
Rayner 1973; Drayer 1974; Edelsten et al. 1981; Hjelt et al. 1983; Lee et al. 
1984; Songer et al. 1986; Salardi et al. 1987; Price and Burden 1992). This 
observation, however, is not universal and has been contested by other studies 
(Evans et al. 1972; Tattersall and Pyke 1973; Petersen et al. 1978; Hoskins et 
al. 1985; Emmerson and Savage 1988). It may be that these different 
observations have arisen due to the use of an inappropriate reference. If the 
controls were not contemporary and did not reflect any secular trends that may 
have occurred since the reference standards were established, the T1 0 children 
might appear to be taller when in fact if more appropriate data were used this 
would not be the case. In the 1994 paper of Brown et ai, the height SO scores 
(SOS) in 184 T1 0 children were calculated using the 1966 UK standards of 
Tanner et al and all the children were taller, however, when contemporary local 
population standards were used only those children diagnosed between 5 and 
10 years of age were taller (Brown et al. 1994). Height at diagnosis continues to 
produce controversial results even in later studies. Several investigators (Blom 
et al. 1992; Price and Burden 1992; Holl et al. 1994; Ahmed et al. 1998; 
Bognetti et al. 1998; Holl et al. 1998a; Scheffer-Marinus et al. 1999) have 
reported taller stature at diagnosis. Huang et al (Huang et al. 2001) divided 
their Chinese cohort into pubertal and prepubertal (admittedly based arbitrarily 
on the average pubertal onset age for Chinese children) and found that only the 
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pubertal girls had a significantly elevated height SDS at diagnosis. Lebl et al 
(Lebl et al. 2003) in a review of 587 T1 D patients born in Vienna and Prague 
from 1962 -1993 (and diagnosed at median ages of 7.9y in boys and 8.4y in 
girls) with a similar genetic background found the girls' mean height SDS at 
diagnosis to be + 0.74 ± 1.46, p<0.01 and boys was + 0.15 ± 1.1, p=0.02. Luna 
and colleagues (Luna et al. 2004) observed in a group of 83 newly diagnosed 
Spanish children that girls had a height SDS of +0.40 whereas the boys' height 
SDS was only +0.08. Whereas Thon (Thon et al. 1992) and Cianfarani 
(Cianfarani et al. 2000) in different European populations found those children 
with diabetes were of equal height at diagnosis to healthy controls. 
The age of diagnosis may also be a factor in the relative height at diagnosis. 
Both Brown and Songer observed that those children diagnosed between 5 and 
10 were taller at diagnosis, those over 10 were of similar height to the 
population and in Brown's sample those diagnosed under 5 years of age were 
shorter, however, it was noted that they did have short parents (Songer et al. 
1986; Brown et al. 1994). 
Different patterns of growth of children before the diagnosis of T1 D may reflect 
the genetic diversity in this disease. The Pittsburg USA study group 
(Anonymous 1989) reported striking differences in their children compared to a 
comparable group from Japan while Ramachandran et al reported normal 
heights at diagnosis in southern India (Ramachandran et al. 1994). Songer et al 
observed that nondiabetic siblings (who are at high risk of the disease) were 
closer in height to their diabetic siblings than were the low risk sibs (Songer et 
al. 1986). 
In twin studies (Leslie et al. 1991), the growth of the twin who subsequently 
developed diabetes was slower 1-2 years before diagnosis compared to the co-
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twin. However, the studies of Blom et ai, Price and Burden and the large 
epidemiological study of Hypponen clearly showed more rapid growth in those 
children who subsequently developed diabetes (Blom et al. 1992; Price and 
Burden 1992; Hypponen et al. 2000). 
1.4.2.2 Growth after Diagnosis 
Although DuCaju (Du Caju et al. 1995) reported normal growth in a longitudinal 
study of Belgium children with T1 0, most studies have detected a loss of height 
SDS in the years following diagnosis (Lee et al. 1984; Thon et al. 1992; Brown 
et al. 1994; Holl et al. 1994; Tillmann et al. 1996; Salerno et al. 1997; Ahmed et 
al. 1998; Bognetti et al. 1998; Holl et al. 1998a; Huang et al. 2001). In a 
retrospective study, Donaghue (Donaghue et al. 2003) compared the height SO 
scores of two groups of T1 0 children. One group was diagnosed between 1974 
and 1990 and the second group between 1991 and 1995. Summarising their 
data in the following table: 
Ht SDS (mean (sd» Diagnosed 1974-90 Diagnosed 1991-95 
At diagnosis 0.28 (1.01) 0.38 (0.99) 
5 years follow-up 0.07 (0.99) 0.37 (0.94) 
1 0 years follow-up 0.04 (0.87) 0.36 (0.89) 
Table 1.4a, T1 0 Children: Height SDS from diagnOSIs, Donaghue 
It can be seen that the more recently diagnosed children have not had a loss of 
height SO scores from diagnosis. The authors ascribed this improvement in 
growth to intensification of insulin therapy that had occurred over the years. 
1.4.2.3 Pubertal growth 
Some studies have suggested that the timing of peak height velocity may be 
delayed in children with diabetes (Du Caju et al. 1995; Tillmann et al. 1996) but 
the longitudinal study of contemporary children with T1 0 has not confirmed this 
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(Ahmed et al. 1998) nor have the studies of Salardi, Brown or Donaghue 
(Salardi et al. 1987; Brown et al. 1994; Donaghue et al. 2003). There appears 
to be general agreement that the pubertal growth spurt in subjects with T1 0 
may be blunted, particularly in girls (Salardi et al. 1987; Brown et al. 1994; Ou 
Caju et al. 1995; Jos et al. 1996). In a few of the early stUdies (Jivani and 
Rayner 1973; Lee et al. 1984) the timing of PHV was reported to be delayed, 
but later studies report normal timing. The Oxford study of Brown et al (Brown 
et al. 1994) indicated that those who were diagnosed under the age of 5 years 
experienced the greatest pubertal height loss. Salardi et al (Salardi et al. 1987) 
reported that girls diagnosed just before puberty had the poorest pubertal 
growth. 
1.4.2.4 Final height 
Although there is a wide reporting of loss of height SOS from diagnosis, the 
general consensus is that most contemporary children with T1 0 will obtain a 
final height that is in the normal population range and appropriate for their family 
(Zachrisson et al. 1997; Scheffer-Marinus et al. 1999; Huang et al. 2001). The 
study by Luna et al showed that in addition to the ht SOS loss from diagnosis, 
the boys but not the girls had a final height SOS of -1.02 (Luna et al. 2004). It 
may be that there is an underestimation of final height in many studies as they 
end before final height is achieved. Heinze et al (Heinze et al. 1993) observed 
that growth might continue (albeit slowly) in diabetic subjects until the age of 20 
years. 
In a retrospective analysis of final heights on 181 subjects with T1 0, Penfold et 
al (Penfold et al. 1995) observed a reduced final height (ht SOS=-0.22) that was 
also low relative to the subject's family. However, other studies have found 
heights very near the mean for the population: Brown et al (Brown et al. 1994) 
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on 80 children followed to final height observed a final height 8DS of -0.06, Holl 
et al (Holl et al. 1994) reported normal final heights on 76 of their subjects, 
Huang (Huang et al. 2001) reported final height SDS's for girls = -0.05 and for 
boys = -0.13. Thus it may be that conclusive data are still to come and that our 
current knowledge is compounded by comparisons of different populations with 
varying ages of diagnoses, glycaemic control and insulin therapy. 
1.4.2.5 Growth in relation to HbA1c 
Although it is tempting to speculate that poor glycaemic control will lead to 
poor growth, it has been difficult to prove a relation between growth and 
glycaemic control as measured by HbA 1 c. Numerous studies have been unable 
to detect any relationship between HbA 1 c and growth in children with T1 D 
(Jivani and Rayner 1973; Hjelt et al. 1983; Clarson et al. 1985; Salardi et al. 
1987; Herber and Dunsmore 1988; Thon et al. 1992; Pitukcheewanont et al. 
1995). The retrospective cross-sectional design of many of these studies may 
have contributed to these discrepancies. Three longitudinal studies identified a 
relationship between growth and HbA 1 c: Wise et al (Wise et al. 1992) reported 
a significant relationship between the two that was more evident in the 
prepubertal years; Gunczler et al (Gunczler et al. 1996) in a group of 79 
subjects followed for 5 years from diagnosis, showed that children with poor 
control (HbA1c>9% ) had a significantly lower growth velocity over the five year 
period than children with better control (lower HbA 1 c); and in their prospective 
study, Ahmed et al. (Ahmed et al. 1998) demonstrated a negative relationship 
between peak height velocity SDS and HbA 1 c in both sexes. Holl et al (Hoi I et 
al. 1998a) demonstrated a significant reduction in final height in children with 
poor control compared to those with good control. 
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1.4.2.6 Growth and insulin dose 
In spite of the importance of insulin in the regulation of IGF-I and the importance 
of both in normal growth, peripheral insulin delivery does not correct the 
imbalances that exist; only portal administration of insulin will totally correct 
these abnormalities. Showing an improvement or relationship in growth relative 
to changes in insulin therapy has not been easily achievable. Ahmed et al 
(Ahmed et al. 1998) found no relationship between insulin dose and PHV SDS 
in their longitudinal study. One study that has shown an improvement in growth 
due to intensified insulin therapy has been that of Rudolf et al (Rudolf et al. 
1982). Donaghue et al (Donaghue et al. 2003) analysed 2 cohorts separated in 
time and demonstrated that the more recently diagnosed group with more 
intensive therapy did not lose height SDS 5 and 10 years from diagnosis. 
1.4.3 Timing of Puberty 
Some of the studies over the past 20 years have reported conflicting 
observations regarding the timing of pubertal onset; DuCaju et al (Du Caju et al. 
1995) reported a noticeable delay in boys and Tillman (Tillmann et al. 1996) and 
Salardi (Salardi et al. 1987) in girls while Clarson et al (Clarson et al. 1985) 
found no delay in their subjects of either sex. Codner et al (Codner et al. 2004) 
in their cross sectional study of 100 Chilean girls with T1 D found no difference in 
the onset of puberty between the T1 D girls and controls but did observe a later 
age of menarche and mean age of breast stages 3, 4 and 5. Summarising this 
in the following table from their data: 
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T10 Controls 
Mean Age N Mean Age N 
82 9.1 23 8.9 103 
83 11.1 17 10.4 90 
84 12.2 15 11.7 72 
Menarche 13 100 12.5 576 
85 13.3 30 12.8 167 
Tabl e 1.4b Girls: T v 10 s Controls, Ages at reaching different puberty stages and menarche, Codner 
The Oxford study of Ahmed et al (Ahmed et al. 1998) showed the age of 
menarche for girls with T1 0 was not significantly different from the mean 
population age. Summarising from this data, ages for menarche, PHV and the 
onset of puberty for both sexes are given in the following table: 
Ages Sex T1D Controls 
Onset of puberty Boys 12.1 ±0.7 11.6±1.1 
Girls 10.9 ± 0.9 11.2 ± 1.1 
PHV Boys 14.0 ± 1.3 14.1 ± 0.9 
Girls 12.0 ± 0.7 12.1 ± 0.9 
Menarche Girls 13.2 ± 0.7 13.2±1.0 
Table 1.4c, Girls and Boys: T1 0 vs Controls; Age of pubertal onset, PHV and menarche, Ahmed 
The Australian study of Donaghue (Donaghue et al. 2003) showed no evidence 
of pubertal delay; there were no differences between the children with T1 0 and 
controls. In addition, there was no significant secular trend. 
1.4.4 Body Composition 
There is a tendency for weight or weight for height to be greater in children with 
T1D compared to controls in both sexes (Than et al. 1992; Hall et al. 1994; 
Pitukcheewanont et al. 1995; Hall et al. 1998b) or only in girls (Mortensen et al. 
1988; Gregory et al. 1992; Bognetti et al. 1995; Du Caju et al. 1995; Danne et 
al. 1997). 
Most of these studies were cross sectional and used weight or BMI as an 
estimate of fatness (with the exception of Gregory et al); instead of any measure 
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of body composition. Another cross sectional study by Codner et al (Codner et 
al. 2004) on 100 girls with T1 D (divided into the 5 pubertal stages) observed that 
BMISDS increased throughout puberty while it remained relatively stable in the 
control girls. The waist-hip ratio decreased during puberty in the control girls but 
not in the girls with T1 D. 
In the prospective longitudinal body composition study of Ahmed et al (Ahmed 
et al. 2001), an increase of 8MI was seen in all children as they progressed 
through puberty. When the analysis was done by body composition, it was 
observed that the girls increased their body fat with puberty while the boys had 
a decrease in percent body fat. Comparing these gains to a control group, 
although both groups of girls gained fat mass, the T1 D girls gained significantly 
more fat mass than controls. Both control and T1 D boys lost percent body fat 
but the loss was greater in the T1 D boys than in the control group. 
There is general consensus that excessive weight for height might relate to 
insulin dose or frequency of insulin injections in subjects with T1 D (Anonymous 
1988; Reichard et al. 1991; Gregory et al. 1992; Anonymous 1995; Bognetti et 
al. 1995; Danne et al. 1997; Mortensen and Hougaard 1997; Holl et al. 1998b). 
1.4.5 Endocrinology of Puberty and Growth in T1D 
1.4.5.1 Adrenal androgens 
There are only a small number of published studies on adrenal androgen levels 
in T1 D and these have reported conflicting results. Several groups have 
observed levels of DHEAS that are similar in their T1 D subjects and controls: 
Meyer et al (Meyer et al. 2000) in a cross sectional study of T1 D pubertal 
subjects (36 boys and 31 girls) and 59 controls found that levels of DHEAS were 
similar between subjects and controls. In an earlier study, Small et al (Small et 
al. 1989) reported comparable results in a group of 17 young adult males with 
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T1D and age matched controls for both DHEAS and androstenedione and 
commented that they also had observed similar results in females. 
Other groups, however, have found lower levels of OHEAS in their T1 0 
subjects; Cohen et al were the first to look at serum OHEAS levels in subjects 
with type I diabetes and they observed lower levels in their subjects than 
controls (Cohen et al. 1984). Loviselli et al (Loviselli et al. 1994) also found low 
levels of OHEAS in a cross sectional study of 15 young males with T1 0 
compared to 18 controls. In a study of 129 children (12.6 ± 3.8y) with T10 and 
458 age-matched controls, Radetti et al (Radetti et al. 1994) reported a OHEAS-
SOS for the T1 0 children of -0.36 ± 0.77 and this was significantly different from 
zero. 
The mechanism of how insulin might affect OHEAS is not clear. It has been 
shown that experimentally induced hyperinsulinaemia decreases adrenal 
androgen levels in humans by inhibiting the 17, 20 lyase activity (Nestler et al. 
1992). Ebeling (Ebeling et al. 1995) gave an acute infusion of insulin in 23 
young adult males with T10 that lowered the levels of OHEAS by 11 % 
(p<0.001). In an earlier study, Nestler (Nestler et al. 1989) had conjectured that 
supraphysiologic levels of insulin might act either via the insulin receptor or IGF-
I receptor. 
1.4.5.2 GH 
Studies on the GH/lGF-1 axis in T1 0 has been a topic of research for at least the 
last 20 years (Amiel et al. 1984; Bloch et al. 1987; Fowelin et al. 1991). It is well 
known that spontaneous overnight growth hormone secretion is higher during 
puberty in subjects with T1 0 compared to controls (Edge et al. 1990; Clayton et 
al. 1994). The highest levels in both groups were noted in puberty stage 2/3 in 
girls and 4/5 in boys corresponding to the time of peak height velocity. The 
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mean overall GH levels are increased at all puberty stages with increases in 
both pulse amplitude as well as baseline concentrations. Halldin et al (Halldin et 
al. 1998) have studied daytime levels of GH in a group of late pubertal girls with 
T1 D. They observed that daytime levels were also elevated. This excessive 
GH secretion results in an increase in insulin resistance (Press et al. 1984), 
which may only exacerbate that seen during normal puberty. Although in 
normal children it has been suggested that the hyperinsulinaemia of puberty 
may enhance growth, the diabetogenic effects of elevated GH levels in T1 0 
subjects (with subsequent antagonistic effects on insulin) may decrease the 
optimal growth potential of these children. 
1.4.5.3 IGF-I 
Paradoxically the levels of insulin-like growth factor-I (IGF-I) in subjects with 
T1D are lower than in puberty-matched controls (Amiel et al. 1984; Taylor et al. 
1988) as are that of its carrier protein IGFBP3 (Batch et al. 1991). This would 
appear to be analogous to a GH resistant state; ie high levels of GH that do not 
produce increased levels of IGF-I and these low levels then feedback to 
encourage a continuing increase in GH production. 
It is known that in the portal hepatic circulation of T1 0 subjects, insulin levels 
are low as are levels of IGF-I, this results in higher levels of the low molecular 
binding protein IGFBP-1. This binding protein has been found to exert an 
inhibitory influence on IGF-I (Taylor et al. 1990) and its high levels may reduce 
the bioavailability of IGF-I (and therefore add to the high levels of GH observed). 
The low levels of IGF-I in T1D have been cited as a possible cause of the 
observed diminished pubertal growth. Although the growth spurt has been seen 
to be sub-optimal in girls more often than boys, it is the IGF-Ilevels in boys that 
have been reported to be lower than in girls (Ahmed et al. 1998). Thus this can 
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only be part of the answer for the diminished pubertal growth, and it may be that 
growth hormone acts directly on the growth plate or that the effects of the sex 
steroids on the GH/lGF-1 axis play more of a role in pubertal growth than IGF-I 
itself. 
1.4.5.4 Insulin 
In T1 0, levels of insulin are high in the peripheral circulation and low in the 
portal vein. It has been demonstrated that it is these portal vein levels that are 
important to maintain normal levels of IGF-I (Dunger et al. 1993). Insulin 
delivery into the portal circulation is not clinically possible although it has been 
shown to normalise the derangements of T1 0 (Shishko et al. 1992). 
Although IGF-I is regulated by GH, insulin enhances IGF-I secretion by its effect 
on the hepatic growth hormone receptor or by a permissive effect on post 
receptor events (Baxter and Turtle 1978; Maes et al. 1986). 
In T1 0, the insulin resistance of puberty cannot be compensated for by 
increased insulin secretion and so to help counter this, the insulin requirements 
of subjects with T1 0 increase substantially during puberty from a usual 0.25-0.5 
units/kg/day to 1.0-1.5 units/kg/day. This usually diminishes after the attainment 
of PHV and levels gradually decrease to prepubertal values. However, the 
intensification of insulin therapy that is generally necessary to maintain 
reasonable glycaemic control has often meant that unacceptable weight gain 
has ensued especially in the girls during late puberty (Anonymous 1988; Ahmed 
et al. 2001). In a longitudinal study, we have shown that young girls with T1 0 
have a significant greater amount of body fat compared to controls in late 
adolescence (Ahmed et al. 2001). Since insulin is regarded as both a hormone 
that can potentiate growth (Caprio 1999) and possibly puberty (through its effect 
on SHBG (Holly et al. 1989)), it is perhaps not surprising that children with T1 0 
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who are reasonably well controlled on adequate insulin replacement will, in 
general, grow and develop normally. 
1.4.5.5 SHBG 
SHBG is important for the transport of the sex hormones in the circulation and 
instrumental in determining their bioavailability (Rosner 1990). In normal 
subjects it was seen that SHBG decreased during puberty and that insulin and 
IGF-I (in boys) correlated negatively to SHBG (Holly et al. 1989). Since it is 
known that levels of IGF-I and portal insulin levels are low during puberty in 
children with T1 0 and in vitro work has shown insulin to decrease SHBG from a 
human hepatoma cell line (Singh et al. 1990; Loukovaara et al. 1995; Kalme et 
al. 2003), it was thought that the levels of SHBG might be high in T1 0 children 
during puberty. The cross sectional study in T1 0 adolescent subjects of Holly et 
al did not observe raised SHBG levels compared to controls (Holly et al. 1992), 
it did, however, show a decrease of SHBG with advancing puberty stages. This 
is in contrast to a study by Christensen et al on adult men with T1 0 where an 
increase in SHBG compared to controls was observed (Christensen et al. 1997). 
The study of Meyer et al on 67 (36 boys) pubertal subjects with T1D found no 
difference in the levels of SHBG at any stage of puberty between the T1 0 group 
and normal controls (Meyer et al. 2000). Whereas Rudberg and Persson 
observed lower absolute SHBG levels in young women (puberty stage 4-5) with 
T1D compared to controls as well as an inverse relationship of insulin dose and 
SHBG (Rudberg and Persson 1995). In Holly's study, the prepubertal T1 0 
children had lower levels of SHBG compared to controls and showed no sex 
difference. It was also observed that neither the duration of diabetes nor 
metabolic control (HbA 1 c) related to SHBG but there was a weak correlation to 
insulin dose however, observed only in the pubertal boys (Holly et al. 1992). 
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Although not reported these authors say they found no abnormalities of sex 
steroids in these subjects. 
1.4.5.6 Leptin 
The discovery of the hormone leptin (Zhang et al. 1994) which is produced by 
adipocytes and regulates appetite, food intake and energy metabolism in 
rodents (Maffei et al. 1995; Vaisse et al. 1996) and humans (Montague et al. 
1997) might help to explain the often reported gains of excess weight in subjects 
with type 1 diabetes (Gregory et al. 1992; Thon et al. 1992; Holl et al. 1994; 
Bognetti et al. 1995; Du Caju et al. 1995; Pitukcheewanont et al. 1995; Danne et 
al. 1997; Holl et al. 1998b). 
The mechanism of excessive weight gain for height in pubertal subjects with 
T1D has not been fully explained. A relationship to insulin dose or frequency of 
insulin injections has often been cited, particularly in girls (Anonymous 1988; 
Anonymous 1995; Danne et al. 1997; Mortensen and Hougaard 1997; Holl et al. 
1998b). Although there remain some discrepancies in the literature (see below) 
most reports are of raised leptin levels in children and adolescents with T1 0 
compared to control children (Kamoda et al. 1998; Kiess et al. 1998; Luna et al. 
1999; Bideci et al. 2002; Soliman et al. 2002; Morales et al. 2004). The 
longitudinal study of Ahmed et al showed that increased levels of leptin existed 
in both the T1 0 boys and girls but it was only the girls who gained more body fat 
than controls (Ahmed et al. 2001). 
It has been postulated that this might reflect 'Ieptin resistance' resulting from the 
peripheral hyperinsulinaemia that invariably occurs in T1 0 treated with 
subcutaneous rather than portal insulin administration (Dunger 1992). Not all 
studies, however, have reported elevated leptin in T1 0 children, Verrotti et ai, 
Myers et al and Karaguzel et al did not find any difference in leptin levels 
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between children and young adults with type 1 diabetes and matched controls 
(Verrotti et al. 1998; Myers et al. 2004; Karaguzel et al. 2006); whereas Kirel et 
al (Kirel et al. 2000) found lower leptin levels in their diabetic children compared 
to controls. 
It is interesting to note the 'permissive' quality of leptin with regards to puberty 
(see section 1.3.8). It has not been reported that children with T1 0 go into 
puberty at earlier ages than controls which one might expect with higher levels 
and if leptin was the 'trigger'. 
1.4.5.7 Sex Steroids 
1.4.5.7.1 Testosterone 
In one of the earliest studies looking at testosterone in T1 0 women, Djursing 
saw slightly elevated SHBG and significantly high testosterone in T1 0 women 
with peripheral hyperinsulinaemia (Djursing et al. 1985). A few years later, 
Small observed testosterone levels in 17 postpubertal T1 0 subjects; all were in 
the normal range and although slightly higher levels of testosterone were 
observed in the T1 D subjects, there was no significant difference (Small et al. 
1989). Rudberg and Persson (Rudberg and Persson 1995) in a small cross 
sectional study of 25 T1 0 young women in late puberty (stage 4-5) observed 
low SHBG and higher testosterone levels in T1 D than control subjects. Meyer 
et al (Meyer et al. 2000) reported conflicting results from a cross sectional study 
of 67 subjects. They observed significantly higher total testosterone and free 
testosterone in both females (p<0.05) and males (p<0.01) with T1 0 than in 
controls at puberty stage 5 but not in any earlier stages. Salardi et al (Salardi et 
al. 2002) also found higher testosterone levels in T1 D stage 5 male adolescents 
and young adults (14.2-33.3y) with a median duration of diabetes of 12 years. 
In one recent study of 50 men (28-51y), Tomar (Tomar et al. 2006) found that 
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more than 90% of patients had a normal testosterone and free testosterone and 
this agreed with Grossman (Grossmann et al. 2008) who studied 69 men (mean 
age 45y) with T1 D and found 70/0 had low «1 Onmol/L) total testosterone (equal 
percent to controls) and 200/0 had low calculated free testosterone (greater 
percent than controls). In recent years, the work of Codner and Escobar-
Morreale on peas in T1 D women has focused on the consistent observations 
of hyperandrogenism in this group of patients (Escobar-Morreale et al. 2000; 
Codner and Escobar-Morreale 2007). 
1.4.5.7.2 Oestrogen 
There is little easily found published work on oestrogens in T1 D children or 
adolescents. Most of the work in T1 D women has been on post menarcheal 
adolescents or women comparing menstrual cycle regularity to controls or 
comparing amenorrhoeic and non-amenorrhoeic diabetic women. Early work by 
Ciognani et al (Cicognani et al. 1978) claimed normal gonadotrophins but 
reduced responses to LHRH in 14 diabetic boys and concluded a limited 
capacity to maintain an adequate pituitary reserve. A disorder of the 
hypothalamus/pituitary/ovarian axis was suggested (Schriock et al. 1984) 
following the observation that girls diagnosed after the age of 11 had a delayed 
menarche compared to controls. This was confirmed by the studies of both 
(Burkart et al. 1989) and (Kjaer et al. 1992) who found that the age of diagnosis 
was inversely related to the age of menarche. None of this, however, 
specifically tells us about E2 levels in puberty. In a discussion by Danielson et 
al (Danielson et al. 2005) on the effect of HbA 1 c on menarcheal age in T1 D 
women, they mention three references with conflicting results: (Djursing et al. 
1982), decreased E2 levels in T1 D;(Zumoff et al. 1990) increased levels and 
(Djursing et al. 1985) similar levels to controls. In a recent study of ovarian 
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function in T1 0 girls, Codner et al observed little difference in basal oestradiol 
levels in T1 0 girls and puberty matched controls (Codner et al. 2005). Thus the 
paucity of available information does not really allow a clear picture on 
oestradiol in T1 0 pubertal children compared to a control group. 
1.4.5.8 Thyroxine 
Since normal growth and pubertal development is dependent on normal thyroid 
levels and children with T1 0 have an increased incidence of autoimmune 
thyroid disease, it is imperative to determine the thyroid status of youngsters 
with T1 D. In the 1980's a number of reports published conflicting results on 
thyroid hormone concentrations in children with T1 0 with some saying levels 
were no different to control children (Gilani et al. 1984; Sluszkiewicz 1986) while 
others reported lower levels in T1 0 compared to controls (Salardi et al. 1984; 
Trimarchi et al. 1984; Dorchy et al. 1985; Chiarelli et al. 1989). Bernasconi et al 
reported that total hormone levels T3 and T 4 were lower as was TBG but the 
free T4 and T3 were normal (Bernasconi et al. 1984). A more recent 
longitudinal study by Connors and Dunger also reported low levels of total T4 
and TBG but found freeT4 within normal limits for both sexes (Connors et al. 
1996). These authors also observed that although duration of diabetes had no 
effect on thyroid hormone concentrations, there was a negative association 
between total T4 or freeT4 and HbA1c. This latter was in general agreement 
with other reports although Trimarchi et al observed a negative correlation 
between disease duration and thyroid hormone levels (Trimarchi et al. 1984). 
1.5 Appraisal of previous research 
• The relationships between hormones, glycaemic control and growth have 
proved difficult to define in T1 0 children. The often small and cross-
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sectional or mixed cross-sectional design of many studies of pubertal 
growth in normal children as well as those with T1 0 may contribute to the 
lack of consensus. To explore events during puberty and reflect changes 
over time, a longitudinal design is essential. 
• There have often not been contemporary longitudinal controls seen at 
visits frequent enough to examine pubertal events. 
• There appear to be no published longitudinal studies in normal children 
or children with T1 0 that compare hormones, growth and pubertal events 
throughout the whole pubertal period. 
1.6 Questions to be addressed by the current study: 
The aim of this research was to explore elements of pubertal growth and 
development and body composition changes in a group of children without 
diabetes and to do the same in children with diabetes including measures of 
HbA 1 c levels and insulin dose. In particular, to explore whether it was possible 
to clarify relationships between these variables and hormones with pubertal 
growth and determine what if any association they might have on the age of 
pubertal onset, PHV and height SOS change both within and between the two 
cohorts. The cohorts comprised 52 T1 0 children (27 boys, 25 girls) aged 7.7-
14.4yrs and 125 control children (54 boys, 71 girls) aged 8.3 -11.96 yrs at first 
visit followed until 16.6 years of age. My objectives were: 
1. To examine within each cohort some components of pubertal growth 
including age at onset of puberty, peak height velocity, age of menarche 
and a measure of pubertal duration. 
2. To explore within each cohort aspects of body composition (fat and fat-
free mass) changes during puberty. 
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3. Comparison of the above in the two cohorts. 
4. Hormonal comparisons during puberty between the two cohorts. 
5. To explore possible relationships between various growth and pubertal 
variables and hormones. 
In summary the main goals of this study are to explore the differences in 
pubertal growth between children with and without type 1 diabetes with special 
emphasis on the hormonal, pubertal and body composition changes that are 
occurring at this time. 
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Chapter 2. Subjects and Methods 
2.1 Subjects: Description of the two cohorts 
2.1.1 Controls 
The control group comprised normal healthy children from a comprehensive 
school in Chard, Somerset, who had participated in a prospective longitudinal 
study of normal growth and hormonal changes during puberty in the 1980's. 
This study was conceived and directed by Professors Preece and Dunger who 
have kindly allowed me to use the data. 
The children and their parents were seen in the four feeder primary schools to 
introduce the study before the children went into the upper school. This was to 
ensure an entry age, particularly in the girls, early enough to ascertain the start 
of puberty. Ethical approval was obtained from the Hospital for Sick Children, 
Great Ormond Street and written consent was obtained from the parents with 
the assent of the children. The children were seen six monthly when 
measurements of height, weight, skinfolds and pubertal assessments were 
made. All measurements were done by one of three observers and all the girls' 
puberty assessments were made by one female observer while one of two male 
investigators assessed the boys. All observers originally trained in the 
Department of Growth and Development at the Institute of Child Health, London. 
Blood samples were taken at each visit for IGF-I, leptin, testosterone, oestradiol, 
androstenedione, dehydroepiandrosterone sulfate (DHEAS), sex hormone 
binding globulin (SHBG), and thyroid function. There were originally 71 girls 
and 54 boys enrolled in the study; however, owing to attrition and lack of data 
due to a variety of reasons (Professor Preece, personal communication), there 
are data on 39 girls with peak height velocity, 47 with reliable menarche ages, 
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and 24 boys with peak height velocity. No data on final height has been 
examined as the children were only followed until 16 years of age. Longitudinal 
hormonal data from 6 monthly measurements exists for varying numbers of 
subjects from 18 to 27. 
Table 2.1 a has details of the children's ages and number of visits: 
GIRLS BOYS 
Median Range Median Range 
At first visit 9.6 8.3-11.96 9.48 8.3-10.2 
At last visit 15.8 10.1-16.6 15.6 9.5-16.5 
Time in study 6.42 0.5-6.43 6.42 0.5-6.42 
No of visits 13 1-14 12 1-14 
.. . . Table 2.1a. Ages at first and last VISit, time In study, number of VISits 
(all; median and range in years) 
This 'Chard' cohort has been used as the contemporary control group for the 
current study of T1 0 subjects to compare age at pubertal onset, age and 
magnitude of peak height velocity, pubertal maturation, hormonal differences 
during puberty and to explore the hormonal effects on growth and puberty. The 
references of Tanner et al have been used to assess the representativeness of 
this sample in terms of pubertal onset, tempo of growth and ages of menarche 
and PHV in particular, the data from the Marshall and Tanner puberty papers 
has been used to compare ages at puberty stages and menarche (Marshall and 
Tanner 1969; Marshall and Tanner 1970). The Freeman et al reference was 
used to calculate height and BMI standard deviation scores (Freeman et al. 
1995). 
2.1.1 T1D cohort 
The study of the Oxford children with diabetes was modelled on the Chard study 
incorporating measurements of growth and puberty assessments as well as 
blood sampling for hormonal determinations. 
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Fifty-two prepubertal children (27 boys, 25 girls) with type I diabetes mellitus 
(T1 D) attending the paediatric diabetes clinic at the John Radcliffe Hospital in 
Oxford were recruited over 8 years for a longitudinal study in growth and 
puberty in the late 1980's. Sixteen girls and nineteen boys were followed to final 
height (defined as a height velocity <1 cm/y). Further subject details are in Table 
2.1b: 
GIRLS BOYS 
Median Range Median Range 
At first visit 9.9 7.7-12.5 11.15 10-14.4 
At last visit 15.8 10.8-18.1 17.96 12.8-19.8 
Duration of diabetes at 2.4 0.64-9.15 6.57 0.9-11.9 
first visit 
Time in study 5.9 1.04-8.36 6.3 2.1-8.9 
Age at diagnosis 7.48 1.5-11.3 4.28 1.1-10.64 
No of visits 19 4-26 21 8-34 
.. Table 2.1b: Ages at first and last VISit, duration of diabetes, time In study, age at diagnOSIs and 
number of visits (all; median and range in years) 
The hospital is a regional specialist centre in childhood diabetes and receives 
referrals from throughout the district. Oxfordshire is a diverse area socially and 
economically; it has a mixture of rural and light industries and is set amongst 
farmland and small market towns with some larger conurbations. 
The Somerset area where the control children came from was comparable to 
the Oxford region with a socio-economic mix that was similar. All the children in 
both groups were from British/European backgrounds. 
As each child in clinic approached the age when it might be feasible to think 
puberty was imminent, in discussion with the consultant and then the child and 
family, MLA explained that their growth and puberty status would be carefully 
monitored at each clinic visit and asked if they were agreeable to this. All 
participants and their parents gave verbal agreement. This approach was 
regarded as part of their routine clinical surveillance as well as trying to gain an 
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insight into the hormonal issues around puberty relating to growth. As such this 
study came under the umbrella of the ethics granted to a more invasive study at 
the time exploring overnight hormonal variation in adolescent patients with T1 D. 
Only one girl withdrew after a few visits since she did not wish to have her 
pubertal status assessed, three other children moved out of the area after 
several visits and one child suffered DKA and cerebral oedema during the 
course of the study and so further assessments on him ceased. 
The children were seen three or four times a year as part of their normal clinic 
routine when height, weight, skinfold measurements and Tanner pubertal 
staging was assessed. MLA took all the measurements on all the children and 
assessed the girls' puberty status; various male clinicians assessed the boys' 
puberty. (All the observers involved in the Chard study as well as MLA were 
originally trained in auxological techniques in the department of Growth and 
Development at the Institute of Child Health, London in the 1970's. Although no 
inter-observer reliability was possible, they were all experienced and highly 
trained.) 
Blood samples were taken annually for C peptide; six monthly for IGF-I, leptin, 
testosterone, oestradiol, androstenedione, dehydroepiandrosterone sulfate 
(DHEAS), sex hormone binding globulin (SHBG) and thyroid function; and at 
each visit for HbA1c. MLA made annual bone age assessments using the 
Tanner-Whitehouse 2 RUS system (Tanner et al. 1983). 
At recruitment, all of the T1 D children were on two injections of intermediate and 
soluble insulin daily, but during puberty 75% were changed to multiple injection 
therapy with three pre-prandial injections of soluble insulin with an intermediate 




All measurements were taken using standard auxological techniques as 
described by N Cameron (Cameron 1984). A full description follows. 
Height. Weight and Skinfold measurements 
Height was measured at each visit using a Harpenden stadiometer (Holtain Ltd., 
Crosswell, Crymmych, Oyfed, Wales); this was a portable one in the case of the 
control subjects. The subjects removed their shoes and stood with their backs 
against the backboard with the back of their heels, buttocks, scapulae and head 
touching the board while they looked straight ahead. The head is in the 
Frankfurt Plane (so that a line drawn from the lower orbit of the eye to the 
external auditory meatus is parallel to the floor), the subject is asked to take a 
breath in and then relax while gentle traction is applied to the mastoid 
processes. The measurement is read to the nearest completed millimetre on 
expiration. 
Weight was measured to the nearest 0.1 kg using a Marsden digital scale 
(Henley on Thames, Oxford) for the T1 0 subjects and a portable beam balance 
for the control subjects. All were weighed in normal indoor clothes with shoes 
removed. 
Subcutaneous skinfold measurements were taken at four sites: biceps, triceps, 
subscapula and suprailiac with a Holtain skinfold caliper (Holtain Ltd) on the left 
side of the body. The location for the measurement of the biceps and triceps 
skinfold was at the half-way point between the acromion and the olecranon 
when the arm was bent at a right angle and this position was marked with ink on 
the lateral aspect of the subject's arm. All the skinfolds are made with a 
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sweeping motion of the forefinger/middle finger and the thumb of the observer's 
left hand. The dial in all cases is read to the nearest completed 0.1 mm. 
Biceps: The observer faces the subject and picks up the skinfold on the anterior 
aspect of the arm with the forefinger/middle finger and thumb of the left hand 
just above the mark where the caliper will be applied, while maintaining this 
'pinch', the observer applies the caliper with the right hand. 
Triceps: The subject stands with his back to the observer while the observer 
picks up the skinfold on the vertical axis of the upper arm midway between the 
lateral and medial surfaces of the arm. Again the observer grips the fold with 
the forefinger and thumb of the left hand slightly higher than the ink mark and 
applies the caliper at the level of the mark while continuing to maintain the 
pinch. 
Subscapula: The observer stands behind the subject who is asked to stand in a 
relaxed position. Using the forefinger and thumb of the left hand the observer 
'sweeps' along the angle of the scapula to the point of the inferior angle where 
the skinfold is picked up. 
Supra-Iliac: The subject faces the observer who picks up the skinfold at a point 
that is 1 cm above and 2cm medial to the anterior superior iliac spine (ASIS). 
This is palpated with the thumb of the right hand while holding the caliper and 
the vertical pinch is then applied with the left hand above the point where the 
caliper is then applied. 
Reliability: This observer has carried out test-retest studies and performed an 
analysis of the differences for both height and the four skinfold measurements. 
Although there are numerous and often a confusing array of reliability statistics 
in the literature, the technical error of the measurement (TEM) has been used 
here to express the precision of the measuring. The interpretation is that 95% 
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of the observer's measurements will be within ± 1.96 of her/his TEM. The 
calculation of TEM = --J (Ldifferences2/2N). A summary of the results is 
presented here and the raw data are in the Appendix, section 8.6. 
Height, Biceps, Triceps, Subscapula, Suprailiac, 
cm mm mm mm mm 
N of pairs 34 36 36 36 36 
L diffs2 1.37 11.98 17.98 7.26 8.09 
L diffs~/2N .02 .17 .25 .10 
.11 
TEM .14 .41 .50 .32 
.34 
TEM*1.96 .28 .80 .98 .62 
.66 
.. Table 2.2a, TEM results for this investigator 
These values compare well with those quoted by Van den Broeck (van den 
Broeck 2001) (www.growthanalyser.org) who states that an experienced 
observer should have a TEM for height <0.25cm and for triceps skinfold 
measurement <0.55mm and subscapular skinfold measurement<0.45mm. 
Ulijaszek and Kerr (Ulijaszek and Kerr 1999) have summarised 29 papers 
reporting reliability statistics from 1972 to 1997 and again the values here agree 
well with their review (see table below). 
More recently, a WHO study group (WHO 2006) reported the reliability in their 
international multicentre growth centres and published both their expert's TEMs 
and the range for the team of measurers and these are presented in the far two 
columns of the table. 
No of TEM TEM WHOTEM WHO TEM range 
studies mean range expert of teams 
Height 19 0.38 0.1-1.3 0.23 0.16-0.29 
Biceps 3 0.17 0.1-0.2 
Triceps 21 0.84 0.1-3.7 0.40 0.39-0.61 
Subscapula 19 1.26 0.1-7.4 0.30 0.29-0.41 
Suprailiac 10 1.16 0.1-3.2 
Table 2.2b, TEM results for WHO investigators 
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2.2.2 Bone Ages 
A left hand and wrist x-ray was taken annually on the T1 0 subjects according to 
the specifications in the manual (Tanner et al. 1983). Bone ages were 
assessed using the 13-bone system that assesses the epiphyses of the radius, 
ulna and short bones (metacarpals and phalanges) (RUS) of the first, third and 
fifth ray. Each bone is considered individually and assigned a stage that is 
defined by up to three criteria (8 stages (a-h) for the ulna and 9 (a-i) for the 
radius and short bones). An individual score is assigned to each and these are 
summed to a total skeletal maturity score. This score is then converted to the 
TW2RUS bone age using a population specific centile chart. 
No formal assessment was made at this time for MLA's bone age reliability. 
However, she was trained by one of the originators of the system (RHW) and 
had in the past performed reliability estimates and the paper by Beunen and 
Cameron (Beunen and Cameron 1980) demonstrated such good reproducibility 
for the TW2RUS system that no further study by MLA was performed. 
2.2.3 Hormone Measurements 
Most of the measurements were made in the same laboratories at the same 
time for the two studies. Jen Jones at the Institute of Child Health kindly 
performed all the IGF-I estimations. The adrenal androgens and SHBG were 
done in Les Perry's laboratory at St Bartholomew's Hospital, London and Dave 
Morrell at the University of Edinburgh did the leptin assays. Thyroid hormone 
and sex steroids were done in the biochemistry dept at the John Radcliffe 
Hospital, Oxford for the T1 0 samples and in Dr Les Perry's lab at 5t 
Bartholomew's Hospital, London for the control samples. Hormone assays over 
the study period of 12 years changed from predominantly in house assays to 
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either commercial kits or to (semi) automated endocrine analysers. In all 
instances before being used the new methods were validated and demonstrated 
to be comparable to the previously used methods. Details of methods with 
coefficients of variation are given in the Appendix, section 8.9. 
2.2.4 Analytical Methods 
2.2.4.1 PHV 
2.2.4.1.1 Description of graphical technique 
Peak height velocity (PHV) was determined by plotting each child's height data 
on an exaggerated scale (x2) and a 'best fit' line was drawn by eye with the aid 
of a flexible lead spline. The height values were then read off every 0.25-year 
(3 monthly) from this smoothed distance curve and annual velocities were 
calculated and plotted at the midpoint of each whole year for every 0.25 of a 
year. These values were plotted and a smoothed curve was then drawn 
through these points. Both the age and magnitude of PHV was read from this 
smoothed velocity curve. 
2.2.4.1.2 Comparison to Preece-Baines 
In their original 1978 paper, Preece and Baines compared their model's 
assessment of PHV magnitude and age of PHV to that obtained by the 
graphical smoothing technique (Preece and Baines 1978). Comparison for age 
of PHV was good with the graphical age being 13.83y for boys and 11.82y for 
girls corresponding to 13.77y and 11.80y respectively. There was, however, a 
significant difference for the magnitude of PHV; graphical 9.62cm/yr for boys 
and 8.32cm/yr for girls compared to 8.69cm/y and 7.58cm/y respectively. 
Graphical smoothing allows far more flexibility than mathematical modelling and 
can follow the data with no preconceived ideas. The user is not constrained by 
any preselected shape or parameters to be included. There are, of course, 
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drawbacks to graphical smoothing, it is laborious and time consuming, it relies 
on one observer and there is no expression of variability (no standard errors can 
be calculated). It was interesting to note that when a visitor in the department 
replotted and smoothed a number of the graphs that this investigator had 
previously done, that the two observers were able to agree incredibly closely on 
both the age and magnitude of PHV. See Appendix section 8.10. 
With the kind help of Or Mario Cortina Borja (Institute of Child Health, London) I 
have compared the graphical technique used in this study with a Preece-Baines 
age at PHV in both groups of subjects presented here. See Appendix, section 
8.11. 
2.2.4.2 SO Score calculations 
Height and 8MI SO Scores were calculated for each child for every visit using 
the Freeman et al references (Freeman et al. 1995). This was done using a 
program from the Child Growth Foundation (2 Mayfield Road, Chiswick, London 
W 4 1 PW). It allows the user to enter the sex, age and variable of interest (i.e. 
height, weight, or BMI) of the child in an excel spreadsheet and calculates the 
SOS using the LMS method of Cole and Green (Cole and Green 1992). 
An exception to this was the calculation of height SO scores for the diabetic 
cohort from diagnosis to final height these were done based on the Tanner et al 
references (Tanner et al. 1966a) as in the original paper (Ahmed et al. 1998). 
Using the 1976 Tanner velocity charts for both sexes, the calculation of 
PHVSOS, adjusting for age of occurrence of PHV, was performed. Three 
parallel straight lines were drawn: one joining the 9ih centile peaks for early, 
average and late spurting children, the second line joining the 50th centile peaks 
again for early, average and late children and the third for the 3rd centile for 
early average and late. For any age that a given child's PHV occurs, it is then 
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possible to read off from this graph both the mean PHV at that age and either 
the 3
rd 
or 9ih centile value. Using the relationship from the standard normal 
distribution of lJ ± 1.880 = 3rd or 9ih (and if we were to choose the 3rd for 
example), solve for the 0 = (lJ -3rd )/1.88 for that age. Subsequently the formula 
SOS = ((x - lJ)/o) is utilised and the age adjusted PHVSOS for the child is 
obtained. (Where x = child's measurement, lJ = population mean, a = 
population standard deviation.) 
2.2.4.3 Comparisons by PHV + years 
Once PHV age was ascertained in each child, this age was designated '0' and 
all measurements were aligned by ± years from PHV. The data was then 
grouped into yearly PHV age groups (± 0.5 year) centered on a whole year. 
Thus anyone seen from -0.50 to +0.49 years around '0' was grouped in the 
whole year '0' grouping. If a subject appeared in any group more than once, the 
data for that individual was averaged for that grouping. 
2.2.4.4 Loess by SPSS 
To explore hormonal changes during pubertal growth in relation to PHV, the 
loess method has been used to identify times of maximal hormone levels. 
SPSS uses a 'Iowess' or 'loess' method to fit a smoothed curve to data. This is 
a method that is described as a 'locally weighted polynomial regression'. The 
acronyms 'Iowess' or 'loess' are derived from the term 'locally weighted scatter 
plot smooth'. It is claimed that it combines the simplicity of linear least squares 
regression with the flexibility of non-linear regression. The process is regarded 
as local since each smoothed value is determined by neighbouring data pOints 
from within a defined range. It is weighted because a regression weight function 
is defined for the data points in the range. The local polynomials fit to each 
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subset of data are either locally linear or locally quadratic. The logic behind the 
method is that the points near the explanatory variable are more likely to be 
related to each other than points further away. Thus more weight is given to the 
nearest data points and less weight to those further away. It is claimed that this 
confers an advantage over some other methods in that it does not require a 
function to fit the model for all the data thus it is very flexible. (From Google 
online help) 
2.2.4.5 Body Composition Equations 
It is well accepted that the equations for the calculation of body composition are 
population specific, therefore this investigator chose those based on British 
children and adolescents (Durnin and Rahaman 1967; Brook 1971) even though 
there are more recent ones available. For the calculation of body density the 
following equations were used as appropriate: 
Author Age Equation 
Brook 1-11y boys D = 1.1690 - 0.0788 x log (sum of 4 skinfolds) 
1-11ygirls D = 1.2063 - 0.0999 x log (sum of 4 skinfolds) 
Durnin & Rahaman 12.7-15.7y boys D = 1.1533 - 0.0643 x log (sum of 4 skinfolds) 
13.2-16.4y girls D = 1.1369 - 0.0598 x log (sum of 4 skinfolds) 
Siri Percent body fat = «4.95/density) - 4.5) x 100 
.. Table 2.2c, Body composition equations 
2.2.4.6 LMS/Cole 
The distribution of the chosen measurement over a specific age range is 
summarised by the construction of three-smoothed age related curves using a 
cubic spline smoother (Cole and Green 1992). These 3 curves are: M, the 
median· S the coefficient of variation of the measurement as it changes with , , 
age; and L the power transformation at each age that is needed so the data are 
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a Gaussian distribution. The three curves are combined to produce a set of 
centile or SOS curves. 
The Dutch Growth Foundation (www.growthanalyser.org) has produced a 
database (Growth Analyser) using the Cole and Green method that allows a 
non-mathematical investigator (such as myself) to generate reference curves 
based on their own control data. The resulting LMS values can then be used to 
calculate SO scores for individual measurements for any group of subjects. 
This has been done in relation to years from PHV using the control children as 
the reference and plotting the T1 0 children on the resulting graphs (Appendix 
8.12.2). 
2.2.4.7 MLwiN 
Multilevel modelling is an extension of ordinary multiple regression. It optimises 
the use of longitudinal data by not requiring an equal number of measuring 
occasions at equal intervals for each subject and thus uses all the available data 
(Baxter-Jones et al. 2003). In other analyses of repeated measures it has been 
necessary that the data conform to strict structures, that the children be seen at 
the same ages and the time intervals between visits be the same. In most 
longitudinal studies this is very difficult to achieve. 
The development of this technique has allowed the handling of data where 
some children are seen only once (cross sectional) and others seen a number 
of different times at varying time intervals. It has allowed the exploration of 
relationships as well as construction of growth norms (Goldstein 1995). Its use 
on mixed longitudinal data permits the fitting of separate curves for groups (i.e. 
girls vs. boys or controls vs. study cohort) as well as individual growth curves 
(Round et al. 1999). Dr Ken Ong has kindly helped apply this technique on 
some of the body composition data reported here. 
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2.2.4.8 General Statistical Methods 
In general, data are presented as means and sd unless otherwise expressed. 
All biochemical data were log transformed to approximate normal distributions 
and parametric analyses have been made. For non-normally distributed 
variables, nonparametric tests were performed. Differences between cohorts 
were by the 2 tailed Student's t-test on logged data or by the Mann Whitney U 
test on non-normal data. Pearson's correlation coefficients were used to 
explore relationships between hormone levels and growth/puberty parameters. 
Multiple linear regressions were employed to explore these relationships. 
Statistical significance was defined as P s 0.05. SPSS has been used (SPSS 
Inc, Chicago, III) the most recent being ver 10. 
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Chapter 3. Growth and Puberty in T1 D and the Control 
Cohort 
3.1 Control cohort and the Tanner references 
The representativeness of the control children has been assessed by comparing 
them to the reference standards of Tanner (Tanner 1962; Tanner et al. 1966a) 
in terms of the age of pubertal onset, age of menarche, age of peak height 
velocity and tempo of growth. 
3.1.1 Boys 
3.1.1.1 Ages at Onset of Puberty and PHV 
The control boys start puberty earlier compared to the UK references of Tanner, 
this is approximately equivalent to a difference of four and a half months. 
Comparison of PHVage between the two groups is, however, very similar. It 
may be that the onset of puberty in the Harpenden Growth Study boys (on 
which the Tanner standards are based) was delayed relative to a more 
representative population or it may be that the assessment of puberty via 
photographs (Harpenden) compared to 'in person' caused a difference or it may 
be related to the inherent variability in pubertal assessment itself. 
Controls Tanner 
G2 11.28 (0.78) 11.64 (1.07) 
PHVage 13.82 (0.97) 14.06 (0.92) 
Table 3.1a, Boys: Ages at Onset of Puberty and PHV, mean (sd) 
3.1.1.2 Tempo of Growth 
Comparing the control boys and the Tanner references (Table 3.1 b) with regard 
to the distribution of genital stages at the time of occurrence of PHV 
demonstrates that in the control cohort, the distribution is spread more evenly 
over stages 3, 4 and 5 whereas three quarters of Tanner's reference group are 
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in stage 4 at PHV and nearly one quarter in stage 5. Again how much of this 
reflects a real difference or a difference in technique/subjectivity of pubertal 
assessments is difficult to assess. Combining stages 4 and 5 would give 71 % in 
late puberty in our control group and 98% in the Tanner group. Thus most boys 
in both samples experience PHV in late puberty although 29% of our controls 
were in early puberty (stages 2-3) when PHV occurred indicating that our control 
boys were in all puberty stages at the time of PHV. 
Genital stage 1 2 3 4 5 
PHV Controls 0 4 25 33 38 
Tanner 0 0 2 76 22 
Table 3.1 b, Boys: Percent In each stage of genital development on reaching PHV 
3.1.2 Girls 
3.1.2.1 Ages at Onset of Puberty, PHV and Menarche 
The ages for pubertal onset, PHV and menarche are similar between our control 
group of girls and the UK references of Tanner. Menarcheal age from Tanner's 
Harpenden Growth study was acknowledged (Marshall and Tanner 1969) as 
being later than girls from more advantaged social circumstances who perhaps 
were more representative of the London population of the time. In fact Marshall 
and Tanner suggested an adjustment of 0.3 year to make their ages more 
representative. Age for menarche in the control cohort falls midway between 
the two quoted Tanner ages. 
Controls Tanner 
82 11.19 (1.19) 11.15 (1.10) 
PHVage 12.35 (0.83) 12.14 (0.88) 
Menarche 13.30 (0.99) 13.47(1.02) Harpenden 
13.00 (1.00) So of England 
Table 3.1c, Girls: Ages at Onset of Puberty, PHV and Menarche, mean (sd) 
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3.1.2.2 Tempo of Growth 
Observations in Table 3.1 d on the girls in the two cohorts in terms of pubertal 
development on achieving menarche and PHV show that there is close 
agreement in the distribution of breast stages at the time of occurrence of peak 
height velocity between the control cohort and the reference group. 
Breast stage 1 2 3 4 5 
PHV Controls 3 28 56 13 0 
Tanner 0 26 51 23 0 
Menarche Controls 0 4 39 40 17 
Tanner 0 1 26 62 11 
Table 3.1d, Girls: Percent In each stage of breast development on reaching PHV and menarche 
The distribution for breast stage attainment at menarche, however, varies 
between the two; it is spread more evenly between stages 3 and 4 in the control 
cohort compared to the predominance in stage 4 for the reference group (similar 
to the differences in the distribution of the boys of genital stages at time of 
PHV). 
3.2 Control cohort, T1D cohort and the Tanner Reference* 
This section is a comparison of the control and T1 D cohorts and the Tanner 
references have been left in for interest not analysis. 
3.2.1 Introduction 
In the Chard study of the control children, there were initially 54 boys and 71 
girls enrolled. The duration of follow-up, median (range) in both boys and girls 
is 6.4 (0.5-6.4) y. PHV was ascertained in 24 boys and 39 girls and reliable 
menarcheal ages are available for 47 girls. Data on final height was not 
examined since the children all moved school between 16 and 17 years of age. 
In the longitudinal study of 52 children with T1 D (27 boys, 25 girls), the duration 
of follow-up, median (range), in girls is 5.9 (1-8.4) Y and in boys 6.3 (2.1-8.9) y. 
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Peak height velocity (PHV) was established in 46 children (24 boys, 22 girls) 
and 35 (17 boys, 18 girls) were followed to final height (growth velocity 1 cm/yr 
or less). During the course of the study 22 girls achieved menarche. 
3.2.2 Boys, Controls vs T1D 
3.2.2.1 Ages at Onset of Puberty and PHV 
(See Appendix for comment on ascertaining the age of pubertal onset). 
There is a significant difference (p<0.0005) between the ages of pubertal onset 
between the control boys and those with T1 0 with the T1 0 boys being a year 
delayed (Table 3.2a). There is no statistical difference in the age at PHV 
between the 2 groups. 
Controls T10 Tanner 
G2 11.28 (0.78) 12.32 (0.94)* 11.64 (1.07) 
PHVage 13.82 (0.97) 14.20 (1.26) 14.06 (0.92) 
Table 3.2a, Boys: Ages at Onset of Puberty and PHV, Controls vs T1 D 
Data are means (sd) 
3.2.2.2 Tempo of Growth: Genital stage at the time of PHV 
The distribution of genital stages at the time of PHV in the control boys is spread 
fairly evenly among stages 3, 4 and 5 whereas more than three quarters of the 
T1D boys are in stage 4 at this time (Table 3.2b). 
Genitalia stage 1 2 3 4 5 
PHV Controls 0 4 25 33 38 
T10 0 0 17 79 4 
Tanner 0 0 2 76 22 
Table 3.2b, Boys: Percent In each gemtal stage at time of PHV 
Looking at the actual numbers in each stage, comparing early (combining 
stages 2 and 3) and mid-late puberty (stages 4 and 5) and performing a chi 
square test: x2 = 4.46 with 1 degree of freedom, p :5 0.05. Control boys are in 
earlier puberty at PHV more often than boys with T1 0 (Table 3.2c). 
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Genitalia stage Stage 2 and 3 Stage 4 and 5 Totals 
Controls 12 12 24 
T1D 5 19 24 
Totals 17 31 48 
Tabl .2 e 3 c, Boys. Numbers m Early and Mid-late puberty at time of PHV 
3.2.2.3 Ages at Reaching Different Stages of Puberty 
T1D boys in this study are significantly older (p<0.0005) starting puberty than 
contemporary controls as already seen in table 3.2a. They are then a similar 
age at entering stage 3 but are older (but not statistically significant) for stages 4 
and 5 (Table 3.2d). 
T1D Controls P 
Pu berty Stage 2 mean 12.32 11.28 <0.0005 
sem 0.21 0.12 
Puberty Stage 3 mean 13.24 13.10 0.65 
sem .21 .23 
Puberty Stage 4 mean 14.11 13.56 0.09 
sem 0.24 0.19 
Puberty Stage 5 mean 15.11 14.55 0.10 
sem 0.30 0.15 
Table 3.2d, Boys: Ages at first reachmg each stage of puberty 
3.2.2.4 Time Intervals during Puberty 
First appearance of G2 to first appearance of G5 
The control boys take longer to go from the first appearance of stage 2 to the 
first appearance of stage 5 than T1 0 boys, median (range): 3.1 (1.1 - 4.6) vs 2.9 
(1.4 - 5.2) Y respectively. Although seemingly a small difference, it was 
statistically significant (P = 0.04). 
From first appearance of G2 to PHV 
The control boys take longer to go from the first appearance of stage 2 to PHV 
than the T1 0 boys, median (range): 2.55 (0.83-4.22) vs 1.84 (0.76-4.33) Y 
respectively, P = 0.02. 
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3.2.2.5 Peak Height Velocity (PHV), age at PHV (PHVage), and PHV-SDS 
There is no difference between the T1 0 and control boys in the magnitude of 
PHV, in the age of its occurrence or in the PHV-SDS adjusted for the age of 
occurrence (Methods) as demonstrated in Table 3.2e. 
BOYS N Mean sd SEM P 
PHVage T1D 24 14.2 1.26 0.26 
Controls 24 13.82 0.18 0.97 0.20 
PHV T1D 24 9.63 1.43 0.29 
Controls 24 10.2 1.46 0.30 0.24 
PHV-SDS T1D 24 0.25 0.98 0.20 
Controls 24 0.46 1.12 0.23 0.50 
Table 3.2e, Boys: T1 D vs Controls, PHVage, PHV, PHV-SDS 
3.2.3 Girls 
3.2.3.1 Ages at Onset of Puberty and PHV: Girls, Controls vs T1D 
The T1 0 girls have a slightly earlier pubertal onset and menarche than the 
control girls but there is no statistical difference in the mean ages for the onset 
of puberty (p = 0.13) or menarche. There is, however, a significant statistical 
difference (p = 0.05) between the 2 groups for the age of PHV occurrence, the 
T1D girls have an earlier PHV. See Table 3.2 f: 
Controls T1D Tanner 
B2 11.37 (1.00) 11.05 (0.60) 11.15 (1.10) 
PHVage 12.35 (0.83) 11.92 (0.69)* 12.14 (0.88) 
Menarche 13.26 (1.02) 13.21 (0.65) 13.0 (1.00)a 
13.47 (1.02)° 
Table 3.2f, Girls: Ages at Onset of Puberty, PHV and Menarche, Controls vs T1D. Means (sd) 
(a=Southern England, b=Harpenden; as in section 3.1) 
3.2.3.2 Tempo of Growth: Breast stage at PHV and Menarche 
PHV: Both control and T1 0 cohorts have more than 80% in breast stages 2 and 
3 at the time of PHV. The T1 0 girls, however, have a higher percentage (50%) 
at stage 2. The Tanner distribution is similar to the controls. 
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Breast stage 1 2 3 4 5 
PHV Control 3 28 56 13 0 
T10 0 50 36 14 0 
Tanner 0 26 51 23 0 
Table 3.2 Girls: P g, ercent In each breast stage at time of PHV 
Using the absolute numbers and combining stages 2 and 3 (early puberty), a chi 
square analysis, X2 = 1.32 with 2 degrees of freedom, showed no significant 
difference between the controls and T1 0 girls in the stages of puberty at PHV 
(Table 3.2h). 
Breast stage Stage 1 Stage 2&3 Stage 4 Totals 
Controls 1 33 5 39 
T10 2 17 3 22 
Totals 3 50 8 61 
Table 3.2h, Girls: Numbers In breast stages at time of PHV 
Menarche: More than %'s of the girls in both the T1 0 and control cohorts (79% 
for controls and 86% for T1 D) are in either breast stages 3 and 4 for menarcheal 
age; however, the T1 0 cohort is shifted to the right with 68% in stage 4 
compared to 40% in the controls. The Tanner references are similar to the T1 0 
cohort (See table 3.2i). 
Breast stage 1 2 3 4 5 
Menarche Controls 0 4 39 40 17 
T10 0 0 18 68 14 
Tanner 0 1 26 62 11 
Table 3.21, Girls: Percent In each breast stage at time of Menarche 
A chi square analysis between the two cohorts using the numbers in breast 
stages 2/3 compared to 4/5 at the time of menarche: X 2 = 3.07, 1 degree of 
freedom, showed no significant difference between the two groups in the stage 
of puberty at the time of menarche (Table 3.2j). 
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Breast stage Stage 2/3 Stage 4/5 Totals 
Controls 21 26 47 
T10 5 17 22 
Totals 26 43 69 
Table 3.2' Gir J, Is. Numbers m breast stages at the time of Menarche 
3.2.3.3 Ages at Reaching Different Stages of Puberty 
The T1 D girls enter puberty at a slightly younger age than the controls and 
reach stage 3 at a very similar age and then are Slightly younger at stage 4 but 
none of these are statistically significant. It is not until stage 5 where there is a 
significant difference (p=O.001) in the age of attainment with the T1 D girls being 
a year later. 
T10 Controls P 
Puberty Stage 2 mean 11.05 11.37 0.32 
sem 0.15 0.15 
Puberty Stage 3 mean 11.99 12.00 0.97 
sem 0.20 0.17 
Puberty Stage 4 mean 12.75 13.06 0.39 
sem 0.19 0.18 
Puberty Stage 5 mean 14.71 13.66 0.001 
sem 0.28 0.16 
Table 3.2k, Girls: Ages at first reachmg each stage of puberty 
3.2.3.4 Time Intervals 
First appearance of B2 to first appearance of B5 
The girls with T1 D take significantly longer (P<O.0005) to go from the first 
appearance of breast stage 2 to the first appearance of breast stage 5 than 
control girls; median (range): 4.1 (1.8 - 5.9) vs 2.5 (1.5 - 4.9) Y respectively. 
B2 to Menarche 
Girls with T1 D take longer than control girls to go from the first appearance of 
breast stage 2 to menarche, median (range): 2.2 (1.2 - 3.4) vs 1.8 (0.3 - 4.3) Y 
but this did not reach statistical significance (P=O.15). 
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Menarche to B5 
Girls with T1 0 take significantly (p<0.0005) longer to go from menarche to the 
first appearance of breast stage 5 than control girls; median (range): 1.1 (-.3-
3.2) vs 0.7 (-0.8-1.3) y respectively. 
B2 to PHV 
Interestingly there is absolutely no difference in the median duration B2-PHV 
between the two cohorts (T1 0 vs controls respectively): 0.95 (-0.3 - 2.7) Y vs 
0.95 (-0.7 - 3.1) y. Note the negative values in the range since 2 girls in each 
cohort appeared to have a PHV before B2 was documented. 
PHV to Menarche 
The girls with T1 0 take longer to go from PHV to menarche, median (range) 1.3 
(0.5-2.3) Y vs 0.9 (-1.0 - 2.0) Y than the control girls. This difference did not 
reach statistical significance (P=.09). 
3.2.3.5 Peak Height Velocity (PHV), Age at PHV (PHVage) and PHV-SDS 
There is no difference between T1 0 girls and controls in the magnitude of PHV 
or in the PHV-SDS adjusted for age of occurrence. T1D girls, however, have 
their PHV at an earlier age (p=0.05) see Table 3.21. 
GIRLS N Mean sd SEM P 
T1D 22 11.92 0.69 0.15 0.05 PHVage 
Controls 39 12.35 0.83 0.13 
T1D 22 7.67 1.11 0.24 0.87 PHV 
Controls 39 7.71 0.96 0.15 
T1D 22 -0.62 0.93 0.20 0.36 PHV-SDS 
Controls 39 -0.41 0.77 0.12 
-Table 3.21, Girls. T1 D vs Controls, PHVage, PHV and PHV SDS 
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3.3 Sex Differences 
3.3.1 PHV Magnitude (cm/yr): T1D vs Controls (Tanner 
reference) 
In both sexes, as previously seen, there was no sign ificant difference between 
the two groups in the magnitude of PHV (Tables 3.2 e and I). There was, 
however, a distinct sex difference between subjects with T1 0 and controls when 
compared with Tanner references for velocity. The age adjusted SOS for PHV 
was significantly reduced in the T1 0 girls (-0.62 ± 0.93, P = 0.001) but not in the 
boys (0.25 ± 0.98, P = 0.11). It is interesting to note that both the T1 0 and 
control girls had blunted spurts (7.67 ± 1.11 cm/yr and 7.71 ± 0.96 cm/yr 
respectively) that were significantly lower than Tanner (8.4 ± 0.9 cm/yr, p < 
0.05). These data are represented in Figure 3.3a, which also demonstrates the 
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3.3.1 Regression of PHV (cm/yr) on Age of PHV 
Girls N B SEM 
T10 22 -0.81 0.31 
Controls 39 -0.58 0.16 
Tanner -0.47 0.17 
Boys 
T10 24 -0.63 0.20 
Controls 24 -0.58 0.29 
Tanner -0.77 0.21 
Table 3.3a. Regression of PHV, cm/yr agamst PHV age 
The details of the regression of PHV (cm/yr) against the age of its occurrence 
(Table 3.3a) are negative as expected. Thus the earlier spurting child has a 
more vigorous peak height velocity. It is interesting to note that the control girls 
and boys of this study have an identical regression coefficient (8= - 0.58) 
whereas Tanner's Harpenden data showed the boys to have a greater 
regression than the girls (- 0.77 vs - 0.47 respectively). The T1 0 girls had a 
larger regression coefficient than the T1 0 boys (- 0.81 vs - 0.63) and therefore a 
spurt occurring a year later in these girls would be 0.81 cm/yr less than one a 
year earlier. In fact the control children (both sexes) and T1 0 boys all had 
regression coefficients of a similar magnitude whereas that of the T1 0 girls was 
much greater. This is illustrated in Fig 3.3b (1-4). 
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3.3.3 Onset of Puberty, T1D: Bone Age vs Chronological Age 
A subset of T1 0 children had bone ages (1W2RUS) available at the onset of 
puberty. The bone ages of the boys were slightly younger compared to their 
chronological ages, however, this did not reach statistical significance, mean 
I 
(sd); 11.75 (1.07) Y compared to 12.10 (0.71) y, P = 0.20. In the girls there was 
an advanced bone age, which was statistically significant, of 11.48 (1.01) Y 
relative to the chronological age of 10.93 (0.86) y, p=0.04. 
Age T10 p 
Boys CA 12.10 ± 0.71 
n = 18 BA 11.7S± 1.07 NS 
Girls CA 10.93 ± 0.86 
n = 19 BA 11 .48 + 1.01 0.04 
Table 3.3b: Chronological and Bone Ages at Puberty Onset, Means,sd. 
3.3.4 PHV and Menarche, T1D: Bone Age vs Chronological Age 
PHV: 
There was no difference between the bone age and chronological age of the 
T1D boys at age of PHV whereas the girls with T1 0 had an advanced bone age 
compared to their chronological age at PHV although this did not reach 
statistical significance (Table 3.3c). 
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Age T10 p 
Boys CA 14.00 ± 1.29 
n = 19 BA 13.98 ± 0.70 NS 
Girls CA 11.96 ± 0.71 
n = 19 BA 12.28 + 0.85 NS 
-
Table 3.3c, Ages on reaching PHV: CA=chronological age, BA=TW2RUS bone age. X (sd) 
Menarche: 
The chronological age at menarche (N=19) was 13.23 ± 0.69y compared to a 
bone age of 13.42 ± 0.60 y and this difference was not statistically significant. 
3.3.5 Height 50S changes 
Height SO scores were calculated for boys and girls in both cohorts at the time 
of first appearance of puberty stage 2 and stage 5 and at the time of PHV. The 
results are in Table 3.3d: 
BOYS T10 Controls 
Stage 2 -0.28 (1.10) 0.06 (1.02) 
PHV -0.15 (1.15) 0.43 (0.94) 
Stage 5 0.18 (1.00) 0.41 (0.93) 
GIRLS 
Stage 2 0.10 (0.93) -0.14 (0.89) 
PHV 0.20 (0.98) 0.10(0.81) 
Stage 5 0.30 (1.05) 0.58 (0.68) 
Table 3.3d, Boys and Girls: T1 0 and Controls, Ht SOS, X (sd) 
There is no statistically significant difference between controls and T1 0 children 
in any of these Ht SO scores at the three points observed. 
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3.3.6 T1 0, Height 50S changes from Diagnosis to Final Height: 
The pattern of change in height SOS in T10 boys and girls at various points 
from diagnosis to final height was different (Table 3.3e). 
At diagnosis the girls were tall relative to the UK references. However at final 
height they were marginally short (height SOS = -0.037 and the loss of height 
SOS from diagnosis to final height was statistically significant (p = 0.014). The 
boys were slightly taller than the reference at diagnosis (height SOS = 0.235) 
but by the onset of puberty their mean HtSOS of 0.06 (1.02) was similar to their 
final height SOS, -0.04 (0.78). Correcting the subjects' final height SOS to allow 
for the midparental height SOS, the girls were significantly short (p = 0.005) 
whereas the boys were not. 
Midpt Final HtSDS T1D Diagnosis PHV Final Ht corrected for HtSDS 
midpt ht 
Boys 0.24 -0.15 -0.04 0.16 -0.17 
Girls 0.81 0.20 -0.04* OAO -0.361" 
Table 3.3e: Mean Height SDS Changes from DiagnOSIs to Final Height 
* P=O.014 From diagnosis to final height 
Y P=O.005 For final height corrected for parents' heights 
3.3.7 T10, Insulin dose and HbA 1 c before and after PHV: 
Changes in insulin dose and HbA 1 c in the years before and after PHV are 
summarised in Table 3.3f. Mean HbA 1 c levels were lower in the girls during the 
years leading up to PHV but increased in both sexes during pubertal growth. 
There was no Significant difference in HbA 1 cat PHV in boys, 9.72 (1.96)% vs. 
8.86 (1.47)0/0, in girls even though there were differences in the PHV-SOS 
between the sexes. The maximum insulin dose during the growth spurt was 
similar in both sexes (1.14 u/kg/day in boys and 1.15 u/kg/day in girls) although 
there were differences in the time at which this dose was achieved (at PHV in 
boys and 2yrs after PHV in girls). Insulin dose at PHV was not significantly 
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different between the sexes: 1.14 (0.17) u/kg/day in boys and 1.10 (0.26) 
u/kg/day in girls. 
Years from PHV -3 -2 -1 0 1 2 3 
Insulin Boys 0.92 1.01 1.04 1.14 1.13 1.08 1.04 dose (0.20) (0.18) (0.16) (0.17) (0.15) (0.14) (0.14) 
Girls 0.78 0.87 0.95 1.10 1.13 1.15 1.03 (0.19) (0.29) (0.24) (0.26) (0.19) (0.21 ) (0.19) 
HbA1c Boys 9.07 9.73 9.73 9.72 9.64 9.89 9.88 (1.82) (1.55) (1.67) (1.96) (1.55) (2.20) (2.36) 
Girls 8.42 8.00* 9.11 8.86 9.73 9.73 10.15 (1.31 ) (1.93) (1.01 ) (1.47) (1.69) (1.66) (1.88) 
o • Table 3.3f. Insulin dose (u/kg/day) and HbA1c (Yo) In the Years Before and After PHV. 
Data are mean (sd). * p<O.027 between boys and girls for HbA1c at PHV-2 years. 
3.3.8 T1D, Insulin dose and HbA 1 c at PHV 
HbA 1 c correlated negatively with PHV-SDS (r = -0.25, Fig 3.3c) in both sexes. 
This was, however, only significant in the boys; r = -0.41, P = 0.05 (the girls: r = 
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Figure 3.3c, T1D Girls and Boys: PHVSDS and HbA1c 
The normal cohort that has been used as a control group is contemporaneous in 
time with the T1 D cohort and from a similar social environment. These control 
subjects of both sexes were found to have similar ages to the Marshall and 
Tanner data for the onset of puberty, timing of their PHV and age of menarche. 
104 
Although the majority of boys in both cohorts experienced PHV in late puberty, 
29% of the control boys were in early to mid puberty compared to Marshall and 
Tanner's predominantly at stage 4. The tempo of growth in the girls was similar 
at PHV but differed with respect to menarche in that an equal percent were in 
stages 3 and 4 as opposed to Marshall and Tanner's data predominantly at 
stage 4. 
Puberty staging is subjective and it must be remembered that the Tanner stages 
were determined on photographs whereas the ratings on the control subjects for 
this study were done in person. Both genital and breast stage 4, however, have 
very definite criteria so this may reflect a real difference between these 2 
groups. It is difficult to categorically state whether this reflects a difference in 
the tempo of pubertal maturation between the two or highlights the problems of 
different techniques and different observers. However, as previously stated, the 
mean age of PHV in both sexes and menarcheal age is similar between the two 
groups. This investigator has therefore concluded that the Chard sample is 
reasonably well validated by the Tanner references and the differences are 
primarily related to the possible earlier tempo of growth with the control boys 
having an earlier pubertal onset with PHV occurring at stages 3, 4 and 5 not 
primarily in stage 4 and in the control girls, menarche appears equally in stages 
3 and 4 not predominantly in stage 4. 
The onset of puberty was a year later in T1D boys compared to controls. 
Control boys were found to be in an earlier stage of puberty at PHV and they 
take longer to go through puberty. There was no difference for PHV, PHV-SDS 
or PHVage. 
The onset of puberty and menarcheal age was slightly earlier in T1 0 girls (not 
statistically significant). At the onset of puberty, some of the T1 0 girls had an 
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advanced bone age relative to their chronological age. By the attainment of 
stage 5 however, they were Significantly older than controls having taken longer 
to go through puberty. There was no significant difference in the tempo of 
growth relating to breast stages at the time of PHV or menarche between the 2 
groups. 
Although there was a difference in the age at PHV with T1 0 girls being 0.4 year 
younger, there was no difference in PHV or PHV-SOS. It is interesting to note 
that both study cohorts of girls have low PHV-SOS's (T1 0: - 0.62, controls: -
0.41). We could speculate if this sample of girls were unusual or was it too 
small a sample or perhaps the 6 monthly visits did not allow as accurate an 
assessment as 3 monthly would have allowed. 
The regression of PHV on age at PHV was negative as expected; it was 
interesting to see that the T1 0 girls had the steepest slope indicating greater 
loss of PHV magnitude with each year later than either the control girls or either 
cohort of boys. 
T10 girls have a statistically significant advanced bone age at the onset of 
puberty but not at PHV or menarche. 
In the T1 0 cohort, height SOS changes through puberty demonstrated that the 
girls were tall at the time of diagnosis but ended up relatively short even when 
their parents' heights were taken into account. This was not so for the boys. 
At the time of PHV, both T1 0 boys and girls had similar doses of insulin (u/kg/d) 
and their maximum dose during the growth spurt was the same although the 
timing was different, the boys had their maximum dose at PHV and the girls at 2 
years after PHV. PHV-SOS was negatively related to HbA 1 c% although this 
was only significant in the boys. There was no relationship between insulin 
dose and PHV-SOS. 
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Chapter 4. Body Composition in T1D and Control 
Cohort 
4.1 Introduction 
As children grow and enter puberty, characteristic sex specific gains in fat mass 
and fat free mass become more evident. Although both sexes put on weight as 
they grow, there is a difference in the partitioning (Wells 2007). Girls tend to 
gain far more fat mass relative to fat free mass and continue this increase into 
late puberty. Boys have a dramatic increase in fat free mass and a decrease in 
percent body fat as they go through puberty. Adolescents of both sexes with 
T1D have been seen to have an increase in weight (or BMI) far more than their 
age related peers (see chapter 1). This excessive weight gain is often more 
evident in girls. 
To compare the body composition changes by age in the two cohorts here, an 
analysis of covariance was used to look at the data longitudinally by entering the 
child's identifier as a fixed factor. This examines the association between 
variables within subjects by fitting parallel lines with a common slope for all 
subjects. Inter-subject variation is shown by differences in the constants and 
the regression coefficient describes the associations between variables (Bland 
and Altman 1995). 
When comparing the cohorts by puberty stage, the mean of the variable in 
question was calculated for each subject in each stage (since children were 
often seen more than once in a puberty stage), so that an individual appears 
only once in any puberty stage. Differences were examined by Mann Whitney U 
non-parametric test. 




4.2.1 BMI By Age 
BMI increased with age In both groups of boys: T1D, B=0.773 ± 0.024, 
p<0.0005; controls, B=0.681 ± 0.026, p<0.0005. Boys with T1D had a greater 
BMI than controls throughout the age range studied ; overall they had 1.46 ± 
0.55 kg/m2 higher BMI than the control boys (MLwiN) . 
4.2.2 BMI By Puberty Stage 
Boys with T1D had higher BMl's at all puberty stages compared to control boys 
and at each stage this was significant (Fig 4.2a). 
Boys 
26 
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Figure 4.2a, Boys: BMI by Puberty Stage 
1 2 3 4 5 
P <0.0005 <0.0005 0.007 <0.0005 <0.0005 
4.2.3 Body Composition by Age 
Percent body fat increased with age in the control boys (B = 0.019 ± 0.008, P = 
0.03) but decreased in the boys with T1 0 (B = - 0.047 ± 0.008, p<0.0005) . 
Overall there was no significant difference between the T1 0 and control boys, 
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Figure 4.2b, Boys: Percent Body Fat by Age 
4.2.4 Body Composition during Puberty 
4.2.4.1 At first appearance of puberty stage 2 and stage 5 
At the first sign of stage 2, T1D boys had significantly more fat mass (p = 0.006) 
and fat free mass (p = 0.001) than control boys and more percent body fat which 
almost reached significance (p = 0.055). 
By stage 5, the only significant difference between the two groups was in the 
greater fat free mass of the T1 0 boys (p<0.0005), Table 4.2a. 
Fat mass Fat free mass Percent BF 
Stage 2 
Controls 5.25 (2.28-15.93) 29.54 (21.42-37.67) 15.58 (8.67-29.95) 
T1D 7.63 (4.86-11.35) 32.81 (28.94-39.95) 18.98 (13.65-22.81) 
P 0.006 0.001 0.055 
Stage 5 
Controls 8.63 (4.53-20.56) 44.70 (37.32-50.22) 16.38 (9.48-30.69) 
T1D 10.15 (6.69-16.08) 49.48 (42.46-58.30) 16.38 (12.40-24.14) 
P 0.068 <0.0005 NS 
Table 4.2a, Boys: Fat mass, fat free mass and percent body fat at stage 2 and stage 5 
Median (range) 
109 
4.2.4.2 Changes During Puberty 
The control boys had no significant change in percent body fat analysed by 
puberty stage although a slight loss was seen (Table 4.2b). This is in contrast 
to the analysis by age where an increase was observed. However, the 
decrease in percent body fat in boys with T1 0 was still evident by pubertal stage 
analysis and this decrement was significantly different to that of the control boys 
(p = 0.008). 
T1D Controls P 
Fat Mass, kg 3.5 ± 0.53 4.7 ± 0.77 0.2 
% Body Fat -3.7 ± 0.78 -0.2 ± 0.96 0.008 
Fat-Free Mass, kg 24.0±1.1 21.9 ± 0.59 0.1 
Table 4.2b, Boys: Change In fat mass, percent body fat and fat free mass dUring puberty. 
Means ±SEM 
4.3 Girls 
4.3.1 BMI by Age 
BMI increased in girls with age: T1D, B=1.0005 ± 0.027, p<0.0005; controls, 
B=0.895 ± 0.031, p<0.0005 and was higher in the girls with T1D compared to 
the control girls throughout the age range studied. Overall, T1D girls had 1.45 ± 
0.69 kg/m2 higher BMI than control girls (MLwiN). 
4.3.2 BMI by Puberty Stage 
In the girls (Fig 4.3a), a significant difference in BMl's between subjects with 
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Figure 4.3a, Girls: BMI by Puberty Stage 
Puberty stage 1 2 3 4 5 
P 0.001 0.04 0.014 0.006 0.001 
4.3.3 Body Composition by Age 
In both girls with T1 0 and control girls, percent body fat increased with age: B = 
0.127 ± 0.007, p<0.0005 and B = 0.180 ± 0.012, p<0.0005 respectively. 
Overall, girls with T1 0 had a higher percent body fat than the control girls by 3.2 



























Figure 4.3b, Girls: Percent Body Fat by Age 
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4.3.4 Body Composition during Puberty 
4.3.4.1 At first appearance of puberty stage 2 and stage 5 
At the first sign of stage 2 the T1 D girls have more fat mass, fat free mass and 
percent body fat than the control girls, however, it is only the differences in the 
fat mass that is significant (p=0.04) at this stage. 
By stage 5, all three measures of body composition are greater in the T1 0 girls 
and highly significant (p<0.0005) Table 4.3a. 
Fat mass Fat free mass Percent bf 
Stage 2 
Controls 8.56 (5.76-15.63) 26.17 (20.38-33.97) 24.81 (19.76-32.60) 
T1D 9.83 (6.22-19.43) 28.94 (21.58-36.27) 26.13 (22.38-34.89) 
P 0.04 0.087 0.087 
Stage 5 
Controls 12.86 (8.60-22.42) 36.17 (30.89-42.28) 26.29 (20.32-34.66) 
T1D 17.01 (13.95-26.85) 40.69 (34.37-47.55) 30.30 (26.34-38.58) 
P <0.0005 <0.0005 <0.0005 
Table 4.3a, Girls: Fat mass, fat free mass and percent body fat at stage 2 and stage 5 
4.3.4.2 Changes During Puberty 
During puberty girls with T1 D gained more body fat than control girls (p = 0.04), 
however, there was no difference between the 2 groups in the gains of fat free 
mass or percent body fat (Table 4.3b). 
T1D Controls p 
Fat Mass, kg 10.7±1.03 8.2±0.41 0.04 
% Body Fat 8.1 ± 1.19 7.6±1.08 0.8 
Fat-Free Mass, kg 13.7±0.81 13.6 ± 0.67 0.9 
Table 4.3b,Glrls: Change In fat mass, percent body fat and fat free mass 
during puberty. Means ± SEM 
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4.4 Body Composition and Leptin during Puberty 
4.4.1 Boys 
In both T1 0 and control boys, leptin levels decreased with age: T1 D, B = -0.040 
± 0.015, P = 0.01; controls, B = - 0.063 ± 0.01, p<0.0005. 
Fat free mass was negatively associated with leptin in both control, B = -0.50 ± 
0.08, P < 0.0005 and T1D boys, B = - 0.45 ± 0.14, P < 0.002 (Fig 4.4a). 
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Figure 4.4a, Boys: Leptin by Fat Mass and by Fat Free Mass 
Although not statistically significant, it can be seen that for any level of fat mass, 
leptin levels are again higher in the T1 0 boys than control boys. 
When both fat mass and fat free mass were entered into the same model, fat 
free mass was negative allowing for levels of fat mass: B = -0.89 ± 0.13, P < 
0.0005 (controls) and B = -0.98 ± 0.18, P < 0.0005 (T1 D) while fat mass was 
positive adjusting for fat free mass in both controls and T1 D boys respectively: B 
= 0.35 ± 0.09, P < 0.0005 and B = 0.71 ± 0.17, P < 0.0005. 
4.4.2 Girls 
Leptin levels increased with age in both girls with T1 D and control girls: Type 1, 
B = 0.179 ± 0.02, p<0.0005; controls, B = 0.143 ± 0.012, p<0.0005. 
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Significant positive associations are seen with both fat mass and leptin and fat 
free mass with leptin in T1 0 and control girls, p < 0.0005: 
Leptin and Fat Mass B se p 
Controls 0.59 0.06 <0.0005 
T1D 1.26 .14 <0.0005 
Leptin and FFM 
Controls 1.40 0.14 <0.0005 
T1D 2.13 0.30 <0.0005 
Table 4.4, Girls. Fat Mass and Fat Free Mass aSSOciatIOns with Leptm 
Considering leptin in relation to body fat and fat free mass, the graphs below 
clearly show that leptin levels are higher for all levels of both fat mass and fat 
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Figure 4.4b, Girls: Leptin by Fat Mass and by Fat Free Mass 
Although previously fat mass and fat free mass had been entered into the same 
model (Ahmed et al. 1999; Ahmed et al. 2001), I have subsequently realised 
that they are highly correlated in both cohorts of girls, r = 0.88 and 0.81 (T1D 
and controls respectively) and since these close associations may make the 
model unstable I have omitted those results here. 
In T1 0 girls, from puberty stage 1 to 4, total daily insulin dose adjusted for 
percent body fat was positively related to leptin levels, B = 0.006 ± 0.003, P = 
0.05. No such relationship was seen in the boys, p = 0.1. 
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4.5 Summary and Discussion 
In all the subjects, BMI increases with both age or puberty stage and the T1 0 
children, especially the boys, have a greater BMI than controls throughout the 
study period. This is in agreement with numerous previous reports (Gregory et 
al. 1992; Thon et al. 1992; Pitukcheewanont et al. 1995; Danne et al. 1997; Holl 
et al. 1998b; Domargard et al. 1999; Dabadghao et al. 2001; Holl et al. 2003; 
Ingberg et al. 2003; Codner et al. 2004; Luna et al. 2004). Percent body fat 
increased with age in control boys but decreased in the T1 0 boys however, 
overall there was no significant difference between the two. Analysis by puberty 
stage of percent body fat revealed no significant change in the control boys 
(although the decrease in the T1 0 boys was still evident). These different 
observations may relate to the different 'time-frame' of analyses by pubertal 
stage compared to chronological age since the pubertal change from the first 
stage 2 to the first stage 5 is shorter than the age time scale. 
At the start of puberty, T1D boys had significantly more fat mass, fat free mass 
and percent body fat than control boys; however, by stage 5 the only significant 
difference was the greater fat free mass of the T1 0 boys. This is in contrast to 
the girls who at the start of puberty only had significant differences in fat mass 
(T1D girls greater) yet by stage 5 all 3 measures of body composition were 
significantly greater in the T1 0 girls. Thus the increases in BMI in girls was 
largely due to the recruitment of fat mass, whereas the higher BMI in boys was 
accompanied by a reduction in percent body fat and recruitment of fat free 
mass. These differences highlight important sexual dimorphism in both cohorts 
as well as the more pronounced effects in the diabetic subjects. It should 
perhaps be noted here that the data may have been better presented if the FM 
and FFM were normalised for height, ie adjusted for body size by dividing by hf 
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and presented as an index (kg/m2) as recommended by Wells (Wells 2001). It 
may be something to consider for the future. 
The mechanism of increased weight gain in T1 D girls is not established 
although a relationship to insulin dose or frequency has been observed (Holl et 
al. 1994; Danne et al. 1997; Mortensen and Hougaard 1997). The conventional 
subcutaneous administration of insulin leads to peripheral hyperinsulinism which 
could lead to the increased adiposity (Dunger 1992). 
The discovery of the hormone leptin (Zhang et al. 1994), which could regulate 
satiety, energy expenditure and weight gain has added another dimension to 
these relationships. Leptin is produced by adipocytes and feeds back through 
the hypothalamic receptors to regulate weight gain and energy expenditure 
(Rohner-Jeanrenaud et al. 1996). Leptin deficiency was originally thought to be 
a cause of obesity (Campfield et al. 1996), but this is unusual, paradoxically, 
obesity tends to be related to high leptin levels, suggestive of leptin resistance 
(Caro et al. 1996). 
In general, reports on leptin levels in T1 D children/adolescents have observed 
higher levels in T1 D subjects compared to controls than would be expected for 
their degree of fat mass (Kamoda et al. 1998; Kiess et al. 1998; Luna et al. 
1999; Bideci et al. 2002; Soliman et al. 2002; Morales et al. 2004) however Kirel 
et al reported lower levels in T1 D children (Kirel et al. 2000) and three groups 
have found similar leptin levels between controls and T1 D subjects (Verrotti et 
al. 1998; Myers et al. 2004; Karaguzel et al. 2006). Indeed in addition, 
Karaguzel et al found no difference in body composition measured by DXA 
between his T1 D children and controls 
Most attempts at intensification of insulin therapy have led to greater weight 
gains than that observed with more standard therapy (Anonymous 1988; 
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Reichard et al. 1991; Anonymous 1995; Danne et al. 1997; Mortensen and 
Hougaard 1997; Holl et al. 1998b). It is possible that the peripheral 
hyperinsulinaemia could lead to greater leptin secretion. Studies by Kolaczynski 
et al (Kolaczynski et al. 1996) showed that insulin did not regulate leptin acutely 
but that long term administration of insulin increased leptin levels both in vivo 
and in vitro and Tuominen (Tuominen et al. 1997) observed that chronically high 
levels of insulin in T1 D young men led to higher leptin levels compared to 
controls but also suggested that unchanged leptin levels before and after a 
euglycaemic hyperinsulinaemic clamp meant that the T1 D subjects were 
resistant to the acute insulin stimulus. 
In spite of higher leptin levels at the start of puberty, girls with T1 D gain more 
body fat during puberty compared to control girls. The term 'Ieptin resistance', 
however, needs to be used with caution as the role of leptin in the regulation of 
normal pubertal weight gain has yet to be confirmed (Ahmed et al. 1999) 
especially as the T1 D boys also had elevated leptin levels and did not gain more 
fat mass but showed higher gains in fat free mass. 
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Chapter 5. Endocrine Changes during Puberty 
5.1 Introduction 
Numerous factors influence the pubertal growth and development of children 
including nutrition and body composition, psychological well-being, physical 
exercise, sleep, genetics and the hormonal environment. Growth hormone's 
action is hypothesized to take one of two routes: either to be mediated by IGF-I 
which then acts either as a classic endocrine hormone (the somatomedin 
hypothesis) or alternatively to act directly causing precursor cells to differentiate 
and produce IGF-I (the dual effector theory), this then signals the local 
generation of IGF-I that is responsible for the clonal expansion of the 
chondrocyte cell line (and thus growth). Insulin acts as an anabolic hormone 
increasing at puberty to compensate for the pubertal insulin resistance which 
then results in a decrease in IGFBP-1 and leads to an increase in the 
bioavailability of free IGF-I. As insulin increases, SHBG decreases which 
subsequently results in an increase in circulating sex hormones. GH pulse 
amplitude is increased by both testosterone and oestradiol (through 
aromatisation from testosterone) and it is thought that estrogens are more 
potent modulators of GH action than testosterone. Leptin has been shown to 
have a 'permissive' effect for the onset of puberty, levels of leptin increase with 
puberty in girls and decrease in boys. Although androgens are thought to 
influence the development of pubic and axillary hair, their role in the initiation of 
puberty remains contentious. Adequate levels of thyroid hormone are 
necessary for normal growth and pubertal development and circulating levels 
appear to decrease during early puberty. 
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All hormones considered here have been explored in relation to a 
developmental scale, i.e. years from peak height velocity and puberty stage 
rather than age. Age, however, was used in the initial data inspection and these 
age graphs are in Appendix 8.12.1. Ascertainment of age at PHV has been 
described in chapter 2 section 2.2.4.1 and for the plots by puberty stage; if a 
child was seen more than once in a puberty stage, the mean in each stage was 
calculated and each child appears only once in a stage. 
Although 8 hormones have been measured in both cohorts, only those that 
appear to differ between the 2 groups are presented here. FT4 was originally 
considered (age graphs are in the Appendix), however, as can be seen in the 
table of geometric means by years from PHV (section 5.9), there is little 
difference between the two cohorts of either sex in levels of FT 4 and so it was 
not considered further. 
All statistical analyses have been done on logged hormone values and 
converted to geometric means in the tables for a more meaningful interpretation. 
Unlogged values are presented on the graphs of grouped data (either in years 
from PHV or puberty stages) as box plots with median and interquartile range 
for visual clarity and the hormone axes have been logged on scatter graphs, 
thereby keeping the real units, for ease of interpretation. 
On the scatter graphs of maximal hormone levels in relation to PHV, the dotted 
lines on the y axis are to aid in the detection of the maximal value achieved and 




5.2.1.1 DHEAS in relation to years from PHV 
DHEAS levels were lower in T1 0 boys compared to controls and increased 
more slowly in relation to years before and after PHV. In a covariance analysis 
with log DHEAS as the dependent variable, years from PHV as a covariate and 
subject id as a fixed factor (to allow for the longitudinal nature of the data) , B ± 
SEM: T1D boys, 0.04 ± 0.007, P <0.0005; and control boys, 0.14 ± 0.006 , 
p<0.0005. Grouping the data in to whole year PHV groups (± 0.5 years) , the 
two cohorts are compared in Figure 5.2a. 
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Figure S.2a, Boys: DHEAS by Years from Peak Height Velocity 
The data has been grouped in whole year PHV groups and is displayed as the median with the interquartile 
range (25th_75th centile) and the 'inner fence' as ± (1.5 (75thc_25thC)) from the edge of the boxes. 
The geometric means of DHEAS by years from PHV and the significance 
between T1 0 and control boys are presented in the following table (Table 5.2a) . 
Boys -2 -1 0 1 2 3 
T10 2.3 2.8 3.6 4.8 4.8 4 .7 
Controls 3.0 4.4 6.3 8.3 10.5 13.2 
P NS 0.04 0.009 0.006 0.003 0.004 
Table S.2a, Boys: DHEAS levels by Years from Peak Height VelOCity (Geometnc Mean) 
These data show that from 1 year before PHV until at least 3 years after, T1 D 
boys have significantly lower levels of DHEAS compared to control boys . 
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5.2.1.2 Maximal DHEAS levels in relation to PHV 
The SPSS graphical method using Loess (Methods 2.2.4) allows a line of best 
fit through the individual data points. Figure 5.2b is a graph of the individual 
points plotted against years from PHV. The maximum value of 5.5micromoliL is 
achieved at 4.5 years after PHV in T1 0 boys and the curve plateaus at this 
value whereas in the control boys a value of 17 micromol/L is achieved at this 
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Figure S.2b, Boys: Attainment of maximum DHEAS levels with relation to Years from PHV 
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Figure S.2c, Boys: DHEAS by Puberty Stages 
Grouping the data by puberty stages , DHEAS levels were lower in T1 0 boys 
compared to controls at all puberty stages and were statistically significantly 
different at stage 3 (p = 0.02) , stage 4 (p = 0.003) and stage 5 (p<O.0005). 
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5.2.2 Girls 
5.2.2.1 DHEAS in relation to years from PHV 
DHEAS levels were lower in T1 D girls compared to controls and increased more 
slowly in relation to years before and after PHV. In a covariance analysis with 
log DHEAS as the dependent variable, years from PHV as a covariate and id as 
a fixed factor (to allow for the longitudinal nature of the data) B ± SEM: T1 0 
girls, 0.03 ± 0.009, p = 0.004; and control girls, 0.10 ± 0.005, p<0.0005. A 
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Figure 5.2d, Girls: DHEAS by Years from Peak Height Velocity 
The data are presented as geometric means of DHEAS by years from PHV and 
the significance between T1 D and control girls is in Table 5.2b. Statistically 
Significant lower levels of DHEAS in the T1 D girls are observed throughout the 
time period stud ied. 
Girls -2 -1 0 1 2 3 
T10 1.7 2.6 2.6 3.1 3.6 3.3 
Controls 4.2 4.5 6.2 7.1 8.9 11 .5 
P 0.003 0.04 0.005 0.001 <0.0005 <0.0005 
it Table 5.2b, Girls: DHEAS levels by Years from Peak Height Veloc y ( Geometric Mean) 
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5.2.2.2 Maximal DHEAS levels in relation to PHV 
The curve for DHEAS in relation to PHV was again exp lored using the Loess 
graphical method in SPSS. 
The maximum value of DHEAS (Figure 5.2e) achieved by T1 0 girls is lower 
than in the control girls (4.0 vs 16.25 micromol/L) and occurs much earlier in 
relation to PHV (0 .75 years after PHV) compared to 5.25 years after PHV in 
control girls. In the latter, the DHEAS may continue to increase; it is difficult to 
say if a plateau has been reached at this point. 
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Figure S.2e, Girls : Attainment of maximum DHEAS levels with relation to Years from PHV 
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Similarly to the boys, DHEAS levels were lower in T1 0 girls compared to 
controls at all puberty stages and this difference became statistically significant 
with the onset of puberty: stage 2, p=0.05; although stage 3 did not reach 
statistical significance (p=0.08) ; however, both stage 4 and stage 5 did , p=O.001 
and p<0.0005 respectively. 
5.3IGF-1 
5.3.1 Boys 
5.3.1.1 IGF-I in relation to years from PHV 
IGF-I levels were lower and increased more slowly in T1 0 boys compared to 
control boys. As the dependent variable in a covariance model , log IGF-I with 
years from PHV as a covariate (id as a fixed factor): T1 0 boys (8 ± SEM) , 0.04 
± 0.006, p<0.0005; control boys, 0.07 ± 0.003, p<0.0005) . Grouping the data 

















N = 10 21 18 23 24 23 22 23 22 23 19 15 13 5 11 2 
-3 -2 -1 0 234 
Years from PHV (whole year age groups) 
Figure 5.3a, Boys: IGF-I by Years from Peak Height Velocity 
To statistically quantify the difference, the data are presented as geometric 
means of IGF-I by years from PHV in table 5.3a and the significance of the 
difference between the two cohorts is given. 
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Boys -3 -2 -1 0 1 2 3 
T10 174.34 149.68 225.05 306.42 315.62 267 .20 241 .68 
Controls 180.60 197.92 268.08 376.96 401 .83 372.24 373.08 
P NS <0.0005 .03 .002 .002 .02 .004 
I -Tab e 5.3a. Boys. IGF I levels (ng/ml) by Years from Peak Height Velocity (Geometric mean) 
The levels of IGF-I were lower in T1 D boys compared to controls from 3 years 
before to 3 years after PHV. This difference became significant 2 years before 
PHV and then remained so throughout the period studied . 
5.3.1.2 Maximal Levels of IGF-I by Years from PHV 
The Loess graphical method (SPSS) was used to explore if and at what time the 
curve of IGF-I reached a maximum/plateau in relation to PHV (Methods 2.2.4). 
The overall values are lower in T1 D boys compared to controls throughout the 
time studied. The maximum value in the T1D boys of 312ng/ml is achieved at 
approximately 0.9 years after PHV compared to 393ng/ml in the control boys at 
1.25 years after PHV (Figure 5.3b). Thereafter the levels decrease in the T1 D 
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Figure 5.3b, Boys: Attainment of maximum IGF-Ilevels in relation to Years from PHV 
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Figure 5.3c, Boys: IGF-I by Puberty Stages 
IGF-I levels were lower in T1 D boys compared to control boys in all puberty 
stages. This was significant in stage 1 (p=0.003) , stage 3 (p=0.02) , stages 4 
and 5 (p<0.0005). 
5.3.2 Girls 
5.3.2.1 IGF-I in relation to years from PHV 
IGF-I levels were lower and increased more slowly in T1 D girls compared to 
control girls when viewed in relation to years before and after PHV. In a 
covariance model , log IGF-I was the dependent variable with years from PHV as 
a covariate (id as a fixed factor) : T1 D girls (8 ± SEM), 0.03 ± 0.007, p<0 .0005; 
control girls, 0.06 ± 0.003, p<0.0005). The levels of IGF-I by whole year PHV 
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Figure 5.3d, Girls: IGF-I by Years from Peak Height Velocity 
Table 5.3b presents the data as geometric means of IGF-I by whole years from 
PHV with the significance between the two cohorts presented. 
Girls -2 -1 0 1 2 3 4 
T10 140.37 191 .68 268.58 315.81 329.71 245.12 254.54 
Controls 181 .39 213.16 311.43 396.22 377.93 300.51 268.59 
P NS NS .06 .009 NS .02 NS 
Table 5.3b, Girls. IGF-I levels by Years from Peak Height Velocity (Geometnc Mean) 
The T1 0 girls have lower levels of IGF-I at every time grouping around PHV and 
this is most statistically significant at one year after PHV. 
5.3.2.2 Maximal Levels of IGF-I in relation to PHV 
Loess was used to determine when and if a maximum level of IGF-I in relation to 
PHV was achieved. The maximum value in T1 0 girls compared to controls is 
lower although it is achieved at a similar time in relation to PHV. In the T1 0 
girls, the maximum of 330ng/ml is achieved at approximately 1.5 years after 
PHV compared to 385ng/ml in the control girls at 1.6 years after PHV (Figure 
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Figure 5.3e, Girls: Attainment of maximum IGF-I levels in relation to Years from PHV 
5.3.2.4 IGF-I in relation to Puberty Stages 
Interestingly, the girls with T1 0 did not have lower IGF-Ilevels compared to 
controls when grouped by puberty stages for stage 2 or 3 although they became 
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Figure 5.3f, Girls: IGF-I by Puberty Stages 
5.4 Androstenedione (A4) 
5.4.1 Boys 
5.4.1.1 A4 in relation to years from PHV 
Levels of A4 were lower and increased more slowly in T1 0 boys than controls in 
relation to years before and after PHV. In a covariance analysis with log A4 as 
the dependent variable, years from PHV as a covariate and id as a fixed factor , 
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B ± SEM: T1D boys, 0.04 ± 0.006, p<0.0005; and control boys, 0.08 ± 0.004 , 
p<0.0005. The data are grouped into whole year PHV groups (± 0.5 year) and 
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Figure 5.4a, Boys: A4 by Years from PHV 
The geometric means of A4 by years from PHV and the significance between 
T1 D boys and control boys are presented in the following table (Table 5.4a). 
Boys -3 -2 -1 0 1 2 3 
T10 3.11 4 .12 4.28 4.31 5.34 6.16 7.01 
Controls 3.59 3.64 4.63 5.63 7.00 8.02 9.25 
P NS NS NS .04 .03 NS NS 
Table 5.4a, Boys: A4 levels nmol/L by Years from Peak Height Velocity (Geometric Mean) 
Looking at the PHV whole year groups in terms of these geometric means, 
although there is a trend for lower levels of A4 in T1 D boys, this only becomes 
statistically significant at PHV, p=0 .04 and one year after PHV, p=0 .03. 
5.4.1.2 Maximal A4 levels in relation to PHV 
Loess was again employed (Methods 2 .2.4) to draw the line of best fit th rough 
the data . The maximal value of A4 achieved by the T1 D boys (Figure 5.4b) is 
lower and later in relation to the timing of PHV than in the control boys: 
8.1 nmollL at 5.3 years after PHV vs 1 0.3nmol/L at 4 .3 years after PHV. On the 
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basis of this data, it is not possible to say whether this is a plateau or whether 
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Figure S.4b, Boys: Attainment of maximum levels of A4 with relation to PHV 
5.4.1.4 A4 in relation to Puberty Stages 
Puberty stage grouping of A4 levels in T1 D and control boys shows little 
difference except at mid/late puberty (Figure 5.4c) . A statistically significant 
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Figure S.4c, Boys: A4 by Puberty Stages 
5.4.2.1 A4 in relation to years from PHV 
Levels of A4 were lower and increased more slowly in T1 D girls than controls in 
relation to years before and after PHV. In a covariance analysis with log A4 as 
the dependent variable , years from PHV as a covariate and id as a fixed factor , 
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B ± SEM: T1D girls, 0.07 ± 0.008, p<0.0005; and control girls, 0.08 ± 0.004 
p<0.0005. To compare the two cohorts , whole year age groups (± 0.5 years) of 
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Figure 5.4d, Girls: A4 by Years from Peak Height Velocity 
The geometric means of A4 by whole year age groupings from PHV and the 
significance between T1 0 girls and control girls are presented in the following 
table (Table 5.4b) . 
Girls -2 -1 0 1 2 3 4 
T10 2 .89 2.37 3.26 4 .94 5.59 6.27 6.29 
Controls 3.46 4 .00 5.71 6.75 7.97 9.21 8.97 
P NS .001 .001 .007 .006 <.0005 .009 
Table 5.4b, Girls: A4 levels by Years from PHV (Geometric Mean) 
Looking at the PHV whole year groups in terms of these geometric means, there 
is a statistically significant difference between the two cohorts at one year 
before PHV, p=0.001 and for all the subsequent time periods stud ied . 
5.4.2.3 Maximal A4 levels in relation to PHV 
Loess was again employed (Methods 2.2.4) to draw the line of best fit through 
the data. The maximal value of A4 achieved by the T1 0 girls (Figure 5.4e) is 
lower than in the control girls although the timing is similar: 7.7nmol/L at 5.1 
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Figure 5.4e, Girls: Attainment of maximum A4 levels with relation to Years from PHV 
5.4.2.4 A4 in relation to Puberty Stages 
A4 analyses in the girls by puberty stage are shown in Figure 5Af. Levels of A4 
tend to be lower in T1 0 girls than controls for all puberty stages except stage 4. 
The difference is highly statistically significant at stage 3, p=O.008 and stage 5, 
p=O.002; and nearly significant at stage 2, p=O.06. 
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Figure 5.4f, Girls: A4 by Puberty Stages 
5.5 SHBG 
5.5.1 Boys 
5.5.1.1 SHBG in relation to years from PHV 
Levels of SHBG decrease from 3 years before PHV to 3 years after PHV in both 
control and T1 0 boys and were higher in T1 0 boys throughout. In a covariance 
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analysis with log SHBG as the dependent variable , years from PHV as a 
covariate and id as a fixed factor; B ± SEM: T1 0 boys, - 0.06 ± .004, p<0.0005 ' 
and control boys - 0.09 ± 0.003, p<0.0005. Grouping the data into whole year 
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Figure 5.5a, Boys: SHBG by Years from Peak Height Velocity 
To quantify the difference between the two cohorts, the data are presented as 
geometric means in the whole year PHV age groups in Table 5.5a. 
Boys -3 -2 -1 0 1 2 3 
T10 74.44 73.84 65.78 49.34 38.34 32.45 30.96 
Controls 66.48 63.97 53.66 36.45 27.97 25.10 24.21 
P NS NS .02 .004 .004 .05 NS 
Table 5.5a, Boys: SHBG levels by Years from PHV (Geometric Mean) 
The mean levels of SHBG are higher in the T1 0 boys from 3 years before to 3 
years after PHV and this is statistically significant 1 year before PHV and 
remains so until 2 years after PHV. The data are insufficient thereafter to 
comment on. 
5.5.1.2 Maximal SHBG levels in relation to PHV 
The Loess SPSS graphical procedure of fitling a best line through the individual 
points has been applied to the SHBG data (Figure 5.5b) . The shape of these 
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graphs in the 2 cohorts of boys is similar and appears as an inverted elongated 
"S". In the T1 D boys; at 1.75 years before PHV, when SHBG is near 73 nmol/L 
, 
the decline appears to accelerate and decreases until 1 year after PHV occurs. 
In the control boys, this period of decrease begins at 1.5 years before PHV 
when SHBG is at a lower level of 58nmoi/L and proceeds until 1 year after PHV. 
In both groups this rate of decrease starts to slow down approximately 1 year 
after PHV and subsequently continues to slowly decrease (perhaps more slowly 
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Figure S.Sb, Boys: SHBG in relation to Years from PHV 
5.5.1.3 SHBG in relation to Puberty Stages 
SHBG levels are higher in each puberty stage for the T1 D boys compared to the 
control boys. This difference is statistically significant at stage 3, p=0.04 and 
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Figure 5.5c, Boys: SHBG by Puberty Stages 
5.5.2.1 SHBG in relation to years from PHV 
SHBG levels decrease from 2 years before PHV to 4 years after in both cohorts 
of girls. In a covariance analysis with log SHBG as the dependent variable , 
years from PHV as a covariate and id as a fixed factor; B ± SEM: T1 D girls , -
0.01 ± .005, p=0.008; and control girls, -0 .04 ± .003, p<0.0005 . Grouping the 
data into whole year age groups (± 0.5 years) , the two cohorts are compared in 
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Figure 5.5d, Girls: SHBG by Years from Peak Height Velocity 
Table 5.5b presents the data as geometric means of SHBG by whole years from 
PHV with the significance of the difference between the two cohorts presented . 
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Girls -2 -1 0 1 2 3 4 
T10 80.82 64.00 58.32 55.80 57.81 54.85 54.72 
Controls 65.83 59.24 53.17 47.47 46.26 42.00 42.49 
P NS NS NS NS .06 .02 NS 
Table 5.5b Girls: SHBG by Years from Peak Height Velocity (Geometric mean) 
The mean levels of SHBG are higher in the T1 0 girls compared to control girls 
throughout the time period studied but this only reaches statistical significance 
at 3 years after PHV. 
5.5.2.2 Maximal SHBG levels in relation to PHV 
A 'best fit' line through the individual points using the Loess method of SPSS 
has been applied to the SHBG data (Figure 5.5e). The shape of these graphs is 
different in the two cohorts of girls. The first phase of the graph in the T1 0 girls 
is a decreasing straight line that starts in the years before PHV until 0.6 years 
after PHV when it then appears to plateau until 3.2 years after PHV and then 
continues a slow decline. At 2.5 years before PHV, SHBG is 78nmoi/L and at 
0.6 years after PHV it has reached 55nmol/L. The picture in the control girls is 
the opposite, the first phase appears to be a steady state until 1.65 years before 
PHV with mean SHBG values of 63nmoi/L and then a straight line decline 
begins that lasts for the study period and if we look until 4 years after PHV when 
levels are 37.5nmol/L. 
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Figure 5.5e, Girls: Attainment of maximal SHBG levels with relation to PHV 
136 
5.5.2.3 SHBG in relation to Puberty Stages 
Levels of SHBG grouped by puberty stages for both cohorts of girls are shown 
in Figure 5.5f. Although SHBG levels are similar or greater in both groups of 
girls, there is no statistically significant difference between the two cohorts 
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Figure S.Sf, Girls: SHBG by Puberty Stages 
5.6.1.1 Leptin in relation to years from PHV 
Levels of leptin were markedly higher in T1 0 boys throughout the study period 
and decreased from 1 year before PHV to 3 years after PHV in both control and 
T1D boys. In a covariance analysis with log leptin as the dependent variable , 
years from PHV as a covariate and id as a fixed factor; B ± SEM: T1 0 boys, -
0.02 ± .006, p<0.0005; and control boys - 0.03 ± 0.004 , p<0.0005. Grouping 
the data into whole year PHV groups (± 0.5 years); the two cohorts are 
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Figure 5.6a, Boys: Leptin by Years from Peak Height Veloc ity 
To quantify the difference between the two cohorts , the data are presented as 
geometric means in the whole year PHV age groups in Table 5.6a . 
Boys -3 -2 -1 0 1 2 3 
T1D 4 .19 3.95 4.73 3.38 3.14 2.97 3.13 
Controls 2.11 2.38 2.38 2.06 1.92 1.91 1.88 
P .006 .001 <0.0005 .001 .002 .001 NS 
Table 5.6a, Boys. Leptm by Years from Peak Height VelOCity (Geometric mean) 
Leptin levels are significantly higher in T1 0 boys throughout the whole study 
period. 
5.6.1.2 Maximal Leptin levels in relation to PHV 
The Loess graphical method (SPSS) was used to explore if and at what time the 
curve of leptin reached a maximum/plateau in relation to PHV (Methods 2.2.4). 
In the T1 0 boys, leptin levels appear to increase to a maximum of 4.2 ng/ml at 
1.5 years before PHV and then slowly decrease and plateau at 2.9 ng/ml at 3 
years after PHV. There does not appear to be an increase in the control boys 
before PHV but rather a plateau at 2.2ng/ml from the start of the study period 
until 1.4 years before PHV and then a decl ine to 1.6ng/ml which is maintained 
from 1 to 1.6 years after PHV and wh ich then may slowly decline although the 
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Figure 5.Gb, Boys: Attainment of maximum levels of Leptin in relation to Years from PHV 
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Figure 5.Gc, Boys: Leptin by Puberty Stages 
Leptin levels were higher in T1 0 boys compared to control boys in all puberty 
stages. This was statistically significant in stages 2, 3, 4 and 5 where the p 
values were <0.0005, 0.007, <0.0005 and <0.0005 respectively. 
5.6.2 Girls 
5.6.2.1 Leptin in relation to years from PHV 
Levels of leptin in the girls were again markedly higher in T1 0 cohort throughout 
the study period. Levels increased from 2 years before PHV to 4 years after 
PHV in both control and T1 0 girls . In a covariance analysis with log leptin as 
the dependent variable , years from PHV as a covariate and id as a fixed factor; 
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B ± SEM: T1 0 girls, 0.08 ± .009, p<0.0005; and control girls 0.06 ± 0.005 
, 
p<0.0005. Grouping the data into whole year PHV groups (± 0.5 years); the two 
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Figure 5.6d, Girls: Leptin by Years from Peak Height Velocity 
To quantify the difference between the two cohorts , the data are presented as 
geometric means in the whole year PHV age groups in Table 5.6b. 
Girls -2 -1 0 1 2 3 4 
T10 4.85 7.61 7.50 7.50 8.96 10.71 12.37 
Controls 2.48 3.14 3.07 3.22 3.96 5.51 6.01 
P <0.0005 <0.0005 <0.0005 <0.0005 <0.0005 <0.0005 .002 
Table 5.6b, Girls: Leptln by Years from Peak Height Velocity (Geometric mean) 
Leptin levels are significantly higher in T1 0 girls throughout the whole study 
period. 
5.6.2.2 Maximal Leptin levels in relation to PHV 
Loess was again used to draw the line of best fit through the leptin data in 
relation to PHV (Methods 2.2.4) . In the T1 0 girls, there is a continual almost 
straight line increase throughout the study period reach ing a maximum of 
12.7Sng/ml at 4.75 years after PHV. The data does not extend beyond that 
point and it is therefore not possible to tell if leptin levels then plateau or 
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continue to increase. In the control girls there is an increase from 3/4 years 
before PHV to 0.4 years before where the level plateaus at 2.95ng/ml until 0.55 
years after PHV. At this point it appears to increase again to 7ng/ml at 4.85 
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Figure 5.6e, Girls: Attainment of maximum levels of Leptin in relation to Years from PHV 
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Figure 5.6f, Girls : Leptin by Puberty Stages 
Leptin levels were higher in T1 0 girls compared to control girls in all puberty 




5.7.1.1 Testosterone in relation to years from PHV 
Testosterone levels were lower and increased more slowly in T1 0 boys 
compared to control boys. As the dependent variable in a covariance model 
, 
log testosterone with years from PHV as a covariate (id as a fixed factor) : T1 0 
boys (8 ± SEM), 0.27 ± 0.01, p<0.0005; control boys, 0.33 ± 0.008, p<0.0005) . 
Grouping the data into whole year PHV groups (± 0.5 years) ; the two cohorts 
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Figure 5.7a, Boys: Testosterone by Years from Peak Height Velocity 
To statistically quantify the difference, the data are presented as geometric 
means of testosterone by years from PHV in table 5.7a and the significance of 
the difference between the two cohorts is given. 
Boys -3 -2 -1 0 1 2 3 
TID 0.43 0.52 1.43 5.44 10.95 14.05 16.72 
Controls 0.39 0.66 3.12 10.23 16.75 19.06 19.97 
P NS NS .001 <0.0005 <0.0005 .009 NS 
Table 5.7a, Boys: Testosterone by Years from Peak Height Velocity (Geometric mean) 
The difference in testosterone levels is statistically significant from one year 
before to 2 years after PHV. 
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5.7.1.2 Maximal Testosterone levels in relation to PHV 
The line of best fit was again drawn by loess (SPSS) through the testosterone 
data in relation to years from PHV. An 'S' shaped curve (the mirror image of the 
SHBG curves) was obtained for both cohorts with a maximum level of 16nmoliL 
of testosterone reached at 4 years after PHV in the T1 D boys and 26nmoliL in 
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Figure 5.7b, Boys: Attainment of maximum levels of Testosterone in relation to PHV 
5.7.1.4 Testosterone in relation to Puberty Stages 
Testosterone levels were lower in T1 D boys compared to control boys in all 
puberty stages. This was significant in all stages except stage 2; stage 1 
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Figure 5.7c, Boys: Testosterone by Puberty Stages 
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5.7.2 Girls 
5.7.2.1 Testosterone in relation to years from PHV 
Testosterone levels were lower in T1 0 girls compared to control girls. As the 
dependent variable in a covariance model, log testosterone with years from 
PHV as a covariate (id as a fixed factor): T1D girls (8 ± SEM), 0.06 ± 0.01 , 
p<0.0005; control girls, 0.11 ± 0.005, p<0.0005) . Grouping the data into whole 
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Figure 5.7d, Girls: Testosterone by Years from Peak Height Velocity 
The data are presented as geometric means of testosterone by years from PHV 
in table 5.7b and the significance of the difference (based on logged data) 
between the two cohorts is given. 
Girls -2 -1 0 1 2 3 4 
TID 0.45 0.48 0.65 0.69 0.99 0.96 1.21 
Controls 0.38 0.43 0.76 1.05 1.14 1.35 1.54 
P NS NS NS .03 NS .06 NS 
Table 5.7b, Girls: Testosterone by Years from Peak Height VelOCity (Geometric mean) 
Although the level of testosterone tends to be lower in the T1 0 girls from the 
time of PHV onwards, it is only statistically significant (p=0.03) at one year after 
PHV. 
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5.7.2.2 Maximal Testosterone levels in relation to PHV 
The line of best fit through the testosterone data in relation to years from PHV 
was again drawn by loess (SPSS). The shape of the curve for the T1 0 girls is a 
rather flattened 'S'shape while that of the control girls appears properly 'S' 
shaped. The curve of the T1 0 girls reaches a maximum of 1.3nmol/L at 5.1 
years after PHV and that of the controls is 1.7nmollL at nearly the same time, 
5.2 years after PHV. 
T1D Girls 
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Figure S.7e, Girls: Attainment of maximum levels of Testosterone in relation to PHV 
5.7.2.3 Testosterone in relation to Puberty Stages 
T1D girls had significantly higher testosterone levels than controls at puberty 
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Figure S.7f, Girls : Testosterone by Puberty Stages 
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5.8 Oestradiol (E2) 
5.8.1 Boys 
Oestradiol was not measured in the control boys and so there is no comparison . 
The geometric means for the T1 0 boys are given for information. 
Boys -3 -2 -1 0 1 2 3 
TID 33.32 26.05 25.25 30.60 36.69 45.09 83.43 
Controls Not done 
Table 5.8a, Boys. OestradIol by Years from Peak HeIght VelOCIty (Geometric mean) 
5.8.2 Girls 
5.8.2.1 E2 in relation to years from PHV 
Levels of E2 increased slowly in both cohorts in relation to PHV. In a 
covariance analysis with log E2 as the dependent variable, years from PHV as a 
covariate and id as a fixed factor, T1D girls (8 ± SEM), 0.17 ± 0.01, p<0.0005; 
control girls, 0.24 ± 0.01, p<0.0005). Grouping the data into whole year PHV 
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Figure 5.8a, Girls: Oestradiol by Years from Peak Height Velocity 
Levels of E2 were higher in T1 0 girls before PHV although this was only 
significant 2 years before PHV, once PHV had occurred levels were higher in 
control girls and this difference was statistically significant 2 years after PHV. 
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Girls -2 -1 0 1 2 3 4 
T1D 38.14 36.97 50.48 117.41 158.46 245.12 254.54 
Controls 18.72 33.14 74 .83 175.08 302.08 300.51 268.59 
P* <0.0005 NS .06 .07 .03 NS NS 
Table 5. i 8b, G rls. Oestradiol by Years from Peak Height VelOCity (Geometric mean) 
5.8.2.2 Maximal E2 levels in relation to PHV 
The best-fit line was again drawn through the data by loess (SPSS) for both 
cohorts. The girls with T1 D appear to have higher levels of E2 three years 
before PHV and their'S' shaped increase reaches a maximum of 240pmoi/L at 
4.7 years after PHV. The control girls start from a lower E2 level at 1-3 years 
before PHV and have a steeper rise to 280 pmol/L at 2.4 years after PHV. 





. .. : .. 
1000 ... '" • 
".. II f:.~ ••• 
.....J ~gg • .:r: • .. , .... 
(5 • • ..., ••• ! ~~~ _________ _ ~ -----O.~ O\~O.-.----~~ ••• ~~-- .. -o . 
'6 100 • a.; •• -:a •• ~ ••• ' •• I , • ~ 50 e. ... e. • . • •• -
o ~g ::""i··· · 
. . .. ,-. . 
20 • • • •• • 
e. • ... , • 
10 • 10-•• - •• 
. e._. .: 
. , . . ' 
~ 500 e.. . . : 
(5 400 • ••••• - : 
E 300 •••• ,.. " a. 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 • 0 0 . 0 c. 0 0 0 o. 0 0 0 0 • 
200 .~ - .. (5 , •• ,. ._ It 
'6 • .c. ' ~ 100 ...... ~ 
U) --.... : -
Q) 50 • •••• • o 40 •• __ ~___ ' 
30 ~ -_ •• 
. ' 
~ ~ ~ ~ ~ ~ 0 1 234 5 6 
Years from PHV Years from PHV 
Figure 5.8b, Girls: Attainment of maximum levels of E2 in relation to PHV 
5.8.2.4 E2 in relation to Puberty Stages 
E2 comparison by puberty stage in the girls is shown in Figure 5.8c. E2 levels 
tend to be higher in control girls compared to girls with T1 D at all puberty stages 
from 2 to 5 although the difference is not statistically significant. The T1 0 girls , 
however, have Significantly higher (p= 0.004) E2 levels prepubertally (stage 1) 
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Figure 5.8c, Girls : E2 by Puberty Stages 
5.9 Free thyroxine (FT4) 
The tables below of geometric means by years from PHV and the graphs of FT 4 
by age in the appendix demonstrate that there is very little difference in the FT 4 
levels during puberty between the two cohorts of children. 
Boys -3 -2 -1 0 1 2 3 
TID 13.76 14.71 14.52 13.59 13.26 14.52 15.86 
Controls 15.93 15.71 14.99 14.01 15.10 15.68 14.53 
P .05 NS NS NS .07 NS NS 
Table 5.9a, Boys: FT4 by Years from Peak Height VelOCity (Geometric Mean) 
Girls -2 -1 0 1 2 3 4 
TID 14.43 13.91 14.18 12.74 13.37 14.54 11.95 
Controls 15.29 14.08 13.17 13.92 14.38 15.53 14.63 
P NS NS NS NS NS NS NS 
Table 5.9b, Girls: FT4 by Years from Peak Height VelOCity (Geometric Mean) 
5.10 Summary and Discussion 
A number of the hormones studied have lower values in the T1 0 children than 
the controls (DHEAS, IGF-I, A4 , testosterone and oestradiol) whether examined 
in terms of peak height velocity or puberty. 
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Dramatic differences were seen in this data for DHEAS, which was lower in the 
T1 D cohort in both sexes before PHV and became progressively more so with 
pubertal progression. The mean maximum values were very different and were 
not achieved until after PHV in both sexes. There was a tempo difference in the 
girls; T1 D girls plateaued at 0.75 years after PHV while in the control girls, levels 
were still increasing at 5.25.years after PHV with a suggestion (but insufficient 
data) that no plateau had yet been reached. Other investigators have seen 
lower levels of DHEAS in T1 D (Cohen et al. 1984; Loviselli et al. 1994; Radetti 
et al. 1994) although Small's study of 17 young men with T1 D (mean age 21 
years) found no difference in DHEAS levels in these subjects and age matched 
controls and no relationship of DHEAS and HbA 1 c (Small et al. 1989). Meyer et 
al found no difference in DHEAS levels in either sex between T1 D subjects and 
puberty matched controls. Their cohort of T1 D adolescents appears to be 
exceedingly well controlled with an insulin dose that did not increase 
significantly during puberty and at stage 5 was 0.98 ± 0.26 U/kg/d in males and 
0.89 ± 0.08 U/kg/d in females. In addition there was no significant difference in 
HbA 1 c levels between puberty groups and at stage 5 they were 8.2 ± 1.4% and 
8.4 ± 2.4% respectively in males and females (Meyer et al. 2000). Couch's 
study of 23 post pubertal T1 D subjects observed that those designated as being 
in poor control (HbA1c>10%) had lower DHEAS levels than those in good 
control (HbA 1 c<8.00/0) (Couch 1992). Ebeling et al explored the relationship of 
hyperinsulinaemia and DHEAS in T1 D subjects using a 4-hour euglycaemic 
insulin clamp and found that DHEAS decreased with high levels of insulin. In 23 
young men with 'good' control (mean HbA1c 7.8%) they observed that mean 
DHEAS concentration was in the normal range but that during an insulin 
infusion DHEAS levels decreased by 11 % (Ebeling et al. 1995). Radetti's study 
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on 129 T1 D children observed a negative and significant DHEAS-SDS (-0.36 ± 
0.77) and a negative correlation of DHEAS-SDS and HbA1c although no 
relation between DHEAS and insulin dose. Citing the work of Kobayashi et al 
(Kobayashi et al. 1983) on the pharmacokinetics of insulin (which showed that 
supraphysiological insulin levels were achieved after each subcutaneous insulin 
injection) they claimed that every insulin administration would be expected to 
lower DHEAS regardless of the dose (Radetti et al. 1994). 
Could we conjecture that in pubertal subjects with T1 D there might be a 
synergistic effect of the insulin resistance of puberty as well as the multiple 
insulin injections that act in concert to suppress the levels of DHEAS in these 
subjects? 
IGF-I was lower in the current T1 D cohort compared to controls throughout the 
time period studied whether considered by years from PHV or by puberty 
stages. Lower levels in T1 D children have almost universally been observed in 
numerous studies over many years (Amiel et al. 1984; Taylor et al. 1988; 
Rogers et al. 1991; Massa et al. 1993; Clayton et al. 1994; Radetti et al. 1997; 
Zachrisson et al. 1997; Cianfarani et al. 2000). While most of these studies 
have been cross sectional and have commented that levels peak at 'midpuberty' 
(Massa et al. 1993) or 'stage 4' (Clayton et al. 1994) our longitudinal study 
reinforces the finding that the peak of IGF-I occurs after PHV in both sexes in 
both control and T1 D children. Although the levels rise throughout puberty in all 
the children, the growth velocity has started to slow while the levels of IGF-I 
continue to rise. The large study of Lofvist et al observed this by noting a 
positive relation between age and IGF-I in early puberty and then a negative 
association in late puberty (Lofqvist et al. 2001). 
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The maximum level in the boys occurred approximately 0.9 years after and 1.25 
years after PHV in T1 D and controls respectively. In terms of puberty stage this 
would appear to be stage 4 with little change in stage 5 in both groups. In the 
girls the time of the maximum level is very similar at 1.5 and 1.6 years after 
PHV, T1 D and controls respectively. As in the boys, this looks like occurring in 
stage 4 with little change in stage 5. 
On a purely speculative note, it would appear that the levels of IGF-I may 
overcome the abnormalities within the diabetic pubertal GHIIGF-I axis/insulin 
resistant pubertal state to enable growth in concert with the rise of GH and sex 
steroids at this challenging time. However, as the demands of the growth spurt 
diminish, there would appear to be a switch in priorities, such that the effects of 
IGF-I and the sex steroids concentrate more on body composition rather than 
growth, ie towards the development of muscle and adipose tissue as well as 
bone development. 
To a certain extent the changes in total IGF-I presented here may not give us a 
true picture, as this does not reflect changes in IGF-I bioavailability. We know 
that IGF-I is modulated by the two binding proteins IGFBP-I (as an inhibitor) and 
BP-3 as the major carrier protein and without knowledge of their levels it is not 
possible to comment on the IGF-I bioavailability. 
By contrast, leptin levels were strikingly higher in the T1 D children compared to 
controls. In all boys, leptin levels decreased with time but whether in relation to 
PHV or puberty stage, the T1 D boys had consistently higher leptin levels than 
controls. Maximum levels of 4.2ng/ml at 1.5 years before PHV are reached 
before decreasing to 2.2ng/ml at 3 years after PHV in the T1 D boys this 
contrasts with a plateau (at 2.2ng/ml) in the years before PHV in the control 
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boys until starting to decline at 1.4 years before PHV to 1.6ng/ml at 1 year after 
PHV. Leptin levels in both groups of girls increase with time and the T1 0 girls 
have higher leptin levels than control girls viewed by years from PHV or by 
puberty stage. The maximum levels (12.75ng/ml, T1D vs 7ng/ml, controls) were 
reached by both groups of girls at the end of the observation period of this study 
but it is likely that the levels continue to increase although the data here is 
insufficient to allow comment. The pattern of increase from before PHV to after 
in the two cohorts of girls appears different with a plateau in the control girls 
around the time of PHV and then a sharp increase, in contrast the T1 0 girls 
appear to have a steady increase in leptin levels in relation to PHV. The 
grouped puberty stage data again shows the marked differences between the 
two cohorts. 
The tendency for leptin levels to increase in girls and fall in boys during puberty 
reflects the sexual dimorphism in body composition relationships to leptin as 
girls gain more fat mass and boys more fat free mass during puberty. This has 
been described by other investigators as well (Blum et al. 1997; Carlsson et al. 
1997; Clayton et al. 1997; Garcia-Mayor et al. 1997). Intriguingly, in spite of the 
continuing decrease in percent body fat in the T1 0 boys and increasing fat 
mass in the girls, higher leptin levels are observed in the diabetic subjects than 
in the controls in both sexes. 
Although it is probable that hyperinsulinaemia in the T1 0 cohort is a major 
determinant of the elevated leptin levels, sex steroids may well playa role. 
Testosterone, which is related to fat free mass, appears to have a role in 
lowering leptin levels although the mechanism is unknown. An inverse 
relationship of testosterone levels and leptin in boys and men has been 
observed (Blum et al. 1997; Clayton et al. 1997; Garcia-Mayor et al. 1997; 
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Mantzoros et al. 1997; Ambrosius et al. 1998} while long-term treatment with 
testosterone in hypogonadal males decreases leptin concentrations 
(Jockenhovel et al. 1997). Adan (Adan et al. 1999) treated ten boys with 
delayed puberty with testosterone for three months and observed a decrease in 
leptin in spite of weight gain and increasing 8MI with no change in insulin 
concentrations. Palmert et al (Palmert et al. 1998) also observed in boys with 
central precocious puberty that leptin levels were lower when testosterone was 
higher before and after GnRH suppression. Wabitsch (Wabitsch et al. 1997) 
using cultured human adipocytes provided evidence for a direct effect of 
testosterone on adipose tissue showing that testosterone decreased leptin 
levels by 62% and suppressed leptin mRNA. 
Oestrogen may enhance leptin levels but the findings are not consistent. 
Shimizu et al (Shimizu et al. 1997b) found that E2 administration increased 
leptin levels in women and they also observed lower leptin levels in 
ovariectomised rats compared to normal rats or to other ovariectomised rats 
given E2 replacement. Casabiell et al (Casabiell et al. 1998) found that E2 
increased leptin in omental tissue from women but not men, and several studies 
reported higher leptin levels during the menstrual cycle in the luteal phase when 
E2 levels are higher (Shimizu et al. 1997a; Mannucci et al. 1998; Messinis et al. 
1998; Riad-Gabriel et al. 1998). Furthermore studies in transsexuals observed 
that testosterone treatment in females to males decreased leptin but a 
combination of E2 and antiandrogen increased leptin in male to female, and this 
was independent of changes in fat mass or the genetic sex (Elbers et al. 1997). 
Countering these observations, several researchers have not found evidence of 
an oestrogen stimulating effect on leptin production. Ainslie et al (Ainslie et al. 
2001) found no evidence of diminished leptin secretion in ovariectomised rats 
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confirming the work of Pelleymounter et al (Pelleymounter et al. 1999) whose 
work in mice led them to conclude that oestradiol does not directly regulate 
leptin secretion or its effects on fat mass but suggested that the two may 
interact in an indirect fashion to affect fat utilisation. Havel et al (Havel et al. 
1996) reported the same levels of leptin in pre and postmenopausal women if 
they were matched for fat mass and observed that HRT did not alter leptin 
levels. In their study of girls with central precocious puberty, Palmert et al 
(Palmert et al. 1998) observed that oestrogen levels had no discernible effect on 
leptin levels before, during or after GnRH suppression. 
These varied results imply a complex relationship between leptin and oestrogen 
and suggest that although oestrogen may not have a direct stimulatory role the 
two may interact in an indirect fashion. 
SHBG levels decreased in both sexes and both cohorts of subjects throughout 
the period studied in agreement with the cross sectional studies of Holly et al 
(Holly et al. 1989; Holly et al. 1992). T1D children of both sexes had higher 
levels compared to controls whether by years from PHV or puberty stage. This 
difference was more marked in the boys compared to the girls. In the boys, the 
decline appears as an elongated inverted'S' shape, at 1.75 years before PHV 
levels are 73nmollL and decreases until about 1 year after PHV when it levels 
out. It is similar in the control boys starting at 1.5 years before PHV at 58nmollL 
and declining until 1 year after PHV when the rate of decline slows. The pattern 
of decline in the two cohorts of girls is very different. At 2.5 years before PHV it 
is near 78nmollL and at 0.6 years after PHV it is 55nmollL where it plateaus. 
Levels in the control girls start at 63nmollL and appear to stay there until starting 
to decline at 1.65 years before PHV as far as the data goes after PHV. 
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The published data are not unanimous on whether levels of SHBG are higher or 
lower in T1 0 adolescents compared to control subjects with some observing 
lower SHBG concentrations (Ebeling et al. 1995; Rudberg and Persson 1995) 
others reporting equal values in T1 0 and controls (Meyer et al. 2000) or higher 
levels in T1 0 subjects (Djursing et al. 1985; Christensen et al. 1997) and the 
group of Holly et al (Holly et al. 1992) who observed lower SHBG levels in the 
T1D children prepubertally but equal concentrations in the pubertal T1 0 
subjects compared to controls. 
Sex steroids have long been believed to exert some degree of control over 
SHBG concentrations (Anderson 1974) and although it was accepted that 
testosterone decreased SHBG (and this fit with increasing levels of testosterone 
during puberty and decreasing SHBG levels), it did not entirely support the 
stimulatory effect that oestrogen was meant to have on SHBG when levels of 
SHBG decrease during puberty in the face of increasing oestrogen levels. 
Treated boys with CDGP (Malhotra et al. 1993) and children with adrenarche 
(Montalto et al. 1989; Balducci et al. 1992; Denburg et al. 2002) were seen to 
have low SHBG attributed to by increased androgen levels. In a recent article 
by Sorensen et al negative associations were found between SHBG and 
testosterone, E2 and DHEAS in boys and DHEAS in girls. This relationship 
remained after correction for BMI and levels of testosterone and E2. In addition 
body composition was assessed and negative relationships seen with BMI and 
percent body fat after adjustment for sex steroids. The conclusion here was that 
increasing fat mass might be partly responsible for the decrease in levels of 
SHBG (Sorensen et al. 2007). This is supported in a review by von Schultz and 
Carlstrom (von Schoultz and Carlstrom 1989) citing earlier work that nutritional 
status is a strong factor in SHBG regulation with obesity having an inverse 
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relationship to SHBG levels. In this review they claimed that there was little 
data to support the claim that endogenous sex steroids were the main 
physiological regulators but rather that they had a modulating influence with the 
main regulation being by GH, IGF-I and possibly other growth factors. 
There is a body of literature to support the role of insulin in the regulation of 
SHBG. The report by Plymate in 1988 (Plymate et al. 1988) that insulin 
decreases SHBG production in the human hepatoma cell line, HepG2, has been 
subsequently supported by the work of others (Singh et al. 1990; Loukovaara et 
al. 1995; Kalme et al. 2003) and suggests that we should expect increased 
SHBG levels as a result of the relative portal hypoinsulinaemia that occurs in 
T1D subjects. In vivo studies by Yki-Jarvinen et al teased out whether it was 
the peripheral insulin concentration, estimated portal insulin levels or whole 
body insulin sensitivity that was the key regulator of SHBG in T1 0 subjects. 
They used the euglycaemic hyperinsulinaemic clamp technique to determine 
whole body insulin sensitivity while portal insulin concentrations were estimated 
using an established equation. The daily insulin dose/kg (as a marker for long-
term insulinisation) was inversely related to SHBG levels and in a multiple 
regression with insulin sensitivity, portal insulin levels, free testosterone, 
oestradiol and T 4 as independent variables, only the portal insulin concentration 
was a significant determinant of SHBG concentration (Yki-Jarvinen et al. 1995). 
In a study suppressing insulin levels in non-diabetic adult male volunteers, 
Pasquali et al observed increased levels of SHBG and cited this as evidence 
that insulin inhibits SHBG production (Pasquali et al. 1995). 
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Free T4 (FT4) was measured in this study and found to be very similar in the 
control and T1 0 subjects throughout the study period. There was no significant 
difference between the two cohorts in either sex when looked at in terms of 
years from PHV except for the boys at 3 years before PHV when P = 0.05. 
Since the sample size for the T1 0 boys was only 7 at this point, however, this 
may not be a very reliable result. The finding of normal FT 4 agrees with the 
results of Connors et al (Connors et al. 1996) although the findings by an Italian 
group in 129 T1 0 children (12.6 ± 3.8 years) compared to 458 healthy age 
matched controls found that not only were the total T 4 levels (92.1 vs 109.2 
nmol/L) lower in the T1 0 children as previously observed by other investigators 
but the free T4 levels (14.6 vs 17.4pmoI/L) were as well (Radetti et al. 1994). 
Testosterone levels in the T1 0 boys are lower than in control boys when 
considered by years from PHV or puberty stage. In the grouped data, the 
difference is significant from one year before to 2 years after PHV. Maximum 
levels achieved were different, T1 0 reached 16nmoi/L four years after PHV 
where the control boys were at 26nmol/L. By puberty stage, T1 0 boys had 
significantly lower concentrations of testosterone compared to controls at all 
stages except at stage 2. 
In the girls, levels of testosterone tended to be lower in the T1 0 girls compared 
to control girls from PHV onwards but this difference was only significant one 
year after PHV, levels between the two cohorts were similar before PHV. 
Maximum levels of 1.3nmol/L and 1.7nmollL were achieved in T1 0 and controls 
respectively near the end of our observation period. Viewed by puberty stage, 
levels were lower in T1 0 girls at all puberty stages from 2-5 but this was only 
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significant at stage 5. T1 D girls had significantly (P = 0.03) higher levels of 
testosterone at stage 1. 
Although the data are not always consistent, most studies report higher levels of 
testosterone in T1 D subjects compared to controls: the early study of Cohen et 
ai, however, found no significant difference in testosterone levels between T1 0 
and control boys within bone age ranges of 11-14.5 years or when matched for 
puberty stages (Cohen et al. 1984), it should perhaps be noted that there were 
only 10 T1 D boys in this study; the cross sectional study of Meyer et al found no 
differences between T1 D and control adolescents of either sex in levels of total 
and free testosterone until puberty stage 5 when they observed greater 
testosterone (P<0.05) and free testosterone (P<0.05) levels in the T1 0 girls and 
boys (Meyer et al. 2000); Salardi et al also observed higher testosterone levels 
in T1 0 boys in stage 5 (Salardi et al. 2002); higher testosterone levels in a 
group of postmenarcheal late pubertal young women with T1 0 was observed by 
Rudberg (Rudberg and Persson 1998); and the study by Djursing also found 
that even those young T1 0 women with normal cycles had higher testosterone 
levels than controls which they felt was of ovarian origin (Djursing et al. 1985); 
this leads of course to the work of both Codner et al and Escobar- Morreale et al 
whose groups have studied the high prevalence of hyperandrogenicity in T1 0 
women (Escobar-Morreale et al. 2000; Codner et al. 2005). Pasquali et al cite 
the role of insulin influencing the levels of testosterone in their study of normal 
men. Suppressing insulin production they observed that testosterone levels 
decreased and thus claimed that this supports the role that insulin stimulates 
testosterone production (Pasquali et al. 1995). Perhaps there needs to be a 
certain level or length of time of chronic hyperinsulinism before the effect on 
testosterone can be observed. It may be that if our diabetic cohort had been 
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followed for a longer period that we would have seen higher testosterone levels 
in our T1 D subjects. However to confuse the issue, Tomar et al reported on 50 
adult men with T1 D aged 23-58 years saying that their total testosterone and 
free testosterone were in the middle of the normal range and that >90% of their 
subjects had normal values (Tomar et al. 2006). Although there is no 
contemporary control group as such, the implication is that these men with T1 0 
do not have elevated testosterone levels. 
It may be that the contrasting results are due to a variety of reasons that include 
small samples in some cases, differing age groups, different disease states, 
inappropriate controls or different nutritional status/levels of obesity and are 
perhaps not entirely comparable. 
It may be that in our sample of T1 0 subjects a combination of low IGF-I levels, 
and hepatic underinsulinisation contribute to low levels of DHEAS and 
testosterone and higher levels of SHBG. 
E2 levels were not measured in the control boys and so no comparison can be 
made. 
In the girls, E2 in the years before PHV was higher in the T1 0 girls than the 
control girls and this was significant at two years before. From PHV onwards 
levels were higher in the control girls with a trend towards significance at PHV 
(P = 0.06) and at 1 year after (P = 0.07) and significant at 2 years after, P = 
0.03. Levels rise more slowly during puberty in T1 0 girls and reach a maximum 
4 years after PHV where the maximum in control girls is achieved at 2.4 years 
after PHV. By puberty stage, E2 levels were lower in T1 0 girls from stage 2-5 
159 
but none of these differences were significant. Prepubertally however, E2 levels 
in T1 D girls were significantly greater (P = 0.004) than those of control girls. 
Data on E2 levels in T1 D adolescents are not easy to find. Djursing et ai's study 
on T1 D women with and without amenorrhoea commented that normally 
menstruating diabetic women had normal free and total oestrogens (Djursing et 
al. 1985). The small study by Zumoff et al followed 5 women with T1 D and 8 
controls each through a menstrual cycle and observed higher oestradiol levels 
in the follicular phase and commented that Djursing's study was not comparable 
since they had not documented normal ovulation (Zumoff et al. 1990). Codner 
et al studied 56 adolescent girls with T1 D and compared to puberty-matched 
controls found basal levels of oestradiol to be similar at all pubertal stages 
(Codner et al. 2005). 
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Chapter 6. Hormonal Associations with Growth and 
Puberty 
6.1 Introduction 
An exploration of associations between various biological outcomes including 
age at onset of puberty, duration of puberty, relative height change and PHV 
variables with the hormones studied is presented here. 
Some differences in puberty and growth have been observed between the two 
cohorts as well as differences in various hormone levels during puberty. The 
aim of this chapter is to explore if and to what extent any of these variables play 
a role in these pubertal events 
6.2 Methods 
Individual regressions were performed with five different dependent variables: 
(1) age at pubertal onset (2) PHVSDS (3) HtSDS change (4) duration from 
stage 2 to PHV and (5) bone age at the start of puberty in T1 0 children. In the 
first instance correlation matrices were executed and presented in the Appendix 
as a source for other researchers but not studied any further here. Complete 
correlation matrices are in Appendix 8.13. Univariable regressions are 
presented in the text for all of the considered variables. Those variables that 
had a p s 0.1 were entered into a backwards stepwise regression model and the 
results of these multivariable analyses follow. The procedure was to do this first 
with sexes kept separate at all times and with the two studies combined 
together labelled 'all boys' or 'all girls' with diabetes (labelled 'disease') included 
as a covariate and then secondly to explore the cohorts independently. The R2 
that is reported is the 'adjusted' R2, the interpretation of which is that it tells us 
how much of the variance in Y is accounted for if the model had been derived 
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from the population from which this sample had come (Field 2005). All analyses 
have been performed on logged hormone values. 
6.3 Age of Pubertal Onset and Hormones at Stage 2 
6.3.1 Question: 
What associations can be demonstrated between the age of the 
onset of puberty and any of the hormones studied? Do these 
associations differ between T1 0 and control children? 
6.3.2 Boys 
In chapter 3 (section 3.2.2.1) it was observed that there was a significant 
difference in the age of pubertal onset between the two cohorts (11.3y in 
controls vs 12.3y in T1 D). 
6.3.2.1 All Boys 
Univariable regressions with Age at Puberty Onset: 
Variable B se P N P adj for 
disease 
1. BMISDS @ G2 .15 .17 .13 .40 46 .53 
2.IGF-1 -.31 1.23 -.04 .80 43 .95 
3. A4 -.45 .70 -.10 .53 40 .40 
4.DHEAS .46 .52 .14 .38 40 .27 
5. E2 Not available for controls 
6.leptin 1.96 .87 .40 .03 29 .73 
7. SHBG .73 1.31 .09 .58 40 1.00 
8. testosterone .16 .44 .05 .73 43 .63 
9. FAI -.02 .41 -.01 .95 40 .83 
In a multivariable regression entering both leptin and 'disease' with age at 
puberty onset as the dependent variable (N=29), only 'disease' has a significant 
effect: B - 1.12 + 0.31, P - 0.001 with {3 - 0.57; P for the model = 0.001 and~ 
= 30.3%. Thus the presence of T1 0 in boys results in a delay in the onset of 
puberty. 
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6.3.2.2 Control Boys 
Univariable Regressions with Age at Puberty Onset: 
Variable B se ~ p N 










-.18 .43 21 
4.DHEAS 1.22 .52 .48 .03 21 
5. E2 Not available 
6.leptin 1.12 .90 .30 .23 18 
7. SHBG 
-1.30 1.44 -.20 .38 21 
8. testosterone .73 .66 .24 .28 22 
9. FAI 
.65 .58 .25 .27 21 
DHEAS has a significant effect in control boys on the age of pubertal onset, B 
1.22 ± 0.52, P = 0.03 with {3 = 0.48, P for model = 0.03 and R2 - 18.4%. 
6.3.2.3 T1 D Boys 
Univariable regressions with Age at Puberty Onset: 
Variable B se ~ P N 
1. BMISDS @ G2 -.50 .27 -.38 .08 23 
2.IGF-1 .41 1.38 .07 .77 21 
3.A4 -.45 1.48 -.07 .76 19 
4.DHEAS -.75 .80 -.22 .36 19 
5. E2 .10 .48 .05 .84 19 
6.leptin -1.21 2.35 -.17 .62 11 
7. SHBG 2.79 2.10 .31 .20 19 
8. testosterone -.11 .51 -.05 .83 21 
9. FAI -.28 .48 -.14 .57 19 
10. HbA1c @ G2 .07 .14 .10 .64 23 
11. ins/kg @ G2 -.33 1.30 -.06 .80 23 
12. bone age @G2 .48 .13 .71 .003 18 
In a multivariable regression entering both BMISDS and bone age@G2 with age 
at puberty onset as the dependent variable (N=18), only bone age at G2 is a 
significant determinant: B = 0.48 + O. 13, P = 0.003 with {3 = 0.71 and R2 = 
46.6%. 
As might be expected, there is a strong and highly significant association of 
bone age and chronological age at the start of puberty. Removing bone age 
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and looking at only BMISDS (N=23): B = - 0.50 + 0.27. P = 0.08 with {3 - - 0.38 
and R2 = 10.1%. 
6.3.2.4 Summary 
In 'all boys', of the various variables considered, only leptin has a significant and 
positive correlation to age at pubertal onset. In a model adjusting for disease 
presence, 'disease' is significant indicating that having T1 0 in the boys is 
associated with a delayed pubertal onset of 1.12 years, P = 0.001 with this 
accounting for 30.3% of the variance in age of onset. 
In the control boys, DHEAS has a significant association with the age at the 
start of puberty. Lower levels of DHEAS at G2 are associated with a younger 
age of pubertal onset. In the T1 0 boys there is no correlation between any of 
the hormones studied and the age at the start of puberty but bone age at this 
time is robustly correlated to the chronological age, r = 0.71, P = 0.003. 
BMISDS has a negative correlation that missed reaching significance, P = 0.08, 
and in a multivariable model with bone age it does not exert a significant effect 
while bone age alone accounts for 46.6% of the variance. 
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6.3.3 Girls 
6.3.3.1 All Girls 
Univariable regressions with Age at Puberty Onset: 
Variable B se P N P adj for 
disease 
1. BMISDS@B2 -.40 .12 -.39 .002 64 .004 
2.IGF-1 1.33 .86 .23 .13 44 .14 
3. A4 .78 .65 .20 .24 36 .30 
4. DHEAS -.16 .33 -.08 .63 36 .47 
5. E2 .99 .34 .41 .006 43 .006 
6.leptin -.12 .68 -.04 .86 21 .62 
7. SHBG -.02 .97 -.003 .99 36 .95 
8. testosterone .74 .53 .22 .17 43 .16 
9. FAI .32 .47 .11 .51 36 .55 
In a multivariable regression entering BMISDS, E2 and 'disease' with age at 
puberty onset as the dependent variable (N=42), both 8M/SOS (8 = - 0.37 + 
0.10
1 
P <0.0005 with {3 - O.4n and E2 (8 = 0.86 + 0.301 P = 0.006 with {1 = 0.361 
are independent significant determinants while 'disease' did not have a 
significant effect. P of model <0.0005 and R2 = 36.2%. 
6.3.3.2 Control Girls 
Univariable regressions with Age at Puberty Onset: 
Variable B se ~ p N 
1. BMISDS -.47 .15 -.44 .003 43 
2.IGF-1 1.02 1.42 .16 .48 23 
3. A4 1.77 1.41 .31 .23 17 
4.DHEAS -.72 .69 -.26 .31 17 
5. E2 1.09 .43 .49 .02 23 
6.leptin -1.56 1.84 -.25 .41 13 
7. SHBG -.23 2.29 -.03 .92 17 
8. testosterone 1.13 .73 .32 .14 23 
9. FAI .58 .72 .20 .80 17 
In a multivariable regression entering BMISDS and E2 with age at puberty onset 
as the dependent variable (N=23), both 8M/SOS and E2 are independent 
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significant determinants: B = - 0.56 ± O. 12, P <0.0005 with {3 - 0.65 and B 0.83 
± 0.30, P = 0.01 with {3 = 0.37 respectivelv: P of model <0.0005 and ~ 61.1%. 
6.3.3.3 T1D Girls 
Univariable regressions with Age at Puberty Onset: 
Variable B se ~ P N 
1. BMISDS@B2 .002 .23 .002 .99 21 
2.IGF-1 1.58 1.02 .33 .14 21 
3.A4 .13 .66 .05 .85 19 
4.DHEAS .06 .34 .05 .86 19 
5. E2 .15 .86 .04 .87 20 
6.leptin .45 .82 .22 .61 8 
7. SHBG .19 .86 .05 .83 19 
8. testosterone -.24 .74 -.08 .75 20 
9. FAI -.34 .62 -.13 .59 19 
10. HbA1c .24 .09 .53 .01 21 
11. ins/kg 1.18 .50 .47 .03 21 
12. BA@ B2 .20 .13 .36 .16 17 
In a multivariable regression entering both HbA 1 c and ins/kg @ B2 with age at 
puberty onset as the dependent variable (N=21), onlv HbA 1 c at B2 is a 
significant determinant, B = 0.24 + 0.09, P = 0.01 with {3 = 0.53; P of model = 
0.01, R2 = 24.6%. 
6.3.3.4 Summary 
In 'all girls' both BMISDS and E2 at the start of puberty have significant 
correlations with the age at pubertal onset. In a multivariable model they are 
both independently significant determinants and account for 36.2% of the 
variance and no 'disease' effect is observed on age of pubertal onset as it was 
in the boys. 
In the control girls, again both BMISDS and E2 at the start of puberty are 
associated with the age of pubertal onset. In the multivariable regression, 
BMISDS has a major effect with 61.1 % of the variance explained by the two 
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variables. Thus girls without T1 0 who have a greater BMISDS at the start of 
puberty will tend to have an earlier puberty adjusting for their E2 levels at the 
start of puberty. 
In the T1 0 girls, as in the T1 0 boys, none of the hormones at the start of 
puberty were identified as playing a significant role in the age of pubertal onset. 
In these girls, however, both HbA 1 c and insulin dose at the start of puberty were 
related to the age of puberty onset. In a model adjusting for each other only 
HbA 1 c remains a significant factor, accounting for 24.6% of the variance. Thus 
girls with poorer metabolic control will tend to have a later pubertal onset, for 
every 1 % increase in HbA 1 c, age at puberty will be delayed by 0.24 of a year (3 
months). Surprisingly BMISOS displays no association with the age of pubertal 
onset in the T1 0 girls. 
6.4 Duration Stage 2-PHV 
6.4.1 Question 
Is it possible to identify if BMI or any of the hormones at the 
start of puberty has an influence on this duration and how 
this may differ between the two cohorts. 
6.4.2 Boys 
Control boys were previously (chapter 3, section 3.2.2.4) observed to have a 
significantly longer duration from the onset of puberty to PHV than boys with 
T1 0, 2.55 vs 1.84 years. 
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6.4.2.1 All Boys 
Univariable regressions with duration from puberty onset to PHV: 
Variable B se ~ 
P adj 
P N for 
disease 
1. BMISDS @ G2 
-.33 .14 -.33 .02 46 .13 
2.IGF-1 
-1.77 1.11 -.24 .12 43 .05 
3.A4 
-.19 .64 -.05 .77 40 .84 
4.DHEAS 
-.68 .47 -.23 .16 40 .11 
5. E2 Not available for control boys 
6.leptin 
-1.59 .68 -.41 .03 29 .06 
7. SHBG .90 1.19 .12 .46 40 .22 
8. testosterone -1.27 .36 -.48 .001 43 <0.0005 
9. FAI -1.02 .33 -.45 .004 40 .001 
Since FAI and testosterone are highly correlated, r = 0.94, P<0.0005; FAI has 
been omitted from the ensuing mUltivariate analysis. 
In a multivariable regression entering testosterone, BMISDS, leptin and 
'disease' with duration from G2 to PHV as the dependent variable (N=29), both 
testosterone (B = - 1.38 + 0.50, P = 0.01 with (3 = - 0.51) and 'disease' (B = -
0.69 + 0.29, P = 0.03 with (3 = - 0.45) are significant independent determinants 
with P of the model = 0.02 and R2 = 20.5%. 
6.4.2.2 Control Boys 
Univariable regressions with duration from puberty onset to PHV: 
Variable B se ~ P N 
1. BMISDS @ G2 -.31 .20 -.33 .13 23 
2.IGF-1 -3.94 1.73 -.45 .03 22 
3.A4 .20 .70 .06 .78 21 
4.DHEAS -.83 .55 -.33 .14 21 
5. E2 Not available 
6.leptin -2.97 .82 -.67 .002 18 
7. SHBG 1.20 1.41 .19 .41 21 
8. testosterone -1.49 .57 -.50 .02 22 
9. FAI -1.13 .53 -.44 .045 21 
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FAI and testosterone are correlated, r = 0.89, P < 0.0005 as well as FAI and 
leptin, r = 0.87, P<0.0005 and thus FAI has been omitted from the multivariate 
analysis. 
Entering testosterone, leptin and IGF-I into a multivariable regression with 
duration from G2 to PHV as the dependent variable (N=18), only testosterone 
has a significant effect. B = - 1.67 + 0.45. P = 0.002 with {3 = - .68; P of the 
model = 0.002 and R2 = 43.3%. 
6.4.2.3 T1D Boys 
Univariable regressions with duration from puberty onset to PHV: 
Variable B se 13 p N 
1. BMISDS @ G2 -.12 .26 -.10 .65 23 
2.IGF-1 -1.16 1.30 -.20 .39 21 
3. A4 -1.43 1.37 -.25 .31 19 
4.DHEAS -.52 .77 -.16 .51 19 
5. E2 .36 .43 .20 .41 19 
6.leptin .85 1.81 .15 .65 11 
7. SHBG 1.92 2.05 .22 .36 19 
8. testosterone -1.18 .41 -.56 .009 21 
9. FAI -1.08 .38 -.57 .01 19 
10. HbA1c @ G2 -.25 .11 -.44 .04 23 
11. ins/kg @ G2 -.41 1.15 -.08 .73 23 
12. bone age @ G2 .04 .16 .06 .80 18 
Testosterone and FAI are highly correlated, r = 0.98, P <0.0005 and so FAI has 
been left out of the multivariate analysis. Entering testosterone and HbA 1 c into 
a multivariable regression with duration G2 to PHV as the dependent variable 
(N=21), testosterone was a significant determinant. B = - 0.92 ± 0.41. P = 0.04 
with {3 = -.43 with a trend towards a significant effect from HbA 1 c. B = -0.20 + 
O. 11. P = 0.09 with {3 = -.35; P of the model = 0.008 and ~ = 34.8%. 
6.4.2.4 Summary 
In 'all boys', BMISDS, FAI, leptin, and testosterone all individually have negative 
correlations with the duration from the start of puberty to PHV. In a multivariable 
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model, testosterone and 'disease' are independently significant determinants of 
this duration. Not having diabetes and adjusting for levels of testosterone at the 
start of puberty, is associated with a longer duration of puberty from G2 to PHV. 
Higher levels of testosterone at the start of puberty, controlling for the 
presence/absence of 'disease', are related to a shorter duration. 
In control boys, FAI, leptin, testosterone and IGF-I (but not BMISDS) are all 
negatively correlated to the G2-PHV duration. Since there are a number of 
highly related and significant correlations, IGF-I, leptin and testosterone were 
entered into the multivariable model and testosterone levels at the start of 
puberty remained significantly negative and so higher levels of testosterone at 
G2 are associated with a shorter duration from G2 to PHV. 
In T1 0 boys, testosterone and HbA 1 c were both negative and significant 
independent determinants of the duration from G2 to PHV thus higher 
testosterone levels at the start of puberty, adjusting for HbA 1 c levels, are related 
to a shorter duration from the start of puberty to PHV. There was a trend for 
HbA 1 c to have an effect and so adjusting for levels of testosterone, a higher 
HbA 1 c at the start of puberty will tend to be associated with a shorter G2-PHV 
duration. 
6.4.3 Girls 
It was previously observed (chapter 3, section 3.2.3.4) that there was no 
difference in the duration from B2 to PHV between the T1 0 girls and control 
girls. 
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6.4.3.1 All Girls 
Univariable regressions with duration from puberty onset to PHV: 
Variable 
P adj 
B se !3 P N for 
disease 
1. BMISDS @ B2 .27 .11 .32 .02 53 .01 
2.IGF-1 
-2.60 .75 -.47 .001 44 .001 
3.A4 
-.34 .70 -.08 .63 36 .44 
4.DHEAS 
.36 .35 .17 .32 36 .42 
5. E2 
-.88 .37 -.35 .02 43 .03 
6. leptin -.19 .75 -.06 .80 21 .40 
7. SHBG .90 1.19 .12 .46 36 .86 
8. testosterone -.92 .55 -.26 .10 43 .12 
9. FAI -.37 .50 -.13 .46 36 .43 
Entering BMISDS, E2, IGF-I, testosterone at B2 and 'disease' into a 
multivariable regression with duration B2 to PHV as the dependent variable 
(N=43), both BM/SOS (B = 0.24 + 0.11, P = 0.03 with B =0.29) and /GF-/ (B =-
2.52 + 0.76, P = 0.002 with B = -.44) are independent significant determinants 
with P of the model = 0.001 and R2 = 25.3%. 
6.4.3.2 Control Girls 
Univariable regressions with duration from puberty onset to PHV: 
Variable B se !3 P N 
1. BMISDS @ B2 .36 .14 .44 .01 32 
2.IGF-1 -2.79 1.22 -.45 .03 23 
3.A4 -.92 1.36 -.17 .51 17 
4.DHEAS .61 .65 .24 .36 17 
5. E2 -.91 .42 -.43 .04 23 
6.leptin 1.93 1.62 .34 .26 13 
7. SHBG .32 2.13 .04 .88 17 
8. testosterone -1.35 .67 -.40 .06 23 
9. FAI -.88 .65 -.33 .19 17 
Entering BMISDS, E2, IGF-I and testosterone at B2 into a multivariable 
regression with duration B2 to PHV as the dependent variable (N=23), both 
BMISOS (B = 0.37 + 0.14, P = 0.02 with B = 0.45) and IGF-/ (B = - 2.63 + 1.08, 
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p = 0.02 with (3 = -.42) are independent significant determinants with P of the 
model = 0.006 and R2 = 34. 1 %. 
6.4.3.3 T1D Girls 
Univariable regressions with duration from puberty onset to PHV: 
Variable B se ~ P N 
1. BMISDS @ B2 .15 .23 .15 .52 21 
2.IGF-1 -2.50 .91 -.53 .01 21 
3. A4 -.39 .90 -.11 .67 19 
4.DHEAS .09 .47 .05 .84 19 
5. E2 -.49 1.13 -.10 .67 20 
6.leptin .10 1.71 .02 .96 8 
7. SHBG -.42 1.18 -.09 .73 19 
8. testosterone .41 .99 .10 .69 20 
9. FAI .64 .84 .18 .46 19 
10. HbA1c @ B2 -.15 .10 -.34 .13 21 
11. ins/kg @ B2 -1.19 .50 -.48 .03 21 
12. bone age @ B2 -.09 .20 -.12 .66 17 
Entering IGF-I and insulin dose at B2 into a multivariable regression with 
duration B2 to PHV as the dependent variable (N=21), IGF-I (8 = - 2.46 + 0.91, 
P = 0.01 with (3 = -.53) is a significant determinant with P of the model = 0.01 
and R2 = 23.9%. 
6.4.3.4 Summary 
In 'all girls' and control girls, IGF-I levels, oestradiol and BMISDS at the start of 
puberty were each related to the B2-PHV duration. In a multivariable model, 
both IGF-I and BMISDS remained as independent significant determinants of 
the duration from B2 to PHV. There is no effect of 'disease'. IGF-I is negative, 
thus higher levels of IGF-I at the start of puberty, adjusting for BMISDS, are 
associated with a shorter duration from the onset of puberty to PHV. BMISDS 
on the other hand has a positive relation with this duration and so those girls 
with a higher BMISDS at the start of puberty, adjusting for IGF-I levels, will take 
longer to go from B2 to PHV. 
172 
In the T1 D girls insulin dose and IGF-I at the start of puberty are related to this 
B2-PHV duration but only IGF-I remained as a significant factor in the 
multivariable model. Thus higher levels of IGF-I at the start of puberty are 
associated with a shorter duration from B2 to PHV and this explains 23.9% of 
the variance on its own. 
6.5 HtSDS Change from Puberty Stage 2 to PHV 
6.5.1 Calculation note 
Ht SDS has been calculated by using an averaged height for each child at the 
time of stage 2 and relating that height to the sex appropriate mean and sd for 
height from the revised growth charts of Tanner Buckler (Castlemead 
Publications) (Tanner and Buckler 1997) which compared well to the means of 
the Freeman et al 1995 British references (Freeman et al. 1995) at the ages 
reported by Marshall and Tanner for stage 2 (Marshall and Tanner 1969; 
Marshall and Tanner 1970). An averaged height was used since most children 
were seen several times in stage 2 and the Marshall and Tanner references 
actually state they used a point midway between each stage since it was 
impossible to ever know exactly when a child entered a particular puberty stage. 
The height SDS was calculated as: (subject's height-mean height at age of ref 
stage 2)/SD at age ref stage 2. HtSDS at PHV has been calculated for each 
child by looking at their height at their age of PHV and using the mean and SD 
at that age from the Tanner Buckler charts which again for the boys were very 
similar to the Freeman values at the same age but for the girls were not and so 
the Tanner height values were chosen since they were felt to better reflect 
values based on a longitudinal trajectory. The hormones for these analyses are 
all logged and averaged from stage 2-PHV. In the T1 D subjects, insulin dose 
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and HbA 1 c have been explored both at stage 2 and averaged (av) from stage 2 
to PHV. 
6.5.2 Question: 
Which of the variables chosen affect the change in HtSDS (which 
could increase or decrease) from the start of puberty to peak height 
velocity in the four groups? Are there differences in the 
associations between T1 0 and control children? 
6.5.3 Boys 
6.5.3.1. All Boys 
Univariable regressions with HtSDS change: 
P adj 
Variable B se ~ P N for 
disease 
1. BMISDS @ G2 -.29 .10 -.39 .008 45 .05 
2.IGF-1 -.09 1.09 -.01 .94 44 .52 
3. A4 .25 .55 .07 .66 43 .79 
4.DHEAS -.33 .33 -.16 .31 43 .09 
5. E2 Not available for controls 
6. leptin -1.43 .54 -.43 .01 34 .06 
7. SHBG 1.12 .82 .21 .18 43 .02 
8. testosterone -.51 .34 -.23 .14 44 .05 
9. FAI -.44 .27 -.25 .11 43 .03 
10. age@G2 -.26 .09 -.41 .006 45 .05 
11. duration G2-PHV .56 .07 .78 <0.0005 45 <0.0005 
In a multivariable model entering BMISDS @ G2, age @ G2, duration from G2-
PHV, leptin and 'disease' with HtSDS change as the dependent variable, 
(N=34), results in both age at G2 and duration from G2 to PHV being 
independently related to HtSDS change in 'all boys': B = - O. 17 + 0.07, P = 0.03 
with {3 = - 0.25 and B = 0.60 + 0.09, P<0.0005 with {3 = 0.71 respectively: P of 
the model <0.0005 and ~ = 65.2%. 
The covariate 'duration from G2 to PHV' overwhelms the model, if it is left out 
and a second model is set up with BMISDS @ G2, age @ G2, leptin and 
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'disease' entered with HtSDS change as the dependent variable (N=34), the 
significant determinant is age at G2 (B - - 0.29 + 0.10, P - 0.009 and 13 - 0.43) 
with a trend towards a significant effect of BMISOS at G2 (B - - 0.21 + 0.11, P 
0.07 and (3 = - 0.28), P of the model = 0.005 and R2 - 24.6%. 
There is no 'disease' effect. 
6.5.3.2 Control Boys 
Univariable Regressions with HtSDS change: 
Variable B se 13 P N 
1. BMISDS @G2 -.24 .15 -.34 .11 23 
2.IGF-1 -.70 1.74 -.09 .40 22 
3.A4 .17 .65 .06 .80 21 
4.DHEAS -.82 .46 -.38 .09 21 
5. E2 Not available 
6.leptin -2.31 .76 -.60 .007 19 
7. SHBG 1.45 1.17 .27 .23 21 
8. testosterone -.52 .61 -.19 .40 22 
9. FAI -.71 .58 -.27 .23 21 
10. age@G2 -.40 .14 -.53 .01 23 
11. duration G2-PHV .56 .11 .74 <0.0005 23 
In a multivariable regression entering DHEAS, leptin, age @ G2 and duration 
G2-PHV with HtSDS change as the dependent variable (N=18), the significant 
determinant is duration G2-PHV: B = 0.61 + 0.14, P = 0.001 and {3 = 0.68 with 
age at G2 not quite significant B = - 0.31 + 0.17, P = 0.09 and {3 = - 0.29; with 
the P of the model <0.0005 and R2 = 59.9%. 
Again, leaving out the covariate, 'duration G2-PHV', the outcome from entering 
DHEAS, leptin and age@G2 with HtSDS change as the dependent variable, 
(N=18) results in leptin as the only significant determinant: B = - 2.34 + 0.78, P = 
0.008 and {3 = - 0.60; with P of the model = 0.008 and ~ = 32.2%. 
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6.5.3.3 T1D Boys 
Univariable regressions with HtSDS change: 
Variable B se ~ P N 
1. BMISDS @G2 -.21 .19 -.24 .29 22 
2.IGF-1 -.68 1.34 -.11 .62 22 
3. A4 -.04 1.06 .008 .97 22 
4.DHEAS -.24 .44 -.12 .60 22 
5. E2 .34 .29 .25 .26 22 
6.leptin .43 1.23 .10 .73 15 
7. SHBG 2.48 1.07 .46 .03 22 
8. testosterone -.71 .36 -.41 .06 22 
9. FAI -.57 .27 -.43 .05 22 
10. age @ G2 -.04 .14 -.06 .79 22 
11. duration G2-PHV .53 .10 .76 <0.0005 22 
12. HbA1c av G2-PHV -.15 .08 -.39 .07 22 
13. HbA1c @G2 -.25 .07 -.62 .002 22 
15. ins/kg av G2-PHV -1.25 .85 -.31 .16 22 
16. ins/kg @ G2 -1.05 .78 -.29 .19 22 
17. bone age@G2 -.06 .12 -.13 .61 17 
NB: SHBG is a carrier protein and as such it may be debated whether it really has 
anything directly to do with growth. Taking this approach, SHBG has been presented in 
the univariable tables for interest but not considered in multivariable analyses. FAI as a 
derived ratio (testosterone/SHBG x 100) has also not been considered in any 
multivariable analyses. 
In a multivariable regression entering testosterone, duration G2-PHV and 
HbA 1 c @ G2 with HtSDS change as the dependent variable (N=22), both 
HbA 1c at G2 (B = - 0.14 + 0.06, P = 0.02 and (3 = - 0.36) and duration G2-PHV 
(B = 0.42 + 0.10, P <0.0005 and (3 = 0.61) are significant with P of the model 
<0.0005 and R2 = 65. 1 %: 
The covariate, 'duration G2-PHV', again overwhelms the model, if it is omitted, 
the outcome from entering testosterone and HbA 1 c @ G2 in a multivariable 
model with HtSDS change as the dependent variable (N=22) leaves just HbA 1 c 
at G2 as significant: B = - 0.25 + 0.07, P = 0.002 and (3 = - 0.62) with P of the 
model = 0.002 and ~ = 35.6%. 
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6.5.3.4 Summary 
In 'all boys' in univariable correlations, BMISDS at G2, age at G2 and leptin 
(averaged from G2 to PHV) are all negatively related to HtSDS change (P = 
0.008, P = 0.006 and P = 0.01 respectively) while duration from G2 to PHV is 
highly positively associated with HtSDS change, P<0.0005. Testosterone and 
FAI are both negative and significantly related to HtSDS change when adjusted 
for 'disease' (P = 0.05 and P = 0.03 respectively). In a multivariable model 
including age and BMISDS at the start of puberty, duration, leptin and 'disease'; 
age and duration were independently related with the HtSDS change that 
occurs between G2 and PHV. A longer duration is associated with a greater 
relative height gain when adjusted for the age of pubertal onset, whereas a 
younger age at G2 is associated with a greater relative height gain. This model 
explains 65.2% of the variance in the outcome. The 'duration' covariate 
overwhelms the model and if it is left out BMISDS and age at the start of puberty 
are both negative and independently associated with relative height gain and 
this model explains 24.60/0 of the variance. 
In control boys, in univariable correlations, leptin levels, DHEAS and age at G2 
are all negatively related to HtSDS change (P = 0.007, P = 0.09 and P = 0.01 
respectively) while duration G2-PHV is positively associated with HtSDS change 
(p<0.0005). In multivariable regression, including age at G2, duration, DHEAS 
and leptin, both age at G2 and duration are independently associated with 
HtSDS change, R2 = 59.9%. The younger the age of G2, adjusting for the 
interval G2-PHV, the greater the relative height gain, and the longer the duration 
from the start of puberty to PHV, adjusting for the age at the start of puberty, the 
greater is the relative height gain. Interestingly, if again duration is omitted from 
this model, leptin remains as the only significant determinant, explaining 32.2% 
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of the variance and lower leptin levels over this time are associated with greater 
relative height gain. 
In the T1 D boys in a univariable correlation, HbA 1 c at the start of puberty and 
testosterone and FAI averaged from pubertal onset to PHV are all negatively 
related to HtSDS change (P = 0.002, P = 0.06 and P = 0.05 respectively) while 
age of pubertal onset is not associated with HtSDS change. Duration from the 
start of puberty to PHV is again robustly associated with the HtSDS change 
during this time. If HbA 1 c, testosterone and duration are entered into a 
multivariable model, HbA 1 c and duration are both significant determinants. This 
model explains 65.1 % of the variance. Thus in T1 D boys, the higher HbA 1 c at 
the start of puberty (ie poorer control), adjusting for pubertal duration, is 
associated with less relative height gain. If the overwhelming influence of 
duration is removed then only HbA 1 c is significant and this explains 35.6% of 
the variance in HtSDS change. 
6.5.4 Girls 
6.5.4.1 All Girls 
Univariable Regressions with HtSDS change: 
P adj 
Variable B se 13 P N for 
disease 
1. BMISDS @ B2 .20 .11 .25 .08 52 .02 
2.IGF-1 -.50 .99 -.08 .61 42 .44 
3. A4 .77 .64 .21 .24 35 .56 
4.DHEAS .59 .31 .32 .06 35 .14 
5. E2 -.17 .42 -.06 .69 42 .43 
6.leptin .25 .53 .09 .64 27 .12 
7. SHBG -1.16 .98 -.20 .24 35 .32 
8. testosterone -.09 .53 -.03 .86 42 .84 
9. FAI .49 .49 .17 .32 35 .42 
10. age@B2 -.56 .09 -.66 <0.0005 52 <0.0005 
11. duration B2-PHV .85 .08 .82 <0.0005 51 <0.0005 
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In a multivariable model, entering BMISDS@B2, age@82, duration 82-PHV, 
DHEAS and 'disease' with HtSDS as the dependent variable, (N=35) both 
duration B2-PHV and age at puberty onset were highly significant with both 
BMISDS at B2 and 'disease' showing a trend towards significance: 
Variable 8 se f3 t P P of Model RLadj 
duration 82-PHV .61 .09 .61 7.02 <0.0005 
'disease' -.23 .12 -.16 1.94 .06 <0.0005 82.2% 
age @ 82 -.39 .08 -.46 -4.85 <0.0005 
8MISDS @ 82 -.11 .06 -.16 -1.77 .09 
Leaving out the covariate, 'duration B2-PHV', which has an overwhelming 
influence, and in 'all girls' is related to age at the start of puberty (r = - 0.58, 
p<0.0005) although admittedly not enough to show up in the collinearity 
statistics/diagnostics of SPSS. 
The results from this model entering BMISDS@B2, age@B2, DHEAS and 
'disease' with HtSDS as the dependent variable (N=35), gives both age at 
puberty onset, B = -0.61 + 0.10, P <0.0005 with {3 = -0.73 and 'disease', B = -
0.50 + O. 17, P = 0.007 with {3 = -0.33. as significant independent determinants 
of HtSDS change from puberty onset to PHV with P of the model <0.0005 and 
R2 = 54.7%. 
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6.5.4.2 Control Girls 
Univariable regressions with HtSDS change: 
Variable 8 se ~ P N 
1. 8MISDS @ 82 .36 .13 .46 .009 31 
2.IGF-1 1.66 1.98 .18 .41 22 
3. A4 -.05 1.35 -.01 .97 16 
4.DHEAS .90 .57 .39 .14 16 
5. E2 -.79 .45 -.37 .09 22 
6.leptin 1.64 .85 .46 .07 16 
7. SH8G -3.00 1.69 -.43 .10 16 
8. testosterone -.71 .64 -.24 .28 22 
9. FAI -.10 .69 -.04 .89 16 
10. age @ 82 -.57 .10 -.73 <0.0005 31 
11. duration 82-PHV .84 .12 .81 <0.0005 30 
In a multivariable regression entering BMISDS@ B2, E2, leptin, age@B2 and 
duration B2-PHV with HtSDS change as the dependent variable (N=16) results 
in both age at puberty onset (B = - 0.37 + 0.17, P = 0.045 and B = - 0.47) and 
duration B2-PHV (B = 0.40 + 0.18, P = 0.04 and B = 0.47) as significant with P 
of the model <0.0005 and R2 = 75.5%. 
Although BMISDS@B2 and leptin are related, r = 0.53, P = 0.04, this is not 
strong enough to conflict in the model and so both have been left in. However, 
the duration B2-PHV is correlated with age at B2 (r = - 0.63, p<0.0005), and 
although not enough to affect the collinearity statistics of the model, duration 
was omitted in a second multivariable model and entering BMISDS @ B2, E2, 
leptin, and age @ B2 with HtSDS change as the dependent variable (N=16) 
results in: age at puberty onset is significant: B = - 0.67 + 0.12, P <0.0005 and B 
= -0.84, P of the model <0.0005 and R2 = 68.5%. 
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6.5.4.3 T1 D Girls 
Univariable regressions with HtSDS change: 
Variable 8 se ~ P N 
1. 8MISDS @ 82 .04 .22 .04 .86 21 
2.IGF-1 -1.60 1.03 -.34 .14 20 
3. A4 .73 .90 .19 .43 19 
4.DHEAS .28 .41 .16 .51 19 
5. E2 2.49 .93 .53 .02 20 
6.leptin .52 1.33 .13 .70 11 
7. SH8G -.01 1.17 -.003 .99 19 
8. testosterone 1.10 .82 .30 .19 20 
9. FAI 1.12 .69 .37 .12 19 
10. age @ 82 -.72 .15 -.75 <0.0005 21 
11. duration 82-PHV .83 .12 .85 <0.0005 21 
12. HbA1c av 82-PHV -.03 .12 -.05 .83 21 
13. HbA1c @ 82 -.20 .09 -.45 .04 21 
15. ins/kg av 82-PHV -1.01 .50 -.43 .06 21 
16. ins/kg @ 82 -1.33 .46 -.55 .01 21 
17. bone age@ 82 -.20 .16 -.31 .23 17 
A multivariable regression entering E2, HbA 1 c @ 82, ins/kg @ 82, age@82 
and duration 82-PHV with HtSDS change as the dependent variable (N=20) 
results in both age at puberty onset (B = - 0.40 + O. 12, P = 0.003 and (3 = - 0.46) 
and duration B2-PHV (B = 0.53 + O. 13, P = 0.001 and [3 = 0.55) as significant 
determinants with P of the model <0.0005 and ~ = 78.7%. 
In the T1 0 girls age at pubertal onset and duration from 82-PHV are correlated, 
r = -0.58, P = 0.006, and again while not enough to appear in the collinearity 
statistics, the effect of duration is strong and so it has been left out to further 
explore other influences. The results from entering E2, HbA 1 c @ 82, ins/kg @ 
82 and age @ 82 with HtSDS change as the dependent variable (N=20): 
Variable 8 se ~ t P P of Model R
2 adj 
age @ 82 -.44 .15 -.50 -2.96 .009 <0.0005 68.4% 
E2 1.40 .65 .30 2.15 .05 
HbA1c @ 82 -.12 .07 -.29 -1.85 .08 
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6.5.4.4 Summary 
In 'all girls' in univariable correlations, age at B2 and duration from B2 to PHV 
are both highly significantly associated (P<0.0005) with HtSDS change between 
the start of puberty and PHV. Both DHEAS averaged over the time period and 
BMISDS at B2 show a slight relationship (P = 0.06 and P = 0.08 respectively) 
although BMISDS became significant when adjusted for 'disease' (P = 0.02). In 
a multivariable model, entering age and BMISDS at B2, DHEAS, duration B2-
PHV and 'disease', both age at puberty onset and duration from B2 to PHV are 
highly significant, P<0.0005 while both 'disease' and BMISDS, adjusted for the 
other covariates, show a trend towards a relation with HtSDS change. This 
model is highly significant (P <0.0005) and explains 82.2% of the variance. 
However, as in the boys, the 'duration' covariate overwhelms the model and if it 
is omitted then both age at the onset of puberty and 'disease' remain the 
significant covariates in a model that now explains 54.7% of the variance. Thus 
not having diabetes is associated with a greater relative height gain adjusting for 
the age of B2. And an earlier age at B2, allowing for disease status, is 
associated with a greater relative height gain. 
In control girls in univariable correlations, age at B2 and duration from B2 to 
PHV are both highly significantly associated with Ht SDS change as is BMISDS 
at B2 while leptin and E2 also show some association. In a multivariable model 
entering these five covariates, age at B2 and duration B2-PHV are 
independently associated with HtSDS change. This model is highly significant 
and explains 75.5% of the variance. Thus earlier puberty and longer duration 
are both independently associated with a greater relative height gain adjusting 
for each other. 
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In T1 D girls in univariable correlations with HtSDS change, the following are 
significant: age at 82, duration 82-PHV, HbA 1 c at 82, ins/kg at 82 and 
averaged levels of E2. When these covariates are entered into a multivariable 
model: age at 82 and duration are again significant explaining 78.7% of the 
variance. If duration is omitted, then age at 82, E2 levels, and HbA 1 c remain in 
the model that explains 68.4% of the variance. Each one is associated with a 
greater relative height gain adjusting for the other two. Thus earlier puberty 
onset in T1 D girls (adjusting for averaged levels of E2 as well as HbA 1 c values 
at 82), higher average levels of E2 (allowing for age at 82 and HbA 1 c values) 
and lower HbA 1 c (ie better control, adjusting for age at 82 and levels of E2) are 
all associated with greater relative height gain from 82 to PHV. 
6.6 PHVSDS and hormones/biological variables at PHV 
6.6.1 Question: 
What hormones or other biological variables i.e., 8MISDS (bone 
age, insulin dose and HbA 1 c in the T1 D cohort) at PHV are 
associated with PHVSDS? Do these associations differ between 
T1 D and control children? 
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6.6.2 Boys 
6.6.2.1 All Boys 
Univariable regressions with PHVSDS: 
Variable B 
P adj 
se ~ P N for 
disease 
1. BMISDS @PHV -.21 .19 -.16 .28 46 .38 
2.IGF-1 2.98 1.49 .29 .05 45 .06 
3.A4 2.41 .79 .43 .004 44 .008 
4.DHEAS -.18 .52 -.05 .74 44 .42 
5. E2 Not available in control boys 
6.leptin -1.00 1.02 -.17 .33 34 .49 
7. SHBG 1.09 1.05 .16 .30 44 .10 
8. testosterone 1.15 .55 .30 .04 46 .06 
9. FAI .46 .47 .15 .34 44 .64 
In a multivariable regression entering testosterone, A4, IGF-I and 'disease' with 
PHVSDS as the dependent variable (N=43), both A4 (B = 2.20 + 0.70, P = 0.006 
with (3 = 0.40) and IGF-I (B = 2.50 + 1.39, P = 0.08 with (3 = 0.25) are 
independent determinants although IGF-I does not quite reach significance; P of 
the model = 0.004, R2 = 20.5% 
6.6.2.2 Control Boys 
Univariable regressions with PHVSDS: 
Variable B se ~ P N 
1. BMISDS -.18 .27 -.15 .51 23 
2.IGF-1 2.28 3.42 .14 .51 23 
3. A4 2.11 1.08 .40 .06 22 
4. DHEAS -.70 .88 -.18 .44 22 
5. E2 Not available 
6.leptin -1.06 1.37 -.18 .45 20 
7. SHBG 3.10 1.58 .40 .06 22 
8. testosterone 3.02 1.06 .53 .009 23 
9. FAI .67 1.19 .12 .58 22 
In a multivariable regression entering testosterone and A4, with PHVSDS as the 
dependent variable (N=22), testosterone is a significant determinant: B = 3.77 + 
1.05, P = 0.002 with {3 = 0.63; P of the model = 0.002 and ~ = 36.2%. 
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6.6.2.3 T1 D Boys 
Univariable regressions with PHVSDS: 
Variable B se ~ P N 
1. BMISDS@ PHV -.19 .35 -.12 .60 23 
2.IGF-1 3.66 1.77 .42 .05 22 
3. A4 2.99 1.48 .41 .06 22 
4.DHEAS -.23 .72 -.07 .75 22 
5. E2 .70 .46 .32 .14 22 
6.leptin .27 3.21 .02 .93 14 
7. SHBG .45 1.61 .06 .78 22 
8. testosterone .36 .77 .10 .64 23 
9. FAI .12 .60 .05 .84 22 
10. HbA1c -.20 .10 -.41 .06 23 
11. ins/kg 1.45 1.21 .25 .24 23 
12. bone age -.35 .25 -.30 .17 22 
In a multivariable regression entering A4, IGF-I and HbA 1 c with PHVSDS as 
dependent variable (N=22), both A4 and IGF-I are independentlv significant 
determinants, B = 2.98 + 1.30, P = 0.04 with {3 = 0.43 and B = 3.46 + 1.55, P = 
0.04 with {3 = 0.42 respectively; P of the model = 0.02 and R2 = 29.2%. 
6.6.2.4 Summary 
In 'all boys', A4, IGF-I and testosterone levels at PHV are all positively and 
significantly correlated with PHVSDS (p = 0.004, P = 0.05, P = 0.04 
respectively). In a multivariable model, A4 is significant adjusting for levels of 
IGF-I and there is a trend towards significance in the same model for IGF-I (P = 
0.08). This model is significant, p = 0.004 and explains 20.50/0 of the variance. 
Higher levels of these hormones at PHV, each adjusting for the other, are 
related to a greater PHVSDS. In the control boys, in a multivariable model, 
testosterone levels at PHV are positively and significantly associated with 
PHVSDS in a model that explains 36.2% of the variance. In the T1 0 boys both 
A4 and IGF-I levels at PHV are independently and significantly related to 
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PHVSDS such that higher levels of these hormones at PHV are associated with 
a greater PHVSDS. This model explains 29.2% of the variance. 
6.6.3 Girls 
6.6.3.1 All Girls 
Univariable regressions with PHVSDS: 
P adj 
Variable B se 13 P N for 
disease 
1. BMISDS @PHV -.27 .11 -.33 .02 52 .03 
2.IGF-1 -.53 1.07 -.07 .62 47 .43 
3.A4 .68 .61 .18 .27 38 .41 
4.DHEAS -.23 .35 -.11 .52 38 .27 
5. E2 .15 .41 .06 .72 46 .90 
6.leptin -.80 .56 -.26 .16 31 .49 
7. SHBG 1.19 .90 .22 .19 38 .16 
8. testosterone .05 .49 .02 .92 47 .99 
9. FAI -.16 .48 -.06 .74 37 .56 
In a multivariable regression entering BMISDS and 'disease' with PHVSDS as 
the dependent variable (N=52), onlv BMISOS has a significant relationship with 
PHVSOS: B = - 0.27 + 0.11. P = 0.02 with {3 = -0.33. P of model = 0.02 and R2 
= 9.1%. 
6.6.3.2 Control Girls 
Univariable regressions with PHVSDS: 
Variable B se 13 P N 
1. BMISDS @PHV -.15 .12 -.24 .21 30 
2.IGF-1 -.78 1.36 -.11 .57 27 
3. A4 .07 1.08 .02 .95 20 
4.DHEAS -.04 .56 -.02 .94 20 
5. E2 -.04 .43 -.02 .94 26 
6.leptin -.38 .79 -.11 .64 20 
7. SHBG .35 1.19 .07 .77 20 
8. testosterone .14 .56 .05 .80 27 
9. FAI .23 .57 .09 .70 20 
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There is no significant relationship between any of these variables at PHV and 
PHVSDS in the control girls. 
6.6.3.3 T1 D Girls 
Univariable regressions with PHVSDS: 
Variable B se 13 P N 
1. BMISDS @ PHV -.52 .23 -.45 .04 22 
2.IGF-1 -1.02 1.87 -.13 .59 20 
3. A4 .87 1.02 .21 .41 18 
4.DHEAS -.67 .55 -.29 .24 18 
5. E2 .34 1.01 .08 .74 20 
6.leptin -.77 1.60 -.16 .64 11 
7. SHBG 2.10 1.37 .36 .15 18 
8. testosterone -.25 .92 -.06 .79 20 
9. FAI -.98 .87 -.28 .28 17 
10. HbA1c @ PHV -.14 .13 -.24 .29 22 
11. ins/kg @ PHV .39 .72 .12 .59 22 
12. bone age @ PHV -.50 .22 -.48 .03 20 
Only BMISDS and bone age at PHV have a significant relationship with 
PHVSDS in these T1 0 girls: r = - 0.45, P = 0.04 and r = - 0.48, P = 0.03. 
In a multivariable regression entering BMISDS and bone age at PHV with 
PHVSDS as the dependent variable (N=20) only bone age is a significant 
determinant: B = - 0.50 + 0.22. P = 0.03 with !3 = - 0.48 and P of the model = 
0.03 with R2 = 18.4%. 
6.6.3.4 Summary 
In 'all girls', BMISDS at the time of PHV was the only variable studied that had 
any association with PHVSDS. This was negative and significant (P = 0.02) 
thus girls who had a greater BMISDS by the time of PHV would have a 
diminished PHVSDS. This only explained 9.1 % of the variance in PHVSDS and 
so there are obviously other as yet unidentified variables involved. Nothing of 
interest was found in the control girls but it should be remembered that the age 
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at occurrence of PHV has already been adjusted for in the calculation of 
PHVSDS. In the T1 D girls an advanced bone age has previously been 
observed at the time of PHV and although BMISDS on its own was negatively 
and significantly related to PHVSDS it was not significant in this model with 
bone age as a covariate. Bone age was a significant (P = 0.03) negative 
determinant of PHVSDS, so those girls who have a more advanced bone age at 
PHV have a lower PHVSDS. 
6.7 PHVSDS and hormones/biological variables averaged from 
Stage 2 to PHV 
6.7.1 Question: 
What effect, if any, do the various hormones (averaged from stage 
2 to PHV) or BMISDS at stage 2 have an on PHVSDS? Do any 
associations differ between T1 D and control children? 
6.7.2 Boys 
6.7.2.1 All Boys 
Univariable regressions with PHVSDS: 
P adj 
Variable B se ~ P N for 
disease 
1. BMISDS @ G2 -.24 .18 -.20 .19 46 .27 
2.IGF-1 .90 1.76 .08 .61 46 .74 
3. A4 1.49 .87 .25 .09 45 .11 
4.DHEAS -.68 .51 -.20 .19 45 .12 
5. E2 Not available for controls 
6. leptin -.84 .98 -.15 .40 36 .81 
7. SHBG 2.95 1.21 .35 .02 45 .005 
8. testosterone .42 .56 .11 .46 46 .55 
9. FAI -.03 .45 -.01 .95 45 .78 
In a multivariable regression entering A4 and 'disease' with PHVSDS as the 
dependent variable (N=4S), there is only a trend towards significance with A4 
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averaged levels from G2-PHV and PHVSDS: 8 - 1.49 + 0.87, P 0.09, with {3 
0.25 and R2 = 4.3%. 
6.7.2.2 Control Boys 
Univariable Regressions with PHVSDS: 
Variable B se r3 p N 
1. BMISDS @G2 -.28 .27 -.22 .31 23 
2.IGF-1 -1.83 2.95 -.13 .54 23 
3. A4 1.11 1.07 .23 .31 22 
4. DHEAS -.87 .80 -.24 .29 22 
5. E2 Not available 
6.leptin -1.32 1.65 -.19 .43 20 
7. SHBG 5.33 1.62 .59 .004 22 
8. testosterone .39 1.04 .08 .71 23 
9. FAI -.67 .96 -.15 .50 22 
None of the hormones averaged over the period from the start of puberty to 
PHV nor BMISDS at the start of puberty have been found to playa significant 
role in PHVSDS in the control boys. 
6.7.2.3 T1 D Boys 
Univariable regressions with PHVSDS: 
Variable B se r3 p N 
1. BMISDS@ G2 -.13 .31 -.09 .68 23 
2.IGF-1 2.45 2.22 .23 .28 23 
3.A4 2.62 1.72 .32 .14 23 
4.DHEAS -.79 .68 -.25 .26 23 
5. E2 .88 .48 .37 .08 23 
6.leptin 1.49 2.01 .19 .47 16 
7. SHBG 1.66 1.84 .19 .38 23 
8. testosterone .32 .67 .11 .63 23 
9. FAI .07 .51 .03 .90 23 
10. HbA1c -.31 .13 -.47 .02 23 
11. ins/kg .64 1.49 .09 .67 23 
12. bone age @G2 -.25 .16 -.36 .14 18 
In a multivariable regression entering HbA 1 c and E2 with PHVSDS as the 
dependent variable (N=23), both HbA 1c (8 = - 0.34 + 0.12, P = 0.009 with {3 = -
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0.51) and E2 (B = 1.00 + 0.42, P 0.03 with [3 = 0.42), P of the model - O. 000 7 
and R2 = 33.4%. 
6.7.2.4 Summary 
In 'all boys' and control boys, there were no hormones averaged from G2 to 
PHV that appear to play any significant role in PHVSDS. There was a modest 
trend with A4 in 'all boys'. In T1 D boys both HbA1c and E2 averaged over the 
time were independently associated with PHVSDS. Adjusting for levels of E2, 
higher HbA 1 c (poorer control) during this time is associated with a lower 
PHVSDS and higher levels of E2 (adjusting for HbA 1 c) with a higher PHVSDS. 
6.7.3 Girls 
6.7.3.1 All Girls 
Univariable regressions with PHVSDS: 
P adj 
Variable B se 13 P N for 
disease 
1. BMISDS@B2 -.27 .12 -.31 .02 52 .04 
2.IGF-1 -.54 .99 -.08 .59 47 .45 
3. A4 .87 .66 .21 .19 39 .22 
4. DHEAS -.10 .35 -.05 .78 39 .59 
5. E2 .52 .45 .17 .26 46 .32 
6. Leptin -.77 .54 -.25 .16 32 .50 
7. SHBG 1.30 .99 .21 .20 39 .18 
8. testosterone .46 .54 .13 .40 47 .45 
9. FAI .02 .51 .007 .97 39 .94 
BMISDS at 82 is significantly (P = 0.02), albeit weakly (r = - 0.31) associated 
with PHVSDS. None of the hormones averaged from the start of puberty to 
PHV are related to PHVSDS 
In a multivariable regression entering BMISDS and 'disease' with PHVSDS as 
the dependent variable (N=52), only BMISDS is significant: B = - 0.27 + 0.12, P 
= 0.02 with [3 = - 0.31 and ~ = 8%. 
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6.7.3.2.Control Girls 
None of the variables considered in the univariable correlation matrix with 
PHVSDS had a correlation with a P value less than 0.2 (it was surprising that 
even BMISDS had a modest association that was not significant: r = - 0.23, P = 
0.21). In the multivariable regression no significant associations were found 
although it should be remembered that the calculation of PHVSDS in itself 
includes an allowance for age of occurrence of PHV. 
6.7.3.3 T1D Girls: 
Univariable regressions with PHVSDS: 
Variable B se 13 p N 
1. BMISDS@B2 -.50 .25 -.43 .05 21 
2.IGF-1 -1.36 1.44 -.21 .36 21 
3.A4 1.25 1.19 .24 .31 20 
4.DHEAS -.47 .55 .20 .41 20 
5. E2 1.66 1.40 .26 .25 21 
6.leptin -.73 1.45 -.16 .63 12 
7. SHBG 2.12 1.38 .34 .14 20 
8. testosterone .10 1.14 .02 .93 21 
9. FAI -.64 .93 -.16 .50 20 
10. HbA1c -.16 .14 -.25 .27 22 
11. ins/kg .32 .68 .11 .64 22 
12. bone age @ B2 -.49 .21 -.52 .03 17 
In a multivariable regression entering BMISDS @ B2 and bone age @ B2 
with PHVSDS as the dependent variable (N=17), BMISDS@B2 is a significant 
determinant of PHVSDS in the T1D girls: B = - 0.68 + 0.26, P = 0.02 with {3 =-
0.43 and R2 = 26.4%. 
6.7.3.4 Summary 
BMISDS at B2 is negatively related to PHVSDS in 'all girls' indicating that 
relatively thinner girls at the start of puberty will have a greater PHVSDS. This 
only accounts for 8% of the variation however so there are still a lot of 
unidentified determinants. No associations with PHVSDS and any of the 
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variables considered here were observed for control girls although again it 
should be remembered that the calculation of PHVSDS includes an adjustment 
for the age of PHV occurrence. In T1 0 girls, only BMISDS (r = -0.43, P = 0.05) 
and bone age at B2 were related (r = - 0.52, P = 0.03) to PHVSDS and in a 
multivariable model only BMISDS retained a significant influence on PHVSDS 
explaining 26.4% of the variance. 
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6.8 Bone Age at Puberty Onset in T1 D Children 
6.8.1 Question 
Is it possible to identify the variables at the start of puberty that 
might affect bone age in the T1 0 children? 
6.8.2 TID Boys 
In this dataset, we have observed that T1 0 boys enter puberty a year later than 
control boys with a bone age that was less than their chronological age although 
not statistically significant (chapter 3, section 3.3.3). 
Univariable regressions with bone age at G2: 
Variable B se ~ P N 
1. BMISDS@G2 -.11 .48 -.06 .83 18 
2.IGF-1 1.65 2.47 .17 .52 17 
3.A4 -3.47 2.57 -.35 .20 15 
4.DHEAS -.05 1.41 -.01 .97 15 
5. E2 .56 .75 .20 .47 16 
6.leptin .32 3.81 .03 .94 10 
7. SHBG 2.78 3.86 .20 .48 15 
8. testosterone .12 .89 .04 .89 17 
9. FAI -.26 .88 -.08 .77 15 
10. HbA1c .52 .22 .52 .03 18 
11. ins/kg .66 2.02 .08 .75 18 
12. CA@B2 .93 .28 .64 .004 18 
A multivariable regression entering HbA 1 c and CA at G2 with bone age at G2 
as the dependent variable (N=18) results in only chronological age as significant 
determinant of bone age at start of puberty: B = 0.93 ± 0.28 with B = 0.64, P = 
0.004 with R2 = 36.9%. 
6.8.3 Summary 
There is no association with any of the hormones studied at the start of puberty 
with the bone age at this time in the T1 0 boys. It is only chronological age and 
HbA 1 c that are significant. When entered into a model together it is only 
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chronological age that appears to exert a significant effect. Thus in T1 0 boys a 
greater chronological age at G2 is associated with a more advanced bone age. 
6.8.4 TID Girls 
Univariable regressions with bone age at B2: 
Variable B se ~ P N 
1. BMISDS@B2 .56 .31 .43 .09 17 
2.IGF-1 1.96 1.59 .30 .24 17 
3. A4 .43 1.25 .09 .74 17 
4.DHEAS .78 .61 .31 .22 17 
5. E2 2.28 1.64 .34 .18 17 
6.leptin 2.58 1.65 .62 .19 6 
7. SHBG -2.25 1.67 -.33 .20 17 
8. testosterone 1.39 1.65 .21 .42 17 
9. FAI 1.46 1.11 .32 .21 17 
10. HbA1c -.03 .18 -.04 .89 17 
11. ins/kg .33 1.05 .08 .76 17 
12. CA@ B2 .65 .43 .36 .16 17 
A multivariable regression entering chronological age and BMISDS at B2 with 
bone age at B2 as the dependent variable (N=17) results in BMISOS being a 
significant determinant B = 0.61 + 0.29 with {3 = 0.47. P = 0.05 adjusting for 
chronological age (B = 0.73 + 0.39 with {3 = 0.40. P = .08) with P of the model = 
0.05 and R2 = 25.1%. 
6.8.5 Summary 
BMISDS at the start of puberty is positively correlated with bone age at pubertal 
onset in the T1 0 girls, but is not quite significant in this sample, P = 0.09. In the 
multivariable model including chronological age and BMISDS, BMISDS remains 
significant adjusting for chronological age. Thus a relatively greater BMI at the 
onset of puberty, adjusting for chronological age at this time, is associated with 
a more advanced bone age at puberty onset. 
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Chapter 7. Conclusions 
The current data collected over many years has provided some fascinating 
insights into the variation and regulation of the timing and endocrine control of 
puberty in children with and without T1 D. A summary of the observations are 
as follows: 
7.1 Timing and variation in pubertal growth in T1 D children 
• Using contemporary controls and population reference comparisons, the 
current study indicates that there are subtle anomalies in the growth of 
children with T1 D. 
• The T1 0 boys had a relatively late pubertal onset but essentially normal 
growth while the girls had a slightly earlier age of pubertal onset 
(compared to controls) with an advanced bone age and a subsequent 
reduced PHV. 
7.2 BMI, Body Composition 
• This longitudinal data has contributed to the understanding of BMI, FM 
and FFM changes during puberty in normal children and those with T1 0 
and the possible role of leptin. 
• BMI increased in all the children over this pubertal time with the T1 0 
children of both sexes having greater BMI levels than controls. 
• The sexual dimorphism in this BMI was expressed as a greater 
acquisition of FFM in the boys and FM in the girls. 
• Leptin was higher in the T1 0 cohort and higher at all levels of fat mass. 
This may represent a degree of leptin resistance in both sexes but it was 
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only the T1 0 girls who gained more FM than controls whereas the T1 0 
boys had higher gains in FFM but still had higher leptin levels. 
7.3 Hormonal Changes during Puberty 
• This unique longitudinal study provides insights relating to hormonal 
changes during normal puberty and their relationship to PHV, puberty 
onset and menarche. The data clearly define hormonal abnormalities in 
IGF-I, DHEAS, leptin and testosterone levels in T1 0 subjects compared 
with controls and the degree to which these may be explained by 
peripheral vs portal insulin administration. 
• In an effort to find explanations for the observed differences between the 
T1D and control subjects this comparative study has tried to establish 
important determinants of the timing and the extent of pubertal variance 
in growth and body composition. 
7.4 Timing of Puberty and Pubertal Growth in Control Boys 
• Curiously the only correlate with timing of puberty was DHEAS, lower 
levels predicting earlier puberty, this is the converse of the 
adrenarche/puberty hypothesis. The variance was only 18.4% and it was 
a relatively small sample. 
• The association between testosterone and the duration from G2-PHV 
was interesting, higher testosterone levels at puberty onset predicted a 
shorter duration and explained 43.3% of the variance. 
• HtSDS change between G2 and PHV was strongly predicted by duration 
G2-PHV. Associations were also observed with leptin and age at start of 
puberty. Lower leptin was associated with greater relative height gain. A 
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later age at start of puberty predictably had a negative effect on 
subsequent height gain. 
• Analysis of PHVSDS and the hormones at PHV revealed that only 
testosterone was significant. Calculation of PHVSDS already allows for 
the effects of age at PHV. 
7.5 Timing of Puberty and Pubertal Growth in Control Girls 
• Timing of puberty onset in girls was strongly related to BMISDS and E2 
levels at the start of puberty (explaining 61 % of the variance). 
• A longer duration from B2 to PHV was also explained by a greater 
BMISDS. 
• These observations raise issues about the accurate timing of pubertal 
onset and whether an earlier B2 and modest elevations in E2 may 
precede the true onset of puberty in overweight girls. Recent discrepant 
observations in the literature associate earlier B2 with overweight but 
there is no similar trend for an earlier menarche. 
• A longer duration was also associated with lower levels of IGF-I. 
Generally children with a higher BMI have higher IGF-I levels but it would 
appear that these determinants are independent. 
• Height gain was strongly predicted by the duration from B2 to PHV and 
an earlier age of puberty onset was associated with a greater height gain. 
• PHVSDS was negatively associated with BMISDS consistent with the 
hypothesis that overweight and early puberty may lead to the blunting of 
the pubertal growth spurt. 
• None of the hormonal variables explained the variation in PHVSDS. 
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7.6 Timing of Puberty and Pubertal Growth in T1D Boys 
• Pubertal growth in T1 0 boys has been observed to be remarkably normal 
(chapter 3) despite low levels of IGF-I, testosterone and DHEAS. 
• The delay in pubertal onset was related to the presence of 'disease' and 
was not explained by hormone levels. The positive association with bone 
age is suggestive of a slowing in the growth tempo. 
• The duration from G2 to PHV was shorter in T1 D boys relative to controls 
as seen in chapter 3. A longer duration was associated with lower 
testosterone levels at the start of puberty. Perhaps the 'disease' effect is 
partly reflected in a trend towards higher HbA 1 c and later pubertal onset. 
• Height gain from G2 to PHV was, as in control boys, strongly related to a 
greater duration G2-PHV, however, a high HbA 1 c was independently 
associated with a reduced height gain. 
• PHVSDS determinants (other than age which is inherent in the 
calculation) varied depending on whether hormones at PHV or hormones 
from G2 to PHV were considered. A4 and IGF-I levels at PHV were 
positive determinants whereas high HbA 1 c values in the time from G2-
PHV were associated with a diminished PHVSDS. 
• Overall the presence of T1 D speeds up the growth tempo and the 
associated low testosterone, A4 and IGF-I levels with high HbA 1 c have 
negative effects on pubertal growth but this is marginal. An interesting 
speculation is whether the high GH levels may, through direct effects, be 
protective of overall growth in boys with T1 D and could also explain the 
increased FFM described in chapter 4. 
198 
7.7 Timing of Puberty and Pubertal Growth in T1 D Girls 
• T1 D girls entered puberty with an advanced bone age although their 
chronological age was similar to controls. 
• Interestingly the onset of puberty was not related to BMISDS as it was in 
the control girls but a higher HbA 1 c at the start of puberty was associated 
with a later age of puberty onset. 
• Bone age at the start of puberty was positively related to BMISDS. 
• Duration of B2-PHV was no different in T1 D girls and controls as seen in 
chapter 3. This duration was negatively associated with levels of IGF-I at 
the start of puberty in both cohorts. Although one might have predicted 
that lower IGF-I levels in the T1 D girls may slow pubertal progression, 
significant IGF-I differences between the cohorts don't usually show up 
until later in puberty. 
• Height gain from B2-PHV was strongly related to both age at onset and 
duration B2-PHV but there was an indication that a high HbA 1 c and low 
E2 levels might also contribute to poor height gain. 
• PHVSDS was negatively associated with BMISDS and bone age; such 
that a higher BMISDS was associated with a lower PHVSDS as was an 
advanced bone age. 
• Overall it would appear that BMISDS, HbA 1 c and bone age at the onset 
of puberty are more important than hormonal changes in the blunting of 
the pubertal growth spurt in T1 D girls. 
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7.8 Summary and highlights from the Conclusions 
In this cohort of T1 D boys, the onset of puberty was later than in controls, but 
pubertal growth appeared to be normal in spite of lower levels of IGF-I, 
testosterone, A4 and DHEAS. There were no hormonal factors identified that 
influenced this delay in onset but rather it appears to be inherent in the disease 
process itself. 
Puberty duration was longer in control boys and was associated with lower 
levels of testosterone. Poorer glycaemic control (higher HbA 1 c) at the start of 
puberty in the diabetic boys, perhaps as part of the disease effect, also played a 
role in shortening pubertal duration. The intensity of the growth spurt (as 
reflected by PHVSDS) was related to testosterone levels in the control boys and 
in the diabetic boys was positively associated with levels of IGF-I and A4 but 
adversely affected by levels of HbA 1 c. A reduced relative pubertal height gain 
was associated with higher values of HbA 1 c. 
Although the pubertal growth tempo was accelerated in T1 D boys compared to 
the controls, the lower levels of IGF-I, A4, DHEAS and testosterone appears to 
playa minimal role. 
The T1 D girls started puberty at a similar age to the control girls but with an 
advanced bone age. Unlike the boys, pubertal onset in the diabetic girls was 
influenced by glycaemic control in that a higher HbA 1 c was associated with a 
delayed pubertal onset. There appeared to be a subsequent slowing down in 
pubertal tempo and the diabetic girls took significantly longer to get to the end of 
puberty (stage 5). The well known positive association of BMI and age at 
puberty onset was observed in the control girls but was not present in the 
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diabetic girls. A greater 8MI at the start of puberty in the diabetic girls was 
associated with a more advanced bone age at this time. 
A greater 8MI was also associated with a longer pubertal duration in control 
girls and in both cohorts a lower IGF-I level at the start of puberty played a role 
in extending the duration from the onset of puberty until PHV. Low oestrogen 
levels in the diabetic girls led to less relative height gain during puberty but as in 
the boys, poorer glycaemic control was also a contributing factor. The diabetic 
girls had a diminished growth spurt that was related to both bone age and 
BMISDS at the time of PHV however none of the hormones studied were 
identified as factors in the growth spurt in the girls. 
Although it is possible that peripheral insulinaemia may be associated with 
increased leptin secretion, it remains an enigma as to why the leptin levels in 
both sexes were higher in the T1 0 cohort compared to the controls but it is only 
the girls who had greater fat mass while the T1 0 boys gained more fat free 
mass. 
Thus these observations reveal a number of sex differences as well as subtle , 
abnormalities that exist in the pubertal growth and development of children with 
T1D. 
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7.9 Strengths and Weaknesses of this study 
Strengths: 
• Longitudinal 
• Contemporary controls with comparable protocols 
• Study comprises both auxology (including experienced observer-
assessed puberty ratings) and biochemistry 
• Seen frequently throughout puberty (3 monthly for diabetic cohort and 6 
monthly for controls) 
• Largely centralised assays 
• Small number of observers trained initially together 
• Long duration of follow up 
Weaknesses: 
• Relatively small sample sizes 
• Not a prospective matched design 
• Observational studies, difficult to prove causality 
• Not followed to final height 
• No bone age in controls 
• No information on menstrual cycle in the girls 
• No measurement of binding proteins for IGF-I 
Despite the caveats, the data here provide a unique window into variations in 
growth, body composition and hormonal changes in young people with T1 D vs 
controls. Larger longitudinal studies with the principal aim of understanding the 
effect of hormonal/metabolic variation on the timing and pubertal variation in 
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growth and body composition in T1 0 would add additional insights and would be 
an interesting future study. 
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Chapter 8. Appendix 
8.1 Lower limits of Assays: 
Where a value for an assay was given as < the lower limit of that assay, a 
number half way between that value and 0 has been used. When the value was 
given as equal to the lower limit than that was recorded as reported, thus 
differentiating between testosterone=0.8 and testosterone=<0.8 (recorded as 
0.4). 
As more sensitive assays have been developed, the lower limits of the assays 
have varied over the years that the data was collected, ie testosterone has 
changed from <0.8 to <0.4. 
8.2 Menarcheal Age: 
For most of the T1 0 girls this was known to the day, for the few where it was 
not, the month was known and in those cases I have used the 15th of that 
month. 
For the control girls the data was recorded as '0' for no menarche and '1' for 
menarche. To calculate the age of menarche I have used the average of the 
two ages on these two occasions provided the interval between them was no 
longer than six months. In those cases where it was greater than six months I 
have not included these girls in the assessment of menarcheal age. 
8.3 Puberty Stage at Menarche in the Control Study: 
Since the exact time of menarche was unknown and even if it could ever be 
known, the chance of knowing the puberty stage at that moment would be slight. 
Therefore the puberty stage assigned at the time of menarche was the one the 
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girl was in at both time '0' and time'1' if they were the same but if the girl had 
progressed in the 6 months then the stage at time '0' was recorded. 
8.4 Choice of hormone values 
Hormones in a particular puberty stage where a child appears more than once 
in that stage have been averaged for that stage. This was regarded as the most 
representative of hormone levels at that point. There will be an innate variability 
and or diurnal variation that the averaged value will smooth out and was felt to 
be more representative of the 'true' value. We can never really know when the 
transition from one stage to another really occurs. 
8.5 Puberty ratings 
Female puberty ratings in both controls and T1 0 were probably more consistent 
than males since one female observer who had been trained by the same 
investigator did each study. In the controls there had been 2 male investigators 
who again had trained with the same original investigator while in the diabetic 
clinic there had been an assortment of male clinicians over the years although 
they were trained by one of the control investigators who himself trained at the 
same original centre. 
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8.6 Reliability 
As mentioned in the text I have used the TEM as the measure of precision as I 
was able to find values in the literature against which to compare. Below are 
the raw data for both skinfolds and height test-retest 
8.6.1 Skinfold Measurements 
Biceps Triceps Subscapular Suprailiac 
child time time diff diff"2 time time diff diff"2 time time diff time time diff 1 2 (1-2) 1 2 (1-2) 1 2 (1-2) diff"2 1 2 (1-2) diff"2 
1 7.4 8.0 -0.6 0.36 12.2 12.4 -0.2 0.04 5.6 5.5 0.1 0.01 5.4 6.0 -0.6 0.36 
2 9.1 8.8 0.3 0.09 16.6 16.0 0.6 0.36 7.2 7.0 0.2 0.04 9.2 9.1 0.1 0.01 
3 8.1 7.8 0.3 0.09 14.2 14.1 0.1 0.01 8.4 8.3 0.1 0.01 8.1 8.1 0.0 0.00 
4 9.8 10.2 -0.4 0.16 15.2 15.4 -0.2 0.04 8.8 8.6 0.2 0.04 9.8 11.4 -1.6 2.56 
5 5.0 6.2 -1.2 1.44 7.6 8.8 -1.2 1.44 4.8 5.3 -0.5 0.25 2.8 3.1 -0.3 0.09 
6 6.2 6.2 0.0 0.00 9.7 8.4 1.3 1.69 5.8 5.7 0.1 0.01 3.0 3.2 -0.2 0.04 
7 3.4 3.8 -0.4 0.16 7.4 7.0 0.4 0.16 5.1 5.0 0.1 0.01 4.2 4.6 -0.4 0.16 
8 3.4 3.8 -0.4 0.16 5.4 4.9 0.5 0.25 4.4 4.4 0.0 0.00 3.6 3.6 0.0 0.00 
9 2.5 2.5 0.0 0.00 4.6 4.6 0.0 0.00 3.5 3.4 0.1 0.01 2.4 2.4 0.0 0.00 
10 10. 10.0 0.6 0.36 17.4 16.0 1.4 1.96 10.8 10.2 0.6 0.36 13.9 13.4 0.5 0.25 
11 7.0 6.6 0.4 0.16 12.0 10.4 1.6 2.56 6.6 6.2 0.4 0.16 6.8 6.7 0.1 0.01 
12 10. 12.2 -1.8 3.24 16.4 17.2 -0.8 0.64 11.2 11.2 0.0 0.00 12.8 13.0 -0.2 0.04 
13 4.2 3.8 0.4 0.16 11.2 11.2 0.0 0.00 5.2 4.8 0.4 0.16 4.4 4.4 0.0 0.00 
14 4.1 4.0 0.1 0.01 7.0 6.6 0.4 0.16 5.2 5.2 0.0 0.00 5.1 5.4 -0.3 0.09 
15 7.8 8.2 -0.4 0.16 13.0 13.1 -0.1 0.01 6.1 6.3 -0.2 0.04 6.1 6.1 0.0 0.00 
16 4.6 5.2 -0.6 0.36 9.4 8.6 0.8 0.64 4.0 4.1 -0.1 0.01 3.3 3.3 0.0 0.00 
17 10. 10.4 -0.1 0.01 17.2 17.0 0.2 0.04 10.2 10.0 0.2 0.04 10.4 10.0 0.4 0.16 
18 8.0 9.4 -1.4 1.96 16.0 15.0 1.0 1.00 8.1 7.0 1 .1 1.21 9.4 9.4 0.0 0.00 
19 7.1 6.4 0.7 0.49 12.1 11.6 0.5 0.25 5.2 5.2 0.0 0.00 4.4 4.1 0.3 0.09 
20 2.4 2.3 0.1 0.01 7.3 6.6 0.7 0.49 4.3 4.4 -0.1 0.01 3.4 3.0 0.4 0.16 
21 10. 10.4 -0.2 0.04 14.4 13.9 0.5 0.25 12.0 10.8 1.2 1.44 8.8 8.9 -0.1 0.01 
22 7.2 8.4 -1.2 1.44 12.6 12.6 0.0 0.00 8.0 8.2 -0.2 0.04 5.6 6.0 -0.4 0.16 
23 9.4 9.4 0.0 0.00 14.2 14.0 0.2 0.04 8.0 7.9 0.1 0.01 7.4 8.5 -1.1 1.21 
24 9.4 9.4 0.0 0.00 12.0 12.0 0.0 0.00 7.8 7.8 0.0 0.00 6.6 7.0 -0.4 0.16 
25 5.9 6.1 -0.2 0.04 12.0 13.0 -1.0 1.00 5.8 5.4 0.4 0.16 4.2 4.7 -0.5 0.25 
26 4.4 4.2 0.2 0.04 9.0 9.8 -0.8 0.64 5.2 5.0 0.2 0.04 3.8 4.0 -0.2 0.04 
27 12. 12.0 0.2 0.04 17.2 17.2 0.0 0.00 9.4 10.4 -1.0 1.00 14.2 15.2 -1.0 1.00 
28 7.4 7.8 -0.4 0.16 16.0 15.9 0.1 0.01 8.8 7.6 1.2 1.44 5.8 6.4 -0.6 0.36 
29 4.2 4.6 -0.4 0.16 9.8 9.0 0.8 0.64 5.2 5.0 0.2 0.04 4.2 3.8 0.4 0.16 
30 4.8 4.4 0.4 0.16 7.1 8.0 -0.9 0.81 4.9 4.8 0.1 0.01 3.3 3.9 -0.6 0.36 
31 4.7 4.3 0.4 0.16 9.9 10.0 -0.1 0.01 4.6 4.7 -0.1 0.01 3.0 3.1 -0.1 0.01 
32 5.2 4.7 0.5 0.25 10.4 9.6 0.8 0.64 4.0 4.2 -0.2 0.04 2.8 3.0 -0.2 0.04 
33 5.1 5.0 0.1 0.01 10.4 10.2 0.2 0.04 5.4 5.4 0.0 0.00 5.4 5.5 -0.1 0.01 
34 7.0 7.0 0.0 0.00 13.2 14.2 -1.0 1.00 6.1 6.2 -0.1 0.01 5.6 5.4 0.2 0.04 
35 5.3 5.2 0.1 0.01 12.0 11.6 0.4 0.16 5.8 5.1 0.7 0.49 4.9 5.4 -0.5 0.25 
36 5.3 5.6 -0.3 0.09 12.0 11.0 1.0 1.00 5.8 5.4 0.4 0.16 4.8 4.9 -0.1 0.01 
L d2 L d2/2N TEM 1.96*TEM 
Bicep 11.98 .166 .41 .80 
Tricep 17.98 .250 .50 .98 
Subsp 7.26 .101 .32 .62 
Spril 8.09 .112 .34 .66 
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8.6.2 Height 
N Time1 Time2 Diff (T1-T2) D"2 
1 137.4 137.5 -0.1 0.010 
2 145.2 145.0 0.2 0.040 
3 125.0 124.9 0.1 0.010 
4 145.7 145.9 -0.2 0.040 
5 142.4 142.5 -0.1 0.010 
6 158.8 159.3 -0.5 0.250 
7 118.5 118.2 0.3 0.090 
8 148.5 148.8 -0.3 0.090 
9 143.3 143.5 -0.2 0.040 
10 145.6 145.8 -0.2 0.040 
11 137.8 137.5 0.3 0.090 
12 153.5 153.2 0.3 0.090 
13 159.3 159.2 0.1 0.010 
14 150.5 150.4 0.1 0.010 
15 146.4 146.2 0.2 0.040 
16 142.4 142.2 0.2 0.040 
17 147.7 147.8 -0.1 0.010 
18 161.8 161.7 0.1 0.010 
19 147.7 147.6 0.1 0.010 
20 163.6 163.8 -0.2 0.040 
21 158.7 158.6 0.1 0.010 
22 174.3 174.1 0.2 0.040 
23 125.1 125.0 0.1 0.010 
24 105.1 105.2 -0.1 0.010 
25 137.2 137.3 -0.1 0.010 
26 152.7 153.1 -0.4 0.160 
27 140.9 140.8 0.1 0.010 
28 143.7 143.5 0.2 0.040 
29 151.1 151.2 -0.1 0.010 
30 146.7 146.6 0.1 0.010 
31 148.8 148.8 0.0 0.000 
32 145.6 145.7 -0.1 0.010 
33 155.0 154.8 0.2 0.040 
34 158.7 158.5 0.2 0.040 
Summaries from above height data: 
TEM 1.96*TEM 
1.37 .02 .14 .28 
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8.7 Comment on the ascertainment of the age of onset of 
puberty: 
A number of children in both the T1 0 and control cohort were seen for the first time 
either in stage 2 or had a stage 2 rating that was more than 6 months after a previous 
rating of a stage 1. This situation occurred since several children were not seen due to 
missed appointments or inadvertently not examined (in the case of some of those with 
T1 D) until they had begun puberty and were found to be in stage 2. There were also 
several control children who appeared to go from stage 1 to stage 3 between their 6-
month visits, whether this meant they moved rapidly through this pubertal time or 
whether it relates to the subjectiveness of the rating is unknown. Although there was 
no statistical difference in the mean age of pubertal onset in any group whether all the 
data was included or only the data of those where a more rigorous approach was 
applied (including only those where a previous stage 1 within a 6 month period was 
available), in order to arrive at as precise an estimate of age of pubertal onset in each 
cohort as possible, only those children with the rigorous approach have been included 
for this analysis. 
This table shows the differences in the ages of pubertal onset if all the data had been 
included (white columns) or just those where the age was more rigorously determined 
(grey columns) . 
! GIRLS I BOYS 
J 
T10 I Controls I T10 I Controls 
N 1 23 16 j 53 45 I 26 21 I 43 42 
Mean 10.91 11.05 11.19 11.37 12.24 12.32 11 .28 11.28 
sd 0.87 0.60 1.19 1.00 0.99 0.94 0.78 0.78 
Median 10.83 10.92 11.18 11.43 12.12 12.13 11 .30 11.28 
Min 8.54 9.95 9.44 10.01 10.83 11.05 10.09 10.09 
Max 12.48 11.87 14.08 13.86 14.67 14.67 13.77 13.77 
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8.8 HbA1 and HbA 1c Methodology Changes 
Prior to 1992 the Department of Clinical Biochemistry at the John Radcliffe Hospital 
used an electrophoretic (electro endosmosis) method for the estimation of glycated 
haemoglobin (Ciba Corning Diagnostics, Halstead UK). This method separates HbA a 
from HbA 1 and HbF which migrate together as a single peak 'HbA1' and is expressed 
as a percentage of the total haemoglobin. 
In February 1992 this method was replaced by the Diamat (Bio-Rad Laboratories, 
Hemel Hempstead, UK) an automated high performance liquid chromatography system 
(HPLC). This machine measures five fractions separately: HbAo, HbA1a, HbA1b, HbA1c, 
and HbF and thus the estimation of HbA1c or 'true' HbA1 can be made (by summing 
HbA1a, HbA1b and HbA1c) without the contribution of HbF. 
The Department of Clinical Biochemistry provided an equation to allow conversion of 
the earlier Corning electrophoresis HbA 1 and the later Diamat HbA1c by HPLC: Derived 
HbA1C = (Corning HbA 1 x 0.86) - 0.4. Where:O.4 = the intercept and represents an 
average value for the contribution of HbF and 0.86 = the slope and allows the 
conversion of 'true' HbA1 (HbA1a+b+c) to HbA1c 
HbA 1 c normal range was 4.3-6.10/0 with the intra-assay imprecision being 1.9 
and 2.2% at HbA 1 c levels of 6.9 and 11.5% respectively, and inter-assay 
imprecision was 2.7 and 2.3% at HbA 1 c levels of 7.0 and 11.6% respectively. 
8.9 Other Laboratory Assays 
Serum samples were separated, stored at -20°C and subsequently used for the 
measurement of testosterone, oestradiol, sex hormone binding globulin (SHBG), 
dehydroepiandrosterone sulfate (DHEAS), androstenedione (A4), insulin-like 
growth factor-I (IGF-I) and thyroid hormones. 
1.Serum IGF-I concentrations were determined by radioimmunoassay (RIA) 
after acid-ethanol extraction (Morrell et al. 1989). The intra-assay 
imprecisions were 5.2 and 4.8% at 27.5 and 220 ng/mL respectively. The 
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inter-assay imprecisions were 12.7 and 10.6% at 77 and 242 ng/mL 
respective Iy. 
2.Free T4 was measured by a two-step, back titration method previously 
validated against an equilibrium dialysis method (Dunger et al. 1990). 
The inter-assay imprecision was 8.6%. 
3. Serum oestradiol was determined using the double antibody Diagnostics 
Products Corp kit (Llanberis, Wales, UK). The inter-assay imprecision 
was <100/0 at the three concentrations tested (approximately 150, 500 
and 1000 pmoI/L). 
4.Serum testosterone and androstenedione were measured using an in-
house RIA after ether extraction. The assays use an iodinated tracer and 
a dextran-coated charcoal separation-step. Between assay imprecision 
was <10% for both assays (Wathen et al. 1987). 
5.SHBG was measured using a 3H saturation assay (Fattah and Chard 
1981). Inter-assay variation was <8% at the concentrations (20,40 and 
70 nmol/L) tested. 
6. DHEAS was determined with in-house reagents. The assay required pre-
dilution of the sample (20-fold) with assay buffer followed by RIA with an 
1251 tracer. Inter-assay imprecision was <10% at the concentrations (2, 
1 0 and 20 ~mol/L) tested (Wathen et al. 1987). 
7.Serum leptin was measured by RIA (Linco Co., St Charles, MO, USA). All 
samples from a given individual were included in the same assay. The 
detection limit of the assay was 0.5 ng/mL (manufacturer's data). None 
of the sample values was less than 1.0ng/mL; therefore, there were no 
undetectable values. Intra- assay imprecisions were 5.7 and 6.7% at 2.5 
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and 12.5ng/ml respectively. Inter-assay imprecisions were 6.6 and 6.80/0 
at 2.5 and 12.5ng/ml respectively. 
Three hormones (testosterone, oestradiol and free T4) were not analysed in the 
same laboratory for both cohorts. The samples for the T1 0 subjects were 
analysed in the Department of Biochemistry at the John Radcliffe Hospital, 
Oxford whereas those for the control children were analysed in the Department 
of Clinical Biochemistry at St Bartholomew's Hospital, London. The assay 
methods previously described in the Appendix refer to those undertaken in the 
latter for the control group; the details below refer to the assays done in Oxford: 
1. Testosterone was measured by an extraction method similar to that used for 
the control group until the mid 90's with an inter-assay imprecision <10%. 
Subsequent testosterone measurements were undertaken using a direct RIA kit 
obtained from Medgenix Diagnostics Ltd. The latter assay used an iodinated 
tracer that did not require extraction due to the high specificity of the coated 
antibodies. The intra-assay imprecision was 4 and 4.7% at 2.6 and 19.78nmol/l 
respectively and the inter-assay imprecision was 8.3 and 8.1 % at 1.67 and 
15.55nmol/l respectively. 
It is difficult retrospectively to assess assay comparability between the two 
laboratory assays during this time period and whether potential differences may 
have invalidated the observed between group differences. Although Medgenix 
had better precision, there was little difference in method bias between the 
extraction RIA methods and the Medgenix assay and thus the results from the 
two labs would be very comparable (Dr Les Perry, London, personal 
communication). In addition, the reference intervals quoted were similar in both 
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laboratories, ie 9-35nmol/l from London and 9-42nmol/l from Oxford for adult 
males (personal communication from Dr Les Perry, London and Dr Tim James, 
Oxford). Therefore any differences between the methods can be considered 
modest compared to the observed differences in testosterone levels between 
the two cohorts of children. 
2. Oestradiol was measured using a competitive radioimmunoassay utilising a 
precipitating second antibody and centrifugation, the kit was from Immuno 
Diagnostic Systems Ltd, and the principle of the method was similar to that used 
in London. Inter-assay imprecision was <100/0. From January 1996, an 
automated competitive enzyme immunoassay method was used, Bayer Immuno 
1 System, inter-assay imprecision <10%. Again it is difficult to ascertain 
retrospectively whether there were significant differences between the methods 
but both laboratories participated in external quality assessment schemes 
(EQA), which are designed to identify significant between laboratory differences. 
Neither laboratory reported any significant EQA problems and differences 
between cohorts are probably physiological. 
3. FT4 was measured by a competitive analogue RIA from Amersham 
International until 1994. Intra-assay imprecision at 5.79 and 36pmol/l was 2.5 
and 3.70/0 respectively and inter-assay imprecision was 5.7 and 5.1 % at 
6.18pmol/l and 37.3pmol/l respectively. From 1994, a competitive enzyme 
immunoassay using a Bayer Immuno 1 System was employed. The intra-assay 
imprecision was 8.9% at 4.63pmol/l, 3.7% at 16.09pmol/l and 2.7% at 
55.98pmol/l. 
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Since little difference was noted between the two groups throughout puberty for 
FT 4 and a general consensus that there is reasonable conSistency among 
laboratories in this measurement (Dr Tim James and Dr Les Perry - personal 
communication), it is highly likely that the observations reported are reasonably 
reliable. 
8.10 Comparison of two observers in the ascertainment of PHV 
age and PHV by the graphical method 
Observer 1 Observer 2 Observer 1-2 
id PHVage PHV PHVSDS PHVage PHV PHVSDS PHVage PHV 
24 14.95 8.20 -0.49 15.25 6.80 -1.54 -0.30 1.40 
25 15.20 9.00 0.33 15.25 8.00 -0.51 -0.05 1.00 
28 15.95 8.30 0.33 15.95 8.40 0.33 0.00 -0.10 
29 13.80 10.30 0.49 13.75 9.40 -0.26 0.05 0.90 
30 12.45 11.30 0.51 12.25 10.80 0.00 0.20 0.50 
31 14.25 7.50 -1.11 14.25 8.00 -1.11 0.00 -0.50 
33 15.80 9.00 0.77 15.80 9.00 0.77 0.00 0.00 
35 12.85 12.20 1.45 12.75 12.20 1.45 0.10 0.00 
36 12.25 10.50 0.00 12.25 10.80 0.00 0.00 -0.30 
37 12.00 10.90 -0.13 12.00 10.90 -0.13 0.00 0.00 
38 15.80 8.20 0.17 15.75 8.40 0.17 0.05 -0.20 
39 13.70 7.20 -2.21 13.50 7.20 -2.31 0.20 0.00 
40 13.45 8.20 -1.79 13.25 8.00 -1.79 0.20 0.20 
41 14.45 11.80 2.05 14.50 11.60 2.05 -0.05 0.20 
42 12.50 11.00 0.25 12.50 11.00 0.25 0.00 0.00 
43 13.50 10.50 0.73 13.25 11.00 0.73 0.25 -0.50 
44 15.25 9.90 1.11 15.25 9.90 1.11 0.00 0.00 
45 14.25 10.30 0.85 14.25 10.30 0.85 0.00 0.00 
47 15.00 8.60 0.09 15.00 8.80 0.09 0.00 -0.20 
46 14.20 10.20 0.66 14.20 10.20 0.66 0.00 0.00 
mean 14.08 9.66 0.20 14.05 9.54 0.04 0.03 0.12 
sd 1.24 1.46 1.01 1.29 1.54 1.09 0.12 0.49 
The closeness of the ascertainment of age at PHV and magnitude by this 
investigator and a colleague working independently was extraordinary and quite 
unexpected. 
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8. 11 Comparison of PB smoothed curves and hand smoothed 
forPHVage 
PHV Age: Preece Baines (Mario) vs Hand Smoothed 
(Lynn) 
Paired SamQles Statistics 
STUDY SEX PHVage Mean sd sem N 
TIDM Girls L 11.92 0.690.15 22 
M 12.21 0.970.21 22 
B0:is L 14.28 1.230.26 23 
M 14.43 1.480.31 23 
Controls Girls L 12.24 0.670.11 37 
M 12.44 1.060.17 37 
B0:is L 13.74 0.920.19 23 
M 13.96 0.950.20 23 
Paired 
Paired SamQles Test Differences 
STUDY SEX PHVage Mean sd sem 95% CI of the Difference 
difference Lower U~~er t 
TIDM Girls L-M -0.29 0.65 0.14 -0.58 0.00 -2.09 
B0:is L-M -0.15 0.460.10 -0.35 0.04 -1.60 
Controls Girls L-M -0.20 0.56 0.09 -0.39 -0.01 -2.15 






There was a consistent difference with the PB model giving an older PHV age 
than the hand smoothed one. 
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8.12 Graphs 
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8.12.2 Reference Charts for Hormones by Years from PHV with 
T1D children plotted 
It is possible to construct graphs using the control cohort as the reference data (Growth 
Analyser program of the Dutch Growth Foundation, www.growthanalyser.org . this 
program uses the LMS method of Cole and Green (Cole and Green 1992). The figures 
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Girls 
Lower DHEAS levels in the T1 0 girls are evident relative to the controls: 
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TIDM Gins : IGF-I by Years from PHY 
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The trend for lower A4 levels in the T1 0 boys is seen. 
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Note the decline with time and the tendency for higher levels of SHBG in the T1 0 boys 
compared to the controls. 
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Girls 
Note the decline with time and a slight tendency for higher levels of SHBG in the T1 0 
girls compared to the controls . 
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Note the decline with time and the obviously higher levels of leptin in the T1 0 boys 
compared to the controls. 
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Girls 
Leptin levels increase with time and there are obviously higher levels of leptin in the 
T1D girls compared to the controls . 
Free Thyroxine 
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The reference graph of FT4 by years from PHV based on control data is presented with 
FT 4 levels of the T1 0 boys plotted on it and not much difference between the two 
cohorts is noted. 
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Girls 
The reference graph of FT 4 by years from PHV based on control data is presented with 
FT 4 levels of the T1 0 girls plotted on it. 
·(;0 -4 .6 -&0 ·3 ,6 ·30 ·2!i -2 .0 .1 ..5 . 1 0 -0 ,0 0 .0 06 1 0 l ' 20 2 '& 30 3 0 .40 46 6 0 
Y@3.rs from PHV 
It has not been possible for this investigator to construct the reference charts for 
testosterone or oestradiol. 
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8.13 Correlation Matrices 
8.13.1 Pubertal Onset 



























































































































































































DHEAS E2 FAI 
0.05 0.04 -0.13 
0.85 0.87 0.59 
19 20 19 
0.22 0.10 -0.05 
0.34 0.65 0.84 
21 22 21 
-001 0.03 0.07 
0.97 0.89 0.76 
21 21 21 
-0.33 0.34 
0.14 0.13 




21 22 21 
0.34 -0.10 
0.13 0.66 
21 21 21 
0.17 -0.05 0.18 
045 0.82 043 
21 22 21 
0.28 -0.02 0.79 
047 0.96 0.01 
9 9 9 
-0.15 -0.22 -0.77 
0.52 0.34 0.00 
21 21 21 
0.37 -0.26 0.74 
0.10 0.24 0.00 
21 22 21 
-0.27 048 0.17 
0.31 0.02 0.53 
16 22 16 
0.33 -0.18 0.06 
0.20 040 0.83 
17 23 17 
0.64 047 0.60 
0.01 0.06 0.01 
17 17 17 
0.21 043 
043 0.09 
17 17 17 
0.21 0.23 
043 0.37 
17 23 17 
0.43 0.23 
0.09 0.37 
17 17 17 
0.39 040 0.57 
0.13 0.06 0.02 
17 23 17 
-0.02 -0.07 0.17 
0.96 0.83 0.63 
10 13 10 
-0.30 0.09 -0.50 
0.24 0.74 0.04 
17 17 17 
0.40 0.44 0.95 
0.11 0.04 0.00 



















































































































































































Correlation Matrix for Age at Pubertal Onset and Hormones at the start of Puberty: 
Boys 
Age 
Pub BMISDS A4 DHEAS E2 FAI IGF-I Leptin SHBG Testos 
Desal 
T1D Age Pub r 1 
-0.38 -0.07 -0.22 0.05 -0.14 0.07 -0.17 0.31 -0.05 
B0:ts Onset P 0.08 0.76 0.36 0.84 0.57 0.77 0.62 0.20 0.83 
N 23 23 19 19 19 19 21 11 19 21 
BMISDS r -0.38 1 -0.19 0.05 0.35 0.00 0.17 0.48 -0.55 0.07 
P 0.08 0.41 0.82 0.11 0.99 0.42 0.14 0.01 0.74 
N 23 26 21 21 22 21 24 11 21 24 
A4 r -0.07 -0.19 1 0.41 -0.02 0.19 -0.04 -0.18 -0.15 0.15 
P 0.76 0.41 0.07 0.92 0.40 0.87 0.60 0.51 0.51 
N 19 21 21 21 20 21 21 11 21 21 
DHEAS r -0.22 0.05 0.41 1 0.11 0.18 -0.05 -0.11 -0.08 0.14 
P 0.36 0.82 0.07 0.64 0.45 0.82 0.74 0.73 0.55 
N 19 21 21 21 20 21 21 11 21 21 
E2 r 0.05 0.35 -0.02 0.11 1 -0.10 -0.14 0.19 0.09 -0.07 
P 0.84 0.11 0.92 0.64 0.68 0.52 0.57 0.71 0.76 
N 19 22 20 20 22 20 22 11 20 22 
FAI r -0.14 0.00 0.19 0.18 -0.10 1 0.37 0.56 -0.47 0.98 
P 0.57 0.99 0.40 0.45 0.68 0.10 0.07 0.03 0.00 
N 19 21 21 21 20 21 21 11 21 21 
IGF-I r 0.07 0.17 -0.04 -0.05 -0.14 0.37 1.00 0.37 -0.18 0.33 
P 0.77 0.42 0.87 0.82 0.52 0.10 0.27 0.43 0.11 
N 21 24 21 21 22 21 24 11 21 24 
Le(2tin r -0.17 0.48 -0.18 -0.11 0.19 0.56 0.37 1.00 -0.61 0.41 
P 0.62 0.14 0.60 0.74 0.57 0.07 0.27 0.04 0.21 
N 11 11 11 11 11 11 11 11 11 11 
SHBG r 0.31 -0.55 -0.15 -0.08 0.09 -0.47 -0.18 -0.61 1.00 -0.30 
P 0.20 0.01 0.51 0.73 0.71 0.03 0.43 0.04 0.18 
N 19 21 21 21 20 21 21 11 21 21 
Testos r -0.05 0.07 0.15 0.14 -0.07 0.98 0.33 0.41 -0.30 1 
P 0.83 0.74 0.51 0.55 0.76 0.00 0.11 0.21 0.18 
N 21 24 21 21 22 21 24 11 21 24 
Control Age Pub r 1 0.13 -0.18 0.47 0.25 -0.07 0.30 -0.20 0.24 
B0:ts Onset P 0.55 0.43 0.03 0.27 0.76 0.23 0.38 0.28 
N 23 23 21 21 21 22 18 21 22 
BMISDS r 0.13 1 0.07 0.25 0.80 0.42 0.73 -0.58 0.42 
P 0.55 0.74 0.26 000 0.04 0.00 0.00 0.05 
N 23 43 22 22 22 23 18 22 23 
A4 r -0.18 0.07 0.06 0.27 -0.11 0.27 -0.13 0.33 
P 0.43 0.74 0.79 0.22 0.63 0.30 0.57 0.13 
N 21 22 22 22 22 22 17 22 22 
DHEAS r 0.47 0.25 0.06 1 0.56 0.06 0.45 -0.25 0.55 
P 0.03 0.26 0.79 0.01 0.81 0.07 0.26 0.01 
N 21 22 22 22 22 22 17 22 22 
FAI 0.25 0.80 0.27 0.56 0.48 0.87 -0.61 0.89 
E2 Not available in Control Bo:ts 
P 0.27 0.00 0.22 0.01 0.02 0.00 0.00 0.00 
N 21 22 22 22 22 22 17 22 22 
IGF-I r -0.07 0.42 -0.11 0.06 0.48 1 0.41 -0.24 0.43 
P 0.76 0.04 0.63 0.81 0.02 0.09 0.28 0.04 
N 22 23 22 22 22 23 18 22 23 
Le(2tin r 0.30 0.73 0.27 0.45 0.87 0.41 -0.56 0.76 
P 0.23 0.00 0.30 0.07 0.00 0.09 0.02 0.00 
N 18 18 17 17 17 18 18 17 18 
SHBG r -0.20 -0.58 -0.13 -0.25 -0.61 -0.24 -0.56 1 -0.21 
P 0.38 0.00 0.57 0.26 0.00 0.28 0.02 0.34 
N 21 22 22 22 22 22 17 22 22 
Testos r 0.24 0.42 0.33 0.55 0.89 0.43 0.76 -0.21 
P 0.28 0.05 0.13 0.01 0.00 0.04 0.00 0.34 













Correlation Matrix for Age at Pubertal Onset and Hormones at the start of 
Puberty: All Boys 
Age Pub E 
Onset BMISDS A4 DHEAS 2 FAI IGF-I Leptin SHBG Testos 
r 1 0.13 -0.10 0.14 -0.01 -0.04 0.40 0.09 0.05 
P 0.40 0.53 0.38 0.95 0.80 0.03 0.58 073 
N 46 46 40 40 40 43 29 40 43 
r 0.13 1 0.06 0.14 0.33 0.19 0.75 -0.41 0.20 
P 0.40 0.72 0.36 0.03 0.20 000 0.01 0.17 
N 46 69 43 43 43 47 29 43 47 
r -0.10 0.06 1 0.14 0.20 -008 0.06 -0.11 0.22 
P 0.53 0.72 0.36 0.19 0.61 0.75 0.50 0.15 
N 40 43 43 43 43 43 28 43 43 
r 0.14 0.14 0.14 0.36 0.00 0.12 -0.20 0.33 
P 0.38 0.36 0.36 0.02 0.98 0.54 0.21 0.03 
N 40 43 43 43 43 43 28 43 43 
Not available for Control Boys 
r -0.01 0.33 0.20 0.36 1 0.42 0.29 -0.53 0.94 
P 0.95 0.03 0.19 0.02 0.01 0.14 0.00 0.00 
N 40 43 43 43 43 43 28 43 43 
r -0.04 0.19 -0.08 0.00 0.42 0.19 -0.22 0.36 
P 0.80 0.20 0.61 0.98 0.01 0.32 0.16 0.01 
N 43 47 43 43 43 47 29 43 47 
r 0.40 0.75 0.06 0.12 0.29 0.19 -0.31 0.20 
P 0.03 0.00 0.75 0.54 0.14 0.32 0.11 0.30 
N 29 29 28 28 28 29 29 28 29 
r 0.09 -0.41 -0.11 -0.20 -0.53 -0.22 -0.31 -0.24 
P 0.58 0.01 0.50 0.21 0.00 0.16 0.11 0.11 
N 40 43 43 43 43 43 28 43 43 
r 0.05 0.20 0.22 0.33 0.94 0.36 0.20 -0.24 1 
P 0.73 0.17 0.15 0.03 0.00 0.01 0.30 0.11 
N 43 47 43 43 43 47 29 43 47 
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Correlation Matrix for Age at Pubertal Onset and Hormones at the 
start of Puberty: All Girls 
Age Pub 
Onset BMISDS A4 DHEAS E2 FAI IGF-I Leptin SHBG Testos 
1 -0.39 0.20 -0.08 0.41 0.11 0.23 -0.04 0.00 0.22 
0.00 0.24 0.63 0.01 0.51 0.13 0.86 0.99 0.17 
64 64 36 36 43 36 44 21 36 43 
-0.39 1 -0.04 0.10 -0.12 -0.02 -0.04 0.55 -0.03 -0.12 
0.00 0.81 0.55 0.45 0.92 0.77 0.01 0.84 0.44 
64 75 38 38 45 38 46 22 38 45 
0.20 -0.04 1 0.33 0.26 0.34 0.15 -0.21 -0.02 0.37 
0.24 0.81 0.04 0.12 0.03 0.37 0.39 0.90 0.02 
36 38 38 38 38 38 38 19 38 38 
-0.08 0.10 0.33 1 0.02 0.38 0.22 -0.44 -0.23 0.34 
0.63 0.55 0.04 0.91 0.02 0.18 0.06 0.16 0.04 
36 38 38 38 38 38 38 19 38 38 
0.41 -0.12 0.26 0.02 0.15 0.26 -0.12 -0.04 0.31 
0.01 0.45 0.12 0.91 0.36 0.08 0.61 0.83 0.04 
43 45 38 38 45 38 45 22 38 45 
0.11 -0.02 0.34 0.38 0.15 0.39 -0.12 -0.59 0.88 
0.51 0.92 0.03 0.02 0.36 0.02 0.62 0.00 0.00 
36 38 38 38 38 38 38 19 38 38 
0.23 -0.04 0.15 0.22 0.26 0.39 1 0.27 -0.18 0.35 
0.13 0.77 0.37 0.18 0.08 0.02 0.23 0.28 0.02 
44 46 38 38 45 38 46 22 38 45 
-0.04 0.55 -0.21 -0.44 -0.12 -0.12 0.27 1 0.18 -0.08 
0.86 0.01 0.39 0.06 0.61 0.62 0.23 0.45 0.72 
21 22 19 19 22 19 22 22 19 22 
0.00 -0.03 -0.02 -0.23 -0.04 -0.59 -0.18 0.18 1 -0.21 
0.99 0.84 0.90 0.16 0.83 0.00 0.28 0.45 0.19 
36 38 38 38 38 38 38 19 38 38 
0.22 -0.12 0.37 0.34 0.31 0.88 0.35 -0.08 -0.21 
0.17 0.44 0.02 0.04 0.04 0.00 0.02 0.72 0.19 
43 45 38 38 45 38 45 22 38 45 
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8.13.2 
Correlation Matrix for Duration (Stage 2 to PHV) and Hormones at Stage 2: 
All Boys 
Our BMISOS 




-045 -041 0.12 -048 -0.24 G2 PHV P 0.02 077 0.15 000 0.03 046 0.00 0.12 N 46 46 40 40 40 29 40 43 43 BMISOS 
-
r -0.33 1 0.06 0.14 0.33 0.75 -041 0.20 0.19 G2 P 0.02 0.72 0.36 0.03 000 0.01 0.17 0.20 N 46 69 43 43 43 29 43 47 47 A4 r -0.05 0.06 1 0.14 0.20 0.06 -0.11 0.22 -008 P 0.77 0.72 0.36 0.19 0.75 0.50 0.15 0.61 
N 40 43 43 43 43 28 43 43 43 OHEAS r -0.23 0.14 0.14 0.36 0.12 -0.20 0.33 000 
P 0.15 0.36 0.36 0.02 0.54 0.21 0.03 0.98 
N 40 43 43 43 43 28 43 43 43 E2 r Not available for Control Boys 
FAI r -0.45 0.33 0.20 0.36 1 0.29 -0.53 0.94 0.42 
P 0.00 0.03 0.19 0.02 0.14 0.00 0.00 0.01 
N 40 43 43 43 43 28 43 43 43 
Leptin r -041 0.75 0.06 0.12 0.29 1 -0.31 0.20 0.19 
P 0.03 0.00 0.75 0.54 0.14 0.11 0.30 0.32 
N 29 29 28 28 28 29 28 29 29 
SHBG r 0.12 -0.41 -0.11 -0.20 -0.53 -0.31 -0.24 -0.22 
P 046 0.01 0.50 0.21 0.00 0.11 0.11 0.16 
N 40 43 43 43 43 28 43 43 43 
Testos r -048 0.20 0.22 0.33 0.94 0.20 -0.24 1 0.36 
P 0.00 0.17 0.15 0.03 0.00 0.30 0.11 0.01 
N 43 47 43 43 43 29 43 47 47 
IGF-I r -0.24 0.19 -0.08 0.00 042 0.19 -0.22 0.36 
P 0.12 0.20 0.61 0.98 0.01 0.32 0.16 0.01 
N 43 47 43 43 43 29 43 47 47 
Correlation Matrix for Duration (Stage 2 to PHV) and Hormones at Stage 2: 
All Girls 
All Girls BMISOS A4 Our 
-
B2 OHEAS E2 FAI IGF-I Leptin SHBG Testos 
BMISOS_B2 r 1 -0.04 0.10 -0.12 -0.02 -0.04 0.55 -0.03 -0.12 0.32 
P 0.81 0.55 0.45 0.92 0.77 0.01 0.84 044 0.02 
N 75 38 38 45 38 46 22 38 45 53 
A4 r -0.04 0.33 0.26 0.34 0.15 -0.21 -0.02 0.37 -0.08 
P 0.81 0.04 0.12 0.03 0.37 0.39 0.90 0.02 0.63 
N 38 38 38 38 38 38 19 38 38 36 
OHEAS r 0.10 0.33 1 0.02 0.38 0.22 -0.44 -0.23 0.34 0.17 
P 0.55 0.04 0.91 0.02 0.18 0.06 0.16 0.04 0.32 
N 38 38 38 38 38 38 19 38 38 36 
E2 r -0.12 0.26 0.02 0.15 0.26 -0.12 -0.04 0.31 -0.35 
P 0.45 0.12 0.91 0.36 0.08 0.61 0.83 0.04 0.02 
N 45 38 38 45 38 45 22 38 45 43 
FAI r -0.02 0.34 0.38 0.15 1 0.39 -0.12 -0.59 0.88 -0.13 
P 0.92 0.03 0.02 0.36 0.02 0.62 0.00 0.00 046 
N 38 38 38 38 38 38 19 38 38 36 
IGF-I r -0.04 0.15 0.22 0.26 0.39 1 0.27 -0.18 0.35 -047 
P 0.77 0.37 0.18 0.08 0.02 0.23 0.28 0.02 0.00 
N 46 38 38 45 38 46 22 38 45 44 
Leptin r 0.55 -0.21 -044 -0.12 -0.12 0.27 1 0.18 -0.08 -0.06 
P 0.01 0.39 0.06 0.61 0.62 0.23 045 0.72 0.80 
N 22 19 19 22 19 22 22 19 22 21 
SHBG r -0.03 -0.02 -0.23 -0.04 -0.59 ~M.N8 0.18 1 -0.21 -0.05 
P 0.84 0.90 0.16 0.83 0.00 0.28 0.45 0.19 0.78 
N 38 38 38 38 38 38 19 38 38 36 
Testos r -0.12 0.37 0.34 0.31 0.88 0.35 -0.08 -0.21 1 -0.25 
P 0.44 0.02 0.04 0.04 0.00 0.02 0.72 0.19 0.10 
N 45 38 38 45 38 45 22 38 45 43 
Our B2-PHV r 0.32 -0.08 0.17 -0.35 -0.13 -0.47 -0.06 -0.05 -0.25 
P 0.02 0.63 0.32 0.02 046 0.00 0.80 0.78 0.10 
N 53 36 36 43 36 44 21 36 43 53 
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Correlation Matrix for Duration (Stage 2 to PHV) and Hormones at Stage 2: 
Control Boys 
Dur 
BMISD IGF- G2_PH 
S G2 A4 DHEAS E2 FAI Leptin SHBG testos I V 
Control BMISD r 1 0.07 0.25 0.80 0.73 -0.58 0.42 0.42 -0.33 
Boys S G2 P 0.74 0.26 0.00 0.00 0.00 0.05 0.04 0.13 
N 43 22 22 22 18 22 23 23 23 
r 0.07 0.06 0.27 0.27 -0.13 0.33 0.11 0.06 
A4 P 0.74 0.79 0.22 0.30 0.57 0.13 0.63 0.78 
N 22 22 22 22 17 22 22 22 21 
DHEAS r 0.25 0.06 1.00 0.56 0.45 -0.25 0.55 0.06 -0.33 
P 0.26 0.79 0.01 0.07 0.26 0.01 0.81 0.14 
N 22 22 22 22 17 22 22 22 21 
E2 Not Available for Control Boys 
FAI r 0.80 0.27 0.56 1.00 0.87 -0.61 0.89 0.48 -0.44 
P 0.00 0.22 0.01 0.00 0.00 0.00 0.02 0.05 
N 22 22 22 22 17 22 22 22 21 
Leptin r 0.73 0.27 0.45 0.87 -0.56 0.76 0.41 -0.67 
P 0.00 0.30 0.07 0.00 0.02 0.00 0.09 0.00 
N 18 17 17 17 18 17 18 18 18 
SHBG r -0.58 0.13 -0.25 -0.61 -0.56 -0.21 0.24 0.19 
P 0.00 0.57 0.26 0.00 0.02 0.34 0.28 0.41 
N 22 22 22 22 17 22 22 22 21 
testos r 0.42 0.33 0.55 0.89 0.76 -0.21 0.43 -0.50 
P 0.05 0.13 0.01 0.00 0.00 0.34 0.04 0.02 
N 23 22 22 22 18 22 23 23 22 
IGF-I r 0.42 0.11 0.06 0.48 0.41 -0.24 0.43 -0.45 
P 0.04 0.63 0.81 0.02 0.09 0.28 0.04 0.03 
N 23 22 22 22 18 22 23 23 22 
Dur 
G2_PH r -0.33 0.06 -0.33 -0.44 -0.67 0.19 -0.50 0.45 
V P 0.13 0.78 0.14 0.05 0.00 0.41 0.02 0.03 
N 23 21 21 21 18 21 22 22 23 
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Correlation Matrix for Duration (Stage 2 to PHV) and Hormones at Stage 2: 
Control Girls 
BMISD SHB testa Dur 
S B2 A4 DHEAS E2 FAI ie~tin G s IGF-I B2 PHV 
Control BMISD r -0.18 0.33 -0.18 0.06 0.38 -0.33 -0.13 -0.05 0.44 
Girls S B2 P 0.49 0.20 0.40 0.83 0.20 0.20 0.56 0.80 0.01 
N 52 17 17 23 17 13 17 23 23 32 
r -0.18 0.64 0.47 0.60 -0.12 -0.06 0.66 0.51 -0.17 
A4 P 0.49 0.01 0.06 0.01 0.73 0.81 0.00 0.04 0.51 
N 17 17 17 17 17 10 17 17 17 17 
DHEAS r 0.33 0.64 0.21 0.43 -0.02 -0.30 0.40 0.39 0.24 
P 0.20 0.01 0.43 0.09 0.96 0.24 0.11 0.13 0.36 
N 17 17 17 17 17 10 17 17 17 17 
E2 r -0.18 0.47 0.21 0.23 -0.07 0.09 0.44 0.40 -0.43 
P 0.40 0.06 0.43 0.37 0.83 0.74 0.04 0.06 0.04 
N 23 17 17 23 17 13 17 23 23 23 
FAI r 0.06 0.60 0.43 0.23 0.17 -0.50 0.95 0.57 -0.33 
P 0.83 0.01 0.09 0.37 0.63 0.04 0.00 0.02 0.19 
N 17 17 17 17 17 10 17 17 17 17 
ie~tin r 0.38 -0.12 -0.02 -0.07 0.17 -0.09 0.08 0.57 0.34 
P 0.20 0.73 0.96 0.83 0.63 0.80 0.78 0.04 0.26 
N 13 10 10 13 10 13 10 13 13 13 
SHBG r -0.33 -0.06 -0.30 0.09 -0.50 -0.09 -0.20 -0.40 0.04 
P 0.20 0.81 0.24 0.74 0.04 0.80 0.43 0.11 0.88 
N 17 17 17 17 17 10 17 17 17 17 
testos r -0.13 0.66 0.40 0.44 0.95 0.08 -0.20 0.48 -0.40 
P 0.56 0.00 0.11 0.04 0.00 0.78 0.43 0.02 0.06 
N 23 17 17 23 17 13 17 23 23 23 
IGF-I r -0.05 0.51 0.39 0.40 0.57 0.57 -0.40 0.48 -0.45 
P 0.80 0.04 0.13 0.06 0.02 0.04 0.11 0.02 0.03 
N 23 17 17 23 17 13 17 23 23 23 
Dur 0.44 -0.17 0.24 -0.43 -0.33 0.34 0.04 -0.40 -0.45 
B2_PH 
V P 0.01 0.51 0.36 0.04 0.19 0.26 0.88 0.06 0.03 
N 32 17 17 23 17 13 17 23 23 32 
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Correlation Matrix for Duration (Stage 2 to PHV) and Hormones at Stage 2: 
T1D Boys 
BMIS OHEA Our 
OS_G E2 
Lepti SHB G2_P HbA 
2 A4 S FAI n G testo IGF-I fWWf~ in kg 1c 
T1D BMIS r 1 0.05 0.35 0.00 0.48 -0.55 0.07 0.17 -0.10 0.25 0.00 
Bo~s OS P 0.41 0.82 0.11 0.99 0.14 0.01 0.74 0.42 0.65 0.23 1.00 
G2 N 26 21 21 22 21 11 21 24 24 23 24 26 
r -0.19 0.41 -0.02 0.19 -0.18 -0.15 0.15 -0.04 -0.25 -0.38 -0.10 
A4 P 0.41 0.07 0.92 0.40 0.60 0.51 0.51 0.87 0.31 0.11 0.67 
N 21 21 21 20 21 11 21 21 21 19 19 21 
OHE r 0.05 0.41 0.11 0.18 -0.11 -0.08 0.14 -0.05 -0.16 -0.28 0.01 
AS P 0.82 0.07 0.64 0.45 0.74 0.73 0.55 0.82 0.51 0.25 0.97 
N 21 21 21 20 21 11 21 21 21 19 19 21 
E2 r 0.35 0.11 0.19 0.09 -0.07 -0.14 0.20 0.21 -0.13 
P 0.11 0.92 0.64 0.68 0.57 0.71 0.76 0.52 0.41 0.38 0.58 
N 22 20 20 22 20 11 20 22 22 19 20 22 
FAI r 0.00 0.19 0.18 -0.10 0.56 -0.47 0.98 0.37 -0.57 0.45 0.32 
P 0.99 0.40 0.45 0.68 0.07 0.03 0.00 0.10 0.01 0.06 0.16 
N 21 21 21 20 21 11 21 21 21 19 19 21 
Lef2ti r 0.48 -0.11 0.19 0.56 -0.61 0.41 0.37 0.15 0.44 0.04 
P 0.14 0.60 0.74 0.57 0.07 0.04 0.21 0.27 0.65 0.17 0.91 
N 11 11 11 11 11 11 11 11 11 11 11 11 
SHB r -0.55 -0.08 0.09 -0.61 -0.30 -0.18 0.22 -0.32 -0.17 
P 0.01 0.51 0.73 0.71 0.03 0.04 0.18 0.43 0.36 0.18 0.47 
N 21 21 21 20 21 11 21 21 21 19 19 21 
testo r 0.07 0.15 0.14 -0.07 0.98 0.41 -0.30 1 0.33 -0.56 0.29 0.37 
P 0.74 0.51 0.55 0.76 0.00 0.21 0.18 0.11 0.01 0.19 0.08 
N 24 21 21 22 21 11 21 24 24 21 22 24 
IGF-I r 0.17 -0.05 -0.14 0.37 0.37 -0.18 0.33 1 -0.20 -0.11 -0.04 
P 0.42 0.87 0.82 0.52 0.10 0.27 0.43 0.11 0.38 0.64 0.84 
N 24 21 21 22 21 11 21 24 24 21 22 24 
Our r -0.10 -0.16 0.20 0.15 0.22 -0.56 -0.20 1 -0.08 -0.44 
G2 P P 0.65 0.31 0.51 0.41 0.01 0.65 0.36 0.01 0.38 0.73 0.04 
N 23 19 19 19 19 11 19 21 21 23 23 23 
in kg r 0.25 -0.28 0.21 0.45 0.44 -0.32 0.29 -0.11 -0.08 1 0.26 
P 0.23 0.11 0.25 0.38 0.06 0.17 0.18 0.19 0.64 0.73 0.23 
N 24 19 19 20 19 11 19 22 22 23 24 24 
HbA1 r 0.00 0.01 -0.13 0.32 0.04 -0.17 0.37 -0.04 -0.44 0.26 1 
P 1.00 0.67 0.97 0.58 0.16 0.91 0.47 0.08 0.84 0.04 0.23 











































DS_B DHE Lepti SHB teste 
Dur 
B2_ 
PHV 2 A4 AS E2 FAI n G s IGF-I 
0.37 0.22 0.10 -0.05 0.80 0.09 -0.17 -0.02 0.15 
0.10 0.34 0.65 0.84 0.01 0.69 0.45 0.92 0.52 
23 21 21 22 21 9 21 22 23 21 
0.37 1 -0.01 0.03 0.07 0.29 0.07 0.12 -0.04 -0.11 
0.10 0.97 0.89 0.76 0.45 0.77 0.59 0.85 0.67 
21 21 21 21 21 9 21 21 21 19 
0.22 -0.01 1 -0.33 0.34 0.28 -0.15 0.37 0.17 0.05 
0.34 0.97 0.14 0.13 0.47 0.52 0.10 0.45 0.84 
21 21 21 21 21 9 21 21 21 19 
0.10 0.03 -0.33 1 -0.10 -0.02 -0.22 -0.26 -0.05 -0.10 
0.65 0.89 0.14 0.66 0.96 0.34 0.24 0.82 0.67 
22 21 21 22 21 9 21 22 22 20 
-0.05 0.07 0.34 -0.10 0.79 -0.77 0.74 0.18 0.18 
0.84 0.76 0.13 0.66 0.01 0.00 0.00 0.43 0.46 
21 21 21 21 21 9 21 21 21 19 
0.80 0.29 0.28 -0.02 0.79 -0.45 0.74 0.10 0.02 
0.01 0.45 0.47 0.96 0.01 0.22 0.02 0.79 0.95 
9 9 9 9 999 998 
0.09 0.07 -0.15 -0.22 -0.77 -0.45 -0.30 -0.07 -0.09 
0.69 0.77 0.52 0.34 0.00 0.22 0.19 0.75 0.73 
21 21 21 21 21 9 21 21 21 19 
-0.17 0.12 0.37 -0.26 0.74 0.74 -0.30 0.15 0.10 
0.45 0.59 0.10 0.24 0.00 0.02 0.19 0.51 0.69 
22 21 21 22 21 9 21 22 22 20 
-0.02 -0.04 0.17 -0.05 0.18 0.10 -0.07 0.15 -0.53 
0.92 0.85 0.45 0.82 0.43 0.79 0.75 0.51 0.01 
23 21 21 22 21 9 21 22 23 21 
0.15 -0.11 0.05 -0.10 0.18 0.02 -0.09 0.10 -0.53 
0.52 0.67 0.84 0.67 0.46 0.95 0.73 0.69 0.01 
21 19 19 20 19 8 19 20 21 21 
-0.31 0.10 -0.14 0.45 -0.24 -0.46 0.04 0.09 0.47 -0.48 
0.17 0.68 0.56 0.05 0.32 0.25 0.88 0.70 0.03 0.03 
21 19 19 20 19 8 19 20 21 21 
0.07 -0.11 0.24 0.21 -0.13 -0.17 -0.16 -0.35 0.36 -0.34 
0.74 0.63 0.30 0.35 0.57 0.66 0.48 0.11 0.09 0.13 









































































8.13.3 HtSDS change from Stage 2 to PHV 




HtSOSll os OHE E Lept Tes Age PH 
PHV-G2 G2 IGF-I A4 AS 2 in SHBG tos FAI G2 V 
All HtSOS r 1 -0.39 -0.01 0.07 -0.16 0.21 -0.25 -0.41 0.78 
Boys II PHV- P 0.01 0.93 0.66 0.31 0.01 0.18 0.1 0.11 0.01 0.00 
N 45 45 44 43 43 34 43 44 43 45 45 
BMISO r -0.39 0.20 -0.15 0.18 0.74 -0.40 0.16 0.13 
P 0.01 0.18 0.33 0.25 0.00 0.01 0.7 0.29 0.40 0.02 
N 45 46 45 44 44 35 44 45 44 46 46 
IGF-I r -0.01 0.20 1 -0.12 0.10 -0.20 0.2 0.31 -0.15 
P 0.93 0.18 0.43 0.51 0.96 0.18 0.0 0.04 0.33 0.15 
N 44 45 46 45 45 36 45 46 45 45 45 
A4 r 0.07 -0.15 -0.12 0.16 -0.09 0.2 0.23 -0.22 0.09 
P 0.66 0.33 0.43 0.29 0.60 0.54 0.2 0.13 0.15 0.56 
N 43 44 45 45 45 35 45 45 45 44 44 
OHEAS r -0.16 0.18 0.10 0.16 1 0.03 -0.36 0.2 0.40 -0.11 
P 0.31 0.25 0.51 0.29 0.85 0.02 0.0 0.01 0.48 0.38 
N 43 44 45 45 45 35 45 45 45 44 44 
E2 Not available for Control Boys 
LeQtin r -0.42 0.74 -0.01 -0.09 0.03 1 -0.12 -0.13 0.50 
P 0.01 0.00 0.96 0.60 0.85 0.50 0.2 0.44 0.00 0.08 
N 34 35 36 35 35 36 35 36 35 35 35 
SHBG r 0.21 -0.40 -0.20 -0.09 -0.36 1 -0.56 0.09 0.15 
P 0.18 0.01 0.18 0.54 0.02 0.50 0.1 0.00 0.58 0.32 
N 43 44 45 45 45 35 45 45 45 44 44 
Testos r -0.23 -0.06 0.29 0.20 0.28 -0.22 1 0.90 0.09 
P 0.14 0.71 0.05 0.20 0.06 0.25 0.15 0.00 0.57 0.00 
N 44 45 46 45 45 36 45 46 45 45 45 
FAI r -0.25 0.16 0.31 0.23 0.40 -0.56 0.9 -0.01 
P 0.11 0.29 0.04 0.13 0.01 0.44 0.00 0.0 0.94 0.00 
N 43 44 45 45 45 35 45 45 45 44 44 
AgeG2 r -0.41 0.13 -0.15 -0.22 -0.11 0.50 0.09 0.0 -001 
P 0.01 0.40 0.33 0.15 0.48 0.00 0.58 0.5 0.94 0.07 
N 45 46 45 44 44 35 44 45 44 46 46 
Our r 0.78 -0.33 -0.22 0.09 -0.14 0.15 -0.46 -0.27 
P 0.00 0.02 0.15 0.56 0.38 0.08 0.32 0.0 0.00 0.07 

















































B2 IGF-I A4 
0.25 -0.08 0.21 
0.08 0.61 0.24 
52 52 42 35 
0.25 -0.04 -0.11 
0.08 0.80 0.53 
52 52 42 35 
-0.08 -0.04 1 -0.05 
0.61 0.80 0.77 
42 42 48 40 
0.21 -0.11 -0.05 
0.24 0.53 0.77 
35 35 40 40 
0.32 0.05 0.24 0.47 
0.06 0.78 0.14 0.00 
35 35 40 40 
-0.06 -0.10 0.08 0.30 
0.69 0.51 0.60 0.07 
42 42 47 39 
0.09 0.64 -0.11 -0.31 
0.64 0.00 0.56 0.11 
27 27 32 28 
-0.20 -0.12 -0.10 0.03 
0.24 0.51 0.54 0.87 
35 35 40 40 
-0.03 -0.08 0.21 0.46 
0.86 0.61 0.16 0.00 
42 42 48 40 
0.17 0.04 0.24 0.43 
0.32 0.81 0.14 0.01 
35 35 40 40 
-0.66 -0.50 0.11 0.03 
0.00 0.00 0.47 0.85 
52 52 43 36 
0.82 0.32 -0.35 0.14 
0.00 0.02 0.02 0.43 














































0.09 -0.20 -0.03 
0.64 0.24 0.86 
27 35 42 
0.64 -0.12 -0.08 
0.00 0.51 0.61 
27 35 42 
-0.11 -0.10 0.21 
0.56 0.54 0.16 
32 40 48 
-0.31 0.03 0.46 
0.11 0.87 0.00 
28 40 40 
-0.32 -0.14 0.44 
0.10 0.38 0.00 
28 40 40 
-0.21 0.00 0.29 
0.26 0.99 0.04 
31 39 47 
1 0.00 -0.19 
0.98 0.30 
32 28 32 
0.00 -0.08 
0.98 0.64 
28 40 40 
-0.19 -0.08 
0.30 0.64 
32 40 48 
-0.16 -0.50 0.86 
0.41 0.00 0.00 
28 40 40 
-0.31 0.10 -0.01 
0.12 0.57 0.94 
27 36 43 
0.24 -0.19 -0.08 
0.23 0.26 0.62 







0.17 -0.66 0.82 
0.32 0.00 0.00 
35 52 51 
0.04 -0.50 0.32 
0.81 0.00 0.02 
35 52 51 
0.24 0.11 -0.35 
0.14 0.47 0.02 
40 43 42 
0.43 0.03 0.14 
0.01 0.85 0.43 
40 36 36 
0.46 -0.19 0.22 
0.00 0.28 0.20 
40 36 36 
0.22 0.25 -0.11 
0.17 0.11 0.49 
39 43 42 
-0.16 -0.31 0.24 
0.41 0.12 0.23 
28 27 27 
-0.50 0.10 -0.19 
0.00 0.57 0.26 
40 36 36 
0.86 -0.01 -0.08 
0.00 0.94 0.62 
40 43 42 
-0.11 0.12 
0.52 0.48 
40 36 36 
-0.11 -0.58 
0.52 0.00 
36 53 52 
0.12 -0.58 
0.48 0.00 


























































G2 IGF-I A4 AS 
-0.34 -0.09 0.06 -0.38 
0.11 0.69 0.80 0.09 
23 22 21 21 
0.40 -0.13 0.27 
0.07 0.57 0.23 
23 22 21 21 
0.40 1 -0.39 0.01 
0.07 0.08 0.97 
22 23 22 22 
-0.13 -0.39 1 0.01 
0.57 0.08 0.98 
21 22 22 22 
0.27 0.01 0.01 1 
0.23 0.97 0.98 
21 22 22 22 
E 
2 
Lepti SHB Test Age 
n G os FAI G2 
-0.59 0.27 -0.19 -0.27 -0.53 
0.01 0.23 0.40 0.23 0.01 
19 21 22 21 23 
0.77 -0.62 0.21 0.63 0.13 
0.00 0.00 0.36 0.00 0.55 
19 21 22 21 23 
0.11 -0.31 0.29 0.46 0.05 
0.64 0.16 0.18 0.03 0.83 
20 22 23 22 22 
0.28 0.07 0.09 0.02 -0.29 
0.25 0.77 0.69 0.94 0.21 
19 22 22 22 21 
0.35 -0.25 0.53 0.56 0.40 
0.14 0.26 0.01 0.01 0.07 
19 22 22 22 21 
Not available for Control Boys 
0.77 0.11 0.28 0.35 1 -0.52 0.42 0.66 0.36 
0.00 0.64 0.25 0.14 0.02 0.07 0.00 0.13 
19 20 19 19 20 19 20 19 19 
-0.62 -0.31 0.07 -0.25 -0.52 1 -0.14 -0.57 -0.32 
0.00 0.16 0.77 0.26 0.02 0.55 0.01 0.15 
21 22 22 22 19 22 22 22 21 
0.21 0.29 0.09 0.53 0.42 -0.14 0.88 0.31 
0.36 0.18 0.69 0.01 0.07 0.55 0.00 0.16 
22 23 22 22 20 22 23 22 22 
0.63 0.46 0.02 0.56 0.66 -0.57 0.88 0.44 
0.00 0.03 0.94 0.01 0.00 0.01 0.00 0.05 
21 22 22 22 19 22 22 22 21 
0.13 0.05 -0.29 0.40 0.36 -0.32 0.31 0.44 
0.55 0.83 0.21 0.07 0.13 0.15 0.16 0.05 
23 22 21 21 19 21 22 21 23 
-0.33 -0.36 0.24 -0.36 -0.53 0.22 -0.50 -0.49 -0.36 
0.13 0.10 0.29 0.11 0.02 0.34 0.02 0.02 0.09 














































































-B2 B2 IGF-I 
0.46 0.18 
0.01 0.41 
31 31 22 
0.46 0.12 
0.01 0.61 
31 31 22 
0.18 0.12 
0.41 0.61 
22 22 27 
-0.01 -0.10 0.04 
0.97 0.73 0.87 
16 16 20 
0.39 0.35 0.28 
0.14 0.19 0.24 
16 16 20 
-0.37 -0.09 0.16 
0.09 0.68 0.45 
22 22 26 
0.46 0.53 0.14 
0.07 0.04 0.56 
16 16 20 
-0.43 -0.44 -0.14 
0.10 0.09 0.56 
16 16 20 
-0.24 -0.03 0.18 
0.28 0.91 0.37 
22 22 27 
-0.04 0.18 0.31 
0.89 0.51 0.18 
16 16 20 
-0.73 -0.65 -0.03 
0.00 0.00 0.90 
31 31 23 
0.81 0.47 -0.22 
0.00 0.01 0.33 
































































Lepti SHB Test Age B2_ 
n G os FAI B2 PHV 
0.46 -0.43 -0.24 0.04 -0.73 0.81 
0.07 0.10 0.28 0.89 0.00 0.00 
16 16 22 16 31 30 
0.53 -0.44 -0.03 0.18 -0.65 0.47 
0.04 0.09 0.91 0.51 0.00 0.01 
16 16 22 16 31 30 
0.14 -0.14 0.18 0.31 -003 -0.22 
0.56 0.56 0.37 0.18 0.90 0.33 
20 20 27 20 23 22 
0.07 0.15 0.68 0.60 0.10 0.17 
0.79 0.53 0.00 0.01 0.72 0.51 
16 20 20 20 17 17 
0.51 -0.26 0.44 0.53 -0.38 0.39 
0.05 0.27 0.05 0.02 0.14 0.12 
16 20 20 20 17 17 
-0.17 0.11 0.34 0.20 0.42 -0.32 
0.49 0.65 0.09 0.41 0.05 0.14 
19 19 26 19 23 22 
1 -0.46 -0.05 0.16 -0.42 0.55 
0.07 0.83 0.54 0.11 0.03 
20 16 20 16 16 16 
0.15 -0.26 0.11 -0.46 0.14 0.27 0.15 -0.35 
0.53 0.27 0.65 0.07 0.54 0.24 0.56 0.16 
20 20 19 16 20 20 20 17 17 
0.68 0.44 0.34 -0.05 0.14 1 0.90 0.14 -0.23 
0.00 0.05 0.09 0.83 0.54 0.00 0.53 0.30 
20 20 26 20 20 27 20 23 22 
0.60 0.53 0.20 0.16 -0.27 0.90 0.00 -0.01 
0.01 0.02 0.41 0.54 0.24 0.00 0.99 0.96 
20 20 19 16 20 20 20 17 17 
0.10 -0.38 0.42 -0.42 0.15 0.14 0.00 1 -0.63 
0.72 0.14 0.05 0.11 0.56 0.53 0.99 0.00 
17 17 23 16 17 23 17 32 31 
0.17 0.39 -0.32 0.55 -0.35 -0.23 0.01 -0.63 
0.51 0.12 0.14 0.03 0.16 0.30 0.96 0.00 
17 17 22 16 17 22 17 31 31 
237 





























































PHV-G2 G2 IGF-I 
Dur 
DHE Lepti SHB Test Age G2_ 
A4 AS E2 n G os FAI G2 PHV 
-0.24 -0.11 0.01 -0.12 0.25 0.10 0.46 -0.41 -0.43 0.06 0.76 
0.29 0.62 0.97 0.60 0.26 0.73 0.03 0.06 0.05 0.79 0.00 
22 22 22 22 22 22 15 22 22 22 22 22 
-0.24 0.27 -0.13 0.29 0.31 0.54 -0.50 -0.17 0.04 0.38 -0.10 
0.29 0.22 0.55 0.18 0.15 0.03 0.01 0.43 0.84 0.08 0.65 
22 23 23 23 23 23 16 23 23 23 23 23 
-0.11 0.27 0.21 0.08 -0.03 0.22 0.02 0.24 0.18 0.12 -0.30 
0.62 0.22 0.34 0.72 0.90 0.41 0.94 0.28 0.42 0.59 0.17 
22 23 23 23 23 23 16 23 23 23 23 23 
0.01 -0.13 0.21 0.43 0.13 0.18 -0.37 0.37 0.52 0.11 -0.27 
0.97 0.55 0.34 0.04 0.56 0.50 0.09 0.08 0.01 0.62 0.22 
22 23 23 23 23 23 16 23 23 23 23 23 
-0.12 0.29 0.08 0.43 0.05 0.07 -0.38 0.08 0.26 0.37 -0.11 
0.60 0.18 0.72 0.04 0.80 0.80 0.07 0.72 0.23 0.09 0.63 
22 23 23 23 23 23 16 23 23 23 23 23 
0.25 0.31 -0.03 0.13 0.05 1 0.28 -0.13 0.01 0.06 0.04 0.12 
0.26 0.15 0.90 0.56 0.80 029 0.56 0.96 0.77 0.86 0.59 
22 23 23 23 23 23 16 23 23 23 23 23 
0.10 0.54 0.22 -0.18 -0.07 0.28 -0.39 -0.38 -0.20 0.01 0.33 
0.73 0.03 0.41 0.50 0.80 0.29 0.13 0.15 0.46 0.97 0.22 
15 16 16 16 16 16 16 16 16 16 16 16 
0.46 -0.50 0.02 -0.37 -0.38 -0.13 0.39 -0.23 -0.53 0.19 0.35 
0.03 0.01 0.94 0.09 0.07 0.56 0.13 0.29 0.01 0.39 0.10 
22 23 23 23 23 23 16 23 23 23 23 23 
-0.41 -0.17 0.24 0.37 0.08 0.01 0.38 -0.23 0.91 0.12 -0.68 
0.06 0.43 0.28 0.08 0.72 0.96 0.15 0.29 0.00 0.59 0.00 
22 23 23 23 23 23 16 23 23 23 23 23 
-0.43 0.04 0.18 0.52 0.26 0.06 0.20 -0.53 0.91 0.06 -0.69 
0.05 0.84 0.42 0.01 0.23 0.77 0.46 0.01 0.00 0.78 0.00 
22 23 23 23 23 23 16 23 23 23 23 23 
-0.06 -0.38 -0.12 -0.11 -0.37 0.04 0.01 0.19 0.12 -0.06 1 0.09 
0.79 0.08 0.59 0.62 0.09 0.86 0.97 0.39 0.59 0.78 0.68 
22 23 23 23 23 23 16 23 23 23 23 23 
0.76 -0.10 -0.30 -0.27 -0.11 0.12 0.33 0.35 -0.68 -0.69 0.09 
0.00 0.65 0.17 0.22 0.63 0.59 0.22 0.10 0.00 0.00 0.68 
22 23 23 23 23 23 16 23 23 23 23 23 
-0.62 0.00 -0.31 0.10 0.34 -0.07 0.17 -0.41 0.27 0.32 0.10 -0.44 
0.00 1.00 0.15 0.65 0.11 0.75 0.52 0.05 0.22 0.14 0.64 0.04 
22 23 23 23 23 23 16 23 23 23 23 23 
-0.29 0.39 -0.17 -0.19 0.11 0.19 0.43 -0.36 -0.02 0.00 0.05 -0.08 
0.19 0.07 0.44 0.39 0.62 0.38 0.09 0.09 0.91 0.99 0.82 0.72 
22 23 23 23 23 23 16 23 23 23 23 23 
-0.13 -0.06 -0.01 -0.19 -0.01 0.17 0.16 0.02 -0.07 -0.10 0.64 0.07 
0.61 0.83 0.98 0.46 0.97 0.51 0.58 0.94 0.79 0.68 0.00 0.80 

























































B2 IGF-I A4 
0.04 -0.34 0.19 










0.13 0.00 0.30 







0.37 0.75 0.85 
o 12 0.00 0.00 
21 21 20 19 19 20 11 19 20 19 21 21 
0.04 -0.11 0.35 0.13 0.12 0.75 0.03 -0.20 0.00 0.00 0.15 
0.86 0.66 0.14 0.60 0.62 0.01 0.89 0.40 1.00 0.99 0.52 
21 21 20 19 19 20 11 19 20 19 21 21 
-0.34 -0.11 -0.30 0.14 -0.22 0.00 -0.05 0.21 0.13 0.21 -0.57 
0.14 0.66 0.20 0.56 0.34 0.99 0.84 0.36 0.58 0.37 0.01 
20 20 21 20 20 21 12 20 21 20 20 20 
0.19 0.35 -0.30 0.06 0.12 0.29 0.11 0.21 0.11 0.20 0.11 
0.43 0.14 0.20 0.82 0.60 0.35 0.65 0.38 0.64 0.40 0.66 
19 19 20 20 20 20 12 20 20 20 19 19 
0.16 0.13 0.14 0.06 -0.08 -0.19 0.00 0.47 0.30 0.19 0.07 
0.51 0.60 0.56 0.82 0.74 0.56 1.00 0.04 0.20 0.43 0.77 
19 19 20 20 20 20 12 20 20 20 19 19 
0.53 0.12 -0.22 0.12 -0.08 0.12 -0.07 0.10 0.13 0.37 0.51 
0.02 0.62 0.34 0.60 0.74 0.71 0.78 0.65 0.58 0.11 0.02 
20 20 21 20 20 21 12 20 21 20 20 20 
0.13 0.75 0.00 0.29 -0.19 0.12 -0.18 0.15 0.21 0.26 0.08 
0.70 0.01 0.99 0.35 0.56 0.71 0.58 0.65 0.52 0.45 0.81 
11 11 12 12 12 12 12 12 12 12 11 11 
0.00 0.03 -0.05 0.11 0.00 -0.07 -0.18 1 -0.32 -0.71 0.11 -0.07 
0.99 0.89 0.84 0.65 1.00 0.78 0.58 0.17 0.00 0.65 0.79 
19 19 20 20 20 20 12 20 20 20 19 19 
0.30 -0.20 0.21 0.21 0.47 0.10 0.15 -0.32 0.81 0.30 0.21 
0.19 0.40 0.36 0.38 0.04 0.65 0.65 0.17 0.00 0.19 0.38 
20 20 21 20 20 21 12 20 21 20 20 20 
0.37 0.00 0.13 0.11 0.30 0.13 0.21 -0.71 0.81 0.35 0.30 
0.12 1.00 0.58 0.64 0.20 0.58 0.52 0.00 0.00 0.14 0.22 
19 19 20 20 20 20 12 20 20 20 19 19 
-0.75 0.00 0.21 -0.20 -0.19 -0.37 -0.26 0.11 -0.30 -0.35 1 -0.58 
0.00 0.99 0.37 0.40 0.43 0.11 0.45 0.65 0.19 0.14 0.01 
21 21 20 19 19 20 11 19 20 19 21 21 
0.85 0.15 -0.57 0.11 0.07 0.51 0.08 -0.07 0.21 0.30 0.58 
0.00 0.52 0.01 0.66 0.77 0.02 0.81 0.79 0.38 0.22 0.01 
21 21 20 19 19 20 11 19 20 19 21 21 
-0.45 0.08 0.27 -0.28 -0.19 -0.16 -0.22 0.02 -0.56 -0.56 0.53 -0.34 
0.04 0.72 0.24 0.24 0.43 0.49 0.51 0.92 0.01 0.01 0.01 0.13 
21 21 20 19 19 20 11 19 20 19 21 21 
-0.55 -0.31 0.35 -0.28 -0.14 -0.12 -0.44 -0.16 -0.03 -0.26 0.47 -0.48 
0.01 0.17 0.13 0.25 0.57 0.61 0.17 0.51 0.91 0.29 0.03 0.03 
21 21 20 19 19 20 11 19 20 19 21 21 
-0.31 0.43 0.23 -0.25 0.37 0.18 0.35 -0.50 0.31 0.44 0.36 -0.12 
0.23 0.09 0.40 0.34 0.16 0.51 0.40 0.05 0.24 0.09 0.16 0.66 
17 17 16 16 16 16 8 16 16 16 17 17 
239 
8.13.4 PHVSDS and Hormones at PHV 
Correlation Matrix for PHVSDS and Hormones at PHV: All Boys 
PHVSD BMLSDS E 
S at PHV IGF-I A4 DHEAS 2 Lel2tin SHBG Testos FAI 
PHVSDS r -0.16 0.29 0.43 -0.05 -0.17 0.16 0.30 0.15 
12 0.27 0.05 0.00 074 0.33 0.30 0.04 0.34 
N 46 46 45 44 44 34 44 46 44 
BMI_SDS at r -0.16 1 -0.11 -0.24 0.08 0.77 -0.22 -0.22 0.03 
PHV 12 0.27 0.46 0.12 0.63 0.00 0.15 0.15 0.86 
N 46 47 45 44 44 34 44 46 44 
IGF-I 0.29 -0.11 0.11 0.07 -0.27 -0.25 0.28 0.33 
12 0.05 0.46 0.48 0.66 0.12 0.11 0.06 0.03 
N 45 45 45 43 43 34 43 45 43 
A4 0.43 -0.24 0.11 1 0.24 -0.30 -0.18 0.40 0.37 
12 0.00 0.12 0.48 0.11 0.10 0.25 0.01 0.01 
N 44 44 43 44 44 32 44 44 44 
DHEAS -0.05 0.08 0.07 0.24 1 0.03 -0.39 0.26 0.35 
12 0.74 0.63 0.66 0.11 0.88 0.01 0.09 0.02 
N 44 44 43 44 44 32 44 44 44 
E2 Not available for Control B0:is 
Leptin -0.17 077 -0.27 -0.30 0.03 -0.10 -0.24 -0.10 
12 0.33 000 0.12 0.10 0.88 0.58 0.17 0.57 
N 34 34 34 32 32 34 32 34 32 
SHBG r 0.16 -0.22 -0.25 -0.18 -0.39 -0.10 1 -0.29 -0.67 
Q 0.30 0.15 0.11 0.25 0.01 0.58 0.06 0.00 
N 44 44 43 44 44 32 44 44 44 
Testos r 0.30 -0.22 0.28 0.40 0.26 -0.24 -0.29 0.88 
12 0.04 0.15 0.06 0.01 0.09 0.17 0.06 000 
N 46 46 45 44 44 34 44 46 44 
FAI 0.15 0.03 0.33 0.37 0.35 -0.10 -0.67 0.88 
12 0.34 0.86 0.03 0.01 0.02 0.57 0.00 000 
N 44 44 43 44 44 32 44 44 44 
240 
Correlation Matrix of PHVSDS and Hormones at PHV: T1 D and Control Boys 
PHVSDS BMLSDS IGF-I A4 DHE E2 Lept SHB Test FAI 
at PHV AS in G os T1D Boys PHVSDS r 
-0.12 0.42 0.41 -0.07 0.32 0.02 0.06 0.10 0.05 
E 0.60 0.05 0.06 0.75 0.14 0.93 0.78 0.64 0.84 
N 23 23 22 22 22 22 14 22 23 22 
BMI_SDS 
-0.12 0.00 -0.05 0.46 0.25 0.46 -0.35 0.13 0.27 
at PHV E 0.60 1.00 0.83 0.03 0.26 0.10 0.11 0.57 0.22 
N 23 24 22 22 22 22 14 22 23 22 
IGF-I r 0.42 0.00 1 0.00 0.00 0.35 0.13 -0.09 0.16 0.16 
E 0.05 1.00 0.98 0.99 0.12 0.67 0.69 0.46 0.48 
N 22 22 22 21 21 21 14 21 22 21 
A4 0.41 -0.05 0.00 0.44 0.20 
-0.54 0.26 0.42 
E 0.06 0.83 0.98 0.04 0.40 0.98 0.01 0.25 0.05 
N 22 22 21 22 22 21 13 22 22 22 
DHEAS r -0.07 0.46 0.00 0.44 1 -0.01 0.42 -0.46 0.06 0.23 
E 0.75 0.03 0.99 0.04 0.97 0.16 0.03 0.80 0.31 
N 22 22 21 22 22 21 13 22 22 22 
E2 r 0.32 0.25 0.35 0.20 -0.01 0.13 -0.26 0.19 0.26 
E 0.14 0.26 0.12 0.40 0.97 0.66 0.25 0.40 0.26 
N 22 22 21 21 21 22 14 21 22 21 
Leptin r 0.02 0.46 0.13 -0.01 0.42 0.13 1 -0.39 0.29 0.37 
E 0.93 0.10 0.67 0.98 0.16 0.66 0.18 0.32 0.21 
N 14 14 14 13 13 14 14 13 14 13 
SHBG 0.06 -0.35 -0.09 -0.54 -0.46 -0.26 1 -0.21 -0.57 
e 0.78 0.11 0.69 0.01 0.03 0.25 0.18 0.35 0.01 
N 22 22 21 22 22 21 13 22 22 22 
Testos 0.10 0.13 0.16 0.26 0.06 0.19 0.29 -0.21 0.90 
E 0.64 0.57 0.46 0.25 0.80 0.40 0.32 0.35 0.00 
N 23 23 22 22 22 22 14 22 23 22 
FAI r 0.05 0.27 0.16 0.42 0.23 0.26 0.37 -0.57 0.90 1 
e 0.84 0.22 0.48 0.05 0.31 0.26 0.21 0.01 0.00 
N 22 22 21 22 22 21 13 22 22 22 
Control PHVSDS r -0.14 0.14 0.40 -0.17 0.40 0.53 0.12 
Bo~s e 0.51 0.51 0.06 0.44 0.45 0.06 0.01 0.58 
N 23 23 23 22 22 20 22 23 22 
BMI_SDS -0.14 1 0.13 -0.19 0.08 0.82 -0.50 -0.19 0.32 
at PHV e 0.51 0.55 0.40 0.72 0.00 0.02 0.39 0.14 
N 23 23 23 22 22 20 22 23 22 
IGF-I r 0.14 0.13 1 -0.10 -0.40 0.03 -0.09 -0.08 
E 0.51 0.55 0.66 0.07 0.29 0.88 0.68 0.74 
N 23 23 23 22 22 20 22 23 22 
A4 0.40 -0.19 -0.10 -0.04 0.22 0.40 0.16 
e 0.06 0.40 0.66 0.86 0.94 0.33 0.07 0.48 
N 22 22 22 22 22 19 22 22 22 
DHEAS r -0.17 0.08 -0.40 -0.04 1 0.16 -0.09 0.13 0.13 
E 0.44 0.72 0.07 0.86 0.53 0.70 0.55 0.57 
N 22 22 22 22 22 19 22 22 22 
E2 Not available for Control Bo~s 
Leptin -0.18 0.82 -0.25 -0.02 0.16 -0.43 -0.07 0.32 
E 0.45 0.00 0.29 0.94 0.53 0.07 0.78 0.18 
N 20 20 20 19 19 20 19 20 19 
SHBG r 0.40 -0.50 0.03 0.22 -0.09 1 0.04 -0.64 
E 0.06 0.02 0.88 0.33 0.70 0.07 0.87 0.00 
N 22 22 22 22 22 19 22 22 22 
Testos 0.53 -0.19 -0.09 0.40 0.13 0.04 1 0.70 
E 0.01 0.39 0.68 0.07 0.55 0.78 0.87 0.00 
N 23 23 23 22 22 20 22 23 22 
FAI 0.12 0.32 -0.08 0.16 0.13 0.32 -0.64 0.70 1 
E 0.58 0.14 0.74 0.48 0.57 0.18 0.00 0.00 
N 22 22 22 22 22 19 22 22 22 
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Correlation Matrix for PHVSDS and Hormones at PHV: All Girls 
PHVSD BMI_SDS 
S at PHV IGF-I A4 DHEAS E2 Leptin SHBG Testes FAI 
-0.33 -0.07 0.18 -0.11 0.05 -0.26 0.22 0.02 -0.06 
PHVSDS P 0.02 0.62 0.27 0.52 0.72 0.16 0.19 0.92 0.74 
N 52 52 47 38 38 46 31 38 47 37 
BMI_SDS -0.33 -0.07 -0.09 0.02 -0.03 0.73 -0.20 0.04 0.11 
atPHV p 0.02 0.64 0.60 0.93 0.86 0.00 0.23 0.82 0.52 
N 52 52 47 38 38 46 31 38 47 37 
-0.07 -0.07 1 0.09 0.44 0.15 -0.14 -0.15 0.27 0.28 
IGF-I P 0.62 0.64 0.61 0.01 0.33 0.47 0.38 0.07 0.09 
N 47 47 47 37 37 45 31 37 46 37 
0.18 -0.09 0.09 0.47 0.42 -0.20 -0.10 0.46 0.42 
A4 P 0.27 0.60 0.61 0.00 0.01 0.31 0.55 0.00 0.01 
N 38 38 37 38 38 37 27 38 38 37 
-0.11 0.02 0.44 0.47 0.37 -0.33 -0.18 0.48 0.51 
DHEAS P 0.52 0.93 0.01 0.00 0.02 0.09 0.29 0.00 0.00 
N 38 38 37 38 38 37 27 38 38 37 
0.05 -0.03 0.15 0.42 0.37 1 -0.16 -0.12 0.42 0.42 
E2 P 0.72 0.86 0.33 0.01 0.02 0.41 0.47 0.00 0.01 
N 46 46 45 37 37 46 30 37 46 36 
-0.26 0.73 -0.14 -0.20 -0.33 -0.16 0.05 -0.14 -0.16 
Leptin p 0.16 0.00 0.47 0.31 0.09 0.41 0.82 0.44 0.42 
N 31 31 31 27 27 30 31 27 31 27 
0.22 -0.20 -0.15 -0.10 -0.18 -0.12 0.05 -0.15 -0.48 
SHBG P 0.19 0.23 0.38 0.55 0.29 0.47 0.82 0.38 0.00 
N 38 38 37 38 38 37 27 38 38 37 
0.02 0.04 0.27 0.46 0.48 0.42 -0.14 -0.15 0.86 
Testes p 0.92 0.82 0.07 0.00 0.00 0.00 0.44 0.38 0.00 
N 47 47 46 38 38 46 31 38 47 37 
-0.06 0.11 0.28 0.42 0.51 0.42 -0.16 -0.48 0.86 
FAI P 0.74 0.52 0.09 0.01 0.00 0.01 0.42 0.00 0.00 
N 37 37 37 37 37 36 27 37 37 37 
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DS PHV IGF-I A4 DHEAS E2 Leptin SHBG Testos FAI 
T1D PHVSDS 1 -0.45 -0.13 0.21 -0.29 0.08 -0.16 0.36 -0.06 -0.28 
Girls p 0.04 0.59 0.41 0.24 0.74 0.64 0.15 0.79 0.28 N 22 22 20 18 18 20 11 18 20 17 
BMLSDS r -0.45 1 
-0.15 0.22 0.07 0.12 0.81 -0.10 -0.10 0.25 
at PHV p 0.04 0.53 0.39 0.78 0.60 0.00 0.70 0.66 0.33 
N 22 22 20 18 18 20 11 18 20 17 
IGF-I -0.13 -0.15 
-0.25 0.31 -0.12 0.05 -0.01 0.26 0.09 
P 0.59 0.53 0.33 0.22 0.63 0.90 0.97 0.28 072 
N 20 20 20 17 17 19 11 17 19 17 
A4 r 0.21 0.22 -0.25 1 0.07 0.33 0.52 0.04 0.30 0.02 
P 0.41 0.39 0.33 0.79 0.18 0.10 0.89 0.23 0.95 
N 18 18 17 18 18 18 11 18 18 17 
DHEAS -0.29 0.07 0.31 0.07 0.05 -0.23 0.00 0.51 0.34 
P 0.24 0.78 0.22 0.79 0.85 0.50 1.00 0.03 0.18 
N 18 18 17 18 18 18 11 18 18 17 
E2 r 0.08 0.12 -0.12 0.33 0.05 0.28 -0.16 0.30 0.25 
P 0.74 0.60 0.63 0.18 0.85 0.41 0.54 0.20 0.34 
N 20 20 19 18 18 20 11 18 20 17 
Leptin r -0.16 0.81 0.05 0.52 -0.23 0.28 -0.06 0.09 0.10 
P 0.64 0.00 0.90 0.10 0.50 0,41 0.87 0.80 0.76 
N 11 11 11 11 11 11 11 11 11 11 
SHBG r 0.36 -0.10 -0.01 0.04 0.00 -0.16 -0.06 -0.36 -0.60 
P 0.15 0.70 0.97 0.89 1.00 0.54 0.87 0.14 0.01 
N 18 18 17 18 18 18 11 18 18 17 
Testos r -0.06 -0.10 0.26 0.30 0.51 0.30 0.09 -0.36 1 0.82 
P 0.79 0.66 0.28 0.23 0.03 0.20 0.80 0.14 0.00 
N 20 20 19 18 18 20 11 18 20 17 
FAI r -0.28 0.25 0.09 0.02 0.34 0.25 0.10 -0.60 0.82 1 
P 0.28 0.33 0.72 0.95 0.18 0.34 0.76 0.01 0.00 
N 17 17 17 17 17 17 11 17 17 17 
PHVSDS r 1 -0.23 -0.11 0.02 -0.02 -0.02 -0.11 0.07 0.05 0.09 
Contro p 0.21 0.57 0.95 0.94 0.94 0.64 0.77 0.80 0.70 
I Girls N 30 30 27 20 20 26 20 20 27 20 
BMLSDS r -0.23 0.09 0.06 0.39 0.01 0.72 -0.43 0.15 0.27 
at PHV p 0.21 0.65 0.79 0.09 0.97 0.00 0.06 0,45 0.24 
N 30 30 27 20 20 26 20 20 27 20 
IGF-I -0.11 0.09 1 0.25 0.52 0.17 0.11 -0.22 0.21 0.37 
P 0.57 0.65 0.29 0.02 0.42 0.64 0.36 0.29 0.11 
N 27 27 27 20 20 26 20 20 27 20 
A4 r 0.02 0.06 0.25 1 0.75 0,41 0.14 -0.16 0.68 0.67 
P 0.95 0.79 0.29 0.00 0.08 0.61 0.51 0.00 0.00 
N 20 20 20 20 20 19 16 20 20 20 
DHEAS -0.02 0.39 0.52 0.75 1 0.54 0.51 -0.32 0,48 0.57 
P 0.94 0.09 0.02 0.00 0.02 0.04 0.16 0.03 0.01 
N 20 20 20 20 20 19 16 20 20 20 
E2 -0.02 0.01 0.17 0.41 0.54 1 -0.11 -0.05 0.47 0.45 
P 0.94 0.97 0,42 0.08 0.02 0.67 0.83 0.02 0.05 
N 26 26 26 19 19 26 19 19 26 19 
Leptin r -0.11 0.72 0.11 0.14 0.51 -0.11 1 -0.33 0.11 0.27 
P 0.64 0.00 0.64 0.61 0.04 0.67 0.21 0.64 0.32 
N 20 20 20 16 16 19 20 16 20 16 
SHBG 0.07 -0.43 -0.22 -0.16 -0.32 -0.05 -0.33 0.05 -0.32 
P 0.77 0.06 0.36 0.51 0.16 0.83 0.21 0.84 0.17 
N 20 20 20 20 20 19 16 20 20 20 
Testos 0.05 0.15 0.21 0.68 0,48 0.47 0.11 0.05 1 0.90 
P 0.80 0.45 0.29 0.00 0.03 0.02 0.64 0.84 0.00 
N 27 27 27 20 20 26 20 20 27 20 
FAI r 0.09 0.27 0.37 0.67 0.57 0.45 0.27 -0.32 0.90 
P 0.70 0.24 0.11 0.00 0.01 0.05 0.32 0.17 0.00 
N 20 20 20 20 20 19 16 20 20 20 
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8.13.5 PHVSDS and Hormones averaged from Stage 2-PHV 
All 
Bo~s 
Correlation Matrix for PHVSDS and Hormones averaged from G2 to 
PHV: All Boys 
PHVSO 
BMI_S 
OHE os at 
S G2 IGF-I A4 AS E2 ie~tin SHBG Testos FAI 
PHVSO r -0.18 0.10 0.22 -0.17 0.37 -0.15 0.32 0.14 0.02 
S ~ 0.23 0.51 0.15 0.28 0.08 0.40 0.03 0.37 0.89 
N 46 45 45 44 44 23 36 44 45 44 
BMI_S r -0.18 0.19 -0.13 0.16 0.31 0.74 -0.39 -007 0.15 
OS at ~ 0.23 0.21 0.41 0.31 0.15 0.00 0.01 0.65 0.34 
G2 N 45 45 44 43 43 23 35 43 44 43 
IGF-I r 0.10 0.19 1 -0.09 0.07 -0.03 -0.01 -0.18 0.28 0.30 
~ 0.51 0.21 0.54 0.63 0.90 0.96 0.23 0.07 0.05 
N 45 44 45 44 44 23 36 44 45 44 
A4 0.22 -0.13 -0.09 1 0.24 0.13 -0.09 -0.15 0.24 0.29 
~ 0.15 0.41 0.54 0.12 0.56 0.60 0.32 0.11 0.06 
N 44 43 44 44 44 23 35 44 44 44 
OHEAS -0.17 0.16 0.07 0.24 1 0.05 0.03 -0.33 0.26 0.37 
~ 0.28 0.31 0.63 0.12 0.80 0.85 0.03 0.09 0.01 
N 44 43 44 44 44 23 35 44 44 44 
E2 Not available for Control Boys 
Leptin -0.15 0.74 -0.01 -0.09 0.03 0.28 -0.12 -0.20 -0.13 
~ 0.40 0.00 0.96 0.60 0.85 0.29 0.50 0.25 0.44 
N 36 35 36 35 35 16 36 35 36 35 
SHBG 0.32 -0.39 -0.18 -0.15 -0.33 -0.13 -0.12 -0.20 -0.54 
~ 0.03 0.01 0.23 0.32 0.03 0.56 0.50 0.20 0.00 
N 44 43 44 44 44 23 35 44 44 44 
Testos 0.14 -0.07 0.28 0.24 0.26 0.01 -0.20 -0.20 0.90 
~ 0.37 0.65 0.07 0.11 0.09 0.96 0.25 0.20 0.00 
N 45 44 45 44 44 23 36 44 45 44 
FAI r 0.02 0.15 0.30 0.29 0.37 0.06 -0.13 -0.54 0.90 
~ 0.89 0.34 0.05 0.06 0.01 0.77 0.44 0.00 0.00 






Correlation Matrix of PHVSDS and Hormones averaged Stage 2-PHV: T1 D and 
Control Boys 
BMI_SO SHB PHVSOS Sat G2 IGF-I A4 OHEAS E2 Leptin G Testos FAI PHVSO r 1 
-0.09 0.23 0.32 -0.25 0.37 0.19 0.19 0.10 0.03 
P 0.68 0.28 0.14 0.25 0.08 0.47 0.38 0.63 090 N 23 23 23 23 23 23 16 23 23 23 
BMLS -0.09 1 0.27 0.29 0.31 0.54 -0.50 -0.17 0.04 OS at p 0.68 0.22 0.55 0.18 0.15 0.03 0.01 0.43 0.84 G2 N 23 23 23 23 23 23 16 23 23 23 
IGF-I 0.23 0.27 0.21 0.08 -003 0.22 0.02 0.24 0.18 
P 0.28 0.22 0.34 0.72 0.90 0.41 0.94 0.28 0.42 
N 23 23 23 23 23 23 16 23 23 23 
A4 0.32 -0.13 0.21 0.43 0.13 -0.18 -0.37 0.37 052 
P 0.14 0.55 0.34 0.04 0.56 0.50 0.09 0.08 0.01 
N 23 23 23 23 23 23 16 23 23 23 
OHEAS -0.25 0.29 0.08 0.43 1 0.05 -0.07 -0.38 0.08 0.26 
P 0.25 0.18 0.72 0.04 0.80 0.80 0.07 0.72 023 
N 23 23 23 23 23 23 16 23 23 23 
E2 0.37 0.31 -0.03 0.13 0.05 1 0.28 -0.13 0.01 0.06 
P 0.08 0.15 0.90 0.56 0.80 0.29 0.56 0.96 0.77 
N 23 23 23 23 23 23 16 23 23 23 
Leptin 0.19 0.54 0.22 -0.07 0.28 1 -0.39 -0.38 
P 0.47 0.03 0.41 0.50 0.80 0.29 0.13 0.15 0.46 
N 16 16 16 16 16 16 16 16 16 16 
SHBG 0.19 -0.50 0.02 -0.38 -0.13 -0.39 1 -0.23 
P 0.38 0.01 0.94 0.09 0.07 0.56 0.13 0.29 0.01 
N 23 23 23 23 23 23 16 23 23 23 
Testos 0.10 -0.17 0.24 0.37 0.08 0.01 -0.38 -0.23 1 0.91 
P 0.63 0.43 0.28 0.08 0.72 0.96 0.15 0.29 0.00 
N 23 23 23 23 23 23 16 23 23 23 
FAI 0.03 0.04 0.18 0.52 0.26 0.06 -0.20 -0.53 0.91 
P 0.90 0.84 0.42 0.01 0.23 0.77 0.46 0.01 0.00 
N 23 23 23 23 23 23 16 23 23 23 
PHVSO 1 -0.17 -0.10 0.15 -0.17 -0.19 0.57 0.13 
p 0.44 0.65 0.51 0.47 0.43 0.01 0.55 0.72 
N 23 22 22 21 21 20 21 22 21 
BMI_S r -0.17 1 0.38 0.22 0.77 -0.59 0.17 0.60 
OS at p 0.44 0.09 0.78 0.36 0.00 0.01 0.46 0.00 
G2 N 22 22 21 20 20 19 20 21 20 
IGF-I r -0.10 0.38 1 -0.04 0.11 -0.29 0.27 0.44 
P 0.65 0.09 0.10 0.88 0.64 0.20 0.22 0.04 
N 22 21 22 21 21 20 21 22 21 
A4 r 0.15 -0.07 -0.37 1 0.11 0.28 0.00 0.17 0.11 
P 0.51 0.78 0.10 0.63 0.25 0.98 0.47 0.62 
N 21 20 21 21 21 19 21 21 21 
OHEAS -0.17 0.22 -0.04 0.11 0.35 -0.19 0.50 0.52 
P 0.47 0.36 0.88 0.63 0.14 0.40 0.02 0.02 
N 21 20 21 21 21 19 21 21 21 
E2 Not available for Control Bo~s 
Leptin r -0.19 0.77 0.11 0.28 0.35 -0.52 0.42 0.66 
P 0.43 0.00 0.64 0.25 0.14 0.02 0.07 0.00 
N 20 19 20 19 19 20 19 20 19 
SHBG 0.57 -0.59 -0.29 0.00 -0.19 -0.52 1 -0.09 
P 0.01 0.01 0.20 0.98 0.40 0.02 0.69 0.01 
N 21 20 21 21 21 19 21 21 21 
Testos 0.13 0.17 0.27 0.17 0.50 0.42 -0.09 1 0.88 
P 0.55 0.46 0.22 0.47 0.02 0.07 0.69 0.00 
N 22 21 22 21 21 20 21 22 21 
FAI r -0.08 0.60 0.44 0.11 0.52 0.66 -0.55 0.88 1 
P 0.72 0.00 0.04 0.62 0.02 0.00 0.01 0.00 
N 21 20 21 21 21 19 21 21 21 
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Correlation Matrix for PHVSDS and Hormones averaged from 82 to 
PHV: All Girls 
BMI_S 
os at 
PHVSOS B2 IGF-I A4 OHEAS E2 ie~tin SHBG Testos FAI 
r 1 -0.31 -0.03 0.21 -0.04 0.18 -0.25 0.18 0.14 0.03 
~ 0.02 0.85 0.18 0.81 0.24 0.16 0.25 0.35 0.83 
N 58 52 48 40 40 47 32 40 48 40 
r -0.31 1 -0.04 -0.11 0.05 0.64 -0.12 -0.08 0.04 
~ 0.02 0.80 0.53 0.78 0.51 0.00 0.51 0.61 0.81 
N 52 52 42 35 35 42 27 35 42 35 
r -0.03 -0.04 -0.05 0.24 0.08 -0.11 -0.10 0.21 0.24 
~ 0.85 0.80 0.77 0.14 0.60 0.56 0.54 0.16 0.14 
N 48 42 48 40 40 47 32 40 48 40 
0.21 -0.11 -0.05 0.47 0.30 -0.31 0.03 0.46 0.43 
~ 0.18 0.53 077 0.00 0.07 0.11 0.87 0.00 0.01 
N 40 35 40 40 40 39 28 40 40 40 
-0.04 0.05 0.24 0.47 0.23 -0.32 -0.14 0.44 0.46 
~ 0.81 0.78 0.14 0.00 0.15 0.10 0.38 0.00 0.00 
N 40 35 40 40 40 39 28 40 40 40 
0.18 -0.10 0.08 0.30 0.23 1 -0.21 0.00 0.29 0.22 
~ 0.24 0.51 0.60 0.07 0.15 0.26 0.99 0.04 0.17 
N 47 42 47 39 39 47 31 39 47 39 
r -0.25 0.64 -0.11 -0.31 -0.32 0.00 -0.19 
~ 0.16 0.00 0.56 0.11 0.10 0.26 0.98 0.30 0.41 
N 32 27 32 28 28 31 32 28 32 28 
r 0.18 -0.12 -0.10 0.03 -0.14 0.00 0.00 1 -0.08 
~ 0.25 0.51 0.54 0.87 0.38 0.99 0.98 0.64 0.00 
N 40 35 40 40 40 39 28 40 40 40 
0.14 -0.08 0.21 0.46 0.44 0.29 -0.19 -0.08 1 0.86 
~ 0.35 0.61 0.16 0.00 0.00 0.04 0.30 0.64 0.00 
N 48 42 48 40 40 47 32 40 48 40 
r 0.03 0.04 0.24 0.43 0.46 0.22 -0.16 -0.50 0.86 
~ 0.83 0.81 0.14 0.01 0.00 0.17 0.41 0.00 0.00 
N 40 35 40 40 40 39 28 40 40 40 
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Correlation Matrix of PHVSDS and Hormones averaged 82-PHV: 
T1 D and Control Girls 
BMI_S 
PHVSD DS at DHEA Testa S B2 IGF-I A4 S E2 ie~tin SHBG s FAI T1D Girls r 
-0.43 
-0.21 0.24 -0.20 0.26 -0.16 0.34 0.02 -0.16 PHVSDS ~ 0.05 0.36 0.31 0.40 0.25 0.63 0.14 0.93 0.50 N 22 21 21 20 20 21 12 20 21 20 
r -0.43 1 -0.11 0.35 0.13 0.12 0.75 0.03 -0.20 000 
BMLSDS ~ 0.05 0.66 0.14 0.60 0.62 0.01 0.89 0.40 1.00 
at B2 N 21 21 20 19 19 20 11 19 20 19 
IGF-I r -0.21 -0.11 
-0.30 0.14 000 -0.05 0.21 0.13 
~ 0.36 0.66 0.20 0.56 0.34 0.99 0.84 0.36 0.58 
N 21 20 21 20 20 21 12 20 21 20 
A4 r 0.24 0.35 -0.30 1 0.06 0.12 0.29 0.11 0.21 0.11 
~ 0.31 0.14 0.20 0.82 0.60 0.35 0.65 0.38 0.64 
N 20 19 20 20 20 20 12 20 20 20 
DHEAS -0.20 0.13 0.14 0.06 1 -0.19 0.00 0.47 0.30 
~ 0.40 0.60 0.56 0.82 0.74 0.56 1.00 0.04 0.20 
N 20 19 20 20 20 20 12 20 20 20 
E2 r 0.26 0.12 -0.22 0.12 -008 0.12 -0.07 0.10 0.13 
e 0.25 0.62 0.34 0.60 0.74 0.71 0.78 0.65 0.58 
N 21 20 21 20 20 21 12 20 21 20 
Leptin -0.16 0.75 0.00 0.29 -0.19 0.12 -0.18 0.15 0.21 
e 0.63 0.01 0.99 0.35 0.56 0.71 0.58 0.65 0.52 
N 12 11 12 12 12 12 12 12 12 12 
SHBG 0.34 0.03 -005 0.11 0.00 -0.18 -0.32 -0.71 
~ 0.14 0.89 0.84 0.65 1.00 0.78 0.58 0.17 0.00 
N 20 19 20 20 20 20 12 20 20 20 
Testos r 0.02 -0.20 0.21 0.21 0.47 0.10 0.15 -0.32 0.81 
~ 0.93 0.40 0.36 0.38 0.04 0.65 0.65 0.17 0.00 
N 21 20 21 20 20 21 12 20 21 20 
FAI r -0.16 0.00 0.13 0.11 0.30 0.13 0.21 -0.71 0.81 1 
~ 0.50 1.00 0.58 0.64 0.20 0.58 0.52 0.00 0.00 
N 20 19 20 20 20 20 12 20 20 20 
Control 1 -0.23 0.12 0.10 0.08 0.13 -0.10 -0.03 0.21 0.18 
Girls PHVSDS e 0.21 0.54 0.67 0.75 0.52 0.68 0.91 0.30 0.44 
N 36 31 27 20 20 26 20 20 27 20 
r -0.23 0.12 -0.10 0.35 0.53 -0.44 -0.03 0.18 
BMLSDS ~ 0.21 0.61 0.73 0.19 0.68 0.04 0.09 0.91 0.51 
at B2 N 31 31 22 16 16 22 16 16 22 16 
IGF-I r 0.12 0.12 1 0.04 0.28 0.16 0.14 -0.14 0.18 0.31 
~ 0.54 0.61 0.87 0.24 0.45 0.56 0.56 0.37 0.18 
N 27 22 27 20 20 26 20 20 27 20 
A4 r 0.10 -0.10 0.04 1 0.71 0.29 0.07 0.15 0.68 0.60 
~ 0.67 0.73 0.87 0.00 0.23 0.79 0.53 000 0.01 
N 20 16 20 20 20 19 16 20 20 20 
DHEAS r 0.08 0.35 0.28 0.71 0.33 0.51 -0.26 0.44 0.53 
~ 0.75 0.19 0.24 0.00 0.17 0.05 0.27 0.05 0.02 
N 20 16 20 20 20 19 16 20 20 20 
E2 r 0.13 -0.09 0.16 0.29 0.33 -0.17 0.11 0.34 0.20 
~ 0.52 0.68 0.45 0.23 0.17 0.49 0.65 0.09 0.41 
N 26 22 26 19 19 26 19 19 26 19 
Leptin -0.10 0.53 0.14 0.07 0.51 1 -0.46 -005 0.16 
~ 0.68 0.04 0.56 0.79 0.05 0.49 0.07 0.83 0.54 
N 20 16 20 16 16 19 20 16 20 16 
SHBG r -0.03 -0.44 -0.14 0.15 -0.26 0.11 -0.46 1 0.14 -0.27 
~ 0.91 0.09 0.56 0.53 0.27 0.65 0.07 0.54 0.24 
N 20 16 20 20 20 19 16 20 20 20 
Testos 0.21 -0.03 0.18 0.68 0.44 0.34 -0.05 0.14 1 0.90 
~ 0.30 0.91 0.37 0.00 0.05 0.09 0.83 0.54 0.00 
N 27 22 27 20 20 26 20 20 27 20 
FAI r 0.18 0.18 0.31 0.60 0.53 0.20 0.16 -0.27 0.90 1 
~ 0.44 0.51 0.18 0.01 0.02 0.41 0.54 0.24 0.00 
N 20 16 20 20 20 19 16 20 20 20 
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